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Abstract 
Despite decades of research and the availability of effective medications, malaria remains a 
significant global health issue. The vast majority of infections are caused by two species: 
Plasmodium falciparum and Plasmodium vivax. There is currently no licensed malaria vaccine 
but an effective vaccine is widely considered necessary to maintain the progress towards 
eradication, particularly given the increasing issues of insecticide and antimalarial resistance 
developing. The manifestations of malaria disease are caused by the blood-stage of the 
parasite against which endemic populations, who are exposed to multiple episodes of malaria, 
develop some degree of natural immunity. It is therefore considered that vaccines against the 
blood-stage may mimic the immunity seen in these individuals. This thesis describes three 
early-phase clinical trials for blood-stage malaria vaccines, all carried out in healthy volunteers 
at the Jenner Institute in Oxford.  
The first of these was a Phase Ia trial of a novel P. vivax blood-stage vaccine, ChAd63/MVA 
PvDBP. This is the only blood-stage vivax vaccine to reach clinical trial and was safe and 
immunogenic, with functional activity of the antibodies induced by vaccination demonstrated 
in vitro. 
The second trial was a Phase I/IIa trial of a candidate P. falciparum vaccine, FMP2.1/AS01B. 
Vaccine efficacy was assessed by blood-stage controlled human malaria infection (CHMI) using 
a model developed for this trial. Although the vaccine did not demonstrate any efficacy, the 
CHMI model was highly reproducible. 
The final Phase Ia trial examined novel P. falciparum vaccines, ChAd63/MVA RH5. This is the 
first clinical trial in which purified IgG demonstrated inhibition of growth of P. falciparum in 
vitro in all strains tested. 
These studies have demonstrated the potential for developing an effective vaccine against 
blood stage vivax and falciparum malaria as well as the potential for using the CHMI model for 
proof-of-concept efficacy testing of novel malaria vaccines. 
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1.1 Background 
There are five Plasmodium species that cause human malaria, by far the most common being 
P. falciparum, which is also the species which causes the vast majority of mortality relating to 
malaria. P. vivax is the second most common species to cause human malaria. The remaining 
three species, P. ovale, P. malariae and P. knowlesi, cause a much lower proportion of cases 
worldwide, with P. knowlesi only relatively recently recognised as a human malaria, although 
primarily a zoonosis (1). Plasmodium species are apicomplexan protozoan parasites 
transmitted by the female Anopheles mosquito which injects sporozoites into the human host 
when it takes a blood meal. The Apicomplexa phylum is so named because of the specialised 
apical complex of organelles within this group of parasites which is essential for invasion (2). 
According to the World Malaria Report 2015 there were an estimated 438,000 deaths annually 
worldwide. Globally, there are thought to be around 3.2 billion people at risk of malaria, with 
sub-Saharan African populations at highest risk of acquiring malaria: approximately 90% of 
deaths are estimated to occur in the World Health Organisation (WHO) African Region. The 
number of global cases of malaria has decreased from an estimated 262 million in 2000 to an 
estimated 214 million cases in 2015. Of the 106 countries with ongoing malaria transmission, 
33 have achieved significant progress towards elimination, estimating fewer than 1000 malaria 
cases in 2015 compared with 13 countries in 2000 (3). The decrease in malaria cases, 
particularly in Africa, has been observed since concerted efforts have been made within the 
framework of the United Nations Millennium Development Goals (MDGs) and with the Roll 
Back Malaria (RBM) initiative. However, challenges to the success of current strategies to 
combat malaria (such as insecticide treated nets (ITNs), indoor residual spraying, and 
antimalarial drugs) include: the development of resistance of Anopheles mosquitoes to certain 
insecticides; the development of resistance of malaria parasites to chemotherapeutic agents 
(4); the absence of a gametocidal drug suitable for mass administration (5); and the risk of re-
importation of malaria into geographic regions previously cleared of malaria using 
environmental elimination measures.  
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The RBM Partnership was launched in 1998 by the WHO, the United Nations Children’s Fund 
(UNICEF), the United Nations Development Programme (UNDP) and the World Bank. A major 
goal of the RBM Partnership is to support the development of a vaccine against malaria as a 
key future strategy for reducing mortality from malaria. The development of an effective 
vaccine may indeed be necessary for the greater goal of global eradication of malaria (6). The 
recently updated Malaria Vaccine Technology Roadmap calls for the development of a vaccine 
against P. falciparum and P. vivax by 2030, that will have protective efficacy of at least 75% 
against clinical malaria, suitable for administration to appropriate at-risk groups and 
development of vaccines to reduce malaria transmission suitable for administration in mass 
campaigns (7). 
1.2 Plasmodium falciparum malaria 
The vast majority of cases of falciparum malaria occur in sub-Saharan Africa. There were an 
estimated 187 (132 – 259) million clinical cases of P. falciparum malaria in sub-Saharan Africa 
in 2015. It is estimated that 663 (542 – 753) million cases have been averted in Africa since the 
introduction of control measures in 2000, the most effective of which has been the 
widespread use of ITNs which is thought to account for 68 (62 – 73)% of the averted cases (8). 
Despite these improvements, malaria still remains the biggest killer of the parasitic diseases, 
with many challenges to the goal of eradication.  
1.2.1 The lifecycle of P. falciparum malaria 
The P. falciparum parasite is injected into the human host (when the female Anopheles 
mosquito takes a blood meal) in the form of sporozoites. The number of sporozoites injected 
varies widely, but has been estimated as an average of 15 in the case of falciparum malaria (9). 
Once injected, the majority of sporozoites make their way from the dermis through the 
bloodstream to the host’s liver, although they may also be transported in the lymphatic system 
(10). In the liver the sporozoites invade hepatocytes and form liver schizonts. These are cells 
full of mitotically dividing parasites (2). This process occurs over 6 – 7 days, at the end of which 
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merosomes are budded from the cell and enter the hepatic sinusoids (11). When these 
merosomes eventually rupture, thousands of merozoite-stage parasites are released into the 
bloodstream, moving from the ‘pre-erythrocytic’ stage of the parasite life cycle to the 
‘erythrocytic’ stage (Figure 1-1). Merozoites invade erythrocytes, where they develop into ring 
stages, trophozoites and then into schizonts. These rupture, releasing merozoites into the 
bloodstream to begin a new cycle. Unlike P. vivax, the P. falciparum parasite can invade 
erythrocytes of all ages, enabling it to achieve far higher levels of parasitaemia. Cycles of 
replication occur every 48 hours and are responsible for the clinical manifestations of malaria 
infection (11). Some trophozoites do not develop into schizonts, but instead develop into 
gametocytes, the sexual-stage of the Plasmodium parasite. These develop over a period of 10 
– 12 days and are essential for the ongoing transmission of malaria (12).  
Inside the mosquito the sporogonic cycle takes place. The microgamete exflagellates and 
enters the macrogamete to form a zygote within the mosquito midgut. The zygotes become 
motile (ookinetes) and penetrate the midgut wall where they develop into oocysts. These 
rupture and release sporozoites which migrate to the mosquito salivary glands, ready to be 
injected when the mosquito takes another blood meal (13). 
 
Figure 1-1: Life cycle of Plasmodium falciparum. 
Reprinted from Cell, Volume 124, Cowman and Crabb, Invasion of red blood cells by malaria parasites, 
755-66., Copyright (2006), with permission from Elsevier 
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Plasmodium merozoite invasion of erythrocytes is a complex process. Merozoites are released 
into the bloodstream when schizonts rupture and then make contact with red blood cells. The 
malaria parasite utilises a complex secretory system, and contains multiple secretory 
organelles, including micronemes and rhoptries. Merozoites are usually only free in the 
circulation for less than a minute, but may take several minutes to make a successful contact 
(14, 15). After an initial interaction with the erythrocyte, the merozoite reorients, so that its 
apical end faces the surface of the cell. A tight junction is formed between the merozoite and 
erythrocyte, and this then moves from the apical to the posterior end of the merozoite. During 
this movement ligands involved in the invasion process are removed, and the erythrocyte 
membrane subsequently encases the merozoite, creating a parasitophorous vacuole around 
the invading parasite along with the rest of the rhoptry contents (proteins and lipids). This 
separates the parasite from the host-cell cytoplasm, providing a hospitable environment for 
development (2, 16). The micronemal parasite ligands (erythrocyte binding antigens, EBAs, or 
Duffy-binding proteins, DBPs) and rhoptry ligands (reticulocyte binding-like proteins, RBLs or 
RBPs) are two families of antigens that are functionally conserved across Plasmodium species 
and are thought to be involved in the tight attachment step between the parasite and new 
host red blood cell. It appears that parasites need at least one member of each of these 
families to invade erythrocytes.  
P. falciparum has multiple erythrocyte binding proteins, including EBA-175, EBA-140, EBA-181 
and EBL-1. The P. falciparum RBL proteins are referred to as reticulocyte-binding protein 
homologues (PfRH), and there have been six identified currently – namely, PfRH1, PfRH2a, 
PfRH2b, PfRH3, PfRH4 and PfRH5 (2). These proteins contribute towards multiple invasion 
pathways for P. falciparum, and therefore redundancy, which may be advantageous for host 
immune invasion and contribute to the ability of the parasite to invade erythrocytes of all ages 
(2, 17, 18). 
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1.2.2 Clinical manifestations of Plasmodium falciparum malaria 
The symptoms and pathology attributable to P. falciparum occur during the erythrocytic 
(blood) stage of infection; the pre-erythrocytic stage is asymptomatic. Children under five 
years of age are the most severely affected; accounting for 70% of deaths from this infection. 
Pregnant women are also at increased risk, and malaria causes indirect mortality from 
abortion and intrauterine growth retardation (19). The reason mortality decreases after the 
age of five is due to the acquisition of natural immunity in children living in endemic areas, 
which decreases the risk of death and severe disease. Those who are not repeatedly exposed 
to malaria infection lose their immunity and remain at risk. Repeated, fairly constant exposure 
occurs in populations with ‘stable’ transmission. In these populations the entomological 
inoculation rate is >10/year and natural immunity is acquired in early childhood. In areas 
where there is unstable transmission, with wide fluctuations in the intensity of malaria 
transmission (entomological inoculation rate <5/year), populations do not develop natural 
immunity and both children and adults are at risk of severe disease. These populations are at 
particular risk of malaria epidemics if there is a sudden increase in the inoculation rate, with 
high incidence of malaria in all age groups and high rates of severe malaria if those infected are 
not promptly and effectively treated (3). 
The initial symptoms of malaria are non-specific, and often described as ‘flu-like’, with fever, 
headaches, myalgia and malaise. If untreated, malaria will progress to cause more severe 
disease. Children are particularly susceptible to severe anaemia and hypoglycaemia, whereas 
adults are more likely to develop pulmonary oedema, acute kidney injury and jaundice. 
Cerebral malaria (causing coma) and acidosis occur in all age groups (19). The features of 
severe malaria are shown in Table 1.1. 
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Clinical features of severe malaria Laboratory and other findings 
 Impaired consciousness (including 
unrousable coma) 
 Prostration, i.e. generalised weakness so 
that the patient is unable to sit, stand or 
walk without assistance 
 Multiple convulsions: more than two 
episodes within 24h 
 Deep breathing and respiratory distress 
(acidotic breathing) 
 Acute pulmonary oedema and acute 
respiratory distress syndrome 
 Circulatory collapse or shock, systolic 
blood pressure < 80mm Hg in adults and < 
50mm Hg in children 
 Acute kidney injury 
 Clinical jaundice plus evidence of other 
vital organ dysfunction 
 Abnormal bleeding 
 Hypoglycaemia (< 2.2mmol/l or < 
40mg/dl) 
 Metabolic acidosis (plasma bicarbonate < 
15mmol/l) 
 Severe normocytic anaemia (haemoglobin 
< 5g/dl, packed cell volume < 15% in 
children; <7g/dl, packed cell volume < 
20% in adults) 
 Haemoglobinuria 
 Hyperlactataemia (lactate > 5mmol/l) 
 Renal impairment (serum creatinine > 
265μmol/l) 
 Pulmonary oedema (radiological) 
High parasitaemia is a risk for increased 
mortality from malaria but the relationship is 
complex and varies depending on transmission 
levels. In low-transmission areas, mortality 
from acute falciparum malaria begins to 
increase with a parasitaemia >2.5%, whereas 
in areas of higher transmission much higher 
parasite densities may be well tolerated. 
Parasitaemia > 20% is associated with a high 
risk in any epidemiological context. 
Table 1.1: Overview of severe malaria manifestations.  
These may occur in isolation or, more commonly, in combination (20). 
1.2.3 Treatment of P. falciparum malaria 
The recommended treatment of falciparum malaria is based on the severity of disease. 
Uncomplicated cases should be treated with an oral Artemisinin combination therapy (ACT) 
such as artemether and lumefantrine or artesunate and amodiaquine, except in pregnant 
women in their first trimester. Quinine + clindamycin therapy is recommended in this group. 
Severe falciparum malaria should be treated with intravenous (IV) or intramuscular (IM) 
artesunate for at least 24 hours and until they can tolerate oral medication. Once a patient has 
received at least 24 hours of IV or IM artesunate, and is able to tolerate oral medication, 
treatment should be completed with 3 days of an ACT (21). 
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1.3 Plasmodium vivax malaria 
Plasmodium vivax is the most common non-falciparum malaria. It is the most geographically 
widespread malaria because the parasite is able to survive in colder climates and at higher 
altitudes than P. falciparum. Infection with P. vivax accounted for approximately 50% of global 
malaria cases outside of Africa in 2015, the majority of which occurred in South-East Asia (3).  
The global incidence of vivax malaria is very difficult to quantify as detection of P. vivax 
infections is more difficult, due to lower parasitaemias than are seen with P. falciparum 
malaria. The WHO estimate that there were 13.8 million cases globally in 2015 (3) but others 
have previously put the estimated figure much higher at 132 – 391 million cases/year and 2.6 
billion people at risk of infection (13). Having long been thought of as a ‘benign’ malaria, it has 
more recently been recognised as a cause of significant morbidity with severe and even fatal 
manifestations (22). There were an estimated 1400 – 14,900 deaths due to P. vivax in 2015, 
the vast majority of which occurred outside sub-Saharan Africa (3). 
Control of P. vivax is challenging, with some re-emergence seen in areas where eradication has 
previously been achieved. This is due to multiple factors including relapses, difficulty detecting 
asymptomatic infection, resistance to antimalarials and a lack of understanding of parasite 
biology (23). Recent calls for control and ‘eradication’ of malaria worldwide (24) have focused 
attention on this neglected disease and the need for development of an effective P. vivax 
vaccine to be used alongside current control methods (7, 25). 
1.3.1 The Plasmodium vivax Lifecycle 
The process of parasite invasion from the skin to the liver is the same in P. vivax as for P. 
falciparum. However, not all P. vivax parasites that enter the liver develop into tissue 
schizonts; some develop into hypnozoites, a dormant form of the parasite not seen in P. 
falciparum infections, that can cause relapse of disease weeks to months (or rarely even years) 
later (Figure 1-2).  
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Similar to P. falciparum, after around 7 days the tissue schizont ruptures, releasing merozoites 
into the bloodstream to begin the erythrocytic cycle. Unlike P. falciparum, which invades 
normocytes, P. vivax preferentially invades reticulocytes. This difference is thought to be due 
to the RBP proteins expressed by the vivax parasite. P. vivax was initially thought to express 
two reticulocyte binding proteins, PvRBP1 and PvRBP2 which bind specifically to reticulocytes 
(2). However, since the P. vivax genome sequence became available it has been demonstrated 
that there are in fact many more than two members in the Pvrbp gene family, with 8 genes 
predicted to be protein-coding (2 of these correspond to the genes encoding the originally 
discovered PvRBP1 and PvRBP2 proteins, Pvrbp1a and Pvrbp2c) (26). These proteins only form 
a committed attachment with reticulocytes and not normocytes (2, 16, 18, 27). This preference 
for reticulocytes limits the parasitaemia seen with P. vivax as reticulocytes only make up 1-2% 
of circulating erythrocytes (13). The equivalent family of proteins in P. falciparum is PfRH1-5. 
 
Figure 1-2: Life-cycle of Plasmodium vivax  
(Reprinted from The Lancet Infectious Diseases, Volume 9, Issue 9, Mueller et al., Key gaps in the 
knowledge of Plasmodium vivax, a neglected human malaria parasite., Pages 555–566, Copyright 
(2009), with permission from Elsevier). 
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Invasion of erythrocytes requires the formation of a moving junction between the merozoite 
and erythrocyte, involving direct interaction between apical ligands of the Duffy-binding like 
(DBL) protein family and erythrocyte receptors. The DBL protein in P. vivax is the Duffy-binding 
protein (PvDBP) which is located in the micronemes and released to the merozoite surface, 
along with other ligands, when required for erythrocyte invasion. This delayed release is 
thought to be a mechanism for evading the host immune system (28, 29). The receptor-
binding domain of P. vivax Duffy-binding protein (PvDBP) maps to a conserved cysteine-rich 
region, referred to as region II (PvDBP_RII), and an interaction between this ligand and the 
Duffy antigen receptor for chemokines (DARC) on erythrocytes is required for invasion. DARC is 
a chemokine receptor, also known as Fy glycoprotein or CD234. Individuals lacking the Duffy 
blood group antigen are resistant to blood-stage P. vivax infection. The high levels of Duffy 
blood group negativity in much of sub-Saharan Africa has essentially led to the disappearance 
of P. vivax from most of the continent, and has arisen independently in Papua New Guinea 
(16).  
The formation of the sexual-stages and development within the mosquito in P. vivax is similar 
again to that of P. falciparum, but gametocytes are present earlier in infection, appearing as or 
before clinical symptoms develop (13). This enables transmission to occur before the onset of 
symptoms, and therefore before any treatment is given, which has important implications for 
control and elimination. 
1.3.2 Clinical Manifestations of P. vivax infection 
The majority of P. vivax infections occur in South and South-East Asia, with children under 5 
years of age being the most at-risk group (30). In endemic areas repeated exposure leads to 
the development of immunity, and in these populations asymptomatic infection may occur. 
Natural immunity is a complex process, with humoral immunity playing an important role. 
Binding-inhibitory antibodies to PvDBP_RII have been associated with natural protection 
against P. vivax blood-stage infection (31). There are many other processes linked to infection 
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and disease from P. vivax, however, including strain-specific virulence (22) and differences in 
the Duffy blood-group antigen (Fy). The Duffy blood-group antigen has two distinct alleles 
which result from a single point mutation in the N terminal region, Fya and Fyb. The ancestral 
allele is believed to be Fyb, but the Fya allele looks to be advancing to fixation in many 
populations in Asia. PvDBP_RII binding has been shown to be significantly lower to Fya than 
Fyb, with the Fyb phenotype associated with a higher risk of infection and disease. This is not 
fully understood but may be due to differences in electrostatic charge between the positively 
charged PvDBP_RII and negatively charged N-terminal region of Fy or differences in Fy 
sulfation. PvDBP_RII-specific antibody titres are not significantly different between the 
phenotypes, suggesting that naturally-acquired immunity may be more effective in 
populations where Fya is the predominant allele (32). 
1.3.2.1  Symptoms of P. vivax malaria 
Features of P. vivax malaria include fever (which may be periodical), headache, myalgia, 
gastrointestinal disturbance, abdominal pain and cough. Symptoms alone cannot differentiate 
P. vivax malaria from P. falciparum malaria (33). Most infections are uncomplicated but severe 
disease can occur. Disease severity is assessed using the severity scoring developed by the 
WHO for falciparum malaria (21) as a severity score specific for vivax malaria has not been 
developed but the severe manifestations are similar.  
1.3.2.2  Severe Manifestations and Mortality 
Having long been considered a ‘benign’ malaria, there is increasing evidence that P. vivax 
causes significant morbidity and some mortality. Splenic rupture has long been accepted as a 
complication of vivax malaria (34) but more recently severe manifestations and complications 
have been recognised. Children aged 0-5 years appear to be at highest risk in endemic 
countries, with more cases of severe malaria associated with P. vivax mono-infection than P. 
falciparum mono-infection reported in this age group (35). The most common severe 
manifestation is anaemia, but other severe manifestations including coma, acute respiratory 
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distress syndrome (ARDS), abnormal bleeding, hepatic dysfunction and renal dysfunction are 
reported (22, 35-38).  
Severe malarial anaemia is most profound in young children in endemic regions and the 
mechanisms for this are not fully understood. In Papua New Guinea severe anaemia 
(haemoglobin <5g/dL) has been reported more commonly in children admitted with severe 
vivax malaria than severe falciparum malaria (39). In the study by Kochar et al. in Bikaner, 
India, severe anaemia was seen in 75% of children presenting with severe vivax malaria 
compared with 81% of those presenting with severe falciparum malaria. However, in the 0-5 
years age group, 75% of those severe vivax had severe anaemia whereas this was only the case 
for 26% of those with severe falciparum malaria. Thrombocytopenia is also commonly seen 
and can be severe, with the need for platelet transfusion reported (35).  
Respiratory distress has been reported as more commonly occurring in young children (aged 
less than 2 years) with vivax malaria than falciparum (35, 38), and there have been several 
reports of ARDS secondary to vivax, including fatal cases (22, 33, 36, 40, 41). 
Cerebral malaria (including status epilepticus and coma) is reported in several studies (37, 42), 
although it occurs much less frequently than in falciparum malaria (33) and has a better 
outcome in terms of mortality. 
Mortality from vivax malaria was originally recognised decades ago when P. vivax was used in 
malaria therapy for the treatment of neurosyphilis. It was recognised that certain strains were 
more virulent and had higher mortality rates in these patients. S.F. Kitchen’s description of 
vivax malaria as ‘benign’ in the Boyd malariology text in 1949, which described death due to 
vivax alone as rare, had a substantial impact on the field. The reduction in vivax malaria 
research in the 1950s, which continued until very recently, meant there was little information 
to contradict this belief (22). Several studies have now reported vivax-associated mortality, 
with similar case fatality rates in those presenting to hospital with severe vivax malaria as is 
seen with severe falciparum (35, 38, 43). An autopsy series carried out in Manaus concluded 
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that in 13 of the 17 patients studied, P. vivax was the cause of death or a significant 
contribution to decompensation of a pre-existing condition, leading to death (44).  
Differences in presentation and in the populations most affected by vivax is likely to be due to 
several confounding factors including comorbidities (for example, malnutrition), strain-specific 
virulence, host genetic factors (for example Fyb blood group antigen), parasite resistance to 
antimalarials and differences in the collection and reporting of data.  
1.4.3 Relapse 
Unlike P. falciparum, P. vivax has a dormant liver-stage known as a hypnozoite which enables it 
to relapse and cause multiple episodes of disease following a single infection (45, 46). Relapse 
is a major cause of morbidity, particularly in young children, and contributes significantly to 
on-going vivax transmission. Relapse periodicity is very variable, occurring within weeks 
(particularly in ‘tropical zones’) to several months later in temperate zones. Not all vivax 
infections relapse; relapse is seen in 20-80% of people following primary infection (46, 47).  
Severe malarial anaemia related to vivax infection may be worsened by relapse. There is a 
significant drop in haemoglobin seen with acute vivax infection (48) but relapses occurring 
before the erythrocyte levels have had chance to return to normal can lead to severe, and 
even life-threatening anaemia (49).  
1.4.4 Treatment of P. vivax malaria 
The recommended treatment for uncomplicated vivax malaria is chloroquine, except in areas 
where chloroquine-resistant vivax has been identified, and in this case an artemisinin-based 
combination therapy (ACT) should be used. For severe vivax malaria, as for severe falciparum 
malaria, treatment should be with an injectable artesunate followed by a full course of ACT 
(21). These drugs are active against the blood-stages of vivax infection but not against the 
hypnozoite. 
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Treatment to avoid relapse is limited as primaquine is currently the only licensed drug that is 
active against the hypnozoite. Primaquine is not 100% effective and causes haemolysis in 
individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, so is by no means an 
ideal drug (46). G6PD deficiency is widespread, with an estimated 350 million people thought 
to be affected, many of these living in vivax-endemic regions (50). Recently it has also been 
shown that different genotypes of the cytochrome P450 allele CYP2D6 lead to variations in the 
ability for individuals to metabolise primaquine, with those heterozygous or homozygous for 
the null allele demonstrating reduced metabolism and therefore risk of treatment failure and 
vivax relapse (51). This has obvious implications for the efficacy of primaquine as a drug for 
radical cure of hypnozoites and therefore as a control/elimination mechanism.  
1.5 Naturally-acquired immunity to malaria 
Individuals frequently exposed to malaria do develop natural immunity after a period of time. 
It is for this reason that in endemic settings the mortality rates from malaria are lower after 
the age of five as, for those who have survived repeated infection in early childhood, a level of 
immunity is achieved and they are protected from severe disease and high parasitaemia (52). 
Immunity may also be seen in the form of premunition, where individuals maintain a low-
grade parasitaemia, which is usually asymptomatic, but provides protection against new 
infections (53). The rate of acquisition of immunity is dependent on the level of exposure, i.e. 
in high intensity transmission settings immunity is acquired at an earlier age than in low or 
medium transmission settings. The dominant presentation of severe malaria also differs 
depending on the age of the individual, for example, severe malarial anaemia is more likely in 
young infants whereas the proportion of severe cases manifest by cerebral malaria increases 
with age, indicating that aged-related physiological changes as well as the intensity of 
exposure contribute to the dominant clinical syndromes associated with malaria infection (52). 
Immunity to malaria is compromised in pregnancy (especially in the first pregnancy) and in 
individuals whose frequent exposure to infection ceases (for example, by moving to a non-
endemic area) (53). This has important implications for interventions which reduce malaria 
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exposure as there is the possibility of catastrophic rebound if malaria is reintroduced into a 
population who have lost their naturally-acquired immunity, as was seen in Madagascar in the 
late 1980s following the malaria control campaigns in the 1950s and 1960s which successfully 
removed the Anopheles funestus vector from the central highlands. The vector was gradually 
reintroduced and following population movement there were huge outbreaks of malaria 
leading to an estimated 40,000 deaths in a population which was no longer immune (54). 
The mechanisms of natural immunity are not fully understood. Presumed mechanisms of 
adaptive immunity include antibody responses against the pre-erythrocytic and erythrocytic 
stages to block hepatocyte invasion by sporozoites, block erythrocyte invasion by merozoites, 
prevent binding of infected erythrocytes to the vascular endothelium and contribute to 
inhibition of the development of the sexual-stages. T cells are also thought to play a role in 
inhibiting development of the parasite during the liver stage (CD8+) and in activating 
macrophages (CD4+) to phagocytose blood-stage parasites. More recently, the role of the 
innate immune system has been more closely studied and studies both in malaria naïve 
individuals exposed to P. falciparum malaria in an experimental infection, as well as data from 
populations exposed to repeated malaria infections indicate that innate immune mechanisms 
are triggered by malaria infection and serve to limit the maximum parasite density (55). 
Although multifactorial, it is widely believed that naturally-acquired immunity is primarily 
directed towards blood-stage parasites, and in P. vivax these arise from both primary infection 
and relapses (56). 
Natural immunity to P. vivax malaria is acquired more rapidly than to P. falciparum but is still 
seen to the highest degree in adults in holoendemic areas. The peak of P. vivax disease occurs 
in young infants at 1.0 – 1.9 years old, whereas for P. falciparum it peaks at 2.0 – 3.9 years of 
age and the proportion of P. vivax infections presenting with severe symptoms rapidly declines 
with age; so that by 1 year of age there is a significantly lower incidence of severe illness 
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attributable to P. vivax compared with P. falciparum in children living in areas endemic for 
both infections (56). 
1.6 Vaccine-induced immunity to malaria 
There is currently no licensed vaccine for malaria, and attempts at developing a vaccine have 
been met with many challenges. Only one malaria vaccine candidate, RTS,S, based on the P. 
falciparum circumsporozoite (CS) protein (the major component of the sporozoite coat) has 
reached Phase III efficacy trials to date (57). 
Attempts to develop an effective malaria vaccine have been ongoing for decades. Initial 
experiments in the 1940s in birds exposed to repeated injections of large numbers of 
inactivated sporozoites of the avian malaria P. gallinaceum demonstrated partial efficacy 
against infection with the homologous parasite delivered by mosquito bite (58, 59). In the 
1960s immunisation studies in mice with X-irradiated sporozoites of the rodent parasite P. 
berghei demonstrated that it was possible to achieve sterile protection (i.e. no patent 
parasitaemia as detected by blood film) in some immunised mice (60), supporting the theory 
that a malaria vaccine was possible. Studies by Clyde et al in Maryland, USA in the 1970s 
demonstrated that protective immunity could be induced in humans following exposure to 
large numbers of X-irradiated sporozoites, both for P. falciparum and P. vivax. However, the 
immunity was species-specific and short lived (lasting between 3 – 5 months), and required 
exposure to hundreds of mosquito bites (61-64). 
Since the 1980s malaria vaccine development has focused more on subunit vaccines than 
whole sporozoites vaccination, although more recently this has been re-examined. The 
discovery that cellular immunity had an important role in protection against the liver-stage of 
the parasite led to the development of different vaccination techniques from protein-in-
adjuvant preparations to DNA vaccines and later viral vectors, which induce strong T cell 
responses (65). Most subunit malaria vaccines target a specific stage of the malaria life cycle- 
either the pre-erythrocytic (sporozoites or liver-stage), erythrocytic or sexual-stages as shown 
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in Figure 1-3. The whole sporozoite vaccination techniques for P. falciparum that have been re-
examined are led by two main approaches. The first of these is immunising malaria naïve 
volunteers by exposing them to the bites of infected mosquitoes whilst preventing the 
development of clinical disease by simultaneous chloroquine administration, as demonstrated 
by Sauerwein’s group in Nijmegan (66). The immunity induced by this approach has been 
shown to remain effective over 2 years after immunisation in some volunteers (67). The 
second approach is the use of cryopreserved sporozoites, as developed by Sanaria®, which 
allow administration without the need for mosquitoes. These have been administered as 
aseptic, radiation-attenuated, metabolically active, purified, cryopreserved sporozoites 
(PfSPZ), which showed protective efficacy when administered intravenously (68). 
Administration of viable sporozoites with simultaneous chloroquine prophylaxis (PfSPZ-CVac) 
has been claimed to have high-level protective efficacy with fewer sporozoites required than 
PfSPZ (69), but this is not the case if the sporozoites are inoculated intradermally (70). 
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Figure 1-3: Plasmodium life cycle stages relevant to vaccine design 
(Reprinted from Philosophical Transactions of the Royal Society B under Creative Commons licence 4.0 
https://creativecommons.org/licenses/by/4.0/legalcode) 
 
1.6.1 Pre-erythrocytic vaccines 
Pre-erythrocytic vaccines target sporozoite- and liver-stage parasites. The most widely 
investigated sporozoite target antigen is the CS protein, which has been developed by 
GlaxoSmithKline (GSK) as the RTS,S vaccine in which the CS protein is fused to hepatitis B 
surface antigen (HBsAg) expressed together with unfused HBsAg (71). After expression, the 
hybrid proteins form particles spontaneously, similar to naturally-occurring HBsAg particles 
(72). When given with GSK’s potent Adjuvant System AS01, RTS,S is able to protect healthy 
adult volunteers against malaria infection with a vaccine efficacy of around 50% (73). This 
vaccine has been administered to thousands of children in endemic countries in a Phase III 
trial, and demonstrated only moderate efficacy (57). The thrombospondin-related adhesion 
protein (TRAP) is perhaps the most studied liver-stage antigen. This has been administered to 
Adrian V. S. Hill Phil. Trans. R. Soc. B 2011;366:2806-
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Life cycle of the malaria parasite illustrating the various stages that are relevant to vaccine design. These are (1) the anopheline 
mosquito vector, used in experimental protocols to immunize with irradiated sporozoites administered by mosquito bite; (2) the 
sporozoite, the target of several vaccines, including RTS,S; (3) the liver-stage, usually targeted by vectored vaccines; (4) the blood-
stage, usually targeted by protein in adjuvant vaccine candidates. Merozoite antigens have been most often included in blood-stage 
vaccines; (5) the gametocyte which along with the ookinete, formed after fertilization in the mosquito midgut, is the source of 
parasite antigens used in sexual-stage transmission-blocking vaccines. Pre-erythrocytic vaccines, which target the sporozoite and the 
liver-stage parasite are intended to prevent infection as well as disease while blood-stage vaccines are intended to prevent clinical 
illness and death. 
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healthy volunteers in the viral vectored heterologous prime-boost vaccination regime using 
the chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) ME-TRAP 
(TRAP combined with a multiple epitope string) with a vaccine efficacy of 21% against 
sporozoite controlled human malaria infection (74). It has also been administered to adults 
and children in endemic settings with no safety concerns and some early efficacy noted in a 
trial in Kenyan adults who were monitored for 8 weeks after vaccination (75). 
The only vivax pre-erythrocytic antigen to reach clinical trials has been PvCSP, an antigen 
derived from the P. vivax circumsporozoite protein. Differences in the amino acid composition 
of the circumsporozoite protein divide this P. vivax antigen into two subtypes; the dominant 
VK210 form and the variant VK247 (76). This antigen has been used in several trials, including 
an efficacy trial in which a chimeric protein containing repeat sequences from both subtypes 
was given as a protein-in-adjuvant formulation with the AS01 adjuvant (VMP001/AS01B). This 
vaccine demonstrated no sterile efficacy, but a significant delay in development of patent 
parasitaemia (thick blood film positivity) in vaccinees compared with controls (77). 
1.6.2 Erythrocytic vaccines (blood-stage) 
There has been less progress in the blood-stage malaria vaccine field than in pre-erythrocytic 
vaccines (65). There are many proteins involved in the invasion of erythrocytes by merozoites, 
and the process is not fully understood. The merozoite is committed to invasion following high 
affinity binding interactions between erythrocyte membrane proteins and merozoite adhesins 
such as the the erythrocyte-binding ligand (EBL) and PfRH proteins. In P. falciparum infection, 
invasion is classically divided into two main pathways: sialic acid (SA)-dependent and SA-
independent.  
The antigens involved in SA-dependent invasion include EBA-175, which binds to the 
glycophorin A (GPA) receptor; EBL-1, which binds to the glycophorin B receptor; EBA-140, 
which binds to the glycophorin C receptor as well as EBA-181 and PfRH1, the receptors for 
which have not yet been identified (78). EBA-175 has been assessed in Phase I trials as a 
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protein-in-adjuvant formulation alone and with the blood-stage antigen merozoite surface 
protein 1 (MSP1), but the vaccine has not progressed to Phase II trials to date (79, 80).  
SA-independent invasion pathway antigens include PfRH4, which binds to complement 
receptor 1; PfRH5, which binds to basigin; MTRAP (found on all motile forms of the malaria 
parasite, including merozoites, sporozoites and ookinetes), which binds to semaphorin 7a; 
MSP1, which binds to band 3 and GPA (which, together, represent the most abundantly 
expressed protein within the plasma membrane of the erythrocyte) and, finally, apical 
membrane antigen 1 (AMA1), which binds to the merozoite rhoptry neck (RON) complex 
protein RON2 after it has been inserted into the erythrocyte membrane (78). The most widely 
studied antigens as blood-stage vaccine candidates are MSP1 and AMA1, both of which are 
considered vital for merozoite attachment to the erythrocyte and subsequent invasion, and 
both of which are antibody targets following infection with P. falciparum (81).  
MSP1 has been developed as a vaccine candidate in protein-in-adjuvant formulations as well 
as in viral vectors (82-84). None of the vaccines have demonstrated efficacy in human trials, 
but studies with MSP1 vaccines in Aotus monkeys have shown that sterile protection can be 
achieved after vaccination (85, 86), however, very high antibody titres are required and 
protection is strain-specific (86). This has significant implications for vaccine development as 
the adjuvants available for human use are not able to induce the same level of antibody 
response as adjuvants (such as Freunds) used in preclinical studies. Furthermore, the 
polymorphism of this antigen also has implications, and presumably leads to the strain-
specificity of vaccine efficacy. In one study site in Mali there were 14 haplotypes of the MSP1 
fragment involved in erythrocyte invasion, MSP119, found in 1363 malaria infections, indicating 
that even in one geographical site multiple polymorphisms are present (87).  
P. falciparum AMA1 is a precursor protein of 83 kDa (88) which is synthesised in the late stages 
of schizont development, before the N terminus is cleaved to give a 66 kDa form (89, 90). Prior 
to schizont rupture the 83 kDa AMA1 is located in the apical end of the merozoite in the 
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micronemes, whereas following schizont rupture AMA1 is localised both apically (in the 83 kDa 
form) and on the merozoite surface (in the 66 kDa form) (89). This surface protein binds to the 
rhoptry neck parasite protein, PfRON2, inserted by the parasite into the host red cell 
membrane, thus forming the tight / moving junction. At the merozoite surface further 
proteolytic cleavage occurs, producing two soluble fragments: a 44-kDa molecule and a 48-kDa 
molecule (91). Antibodies to AMA1 have been shown to prevent processing and circum-
merozoite redistribution and shedding of the protein. Without AMA1 undergoing these 
processes red blood cell invasion is inhibited (92). Vaccines against AMA1 have been 
developed using both protein-in-adjuvant and viral vector approaches. A study in Oxford with 
the viral vectored vaccines ChAd63/MVA AMA1 administered alone or with ChAd63/MVA 
MSP1 demonstrated low-level efficacy, but this was likely due to a pre-erythrocytic effect 
rather than efficacy during the blood-stage of infection (83). The leading recombinant protein 
vaccine, known as FMP2.1, was developed by the Walter Reed Army Institute of Research 
(WRAIR) and based upon the 3D7 clone sequence of AMA1 (93). This vaccine was formulated 
in the Adjuvant System AS01 or AS02 from GlaxoSmithKline (GSK) and had previously been 
tested in Phase I/IIa trials in the USA (94, 95) and in field trials in Malian adults and children 
(96, 97). The Phase IIb field trial in 400 Malian children using the FMP2.1/AS02 formulation 
was reported to show 64.3% efficacy (hazard ratio 0.36, 95% CI 0.08-0.86, P=0.03) in a pre-
defined secondary analysis against clinical malaria with 3D7-type parasites (defined by eight 
immunologically important AMA1 polymorphisms in the cluster 1 loop of domain I), although 
the number of cases meeting this definition was small (97, 98). This allele-specific efficacy, 
seen in the first malaria season, did not extend into the second season of follow-up (99). 
P. falciparum reticulocyte-binding protein homologue 5 is expressed in merozoites and 
localises to the apical complex. It is not found in P. vivax parasites but is expressed in all P. 
falciparum strains tested so far. Two reports have demonstrated that the gene is essential for 
parasite survival (i.e. cannot be knocked out) (100, 101). PfRH5 binds to its receptor basigin, 
the Ok blood group antigen, in a complex with two other P. falciparum proteins, PfRh5-
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interacting protein (PfRipr) and cysteine-rich protective antigen (CyRPA). During invasion, the 
three proteins co-localise and the junction formed between the merozoite and red blood cell. 
Binding of the complex to basigin triggers the release of Ca2+ and formation of the tight 
junction (102).  This interaction is essential for red blood cell invasion (103). No vaccines 
against the RH5 protein have previously entered clinical trials, but pre-clinical data have shown 
very promising results with high-level efficacy induced by PfRH5 vaccination against 
heterologous strain challenge in an in vivo Aotus monkey P. falciparum challenge model (104).  
No blood-stage P. vivax vaccines have previously reached clinical trial. The most promising 
antigen currently in clinical development is the Duffy-binding protein. As described above, 
interaction between DARC on the surface of red blood cells and region II of the Duffy-binding 
protein (PvDBP_RII) on the vivax parasite is essential for merozoite invasion of erythrocytes. 
Antibodies induced by a vaccine to this protein should therefore inhibit invasion. This is 
supported by i) the demonstration of naturally-acquired antibodies to this antigen in 
individuals living in vivax-endemic regions which can partially inhibit merozoite invasion in 
short term in vitro culture (105) and ii) the association of natural responses with protection 
against blood-stage P. vivax infection (31). The serological response to PvDBP_RII increases 
with age, which suggests a boosting effect through recurrent infections (106). A recombinant 
PvDBP_RII protein from the Salvador I reference strain has been expressed in E. coli and used 
to immunise Aotus monkeys with Freund’s adjuvant or Montanide ISA 720. This demonstrated 
the induction of high-titre specific antibodies and partial protection against challenge with 
Salvador I strain P. vivax blood-stage parasites, with the demonstration of longer pre-patency 
periods (i.e. before thick blood film positivity) as well as lower parasitaemias in the monkeys 
immunised with recombinant protein in Freund’s adjuvant compared with controls (107). 
There are conflicting arguments regarding the issue of polymorphism. The fact that PvDBP_RII 
is under positive selection has been demonstrated by the fact that most of the polymorphic 
residues in PvDBP are found in region II (28). This effect of immune pressure is also supported 
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by a higher frequency of non-synonymous mutations compared to synonymous mutations, 
suggesting that in populations tested PvDBP is under strong positive selection, and a decline in 
the frequency and diversity of PvDBP_RII haplotypes in blood samples from individuals living in 
an endemic area with increasing age. This was assumed to be due to the development of 
partial immunity to multiple vivax strains in adults, meaning that parasitaemias following 
infections are lower and more rapidly cleared compared with children who have not 
developed any natural immunity. However, this finding may also be due to difficulties in 
detecting variants in blood samples from adults in endemic areas due to the low parasitaemias 
(108). Polymorphism in PvDBP is likely to be a challenge for vaccine development. A study by 
Chootong et al in Thailand demonstrated that naturally-acquired PvDBP_RII antibodies do 
inhibit binding between PvDBP_RII and Duffy-positive erythrocytes, but inhibition activity did 
not correlate with the level of anti-PvDBP_RII responses seen (i.e. some ‘low responders’ 
showed high levels of inhibition whilst ‘high responders’ showed low levels). One explanation 
for this is a strain-specific response (109). However, it is claimed that conservation of the 
contact residues that form the DARC-recognition site would mean that vaccine-induced 
antibodies would provide protection across diverse strains (16). A study using monoclonal 
antibodies generated against PvBDP_RII examined their reactivity to a panel of seven allelic 
variants and showed that some monoclonal antibodies were broadly inhibitory when 
functionally assessed in an erythrocyte binding assay, whereas others were not. This 
demonstrates that a high titre of antibody alone may not be sufficient for protection, but the 
optimisation of antibody specificity is vital (28). Recently the structure of the first inhibitory 
monoclonal antibody (mAb) bound to PvDBP_RII has been identified, along with two other 
inhibitory mAbs against this antigen. These were found to recognise broadly conserved 
epitopes in the DBP sequence and will likely be effective against multiple strains. Using these 
structures, DBP vaccines can be designed to confer strain-transcending protection (110). 
Interestingly, the use of adjuvants which are Toll-like receptor (TLR) 4 agonists (e.g. AS02) has 
been shown to increase the breadth of the antibody response to PvDBP_RII and improve 
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antigen neutralisation when the recombinant protein is formulated with these (111), indicating 
that correct adjuvant choice for a blood-stage protein vaccine is also very important. 
The three blood-stage antigens used in the vaccines described in the trials in this thesis are 
AMA1, RH5 and PvDBP. Unlike AMA1, which does not have a known host receptor, but instead 
binds to the RON complex which is deposited in the erythrocyte by the merozoite (102), the 
receptors for RH5 (basigin) and PvDBP (DARC) are found on the surfaces of many different cells 
throughout the body. This potentially has implications for these vaccines as the antigen could 
potentially bind to cells expressing these receptors. Furthermore, other molecules also bind 
these receptors, for example, IL-8 and melanoma growth stimulating activity (MGSA) 
chemokines which bind DARC. The binding of these chemokines can block the binding of Duffy 
positive erythrocytes to P. vivax DBL domains, demonstrating that these binding sites overlap 
with those of the parasite but also that these chemokines bind competitively (16). Basigin also 
has a large number of molecules which interact with it in its various isoforms in different sites 
in the body (112). Notably, the binding of RH5 to basigin is a low affinity interaction, and easily 
blocked with a low concentration of anti-basigin monoclonal antibodies (103), suggesting RH5 
antigen would unlikely outcompete natural ligands if RH5 protein is administered as a vaccine. 
The competitive binding of other molecules to both of these receptors would perhaps also 
reduce the potential for binding of vaccine antigen. However, the main question arises as to 
what extent vaccine antigen would bind to these receptors in the context of immunisation. In 
the case of vaccines described in this thesis, viral vectored vaccines encoding the PvDBP and 
RH5 antigens are administered intramuscularly and it is therefore unlikely that antigen will be 
distributed widely beyond the draining lymph nodes; as has been demonstrated in mouse 
models comparing vaccination routes with MVA vaccines where intramuscular injection was 
associated with highly localised priming of the immune response (113). Most importantly, the 
immune responses induced by the vaccinations will be targeting parasite antigens rather than 
human receptors, so there should not be a risk in safety in inducing these immune responses, 
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whereas that would obviously not be the case if the responses were directed at widely 
distributed receptors. 
1.6.3 Transmission-blocking vaccines (sexual/mosquito-stages) 
The final class of malaria vaccines in development are the transmission-blocking vaccines 
(TBV). These aim to prevent onward transmission of the disease in endemic communities by 
blocking development of the parasite within the mosquito vector. Low levels of 
polymorphisms are expected in antigens expressed in the sexual- or mosquito-stages given 
they are under low human immune pressure, if any. The aim of a transmission-blocking 
vaccine is in control and elimination of malaria, particularly in areas of low endemicity or 
epidemics (23, 114). This type of vaccine potentially has issues regarding acceptability as it is 
an ‘altruistic’ vaccine. It does not offer direct protection to the individual, but if a community is 
vaccinated with a successful TBV the rates of malaria for that community will fall. These 
vaccines could also be used in combination with a pre-erythrocytic or blood-stage vaccine 
candidate to afford protection to the vaccinated individual as well as preventing transmission 
(115).  
Two transmission-blocking candidate vaccine antigens have reached Phase I clinical trials: P25 
(including the P. falciparum antigen Pfs25 and the equivalent P. vivax antigen, Pvs25) and 
Pfs230. A clinical study of a Pfs230 vaccine is currently being conducted in Mali but no results 
are yet available (NCT02334462). P25 is the most developed candidate in the clinical pipeline 
and the only TBV for which trial results have been published.  
P25 proteins are present on the ookinete surface of all Plasmodium species and are important 
for survival of the parasite within the mosquito midgut. P25 is expressed on the surface of 
Plasmodium gametes from the initiation of emergence through to ookinete invasion of the 
mosquito mid-gut (116). The flat, triangular P25 molecule forms a protective interlocking sheet 
on the surface of the ookinete, along with the Pfs28 protein. Pre-clinical studies have 
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demonstrated that vaccination with both Pfs25 and Pvs25 can produce transmission-blocking 
antibodies (117).  
Both Pfs25 and Pvs25 vaccines have reached Phase I clinical trials. Both antigens were given 
with the adjuvant Montanide ISA 51 but the trial had to be stopped early due to unexpected 
reactogenicity, which was thought to be due to the specific antigen-adjuvant combination 
(118). Another vivax transmission-blocking vaccine, Pvs25H adsorbed onto the adjuvant 
Alhydrogel, also reached Phase I clinical trials. Transmission-blocking activity was assessed by 
the ability of vaccine-induced antibodies to inhibit oocyst development in a mosquito 
membrane feeding assay using P. vivax infected blood from 12 patients. A positive correlation 
between antibody level (as measured by enzyme-linked immunosorbent assay [ELISA]) and the 
number of infected mosquitos was seen, with the five sera with the highest antibody levels at 
day 194 giving a 20-30% reduction in number of infected mosquitos, however transmission-
blocking activity was insufficient for a practical malaria transmission-blocking vaccine (114).  
A Phase Ia study of the Pfs25 antigen fused to a molecular adjuvant IMX313 (a chimeric version 
of the oligomerisation domain from chicken complement inhibitor C4bp) expressed in the 
ChAd63 and MVA viral vectors is currently ongoing in Oxford (NCT02532049). This follows 
promising pre-clinical data showing that vaccination with the Pfs25-IMX313 fusion led to a 10-
fold improvement in antibody immunogenicity as well as significantly better transmission-
blocking activity in a membrane feeding assay (119). Whether this improvement in 
immunogenicity (and efficacy) will be seen following vaccination in humans remains to be 
seen. 
1.7 Immune responses to vaccine adjuvants 
Adjuvants have long been used to increase the adaptive immune response to vaccination, 
particularly for subunit vaccines. Access to effective adjuvants has historically been difficult 
and therefore, one of the main advantages of the viral vectors used in two of the clinical trials 
described in this thesis was that, because they are live viruses, an adjuvant is not required. 
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One of the trials described in this thesis (VAC054; Chapter four) used an adjuvant, namely the 
Adjuvant System AS01, developed by GSK, with a recombinant protein antigen.  
The development of adjuvants has progressed from just aiming to increase the adaptive 
immune response to vaccination to also guide the type of response, thereby producing the 
most effective response for a particular pathogen. This has meant developing adjuvants to 
focus the response produced, e.g. inducing a T helper 1 (Th1) skewed response versus Th2 
cells; increasing memory cell generation; inducing a more rapid initial response and altering 
the breadth, affinity or specificity of the response (120). Developing improved adjuvants, 
especially for more challenging pathogens such as malaria, has meant recognising that a 
broader response than merely inducing antibodies is likely to be required, including cell 
mediated immunity with activated CD4+ and CD8+ T cells. Cytokines secreted by CD4+ T cells 
are able to activate macrophages as well as assisting the development of high-affinity 
antibodies and memory B cells by antibody-producing cells (121). Viral vectors are particularly 
effective at inducing a T cell response, and due to their direct infection of cells and the 
endogenous MHC class I antigen presentation pathway, are able to induce CD8+ T cell 
immunity directly. Protein vaccines however are exogenous and therefore require formulation 
with an adjuvant which facilitates entry into the MHC class I processing pathway, triggers 
activation of dendritic cells and the production of interferon (120). 
Adjuvants interact with the innate immune system initially, and through mimicking some 
aspects of the natural response to pathogens, can be used to tailor the adaptive response in 
order to maximise vaccine efficacy (121). The AS01 adjuvant used in VAC054 is liposome-based 
and contains 3-0-desacyl-4’ monophosphoryl lipid A (MPL), derived from the cell wall 
lipopolysaccharide of the Gram negative Salmonella minnesota R595 strain and QS21, a 
triterpene glycoside purified from the bark of the South American tree Quillaja saponaria 
(122).  
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MPL stimulates the activation of the innate immune system via Toll-like receptor 4 (TLR4), 
directly activating antigen-presenting cells (APCs) which express this receptor. This occurs 
through activation of NF-κB transcriptional activity and subsequent proinflammatory cytokine 
expression (e.g. TNF-α and IL-6) (123). The immune response to MPL has been found to be 
skewed towards a Th1 profile (required for protection against intracellular pathogens), with 
the promotion of IFN-γ production by Ag-specific CD4+ T cells (123, 124). Use of MPL in 
vaccines has been shown to typically boost serum antibody titres 10 to 20-fold compared with 
vaccine alone (125). QS21 stimulates CD8+ T cells and promotes antigen-specific antibody 
production, although the signalling pathways are not fully understood (121). 
Studies in mice have demonstrated that following intramuscular injection of AS01 cytokine 
levels increase in the muscle within 3 hours, suggesting production by local cells, including 
stromal cells. The antigen and adjuvant were cleared rapidly from the muscle, excluding a local 
depot effect that has been demonstrated with other adjuvants. The production of cytokines 
leads to the recruitment of neutrophils and monocytes to the muscles. Simultaneously, 
adjuvant and antigen are rapidly transported to the draining lymph nodes. There is an influx of 
neutrophils, monocytes, dendritic cells and T cell populations into the lymph node (121). The 
immune responses at the injection site following vaccination with the AS01 adjuvant are 
demonstrated in Figure 1-4. During migration to draining lymph nodes, dendritic cells recruited 
at the vaccination site present antigens and mature into efficient APCs. Within the lymph 
node, AS01 and antigen may activate resident dendritic cells and the activated dendritic cells 
go on to activate T cells which then differentiate into effector populations and later, into 
memory cells. CD4+ T cells secrete cytokines which stimulate antigen-specific B cells to divide 
into antibody-secreting cells and memory B cells. Memory cells and effector cells will 
ultimately enter the bloodstream from the lymph nodes (121).  
The differences between AS01 and other adjuvants include: a lack of depot effect; increased 
populations of activated APCs and a higher antigen-specific response with a synergistic effect 
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of MPL and QS21. The response is also directed towards a predominantly IFN-driven pathway, 
which is thought to contribute towards a stronger cellular immune response and promote 
antibody isotype switching (121).  
 
Figure 1-4: Immune responses following intramuscular vaccination with AS01-adjuvanted 
vaccine at the injection site. 
The immune response to an AS01-adjuvanted vaccine injected into a muscle involves multiple cellular 
interactions. The adjuvant effect requires the spatial and temporal co-localization of AS01 and antigen. 
The two immune-stimulatory components of AS01, MPL and QS-21, act synergistically together to 
stimulate the release of immune mediators by innate cells allowing an enhanced neutrophil and 
monocyte recruitment at the injection site. The AS01-adjuvanted vaccine induces an early and transient 
activation of the innate immune response. Cellular and cytokine responses peak at day 1 and are fully 
resolved by day 7 (121).  
(Reprinted from Expert Review of Vaccines, DOI: 10.1080/14760584.2016.1213632, Didierlaurent et al, 
with permission from Taylor and Francis) 
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1.8 Methods for investigating immune responses to vaccination 
Vaccines aim to induce a targeted immune response against the pathogen of interest. For most 
vaccines this equates to inducing a specific antibody response against the antigen or antigens 
in the vaccine. Antibodies are a particularly important immune mechanism for extracellular 
pathogens, but intracellular pathogens are better targeted by activated T cells. The most 
successful malaria vaccine to date, RTS,S, demonstrated that the main correlate of protection 
was a high antibody titre against the circumsporozoite protein, although low levels of induced 
CD4+ T cells may also contribute to vaccine efficacy (126-128). 
Measurement of vaccine-induced antibody can be done ELISA, which measures the presence 
of antigen-specific antibody in serum from a vaccinated or exposed individual. Antibody levels 
following ChAd63/MVA viral vectored vaccines typically peak around 4 weeks after the MVA 
boost vaccination (129). Protein-in-adjuvant vaccines are typically given in three doses 4 weeks 
apart, with the peak response seen 2 – 4 weeks after the final vaccination. This assay allows 
quantification of the antibody response by determining the antibody level as a µg/mL 
measure, although this requires conversion either by calibration free concentration analysis 
(CFCA) of antigen-specific antibody or by affinity purification of antigen-specific IgG (130). 
ELISAs can also be carried out to evaluate the avidity of the antibodies induced by vaccination, 
which gives an indication of antibody quality, and to assess the isotypes of the antibodies. 
Functional assays can be carried out to evaluate antibodies induced by vaccination using in 
vitro techniques. An example of this type of assay in P. vivax is the DARC binding inhibition 
assay, which measures functional binding of P. vivax Duffy-binding protein region II (PvDBP – 
the vaccine antigen) to the Duffy antigen receptor for chemokines. The presence of functional 
anti-PvDBP antibodies results in a relative level of percentage binding inhibition (16). In P. 
falciparum malaria, the growth inhibition activity (GIA) assay is used to assess antibody 
function. This involves adding purified IgG from vaccinated (or naturally immune) volunteers to 
a culture of parasitised human erythrocytes and measuring subsequent parasite growth after 
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40 hours of culture using a biochemical assay specific for parasite lactate dehydrogenase 
(LDH). Results are then compared with results obtained from parasites incubated with a pool 
of malaria-naïve human serum (control) and with uninfected erythrocytes (131). Antibodies 
with functional activity against blood-stage malaria will inhibit growth of P. falciparum in 
culture, and this has been found to correlate with the antibody level induced by vaccination 
(130). This assay cannot be used to assess the functional activity of P. vivax blood-stage 
vaccine candidates as the parasite does not survive long-term culture, but an ex vivo invasion 
inhibition assay has been developed for use in endemic countries (as it requires access to 
clinical isolates of P. vivax) which has demonstrated that a monoclonal antibody against DARC 
is able to almost completely inhibit invasion and provides a potential method for assessing 
antibodies induced by vaccination (132). 
Cell-mediated vaccine-induced immune responses can be measured by the production of 
interferon gamma (IFN-γ) by antigen-specific T cells. This is done using the ex-vivo IFN-γ 
enzyme-linked immunospot (ELISPOT). This assay allows enumeration of T cells and detection 
of individual IFN-γ-secreting cells from stimulated human peripheral blood lymphocytes (133). 
T cell responses typically peak 2 weeks after vaccination with a simian adenoviral vectored 
vaccine and a week after MVA boost. Protein-in-adjuvant vaccines typically do not induce a 
marked T cell response, but the AS01 adjuvant developed by GSK has been designed with a 
specific aim to improve cell-mediated immunity (122). 
1.9 Methods for evaluating malaria vaccine efficacy 
Whilst the in vitro methods described above give some information about the functional 
activity of antibodies induced by vaccination, this does not necessarily translate to vaccine 
efficacy. Animal models have been used for many years to study the mechanisms of 
Plasmodium infection, immunity against the parasite and in the development of vaccines 
(which first began in the 1940s) (58, 59) and antimalarial drugs. The most widely used model is 
the murine model in which mice can be infected with one of four rodent malaria species (P. 
50 
 
berghei, P. chabaudi, P. vinckei, or P. yoelii) or, more recently, with P. falciparum malaria in 
Severe Combined Immunodeficiency (SCID) mice receiving continuous injection of human 
erythrocytes (134). The mouse model has been very useful in furthering understanding of the 
malaria parasite(s), but there are limitations in the comparisons that can be made between 
murine and human malaria. Non-human primate models have also been used, with various 
primate malarias providing useful models for studying syndromes seen with human malaria- 
for example, P. cynomolgi which is very similar to P. vivax (135). Whilst these models provide 
key pre-clinical data for vaccine development, an effective vaccine in an animal model often 
does not translate into an effective human vaccine, necessitating human trials to assess 
efficacy. 
The traditional method for assessing vaccine efficacy is to vaccinate a population at risk of the 
disease and compare the outcome to unvaccinated controls in Phase II or Phase III efficacy 
trials. These trials typically require large numbers of participants and there are many 
unpredictable and confounding factors such as differences in annual rainfall and co-infections 
with other pathogens. The only malaria vaccine to have reached Phase III trials to date is the 
RTS,S vaccine developed by GSK. The efficacy of this vaccine was assessed in over 15,000 
children at eleven centres in seven sub-Saharan African countries with moderate efficacy 
which waned during the follow-up period (57). These types of study obviously involve huge 
cost and logistics, and therefore it is prudent only to take forward vaccines which have shown 
promise at an earlier phase into these large studies. 
For many years the malaria field has used the controlled human malaria infection (CHMI) 
model to enable small proof-of-concept efficacy studies to take place in non-endemic settings 
and allow early indications of vaccine efficacy. These studies have several advantages over the 
traditional field efficacy trials as they require much smaller numbers of participants, can be 
conducted in non-endemic settings in a controlled environment, allow specific strains of 
malaria to be assessed and are not subject to the unpredictability of seasonal malaria 
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outbreaks. The CHMI model has particularly been used for P. falciparum studies, but several P. 
vivax CHMI studies have also now been carried out (77, 136, 137). There are several methods 
for CHMI, including via mosquito bite (11, 83, 95, 138), via injection of cryopreserved 
sporozoites (139) and by intravenous injection of parasitised red blood cells (11, 140, 141).  
CHMI vaccine efficacy studies involve deliberately infecting volunteers vaccinated with the 
candidate vaccine alongside unvaccinated infectivity controls and monitoring them for 
development of clinical malaria. Patent parasitaemia is either diagnosed by thick blood film or 
when a predetermined threshold is reached on parasite level detected by quantitative 
polymerase chain reaction (qPCR). Treatment is commenced either at the point of diagnosis or 
at the end of the follow-up period if the volunteer has been protected from malaria. This 
method of assessing vaccine (or drug) efficacy is used in several centres around the world and 
has been found to be a safe and useful tool for early vaccine efficacy assessment. The ease 
with which the infection can be diagnosed, as well as its well-known time course and the 
availability of completely effective treatment mean that this mechanism for studying malaria 
has been accepted. These studies are obviously still subject to limitations from both an ethical 
point of view (using as few volunteers as possible to answer the study question) and a logistical 
point of view given the close follow-up of volunteers that is required after infection. 
1.10 Development of viral vectored malaria vaccines 
Development of effective malaria vaccines is difficult for many reasons. Immunity to malaria is 
complex and not fully understood, and vaccines have struggled to elicit adequate levels of 
protective antibody or a broad enough response. Protein vaccines have been the most 
commonly developed vaccines. Proteins have to be given with a potent adjuvant in order for 
them to achieve adequate immunogenicity. Access to adjuvants is limited and combination 
with an adjuvant may produce unacceptable side effects. Protein vaccines also have other 
drawbacks. Producing conformationally correct proteins to Good Manufacturing Practice 
(GMP) standard can be difficult, as has been seen with production of the PvDBP_RII protein 
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(Chetan Chitnis, International Centre for Genetic Engineering and Biotechnology, India; 
personal communication).  
For some years viral vectors have been being developed as an alternative method of 
vaccination to bypass some of these issues. The viruses encode malaria antigens of interest 
that are then expressed when the viruses are taken up in the body. Viral vectored vaccines 
have been used in a wide range of pathogens including respiratory syncytial virus (RSV) (142), 
human immunodeficiency virus (HIV) (143, 144), malaria (84, 145-148), tuberculosis (149), 
Hepatitis C (150), influenza (151, 152), Ebola (153). and human papilloma virus (HPV) (154) The 
simian adenovirus ChAd63 and MVA vectors have been used in previous vaccine trials in 
Oxford encoding the P. falciparum malaria antigens ME-TRAP, AMA1, MSP1 and CS (83, 84, 
129, 138, 155). The viral vectors are unable to replicate in human cells but are able to produce 
strong antigen-specific antibody and T cell responses following heterologous prime-boost 
vaccination (83, 84, 129, 148). Viral vectors had not previously been used in clinical trials of P. 
vivax vaccines but have been shown to be immunogenic in pre-clinical models (156, 157). Viral 
vectored vaccines have also been developed for the P. falciparum antigen RH5, which have 
been shown to be immunogenic in pre-clinical studies, with efficacy against blood-stage CHMI 
in Aotus monkeys (104, 158). 
1.10.1 The ChAd63 Viral Vector 
ChAd63 is a simian adenovirus. These adenoviruses exhibit hexon structures homologous to 
human adenoviruses and are not known to cause pathological illness in humans. Hexons are 
the major capsid proteins in adenoviruses; they are potently immunogenic and the main target 
of neutralising antibodies. Simian adenoviruses have been developed as viral vectors following 
concerns that pre-existing immunity to human adenoviral serotypes could limit future 
widespread use of these viruses (159). Low titres of neutralising antibodies to chimpanzee 
adenoviruses are found in less than 5% of humans in the US (160). The essential E1 gene 
region of the virus has been deleted so the ChAd63 vaccine vector is replication-deficient. The 
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virus cannot propagate in human cells within the body as it requires cells expressing E1 gene 
products. The E3 locus is additionally deleted, and the E4orf6 region has been replaced with 
that from AdHu5. These measures prevent homologous recombination with the E1 gene from 
the producer cell line and subsequent production of replication competent virus, and improve 
the yield of the ChAd63 virus during production. 
The ChAd63 viral vector encoding various malaria antigens, including ME-TRAP, AMA1, MSP1 
and CS has been administered to over 1000 individuals through studies conducted by the 
Jenner Institute in the UK and Africa. There have been no significant safety concerns relating to 
these vaccines. ChAd63 vaccine doses are measured in viral particles (vp). Doses of up to 2 x 
1011 vp have been safely administered to healthy UK adults. 
1.10.2 The MVA Viral Vector 
MVA is a highly attenuated poxviral vector and as such, is unable to replicate efficiently in 
human and most other mammalian cells (161). The vector’s viral and recombinant gene 
expression is unimpaired as the replication defect occurs at a late stage of virion assembly 
(162). The MVA vector was attenuated by continually passaging the chorioallantois vaccinia 
Ankara (CVA) strain on chicken embryo fibroblast cells over 570 times, resulting in six deletions 
in the CVA genome and multiple mutations (163, 164). MVA was licensed for use in Germany 
in 1977 and administered to over 120,000 individuals as a pre-vaccine before the second 
traditional smallpox vaccination was administered. Pre-vaccination with MVA led to lower 
reactogenicity following the smallpox vaccine (163). 
MVA-based vaccine constructs have now been developed for use in studies of a wide range of 
infections including HIV (143, 144), malaria (83, 84, 129, 145, 148), Hepatitis C (150), 
tuberculosis (149) and Ebola (153). These studies have demonstrated that the vector is safe 
and immunogenic and, despite being highly attenuated, induces strong cellular immune 
responses (165). Previous vaccine regimes using MVA boost following an adenovirus prime 
have shown significant boosting of the cellular and humoral immune responses against the 
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encoded transgene in clinical studies (83, 84, 129). MVA vaccine doses are measured in 
plaque-forming units (pfu). 
1.11 Hypothesis and aim of work 
The hypothesis relating to work in this thesis is that blood-stage Plasmodium falciparum and 
Plasmodium vivax vaccines can be developed by targeting antigens which the parasites require 
in order to invade human red blood cells. 
The aim of this work is to evaluate three candidate malaria vaccines, one P. vivax vaccine and 
two P. falciparum vaccines, in three clinical trials. Two of these trials (VAC051 and VAC057) will 
be Phase Ia first-in-human studies assessing the safety and immunogenicity of the vaccines in 
healthy volunteers. The vaccines in both of these studies are based on the ChAd63 and MVA 
viral vectors encoding a blood-stage malaria antigen.  
Chapter three describes a Phase Ia trial (VAC051) of ChAd63 and MVA encoding the PvDBP 
transgene for the P. vivax vaccine. The hypothesis for this vaccination regime is that the 
vaccine will be safe and antibodies induced by vaccination will have activity against P. vivax 
Duffy-binding protein, as assessed in a functional assay examining binding between DBP and 
its receptor, DARC. 
Chapter four examines a vaccine which has previously demonstrated evidence of some strain-
specific efficacy in a field trial but not against CHMI. This study will assess the safety, 
immunogenicity and efficacy of the P. falciparum candidate blood-stage vaccine FMP2.1/AS01. 
Efficacy will be assessed using blood-stage CHMI with a malaria strain homologous to the 
vaccine strain. The hypothesis is that the parasite multiplication rate (PMR) in vaccinated 
volunteers will be lower than in unvaccinated infectivity controls due to the vaccine-induced 
immune response to the P. falciparum antigen AMA1. 
Chapter five describes the Phase Ia trial (VAC057) of the ChAd63 and MVA vectors encoding 
the RH5 transgene for a P. falciparum vaccine. The hypothesis for this trial is that the 
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ChAd63/MVA RH5 vaccination regime will be safe and immunogenic in healthy volunteers, and 
induce functional antibodies which are able to inhibit parasite growth in vitro. 
1.12 Authorship statement  
The work presented in this Thesis relating to the clinical trials described in Chapters three to 
five is part of a collaborative effort. Unless otherwise stated, I undertook the work described. 
The conduct of the trials was greatly assisted by the Jenner Institute Clinical Trials team, 
including Alison Lawrie, Rachel Roberts, Ian Poulton, Natalie Lella, Mary Smith, Raquel Lopez 
Ramon, Oliver Griffiths, Megan Baker, Celia Mitton, Paula Marriott, Charlotte Tyson, Emma 
Bakpa, Tommy Rampling, Navin Venkatraman and Morven Wilkie. The VAC054 trial (Chapter 
four) was also conducted at sites in London (Imperial NIHR/ Wellcome Trust Clinical Research 
Facility [WTCRF]) and Southampton (NIHR WTCRF). VAC057 (Chapter five) was also conducted 
in Southampton. I am very grateful to all staff involved in the study teams at both sites for 
their help in recruiting and following-up participants for these studies. All trials were 
sponsored by the University of Oxford, and Professor Adrian Hill was Chief Investigator. 
Sarah Silk, Sean Elias and Kathryn Milne processed and stored samples for immunological 
analyses (Chapters three to five) and Nick Edwards performed the qPCR (Chapter four). 
Rebecca Brown and Simon Draper prepared the blood-stage inoculum for blood-stage CHMI 
(Chapter four). Simon Draper and Alexander Douglas assisted with the parasite modelling 
(Chapter four).  
Blood samples for haematology, biochemistry and serology (for Epstein Barr virus [EBV], 
cytomegalovirus [CMV], HIV, Hepatitis B and C) were processed at the Oxford University 
Hospitals’ NHS Foundation Trust laboratories, Oxford (Chapters three to five), at the University 
Hospital Southampton NHS Foundation Trust laboratories, Southampton (Chapters four and 
five) and at Imperial College Healthcare NHS Trust laboratories, London (Chapter four). 
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Chapter two: 
Materials and Methods 
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2.1 Materials 
2.1.1 Vaccines 
2.1.1.1  ChAd63 PvDBP 
ChAd63 is a replication-deficient simian adenovirus, as described in Section 1.9.1. ChAd63 
PvDBP expresses the Plasmodium vivax antigen PvDBP, which is a synthetic gene insert 
encoding the conserved, cysteine-rich Region II of the P. vivax Duffy-binding protein. The 
sequence in the vaccines is based on the Salvador I (SalI) strain of P. vivax, amino acids (αα) 
194–521. The PvDBP_RII sequence was fused with the human tissue plasminogen activator 
(tPA) secretory leader sequence and the transgene is driven by a CMV promoter (157). tPA 
ensures the PvDBP_RII antigen is secreted from the immunised (virally infected) cell. In the 
vast majority of cases P. vivax requires interaction between the Duffy-binding protein and 
DARC in order to invade red blood cells. 
ChAd63 PvDBP was manufactured under GMP conditions by the Clinical Biomanufacturing 
Facility (CBF), University of Oxford, and supplied as a liquid in sterile aliquots in 2.0 mL clear 
glass vials. ChAd63 PvDBP was supplied to the clinical site by the CBF having been labelled for 
investigational use only. The vaccine was stored in a locked, temperature controlled freezer 
between -70⁰C and -90⁰C, and all movements/ administration of the vaccine were recorded in 
an accountability log. 
2.1.1.2  MVA PvDBP 
MVA is a highly attenuated vector that is unable to replicate efficiently in human and most 
other mammalian cells, as described in Section 1.9.2 (161). MVA PvDBP is a recombinant MVA 
expressing the P. vivax antigen PvDBP. The insert is the same as that used in the ChAd63 
PvDBP vaccine. 
MVA PvDBP was manufactured under GMP conditions by IDT, Germany and supplied as a 
liquid formulation in Tris buffer. The virus suspension was supplied as sterile aliquots in 2.0 mL 
clear glass vials. Final batch certification and associated labelling took place at the CBF. The 
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vaccine was stored in a locked, temperature controlled freezer between -70⁰C and -90⁰C, and 
all movements/ administration of the vaccine were recorded in an accountability log. 
2.1.1.3  FMP2.1/AS01B 
The vaccine FMP2.1 is a recombinant protein of the Plasmodium falciparum 3D7 clone of 
AMA1. It was produced under GMP at the WRAIR BioProduction Facility. FMP2.1 is a 
lyophilised preparation of the majority of the ectodomain of P. falciparum AMA1. The gene 
encoding the FMP2.1 protein was chemically synthesized to contain an E. coli-optimized codon 
usage to encode 478 amino acids representative of amino acids 83 to 531 of the AMA1 protein 
with two attached His-tags. The amino acid sequence is: MAHHHHHHPGGSGSGTMH-[AMA1 
amino acids 83 to 531]-AAALEHHHHHH. 449 of the amino acids are derived from the merozoite 
protein AMA1 of the 3D7 clone of P. falciparum. The protein is produced in and purified from 
E. coli bacteria (93, 95, 97). The vaccine was administered with AS01B, a liposome-based 
Adjuvant System developed by GlaxoSmithKline (GSK) (122). Mixing of the vaccine and AS01B 
took place immediately before vaccination. 
The vaccine and adjuvant were labelled and released for investigational use only in trial 
VAC054 by the CBF, and then transferred to the clinical sites. Both the vaccine and adjuvant 
were stored between +2 and +8°C in a locked fridge. 
Further details about the vaccine and adjuvant can be found in Chapter four. 
2.1.1.4  ChAd63 RH5 
ChAd63 RH5 is a recombinant replication-defective chimpanzee adenovirus expressing the 
Plasmodium falciparum antigen RH5; a synthetic gene insert encoding the reticulocyte-binding 
protein homologue 5 (PfRH5) which is one of the reticulocyte binding-like (RBL or P. falciparum 
RBP homologue (PfRH)) proteins which are involved in parasite invasion of red blood cells. 
PfRH5 is expressed in all P. falciparum strains tested so far, and is essential for parasite survival 
given two reports that the gene cannot be knocked out (100, 101). PfRH5 binds to its receptor 
basigin, the Ok blood group antigen, and this interaction mediates an essential interaction 
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required for red blood cell invasion by all tested strains of P. falciparum (103). A full-length 
PfRH5 transgene based on the 3D7 clone of P. falciparum was used in the ChAd63 RH5 vaccine 
(104). Similar to the ChAd63 PvDBP vaccine described above, the antigen was fused with the 
tPA secretory leader sequence and the transgene is driven by a CMV promoter. 
ChAd63 RH5 was manufactured under Good Manufacturing Practice (GMP) conditions by 
ADVENT S.r.l. (GSK) and supplied as a liquid in sterile aliquots in 2.0 mL clear glass vials. Final 
batch certification and associated labelling took place at the CBF before transfer to the clinical 
sites. The vaccine was stored in a locked, temperature controlled freezer between -70⁰C and -
90⁰C, and all movements/ administration of the vaccine were recorded in an accountability 
log. 
2.1.1.5  MVA RH5 
MVA RH5 is a recombinant MVA expressing the P. falciparum antigen PfRH5. MVA RH5 used 
the same vector described above for MVA PvDBP and the same antigen insert as ChAd63 RH5. 
MVA RH5 was manufactured under GMP conditions by IDT, Germany and supplied as a liquid 
formulation in Tris buffer. The virus suspension is supplied as sterile aliquots in 2.0 mL clear 
glass vials. Final batch certification and associated labelling took place at the CBF before 
transfer to the clinical sites. The vaccine was stored in a locked, temperature controlled freezer 
between -70⁰C and -90⁰C, and all movements/ administration of the vaccine were recorded in 
an accountability log. 
2.1.2 Plasmodium falciparum Controlled Human Malaria Infection Inoculum 
The infectious inoculum for the CHMI study (VAC054; Chapter four) was produced by Drs 
Gregor Lawrence, Allan Saul and colleagues at the Queensland Institute of Medical Research 
(QIMR) in Brisbane, Australia in 1994 (166). The protocol for the study was reviewed and 
approved by the QIMR Ethics Committee and the Healthy Volunteer Studies Research Ethics 
Subcommittee, Lothian Health Board (Edinburgh). Procedures were designed to minimise the 
risk of other infectious agents in the cryopreserved samples. 
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Laboratory-reared Anopheles stephensi mosquitoes were infected with the P. falciparum clone 
3D7 (a chloroquine-sensitive strain) by membrane feeding on a blood meal containing 
gametocytes. Ten and fourteen days later, the mosquitoes were fed on two volunteers. 
Parasitaemia in the volunteers was followed by daily microscopy from day 4 after infection. 
Blood was taken from the volunteers 6 hours after they developed fever, when both were 
microscopically parasite positive. The volunteers were treated with chloroquine soon after 
blood was drawn with complete recovery. 
Initial development of the blood inoculum used in VAC054 is described by Cheng et al. 1997 
(166). The inoculum used for all volunteers comes from one of the donors described above. 
This is because the second donor (whose blood has not been used) had a much lower 
parasitaemia (140).Blood was collected at the Australian Red Cross Blood Bank in an aseptic 
manner using standard blood bank equipment. The leukocytes were removed with a leukocytic 
filter. The thawing and washing of the cells reduced the amount of serum transferred with the 
red cells by a factor of 1000, compared to injecting the same volume of blood. The volume of 
inoculum to be given to each volunteer contains a very small volume of red blood cells, 
equivalent to only 1.5 to 4 microlitres of blood.  
The red cells were cryopreserved using a protocol from the American Association of Blood 
Banks Technical Manual that is normally employed for freezing blood from patients and donors 
with rare blood groups. Blood from both volunteers was group O and Rhesus negative (166).  
The P. falciparum CHMI inoculum is stored cryopreserved in vapour phase liquid nitrogen at -
178⁰C (-160⁰C to -196oC) at Fisher BioSciences in Herefordshire, UK, in compliance with the 
requirements of ISO 9001:2015. The inoculum has been temperature monitored throughout 
the long term storage at this facility. 
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2.1.3 Buffers and solutions 
LymphoprepTM: ready-made, sterile and endotoxin tested solution for isolation of pure 
lymphocyte suspensions (Axis Shield 1114545). 
R0: Cell culture media consisting of 500mL RPMI (Sigma R0883) with 5 mL Pen/strep (0.1 
mg/mL) (Gibco BRL/Invitrogen 15140-122) and 5mL L-glutamine (4mM) (Gibco 25030-24). 
R10: Cell culture media consisting of 500mL RPMI (Sigma R0883) with 5mL Pen/strep (0.1 
mg/mL) (Gibco BRL/Invitrogen 15140-122), 5mL L-glutamine (4mM) (Gibco 25030-24) and 
50mL heat-inactivated, filtered standard foetal calf serum (FCS) (Biosera S1810). 
Red blood cell (RBC) lysis solution: (Qiagen 158902/4). 
Phosphate buffered saline (PBS): 0.01 M (Sigma P3813): NaCl 0.138 M; KCl - 0.0027 M, pH 7.4. 
Sachets reconstituted in distilled or deionised water. 
PBS/Tween: PBS (Gibco 21600-069) 0.01M Tween 0.05%: made by dissolving sachets in dH2O. 
Dimethyl sulfoxide (DMSO): sterile filtered and endotoxin tested (Sigma D2650). 
Staphylococcal enterotoxin B (SEB): Superantigen consisting of a single polypeptide chain 
containing 239 amino acids which induces apoptosis in T cells (Sigma S4881). 
StartingBlockTM T20 Solution: T20 in PBS blocking buffer (Fisher 10270404). 
Development Buffer (DB): 4-Nitrophenylphosphate tablets (Sigma N2765) dissolved in 
diethanolamine buffer (Fisher 34064) to give final concentration of 1mg/ml. 
Casein: blocking buffer (ThermoFisher 37528). 
DPBS: Dulbecco’s phosphate buffered saline (Sigma D8537). 
NaSCN: Sodium thiocyanate (Sigma 251410). 
Extravidin-AP: Extravidin-alkaline phosphatase buffered aqueous solution in 0.05 M Tris-HCl 
buffer, pH 8.0, containing 1 mM MgCl2, 1% bovine serum albumin and 15 mM sodium azide 
(Sigma E2636). 
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BCIP/NBT: 5-bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazolium plus solution – 
ELISPOT developing buffer (Europa bioproducts Ltd M0711A-1000). 
Diphtheria toxoid: diluted in PBS to 10 µg/mL (NIBSC 02/176) 
SAC: Staphylococcus aureus Cowans Strain (Calbiochem 507858). 
CpG-2006: 0.2mg/mL (TCG-TCG-TTT-TGT-CGT-TTT-GTC-GTT) (Invivogen) 
PWM: Pokeweed mitogen made up to 1 mg/mL stock (Sigma L-9379) 
2.1.4 Recombinant proteins 
Recombinant PvDBP_RII protein was produced at the Jenner Institute in the Drosophila S2 
expression system (Expres2ion). Recombinant DARC (His-tagged) was produced at the Jenner 
Institute. Recombinant PfAMA1 was produced at the Jenner Institute in HEK293 cells (3D7 
clone) (167) and provided by an external collaborator, Dr Mike Blackman (NIMR, London, UK) 
(FVO clone). Recombinant PfMSP119-GST fusion proteins were produced in E. coli (168) and 
purified by affinity chromatography according to Jenner Protocol J136. Recombinant PfRH5 
was produced at the Jenner Institute in Drosophila S2 cells (169). These recombinant proteins 
were used for secondary assays described below. 
2.2 Methods: Study preparation, participant enrolment and 
safety analysis  
For each trial I prepared the study documents which were then reviewed and approved by the 
Sponsor (Clinical Trials Research Governance department, CTRG, University of Oxford). 
Following Sponsor approval, each trial was submitted for ethical approval to the National 
Research Ethics Service (NRES) Oxford A ethics committee and to the Medicines and 
Healthcare products Regulatory Agency (MHRA). For VAC054 (Chapter four) and VAC057 
(Chapter five) approval from the Research and Development departments at the NHS 
collaborating sites was applied for and gained prior to starting the trials at these sites. The 
VAC054 trial also underwent ethical review by the Western Institutional Review Board (WIRB) 
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in the USA as a condition of funding (the trial was funded by USAID). The VAC051 (Chapter 
three) and VAC057 trials also received approval by the Genetic Modification Safety Committee, 
Oxford University Hospitals NHS Trust to use the viral vectored vaccines as a Class I activity 
under the Genetically Modified (Contained Use) Regulations 2000.  
The Chief Investigator for all trials was Professor Adrian Hill, but the conduct of the trials was 
delegated to me as lead clinician. All trials were monitored to ensure the rights and wellbeing 
of human subjects were protected and that the conduct of the study was in compliance with 
the protocol, regulatory and ICH GCP requirements. All monitoring for these studies was 
carried out by CTRG. 
Study-specific methods, such as study design, approvals and inclusion/exclusion criteria are 
described in the Chapters relating to each trial (see Chapters three to five). 
2.2.1 Recruitment of volunteers 
Healthy volunteers were recruited to the studies by various means. Advertising was carried out 
with posters approved by the Oxford ethics committee in public places and in 
newspapers/advertising leaflets. There are healthy volunteer databases at the sites used in 
Oxford, Southampton and London through which some volunteers were contacted. The 
department has a website through which information about the trials and contact details for 
arranging a screening visit can be found. Social networking sites (Facebook and Twitter) were 
also used to inform potential participants about the trials. Recruitment of volunteers was 
coordinated in Oxford and London by the Recruitment Coordinator (Sam French and Natalie 
Lella) and in Southampton by their local study team. Once interest in a trial had been 
registered the volunteer was sent the Participant Information Sheet (Appendix 1) by email and 
invited to attend a screening visit. For all studies there was a minimum of 24 hours between 
the information sheet being sent out and the volunteer attending a screening visit. 
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2.2.2 Screening Visit and Informed Consent 
The screening visits took place up to 90 days before participants were enrolled in the study 
(participants were considered to be enrolled once they had received a vaccination). At this visit 
the information sheet is explained to the volunteer and they were given the opportunity to ask 
any questions. This was carried out by me for volunteers recruited in Oxford and London, and 
by the local study team in Southampton. The details of the trial, the potential risks and the 
responsibilities of the participant once enrolled were explained before volunteers signed a 
consent form (Appendix 2). For the VAC054 trial (Chapter four) volunteers were also required 
to complete an informed consent questionnaire (Appendix 3) to ensure they had understood 
the information and risk relating to the trial, in particular to malaria infection. Participants had 
to answer all questions correctly but were allowed to re-take the same questionnaire following 
further discussion if they failed to do this on their first attempt. The following general 
principles were emphasised: 
 Participation in the study is entirely voluntary. 
 Refusal to participate involves no penalty or loss of medical benefits. 
 The volunteer may withdraw from the study at any time. 
 The volunteer is free to ask questions at any time to allow him or her to understand 
the purpose of the study and the procedures involved. 
 The study involves research of an investigational vaccine. 
 There is no direct benefit from participating. 
 The volunteer’s GP will be contacted to corroborate their medical history. 
 The volunteer will be registered on the TOPS database (The Over-volunteering 
Prevention System; www.tops.org.uk). 
 The volunteer’s blood samples taken as part of the study will be stored indefinitely and 
samples may be sent outside of the UK and Europe to laboratories in collaboration 
with the University of Oxford. These will be anonymised. 
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If the volunteer consented to participate in the study, they were then asked details of their 
medical history and underwent a physical examination, as well as baseline blood tests (full 
blood count, urea & electrolytes, liver function tests and serology for Hepatitis B, Hepatitis C 
and HIV). Their GP was contacted by letter, giving information about the trial, and asked to 
respond to try to ensure any medical or psychiatric reasons for exclusion from the trials (which 
had not been disclosed by the volunteer at screening) were picked up. For VAC054 an ECG was 
carried out, and cholesterol and magnesium levels were also checked with the other 
biochemistry tests. 
The inclusion and exclusion criteria for each trial are detailed in each trial Chapter. 
2.2.3 Study design and procedures 
The study design for each trial is detailed in the Chapter relating to that trial (i.e. Chapter three 
for VAC051, Chapter four for VAC054 and Chapter five for VAC057). The schedules of 
attendance for volunteers taking part in each study can be found in Appendix 4. Data at clinic 
visits were recorded into the case report form (CRF) by study staff. This was a paper CRF in the 
VAC051 trial, with anonymised data subsequently entered into an OpenClinica database, with 
double data entry carried out by two members of the study team for each visit entry. In the 
VAC054 and VAC057 trials, data were entered directly into an electronic CRF (eCRF) in clinic so 
this functioned as both source data and database. Blood tests carried out at the NHS 
laboratories were received as paper reports which were signed off by me in Oxford, or one of 
the clinicians at other trial sites. These results were then entered into the OpenClinica 
database by study staff. For all interim and final analyses data were exported from the 
OpenClinica database and processed by the data manager (Jack Quaddy) before I analysed the 
data.  
2.2.4 Assessment of Safety 
The safety of the vaccines in the three clinical trials discussed in this thesis was assessed using 
actively and passively collected data on any adverse events (AEs) as described in the ‘Methods’ 
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section of each trial Chapter. Participants were asked to record both solicited and unsolicited 
AEs on diary cards (paper or electronic) given to them on the day of vaccination. Examples of 
the diary cards used are included in Appendix 5. Data from paper diary cards were entered into 
the OpenClinica database by study staff. The electronic diaries (eDiaries) were analysed 
directly as AE data were exported already processed into an Excel spreadsheet directly from 
the diaries. Safety was assessed by the frequency, incidence and nature of AEs and serious 
adverse vents (SAEs) arising during the study. 
For each vaccine a Development safety update report (DSUR) was submitted to the regulatory 
authority annually whilst the trials were ongoing. This contained safety information relating to 
the vaccine over the preceding year. In addition, the Investigator Brochures were also updated 
annually with new safety information. 
2.2.4.1  Definitions 
Adverse Event (AE) 
An AE is any untoward medical occurrence in a volunteer, which may occur during or after 
administration of an Investigational Medicinal Product (IMP) and does not necessarily have a 
causal relationship with the intervention. An AE can therefore be any unfavourable and 
unintended sign (including an abnormal laboratory finding), symptom or disease temporally 
associated with the study intervention, whether or not considered related to the study 
intervention. 
Adverse Reaction (AR) 
An AR is any untoward or unintended response to an IMP. This means that a causal 
relationship between the IMP and an AE is at least a reasonable possibility, i.e., the 
relationship cannot be ruled out. All cases judged by the reporting medical Investigator as 
having a reasonable suspected causal relationship to an IMP (i.e. possibly, probably or 
definitely related to an IMP) will qualify as adverse reactions. 
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Unexpected Adverse Reaction  
An adverse reaction, the nature or severity of which is not consistent with the applicable 
product information (e.g. the Investigator’s Brochure [IB] for an unapproved IMP) is 
considered as an unexpected adverse drug reaction (ADR). 
Serious Adverse Event (SAE) 
An SAE is an AE that results in any of the following outcomes, whether or not considered 
related to the study intervention. 
 Death  
 Life-threatening event (i.e., the volunteer was, in the view of the Investigator, at 
immediate risk of death from the event that occurred). This does not include an AE 
that, if it occurred in a more severe form, might have caused death. 
 Persistent or significant disability or incapacity (i.e. substantial disruption of one’s 
ability to carry out normal life functions). 
 Hospitalisation, regardless of length of stay, even if it is a precautionary measure for 
continued observation. Hospitalisation (including inpatient or outpatient 
hospitalisation for an elective procedure) for a pre-existing condition that has not 
worsened unexpectedly does not constitute a serious AE. 
 An important medical event (that may not cause death, be life threatening, or require 
hospitalisation) that may, based upon appropriate medical judgment, jeopardise the 
volunteer and/or require medical or surgical intervention to prevent one of the 
outcomes listed above. Examples of such medical events include allergic reaction 
requiring intensive treatment in an emergency room or clinic, blood dyscrasias, or 
convulsions that do not result in inpatient hospitalisation. 
 Congenital anomaly or birth defect. 
 
Serious Adverse Reaction (SAR) 
An adverse event (expected or unexpected) that is both serious and, in the opinion of the 
reporting Investigator or Sponsors, believed to be possibly, probably or definitely due to an 
IMP or any other study treatments, based on the information provided. 
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Suspected Unexpected Serious Adverse Reaction (SUSAR) 
A serious adverse reaction, the nature and severity of which is not consistent with the 
information about the medicinal product in question set out in the IB or Summary of Product 
Characteristics (SmPC). 
Solicited AEs 
Solicited AEs are those commonly seen after vaccination, and are divided into local and 
systemic AEs. Local AEs include redness, swelling, itching, warmth and pain at the injection 
site. Systemic AEs include fever/ feverishness, headache, nausea, malaise, myalgia and 
arthralgia. Solicited AEs are expected to occur, and generally resolve, within the first seven 
days after vaccination. Any adverse events not listed as a solicited AE or occurring after the 
defined time (usually seven days after vaccination) are termed unsolicited AEs. Local AEs are 
graded by severity according to the criteria shown in Table 2.1. Criteria for assessing 
abnormalities in physical observations (vital signs) are shown in Table 2.2. These criteria were 
not specified for the VAC051 trial, and were developed through VAC054 and VAC057. The 
table shows the criteria for VAC057 and VAC054 where they differed. Changes were made to 
reflect the UK National Institute for Health and Care Excellence (NICE) clinical guidelines on 
stages of hypertension (170). Systemic AEs other than fever (solicited and unsolicited) are 
graded according to the criteria shown in Table 2.3 
The maximum reported severity of an AE is reported in the results section of each trial 
Chapter, i.e. if a volunteer had an AE which lasted 3 days and was mild for 2 days but severe 
for one this has been reported as ‘severe’. 
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Adverse Event  Grade  Intensity  
Pain at injection site 
1 Pain that is easily tolerated 
2 Pain that interferes with daily activity 
3 Pain that prevents daily activity 
Erythema at injection site* 
1 >3 - ≤50 mm 
2 >50 - ≤100 mm 
3 >100 mm 
Swelling at injection site 
1 >0 - ≤20 mm 
2 >20 - ≤50 mm 
3 >50 mm 
Table 2.1: Severity grading criteria for fever, injection site pain, erythema and swelling.  
*erythema ≤3mm is an expected consequence of skin puncture and will therefore not be 
considered an adverse event. 
 
Physical observations  Grade 1  
(mild) 
Grade 2  
(moderate) 
Grade 3  
(severe) 
Fever (oral) °C 
 
37.6°C - 38.0°C 38.1°C – 39.0°C >39.0°C 
Tachycardia (beats per minute 
[bpm]) 
 
101 - 115 116 – 130 >130 
Bradycardia (bpm)* 
 
50 – 54 40 – 49 <40 
Systolic hypertension (mmHg) 
VAC057 141 - 159 160 – 179 ≥180 
VAC054 141 - 150 151 - 155 >155 
Diastolic hypertension (mmHg) 
VAC057 91 - 99 100 – 109 ≥110 
VAC054 91 - 95 96 - 100 >100 
Systolic hypotension (mmHg)** 
 
85 - 89 80 – 84 <80 
Table 2.2: Criteria for grading severity of clinically significant abnormal physical 
observations. 
Observations should have been taken at rest (after ≥10 minutes at rest defined for VAC057) 
*Applicable only when resting heart rate is between 60 – 100 beats per minute. Use clinical 
judgement when characterising bradycardia among some healthy subject populations, for 
example, conditioned athletes. This criterion was not defined for VAC054. 
**Only if symptomatic (e.g. dizzy/ light-headed) 
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GRADE 0 None 
GRADE 1 Mild: Transient or mild discomfort (< 48 hours); no medical intervention/therapy 
required 
GRADE 2 Moderate: Mild to moderate limitation in activity - some assistance may be needed; no 
or minimal medical intervention/therapy required 
GRADE 3 Severe: Marked limitation in activity, some assistance usually required; medical 
intervention/therapy required, hospitalisation possible 
Table 2.3: Severity grading criteria for systemic AEs. 
 
2.2.4.2  Causality Assessment 
In each trial, for each unsolicited AE, an assessment of the relationship of the AE to the study 
intervention(s) was undertaken. Solicited AEs occurring within the first seven days after 
vaccination were considered to be at least possibly related to vaccination. I categorised the 
relationship of the AE as unrelated, unlikely to be related, possibly related, probably related or 
definitely related (Table 2.4). Alternative causes of the AE, such as the natural history of pre-
existing medical conditions, concomitant therapy, other risk factors and the temporal 
relationship of the event to vaccination were considered.  
0 No 
Relationship 
No temporal relationship to study product and 
Alternate aetiology (clinical state, environmental or other interventions); and 
Does not follow known pattern of response to study product 
1 Unlikely Unlikely temporal relationship to study product and 
Alternate aetiology likely (clinical state, environmental or other interventions) and 
Does not follow known typical or plausible pattern of response to study product. 
2 Possible 
 
Reasonable temporal relationship to study product; or 
Event not readily produced by clinical state, environmental or other interventions; or 
Similar pattern of response to that seen with other vaccines 
3 Probable 
 
Reasonable temporal relationship to study product; and 
Event not readily produced by clinical state, environment, or other interventions or  
Known pattern of response seen with other vaccines 
4 Definite 
 
Reasonable temporal relationship to study product; and 
Event not readily produced by clinical state, environment, or other interventions; 
and  
Known pattern of response seen with other vaccines 
Table 2.4: Guidelines for assessing the relationship of vaccine administration to an AE. 
71 
 
2.2.4.3  Laboratory AEs 
Blood samples were taken during each trial to monitor for any AEs relating to haematological 
or biochemical changes following vaccination of volunteers. These blood samples were 
analysed either at the Oxford NHS laboratory or at the local NHS laboratories in trials involving 
other sites. For VAC051, laboratory abnormalities were assessed according to Table 2.5. After 
this trial I set up a more comprehensive laboratory AE severity grading table to be used across 
trials conducted at the Jenner Institute. It was also recognised that each laboratory has 
different normal reference ranges for some blood tests, so site-specific grading tables were 
produced by me, with support from other clinical research fellows based at the Jenner 
Institute and Southampton. These can be found in Appendix 6. 
 
Laboratory Test Grade 1 Grade 2 Grade 3 
Hgb (female) – decrease from testing 
laboratory LLN in gm/dl 
>1.0 - <1.5 ≥1.5 & <2.0 ≥2.0 
Hgb (male) – decrease from testing 
laboratory LLN in gm/dl  
≥1.5 & <2.0 ≥2.0 & <2.5 ≥2.5 
Absolute neutrophil count (ANC, cells/mm
3
) 1000-1499 500-<1000 <500 
Leukopenia (WBC, cells/mm
3
) <3500 - ≥2500 <2500 - ≥1500 <1500 
Lymphocytes Decrease  (cell/mm
3
) 750 – 1,000 500 – <750 250 – <500 
Platelets (cells/mm
3
) 125,000 – 
135,000 
100,000 – 
<125,000 
20,000-<100,000 
Bilirubin – when accompanied by any 
increase in Liver Function Test increase by 
factor  
1.1–1.25 x ULN  >1.25–1.5 x ULN  >1.5–1.75 x ULN  
ALT 1.25–2.5 x ULN >2.5–5.0 x ULN >5.0 x ULN 
Creatinine 1.1–1.5  x ULN >1.6–3.0 x ULN >3.0 x ULN 
Table 2.5: Severity grading criteria for clinically significant abnormalities for VAC051 trial 
(171). 
Hgb = Haemoglobin, LLN = lower limit of normal, ANC = absolute neutrophil count, WBC = 
white blood cells, ALT = alanine transferase, ULN = upper limit of normal. 
 
72 
 
2.2.5 Compensation for trial participants 
Compensation for volunteers taking part in the trials described in this thesis was calculated on 
a pro rata basis. Participants were compensated according to the following: 
 Travel expenses: 
o £10 per visit. Where travel expenses were greater than £10 per visit because 
the volunteer lived outside the city of the trial site, the volunteer was given 
further reimbursement to meet the cost of travel necessary for study visits. 
 Inconvenience of blood tests: 
o £10 per blood donation 
 Time required for visit:  
o £20 per hour 
Volunteers taking part in the VAC054 CHMI trial (Chapter four) were also compensated 
£20/hour illness compensation for 24 hours following CHMI. 
2.3 Methods: Immunology 
2.3.1 Blood separation 
In all trials detailed in this thesis, blood samples for immunology were collected before 
vaccination (as baseline) and at several time-points following vaccination(s), as per the study 
designs. Blood was collected in serum and lithium heparinised vacutainer tubes (BD 
bioscience) and transported to the Jenner Institute laboratories for processing. This was 
carried out by Kathryn Milne, Sarah Silk and Sean Elias. 
Separation of peripheral blood mononuclear cells (PBMC) and serum were carried out as per 
Jenner Standard Operating Procedure (SOP) ML002: Malaria PBMC Separation and Freezing 
(Appendix 8). Briefly: 
 Serum tubes were spun at 706 xg for five minutes; serum was collected with a transfer 
pipette and stored in aliquots. These were then stored at -80⁰C. 
 Heparinised blood was poured into Leucosep tubes (Greiner 227209) which had been 
pre-prepared with 15 mL LymphoprepTM, spun so that it was below the porous filter 
disc. Leucosep tubes containing heparinised blood were spun at 1000 xg for 13 
minutes at room temperature (brakes off). The plasma fraction was aliquoted and 
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stored at -80⁰C before the excess plasma containing PBMC was poured into a Falcon 
tube. This was then topped up with R0 and spun at 706 xg at room temperature for 
five minutes. The supernatant was poured off, cells were re-suspended in R0 and the 
spin/wash process was repeated. RBC lysis solution was used if there was significant 
contamination of the pellet with RBC. The cells were then re-suspended in 10 mL of 
R10 for counting. Cells were counted using a CasyCounter. Following counting, cells 
were re-suspended and used for the ex-vivo IFN-γ ELISPOT assay or stored in 1mL 
aliquots of 5 - 10 million cells/cryovial in filtered, heat-treated FCS and 20% DMSO. 
These were initially stored at -80⁰C before transfer to liquid nitrogen storage 1 – 3 
days later. 
2.3.2 Thawing of PBMC 
ASC and mBC ELISPOTS were carried out using frozen PBMC for most assays. PBMC had been 
stored in liquid nitrogen following the separation process described above. Vials were 
removed from liquid nitrogen on the day of the assays and thawed in a water bath at 37⁰C 
before being added to warmed (37⁰C) R10 media in Falcon tubes. Cells were spun at 706 xg for 
5 minutes at room temperature, supernatant was discarded and cells were then re-suspended 
in R10. Benzonase was added to each Falcon tube (1 µL per 1 x 106 PBMC in the thawed 
cryovial) and suspended cells were incubated for at least 1 hour at 37⁰C. Tubes were spun 
again at 706 xg for 5 minutes, supernatant was discarded and 10 mL of R10 was added to 
resuspend cells prior to counting using a Casycounter. After counting, cells were suspended in 
R10 at 5 x 106 cells/mL for ASC ELISPOTs and 2 x 106 cells/mL for mBC ELISPOTs. 
2.3.3 Ex-vivo IFN-γ ELISPOTs 
Ex-vivo IFN-γ ELISPOTs were carried out on fresh PBMC for all participants in each trial to 
assess the kinetics and magnitude of the vaccine-induced T cell responses over time. Samples 
were processed and analysed according to the Jenner Institute SOP ML006: Ex Vivo ELISPOT 
(Appendix 8). Assays were carried out within 4 hours of blood being collected from the 
participant. These assays were carried out by Kathryn Milne, Sarah Silk and Sean Elias.  
74 
 
ELISPOT plates (Millipore, MAIPS4510) were prepared the preceding day with 50 µL of coating 
solution (10 µL of catcher antibody [1-D1K] per 1 mL of ELISPOT coating buffer) added to each 
well and then left overnight at 4⁰C. Peptide pools (5 µg/mL) were pre-aliquoted into 96 well 
plates at the start of the trial and stored at -80⁰C until needed.  
On the day of sample processing the plates were blocked with R10 for 1 – 8 hours after being 
washed three times with sterile PBS. The PBMC isolated from whole blood (as described in 
Section 1.3.1) were plated at 250,000 cells per well for an 18-20 hour re-stimulation with 
overlapping peptides spanning the antigen of interest: P. vivax DBP_RII (Salvador I allele) for 
VAC051; P. falciparum AMA1 (3D7) for VAC054; and P. falciparum RH5 (3D7) for VAC057. The 
positive control for the assay was 10 µg/mL PHA plus 0.02 mg/mL SEB and negative control 
was R10 media + DMSO. All samples were tested in triplicate for each peptide pool. After 
overnight incubation, cells were discarded, plates were washed and 50 µL of a second, 
biotinylated monoclonal antibody against human IFN-γ (7-B6-1-Biotin, concentration 1 µg/mL) 
(Mabtech, 3420-2A) was added and the plate incubated for 2 - 4 hours (room temperature). 
After another wash step, streptavidin alkaline phosphate (Mabtech, 3420-2A) (diluted 1:1000 
in PBS) was added before a further incubation at room temperature for 1-2 hours. Plates were 
washed and the alkaline phosphate substrate (developer) was added (50 µL/well). The plate 
was left to develop for approximately 3 – 15 minutes until spots were clearly visible. Spots 
were counted using an automated plate counter and results obtained by subtracting any 
background response (from negative control wells) and then taking the average of the 
triplicate wells. Results are expressed as IFN-γ spot-forming-units (SFU) / million PBMC. 
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2.3.4 ELISAs 
2.3.4.1  Antigen-specific IgG ELISAs 
The kinetics and magnitude of the serum IgG antibody responses against the antigen of 
interest for each trial (PvDBP_RII for VAC051, AMA1 for VAC054 and RH5 for VAC057) were 
assessed over time by ELISA. Following CHMI in VAC054 an anti-MSP119 ELISA was done 
looking for evidence of seroconversion in infectivity control volunteers and in control 
volunteers from six previous CHMI studies with samples from before CHMI (dC-1) and 4 weeks 
after blood stream infection (74, 83, 138, 172, 173). These assays were carried out by me and 
Sarah Silk. 
Anti-PvDBP_RII IgG ELISA (VAC051; Chapter three) 
This ELISA was carried out as per Jenner Institute SOP ML026: DBP ELISA (Appendix 8). Briefly, 
96 well Nunc-Immuno Maxisorp plates were coated with recombinant PvDBP_RII (Salvador I 
strain) at a concentration of 2µg/ml in PBS and left overnight. Plates were washed with 
PBS/Tween six times and blocked for 1 hour with StartingBlockTM T20 buffer (Fisher, UK). A 
standard curve and internal control samples were prepared from the reference serum (VAC051 
volunteer 028 day 84 serum sample) and added to the plate with the serum samples from trial 
volunteers. All samples were diluted in StartingBlockTM T20 solution. The serum samples were 
added in triplicate to the ELISA plate (Figure 2-1). After a two hour incubation the plates were 
washed and alkaline phosphatase conjugated goat anti-human IgG (γ-chain) (Sigma) diluted 
1:1000 in StartingBlockTM T20 solution was added. After a further one hour incubation, 
followed by a wash step, 4-nitrophenyl phosphate substrate (Sigma) diluted in diethanolamine 
buffer (Fisher Scientific, UK) (DB) was added to detect antibodies. An ELx800 microplate reader 
(BioTek, UK) was used to read optical density at 405nm (OD405). The reciprocal of the dilution
 
giving an OD405 of 1.0 in the standardised
 assay was used to assign an ELISA unit value of the 
standard. The standard curve and Gen5 ELISA software v2.07 (BioTek, UK) was used to convert 
the OD405 of individual test samples into ELISA units. 
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Figure 2-1: Antigen-specific IgG ELISA plate layout 
Blue S1 – S22 = test sera (added in triplicate); Pink 1 – 10 = standard curve dilutions (in duplicate); 
Internal control (as per ELISA protocol); Blank = blocking solution (as per ELISA protocol, e.g. 
StartingBlock
TM
 T20) 
 
Anti-AMA1 and anti-MSP1 IgG ELISAs (VAC054; Chapter four) 
These ELISAs were carried out as per Jenner Institute SOP ML023: P. falciparum MSP1 and 
AMA1 ELISA (Appendix 8). Briefly, 96 well Nunc-Immuno Maxisorp plates were coated with 
recombinant AMA1 or recombinant MSP119 at a concentration of 2µg/ml in PBS and left 
overnight. Plates were washed six times with PBS/Tween and then blocked for 1 hour with 
Casein blocking buffer. A standard curve and internal control samples were prepared from the 
reference serum (human hyperimmune serum from Kilifi, Kenya diluted 1:100) and added to 
the plate with the serum samples from trial volunteers. The serum samples were diluted and 
added in triplicate to the ELISA plate (see Figure 2-1). After a two hour incubation the plates 
were washed and the alkaline phosphatase-conjugated secondary polyclonal goat anti-human 
IgG (γ-chain) antibody was added. After a further one hour incubation, followed by a wash 
step, developer (DB) was added. The developer was left for 10 - 25 mins (antigen dependent) 
and the absorbance at 405nm (OD405) was read using a plate reader. The result was obtained 
by taking an average of the triplicate wells for each test sample, and using the standard curve 
to assign MSP1 or AMA1 ELISA arbitrary units (AU). Samples with an OD <0.15 were considered 
negative. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 
B S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 
C S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 
D S13 S14 S15 S16 S17 S18 S19 S20 S21 S22 
Internal Control 
 
E S13 S14 S15 S16 S17 S18 S19 S20 S21 S22 
F S13 S14 S15 S16 S17 S18 S19 S20 S21 S22 
G 1 2 3 4 5 6 7 8 9 10 
Blank 
H 1 2 3 4 5 6 7 8 9 10 
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Calibration-free concentration analysis (VAC054; Chapter four) 
CFCA was used to convert AMA1 OD-based ELISA units to antigen-specific µg/mL using a 
Biocore T200 instrument, a Biotin CAP chip and T200 control and evaluation software (all from 
GE Lifesciences, UK) with methodology previously published (167). This work was performed 
by Sandy Douglas using serum samples from three individuals with a range of ELISA-measured 
anti-AMA1 IgG responses. The CFCA-measured antigen-specific antibody concentrations for 
each individual against 3D7 and FVO sequence AMA1 were combined with the known total IgG 
ELISA AU measurements for the same samples to derive an AU-to-μg/mL conversion factor. For 
each AMA1 allele, the mean of the conversion factors measured for the three subjects was 
calculated and applied to the AU ELISA measurements for other participants so that all ELISA 
results could be expressed in μg/mL units. 
Anti-RH5 IgG ELISA (VAC057; Chapter five) 
Anti-RH5 IgG ELISAs were carried out as per Jenner Institute SOP ML011: RH5 ELISA (Appendix 
8). Briefly, 96 well Nunc-Immuno Maxisorp plates were coated with recombinant PfRH5 at a 
concentration of 2µg/ml in PBS and left overnight. Plates were washed six times with 
PBS/Tween and then blocked for 1 hour with Casein blocking buffer. A standard curve and 
internal control samples were prepared from the reference serum (VAC057 Volunteer 1020 
G2B d84 serum sample) and added to the plate with the serum samples from trial volunteers. 
The serum samples were diluted and added in triplicate to the ELISA plate (see Figure 2-1). 
Secondary antibody, development and ELISA result readout steps were carried out as 
described above for PvDBP, AMA1 and MSP1 ELISAs. 
2.3.4.2  Avidity ELISAs 
The avidity ELISAs for all trials were carried out as per Jenner Laboratory Protocol J177: Human 
Whole IgG Avidity ELISA. Briefly, 96 well Nunc-Immuno Maxisorp plates were coated with the 
recombinant protein of interest (e.g. AMA1) diluted in DPBS to a concentration of 2 µg/mL and 
left overnight. Following a wash step with PBS/Tween, plates were blocked with Casein for 1 
hour and then a further wash step was carried out. Serum samples were diluted using 
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standardised ELISA results so that each individual serum would reach an OD of 1 when read 
(e.g. if sample has an ELISA result of 3000 AU, dilute serum 1:3000) and added in duplicate 
down the plate. After a 2 hour incubation, plates were washed and an increasing 
concentration of NaSCN diluted in PBS was added down the plate from 0M to 7M (Figure 2-2). 
Plates were left for 15 minutes before a further wash step. Secondary goat anti-human γ-chain 
whole IgG alkaline phosphatase conjugate antibody (diluted 1:1000 in Casein) was added and 
plates were left for 1 hour. After a final wash step, DB was added and plates were left to 
develop until the OD of the wells in row A (see Figure 2-2) reached 1. The OD was the read at 
405 nm on a Biotek ELx800 microplate reader with Gen5 software. 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 0 S1 S1 S2 S2 S3 S3 S4 S4 S5 S5 S6 S6 
B 1M S1 S1 S2 S2 S3 S3 S4 S4 S5 S5 S6 S6 
C 2M S1 S1 S2 S2 S3 S3 S4 S4 S5 S5 S6 S6 
D 3M S1 S1 S2 S2 S3 S3 S4 S4 S5 S5 S6 S6 
E 4M S1 S1 S2 S2 S3 S3 S4 S4 S5 S5 S6 S6 
F 5M S1 S1 S2 S2 S3 S3 S4 S4 S5 S5 S6 S6 
G 6M S1 S1 S2 S2 S3 S3 S4 S4 S5 S5 S6 S6 
H 7M S1 S1 S2 S2 S3 S3 S4 S4 S5 S5 S6 S6 
Figure 2-2: Avidity ELISA plate layout 
S1 – S6: Diluted serum samples are added in duplicate down the plate. NaSCN is added in increasing 
concentration (0 - 7M down the plate). 
 
2.3.4.3  Isotype ELISAs 
The isotype ELISAs for all trials were carried out as per Jenner Laboratory Protocol J255: 
Human Isotype ELISA. Briefly, six 96 well Nunc-Immuno Maxisorp plates were coated with the 
recombinant protein of interest (e.g. AMA1 at a concentration of 2 µg/mL), native human 
IgG1-4, IgA and positive control serum diluted 1:1000 as per Figure 2-3. One plate was coated 
for each isotype measured (IgG1-4, IgA and IgM). Plates were labelled IgG1, IgG2, IgG3, IgG4, 
IgA and IgM. All antigens and isotype controls were diluted in DPBS. Coated plates were left 
overnight. 
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 1 2 3 4 5 6 7 8 9 10 11 12 
A CA CA CA CA CA CA CA CA CA CA CA CA 
B CA CA CA CA CA CA CA CA CA CA CA CA 
C CA CA CA CA CA CA CA CA CA CA CA CA 
D CA CA CA CA CA CA CA CA CA CA CA CA 
E CA CA CA CA CA CA CA CA CA CA CA CA 
F CA CA CA CA CA CA CA CA CA CA CA CA 
G 1 2 3 4 A K CA CA CA CA CA CA 
H 1 2 3 4 A K CA CA CA CA CA CA 
Figure 2-3: Plate coating layout for isotype ELISA 
1-4 – Native human IgG1-4. 
A – Native human IgA. 
K – Kilifi serum, 5H at 1:1000 dilution. 
CA- Coating antigen (e.g. AMA1)  
Following a wash step (PBS/Tween x 6) plates were blocked for 1 hour with Casein. Serum 
samples were diluted at 1:100 and added to plates in duplicate after a wash step. Following a 2 
hour incubation, plates were washed again with PBS/Tween before the corresponding 
secondary antibody (1:1000) was added (e.g. anti-human IgG1 added to IgG1 plate). Plates 
were left for 1 hour before a further wash step, then Extravidin-AP (1:5000) was added to all 
plates except the IgA plate (Extravidin-AP not required for this plate as anti-IgA antibody is 
already conjugated to AP) and plates were left for 30 minutes. Following a final wash step, DB 
was added and OD read at 405 nm on a Biotek ELx800 Microplate Reader with Gen5 software. 
2.3.5 ASC ELISPOTs 
ASC ELISPOTs were carried out as per Jenner Protocol J205: Blood Stage Malaria Human ex-
vivo ASC ELISPOT. These assays were carried out by me, Sarah Silk and Sean Elias and were 
done in a Class II microbiological safety cabinet. Briefly, plates were coated with the antigen of 
interest (e.g. AMA1) (to detect antigen-specific IgG-secreting cells), PBS (negative control 
wells), polyvalent goat anti-human IgG (for detection of total IgG secreting cells) and 
diphtheria toxoid (positive control) and left overnight. Plates were washed three times with 
sterile PBS and then blocked with R10 for at least 1 hour. PBMC were retrieved from liquid 
nitrogen storage, thawed and counted using a Casycounter (see Section 2.3.2). Cells were then 
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re-suspended in R10 at a concentration of 5 x 106 cells/mL. The cell suspension was added to 
the plate with around 250,000 cells per well in the control wells (negative and positive) and 
some of the IgG and antigen wells. Dilutions of 125,000 cells and 50,000 cells were also added 
for the antigen wells, and a dilution of 10,000 cells per well was also added for two of the IgG 
wells. The plates were incubated at 37⁰C overnight. The following day, plates were washed 
with PBS/Tween (six times) and secondary goat-anti-human IgG (γ chain specific) antibody was 
added (1:5000). Plates were left for 4 hours before a further wash step. BCIP/NBT 
development buffer was then added until spots had developed (3 - 5 minutes). Plates were 
washed and left to dry before spots were counted using an AID ELISPOT reader. The 
automated counts were checked and corrected by eye to ensure only spots consistent with IgG 
secreting ASCs were counted. 
2.3.6 mBC ELISPOTs 
mBC ELISPOT assays were carried out as per Jenner Protocol J204: Blood-Stage Human 
Memory B cell ELISPOT. These assays were carried out in a Class II microbiological safety 
cabinet by me, Sarah Silk and Sean Elias. PBMC were removed from liquid nitrogen storage and 
thawed as described in Section 2.3.2, before being re-suspended in R10 at a concentration of 2 
x 106 cells/mL. A minimum of 6 million cells/volunteer were prepared. For each volunteer, 500 
µL of the cell suspension were added to 6 wells of a 24 well plate, yielding 1 x 106 cells/well. A 
stimulation mix containing SAC (diluted 1:2400), PWM (diluted 1:6000) and CpG (diluted 
1:200) was added to 5 of the 6 wells per volunteer, with R10 added to the final ‘unstimulated’ 
well. The 24 well plates were transferred to an incubator at 37⁰C and 5% CO2 for 6 days. 
MAIP ELISPOT plates were prepared on day five by coating with the antigen of interest (e.g. 
AMA1) at the concentration specified in the protocol (typically 5 µg/mL) of the antigen 
solution for peak time-points for the stimulated cells. The antigen was also added to wells for 
the unstimulated cells for each volunteer. Positive and negative control wells were coated with 
Diphtheria toxoid and PBS respectively. Wells were also coated with polyvalent goat anti-
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human IgG at 50 µg/mL, and at serial dilutions of 1:100 and 1:1000. The plate layout is shown 
in Figure 2-4. Once coated, plates were left overnight at 4⁰C. 
 
Figure 2-4: Plate layout for mBC ELISPOTs at peak time-points. 
ELISPOT plates were coated with PBS (green) for negative control wells, the antigen of interest (e.g. 
AMA1) (pink) for stimulated cells and unstimulated cells (undiluted), polyvalent goat anti-human IgG 
(purple) and diphtheria toxoid (blue) for positive control wells. Remaining wells (blanks) were coated 
with PBS (grey). 
 
On day six, plates were washed with sterile PBS and then blocked with R10 for at least 1 hour 
at 37⁰C. The cultured cells from the 24 well plates were harvested by gentle resuspension in 
R10. All stimulated cells from a single volunteer were re-suspended in the same 50 mL Falcon 
tube. Unstimulated cells were re-suspended in a 15 mL Falcon tube and all tubes were spun at 
706 xg for 5 minutes. Supernatant was discarded and cells were re-suspended in R10 for a 
further wash step. Following this, cells were again re-suspended in R10 before being counted 
using the Casycounter. Cells were then re-suspended in R10 to a concentration of 2 x 106 
cells/mL for stimulated cells and 1 x 106 cells/mL for unstimulated cells. Stimulated cells were 
added to the ELISPOT plate at 100 µL/well for control wells and for six of the antigen wells as 
well as two of the IgG wells for each volunteer. Dilutions of 1:2 and 1:5 of the cell suspension 
were added to six wells for each volunteer, and dilutions of 1:100 and 1:1000 were added to 
two wells for each volunteer. 100 µL of the unstimulated cell suspension was added to 3 wells 
for each volunteer. Plates were transferred to an incubator and left at 37⁰C and 5% CO2 
overnight.  
e.g. 
AMA1
(unstim)
IgG
Volunteer 
1
Volunteer 
2
Diphtheria 
toxoid
PBS Antigen of interest (e.g. AMA1)
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On day seven, plates were developed using the same method described above for ASC 
ELISPOTs, and after being left to dry were counted on the ELISPOT reader as described for ASC 
ELISPOTs. 
2.3.7 Preparation of P. falciparum inoculum for blood-stage CHMI (Chapter 
four) 
The inoculum used for CHMI was produced by Drs Gregor Lawrence, Allan Saul and colleagues 
at QIMR in Brisbane, Australia in 1994 and consists of aliquots of P. falciparum (clone 3D7) 
infected erythrocytes taken from a single donor (140, 141, 166). Aliquots have been 
cryopreserved in vapour phase liquid nitrogen at -178⁰C in the UK, and one of these was used 
for the VAC054 trial to infect all participants with P. falciparum malaria. Preparation was 
carried out as per Jenner Institute SOP ML021: Preparation of malaria-infected blood for 
injection (Appendix 8). This was carried out by Rebecca Brown and Simon Draper. Briefly, a 
single vial was thawed in a derogated containment level III laboratory area using solutions 
licensed for clinical use and single-use disposable consumables. A class II microbiological safety 
cabinet (MSC) was used to prepare the inocula. The MSC was fumigated with hydrogen 
peroxide and decontamination validated prior to use. 0.2 volume 12 % saline was added 
dropwise to 1.6 mL of thawed infected blood, left for 5 min, and an additional 10 volumes of 
1.6% saline added dropwise. This was centrifuged for 4 min at 830 xg, the supernatant was 
removed, and 10 mL of 0.9% saline was added dropwise. The cell pellet was washed twice in 
0.9% saline and re-suspended in 0.9% saline in a sterile syringe for injection. The injection 
volume per volunteer was 5 mL containing an estimated 1000 parasitised erythrocytes based 
on microscopic estimates of the donor’s parasite density prior to freezing. The clinical 
inoculum was also added to aerobic and anaerobic culture bottles (BACTECTM) following 
preparation and shown to be negative for bacterial contamination. 
Parasite viability was assayed by limiting dilution assay with a 10 day culture period as per 
Jenner Institute SOP ML022: Blood Stage Challenge Viability Assay (Appendix 8). The methods 
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were similar to those described previously for blood-stage CHMI trials at the Jenner Institute 
using the same inoculum (174, 175). Wells were scored positive or negative for replicating 
parasites using qPCR. A plate of identical dilutions of the inoculum that had been frozen 
without incubation was used as a negative control because the qPCR assay (see Section 2.3.9) 
can also detect dead parasites. There was no detectable amplification from negative control 
wells, and unincubated wells which had received a 100-fold greater parasite inoculum gave 
results of 323-445 arbitrary amplification units. Cultured wells plated at an estimated 1.5 
parasites/well gave a clear bimodal distribution, with 20/40 wells giving results of <54 units 
(suggesting they contained no viable parasite), while 20/40 wells gave results of >24,000 units 
(suggesting they had contained at least one viable parasite at the start of the culture period). 
The number of viable parasites/mL of inoculum could then be calculated with reference to the 
Poisson distribution, and viability expressed as a percentage of the pre-freezing microscopy-
estimated parasitaemia calculated using the RBC count/mL of inoculum. This was calculated to 
be 69%, i.e. approximately 690 viable parasites injected per volunteer. 
2.3.8 Thick blood film preparation and interpretation (Chapter four) 
Thick blood films were prepared and interpreted according to Jenner Institute SOP ML009: 
Collection, preparation and slide reading: Malaria Challenge Studies (Appendix 8). This work 
was carried out by experienced microscopists from Kemri, Kenya (Joseph Muita, Pauline Titus 
and Kebba Konteh), who were resident in Oxford for the duration of the CHMI period in 
VAC054. Briefly, a small drop of blood, collected from the volunteer in an EDTA vacutainer 
tube, was prepared on a microscope slide by spreading the drop thinly and allowing it to dry. 
The slide was then dipped in Field’s stain A for 3 seconds, before being rinsed in clean water 
for 3 seconds and then dipped in Field’s stain B for a further 3 seconds. The slide was allowed 
to dry and was then examined under oil immersion at high power (1000x) with 200 fields read 
by an experienced microscopist. Any parasites identified by the microscopist were reviewed by 
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either me or another clinical research fellow for visual confirmation. Thick blood films were not 
quantified for parasite density. 
2.3.9 Parasite qPCR (VAC054; Chapter four) 
Quantitative PCR was carried out on EDTA blood samples collected from participants after 
CHMI in the VAC054 trial and processed as per Jenner Institute SOP ML008: Malaria qPCR 
(Appendix 8). This work was led by Nick Edwards, with support from Jenner laboratory staff. 
Briefly, blood was filtered to reduce white cell content and DNA was extracted from filtered 
blood using the Qiagen Blood Mini Kit. 10% of each extraction (total eluate volume = 50 μL, 
with 5 μL used per assay) was run in triplicate for qPCR – equivalent to 150 μL blood directly 
assessed. The qPCR assay used Forward and Reverse primers 80 µMol scale (Custom; Applied 
Biosystems, 4304971), Taqman FAM-NFQ-MGB Probe 20 µMol scale (Custom; Applied 
Biosystems, 4316033) and Taqman Universal PCR Master Mix (with Amperase UNG; Applied 
Biosystems, 4304437). The Taqman probe-based PCR amplifies a 133 base pair (bp) product 
from the multicopy (three per parasite) 18S (small subunit) ribosomal RNA genes of P. 
falciparum. The probe then binds to the PCR product and is hydrolysed on each PCR cycle, 
releasing the fluorophore which is detected in a quantitative manner (176). 
Parasites per mL (p/mL) equivalent mean values were generated by a standard Taqman 
absolute quantitation, against a defined plasmid standard curve with an ABI StepOne Plus 
machine and v2.3 software. Default Universal qPCR and quality control (QC) settings were used 
apart from the use of 45 cycles and 25 μL reaction volume. Based upon results obtained using 
dilution series of microscopically-counted cultured parasites, this method has a lower limit of 
quantification (LLQ, defined as % coefficient of variation [CV] <20%) of around 20 p/mL blood 
(177). Counted parasite dilution series results suggest that the lower limit of probable 
detection (LLD, i.e. a probability of >50% of ≥1 positive result among three replicate qPCR 
reactions) is in the region of 5 p/mL, while samples at 1 p/mL are consistently negative (24/24 
qPCR reactions). Positive results in this assay are therefore essentially 100% specific for 
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genuine parasitaemia, with positive results beneath the LLQ likely to signify parasitaemia in the 
range 2-20 p/mL. 
For quality control purposes, qPCR samples were re-tested if; 
 Replicates included a mixture of positive and negative (in terms of amplification) 
results with one or more positive results >100 p/mL.  
 The % CV of any results were high outliers.  
Following the QC steps above, qPCR data, including any 0 values, were used to generate the 
mean result for each time-point. 
2.3.10  Parasite multiplication rate (PMR) modelling (Chapter four) 
Modelling of qPCR-derived PMR was carried out by Sandy Douglas and Simon Draper. This had 
been pre-specified in the VAC054 trial protocol as the primary study endpoint, and the 
comparison of the endpoint between the two groups constituted the pre-specified primary 
analysis for vaccine efficacy.  
The arithmetic mean of the three replicate qPCR results obtained for each individual at each 
time-point was used for model-fitting. Negative individual replicates were assigned a value of 0 
p/mL for the purposes of calculating the arithmetic mean of triplicates (where at least one of 
the three readings was positive). As previously reported, qPCR data points which, based upon 
the mean of the three replicates, are negative or below the LLQ (< 20 p/mL) up until the first 
quantifiable result for that subject (i.e. ≥20 p/mL) were treated as missing, while negative or 
sub-quantifiable data points after that subject’s first quantifiably positive result were replaced 
with values of half the LLQ (i.e. 10 p/mL) (177). PMR was then calculated using a linear model 
fitted to log10-transformed qPCR data (177).  
On the day of CHMI, all volunteers were inoculated by 11:30am, within 2 hours and 13 minutes 
of the inoculum being thawed. For modelling purposes, the follow-up visits, where blood 
samples were collected for thick blood film and qPCR were taken to occur at 9:00am in the 
morning (i.e. dC+1 was 0.9 d post-infection), and 6:00pm in the evening (i.e. 0.37 d later). As 
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previously, fitted lines were constrained to pass through the known starting parasitaemia, 
calculated from the results of the limiting-dilution-based assay of the number of viable 
parasites in the inoculum, and a weight-based estimate of each volunteer’s blood volume (70 
mL/kg) (83). PMR was modelled for all volunteers that underwent blood-stage CHMI, given 
they all had ≥5 data points above the LLQ (the criterion for proceeding to model the PMR) (83). 
2.3.11  Functional assays of immunity 
2.3.11.1  PvDBP – DARC Binding inhibition assays (Chapter three) 
The functional activity of IgG induced by vaccination with ChAd63/MVA PvDBP in VAC051 was 
assessed by a binding inhibition assay. These assays were carried out at the Jenner Institute by 
David Llewellyn and Tom Rawlinson, according to Jenner Laboratory Protocol J363: DARC-Duffy 
binding protein binding inhibition assay with human and mouse serum. Briefly, 96-well ELISA 
plates were coated with recombinant DARC (His-tagged) and incubated at 4⁰C overnight. 
Plates were washed with PBS/Tween (x 6) the following day and blocked with 2% milk (diluted 
in PBS) for 2 hours at 37⁰C. Recombinant PvDBP_RII was diluted to 0.1 µg/mL in 0.25% milk (in 
PBS). Serum was also diluted in 0.25% milk. Recombinant PvDBP and sera were combined 30 
minutes before the end of the blocking incubation and left at room temperature. Following the 
blocking incubation, the ELISA plates were washed in PBS/Tween (x 6) and the PvDBP_RII-
serum mix was added to each well, excluding negative control wells (PvDBP_RII incubated with 
day 0 serum or no serum). The plates were then incubated at 37⁰C for 1 hour. After a further 
wash step, diluted serum from rabbits immunised with PvDBP_RII (157) (1:1000 in 0.25% milk) 
was added to each well. Plates were left for 1 hour then washed again before anti-rabbit IgG 
AP 1:1000 antibody was added to each well. The plates were left for a further hour before a 
final wash step. DB was then added and the OD read at 405 nm on Bio-tek ELx800 Microplate 
Reader with Gen5 software. Plates were developed to a point determined by the OD of the 
development controls wells (i.e. when the negative control wells, which did not contain any 
potential blocking agents, reached an OD = 1.0). 
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Serum was also sent to the International Centre for Genetic Engineering and Biotechnology 
(ICGEB), India were DARC-PvDBP binding inhibition was assessed by Rushdi Shakri (178). At 
ICGEB, sera were analysed for binding inhibition against four variants of PvDBP_RII: Sal I 
(homologous to the vaccine), PvP, PvAH and PvO. Two kinds of binding assays were used. The 
first of these was a Bioplex-based assay in which recombinant DARC-Fc was coated on 
magnetic, fluorescent beads and recombinant PvDBP_RII with C-terminal 6-His tag was 
allowed to bind in the presence or absence of sera from volunteers in VAC051. Binding was 
detected with anti-6-His monoclonal antibodies. The second of these assays was an ELISA-
based assay (178). Briefly, recombinant DARC-Fc was coated on an ELISA plate and 
recombinant PvDBP_RII was allowed to bind in the presence or absence of sera from VAC051 
volunteers. Binding was detected with antibodies against the 6-His tag. Standard curves based 
on known amounts of PvDBP_RII were developed for both the Bioplex and ELISA based binding 
assays and used to determine the percent inhibition. 
2.3.11.2  In vitro assay of GIA (Chapters four & five) 
Serum samples for vaccinated volunteers in VAC054 and VAC057 were sent to the NIH 
Reference Center in the USA to assess GIA. This work was led by Kazutoyo Miura. The methods 
used in this assay have been published previously (130, 131). Briefly, IgG was purified from 
serum and concentrated to 10 mg/mL. The purified IgGs were preadsorbed with uninfected 
human O+ red blood cells for 1 hour in order to remove any anti-human erythrocyte antibodies 
and were sterilised and heat inactivated before being used in the assay. Each test IgG was 
incubated with human erythrocytes which contained late trophozoite and schizont stages of P. 
falciparum parasites prepared by Percoll gradient and/or 5% sorbitol treatment. GIA was 
assessed over a single growth cycle, measuring parasite LDH after 40 hours of culture and 
using this to calculate relative parasitaemia levels. Results obtained using the test IgGs were 
compared with those obtained with parasites incubated with a pool of malaria-naïve human 
serum and uninfected erythrocytes as controls (131). The IgG samples were all initially tested 
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at 10 mg/mL, followed by a dilution series for positive samples to determine the concentration 
of purified IgG that gave 50% GIA (EC50).  
2.4 Statistical analyses 
The immunology data for all trials were analysed using GraphPad Prism version 5.04 for 
Windows (GraphPad Software Inc., California, USA). A value of P < 0.05 was considered 
significant. Safety data were analysed in Microsoft Excel 2010; studies were not powered to 
analyse statistically significant differences in safety data so these were assessed descriptively. 
The Phase Ia trials (VAC051 and VAC057) were powered to detect a mean two-fold 
improvement in either T cell or antibody immunogenicity between the two boosted groups 
(Group 2B and Group 2C) at a significance level of P = 0.05 with 76% power. 
The VAC054 study was powered to detect a 33% decrease in mean PMR in vaccinees 
compared with controls with ≥80% power. The power calculations for this study were 
performed by Nicola Williams at the Centre for Statistics in Medicine at the University of 
Oxford using data from previous blood-stage CHMI trials in Oxford and at the Radboud 
University Nijmegen Medical Centre in the Netherlands (179). These historical data suggested 
the CV in the controls may range from 22% (Nijmegen where the mean PMR was 10) to 33% 
(Oxford where the mean PMR was 12). Given the logistical challenges of a blood-stage CHMI 
study, the decision was made not to include any more than thirty volunteers. A study design 
with 15 controls versus 15 vaccinees consistently provided the best power to observe a 33% 
reduction in mean PMR when allowing for this CV in the controls, and an increased CV in the 
vaccinees. 
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Chapter three: 
A Phase Ia clinical trial to assess the 
safety and immunogenicity of new 
Plasmodium vivax malaria vaccine 
candidates ChAd63/MVA PvDBP 
(VAC051) 
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3.1 Authorship statement 
I set up the VAC051 clinical trial with the assistance of Alison Lawrie, Rachel Roberts, Ian 
Poulton, Susanne Hodgson, Adrian Hill and Simon Draper. This involved preparation of the 
study documents with submission for ethical and regulatory approval. The Chief Investigator 
(CI) for this trial was Adrian Hill. 
I screened and enrolled volunteers for the trial. Vaccinations and follow-up visits were 
conducted by me and also by the nursing team: Ian Poulton, Mary Smith and Adrienne Cook. 
Laboratory assays in Oxford were carried out by me and by Kathryn Milne, Sarah Silk, Sean 
Elias and Tom Rawlinson. Assays were also carried out at the ICGEB by Rushdi Shakri. Details 
about who carried out each assay can be found in Section 1.3.3.  
3.2 Introduction 
3.2.1 Development of a blood-stage P. vivax vaccine 
A viral vectored Plasmodium vivax vaccine has been developed at the University of Oxford in 
collaboration with Chetan Chitnis at the ICGEB, India. Similar to vaccine candidates for P. 
falciparum previously developed at the Jenner Institute in Oxford, this uses the simian 
adenovirus ChAd63 and MVA in a heterologous prime-boost regime. The antigen in these 
vaccines is the Duffy-binding protein region II (PvDBP) of the P. vivax malaria parasite Salvador 
I strain, and these vaccines are therefore referred to as ChAd63 PvDBP and MVA PvDBP (157). 
The VAC051 Phase Ia clinical trial was the first trial to use the ChAd63/MVA PvDBP vaccines in 
humans. 
3.2.2 PvDBP as an antigen 
The micronemal parasite ligands (Duffy-binding proteins, DBP or erythrocyte binding antigens, 
EBAs) are a family of antigens that are functionally conserved across Plasmodium species and 
are thought to be involved in the tight attachment step between the parasite and new host 
cell, but only one gene copy exists in P. vivax. Knockout studies of the orthologous P. knowlesi 
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DBPα gene prevent invasion of Duffy-positive erythrocytes by this highly related parasite in 
vitro (180). 
Unlike P. falciparum which utilises multiple redundant invasion pathways for human 
erythrocyte invasion (2, 17), P. vivax requires interaction with DARC in the vast majority of 
cases. Interaction with DARC is mediated by PvDBP, in particular with the receptor-binding 
domain which maps to a conserved cysteine-rich region, referred to as region II. The Duffy-
binding protein belongs to the EBL family of proteins found in all Plasmodium species. The 
other family of Plasmodium proteins known to be involved in red blood cell invasion are the 
RBL family. In Plasmodium vivax this family of proteins are referred to as reticulocyte binding 
proteins (PvRBPs), whereas in P. falciparum they are referred to as reticulocyte binding protein 
homologues (PfRHs) (26). P. vivax was initially thought to express two reticulocyte binding 
proteins, PvRBP1 and PvRBP2 which bind specifically to reticulocytes and not normocytes, 
presumably explaining the host-cell preference of P. vivax (2). However, since the P. vivax 
genome sequence became available it has been demonstrated that there are in fact many 
more than two members in the Pvrbp gene family, with 8 genes predicted to be protein-coding 
(2 of these correspond to the genes encoding the originally discovered PvRBP1 and PvRBP2 
proteins, Pvrbp1a and Pvrbp2c) (26). There are some significant similarities between some of 
the PvRBP proteins and some of the PfRH proteins, which are known to be involved in invasion 
of red blood cells in P. falciparum infection. This suggests that these proteins may be involved 
in reticulocyte sensing, and even in erythrocyte invasion (26, 181). In particular, the PvRBP2a 
protein shows significant similarity with PfRH5 which is essential for the invasion erythrocytes 
by P. falciparum (this protein is discussed in more detail in Chapter five). The crystal structures 
for both of these proteins have been determined (181, 182) and show similar general 
architecture, although also some striking differences have also been identified, particularly in 
terms of the surface properties. PvRBP2a has been shown to bind erythrocytes (not only 
reticulocytes) but the erythrocyte surface receptor has not yet been identified (181). 
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Individuals who lack the Duffy blood group antigen are resistant to blood-stage P. vivax 
infection, providing evidence for the non-redundant nature of this invasion pathway. Duffy 
blood group negativity has essentially led to the disappearance of P. vivax from much of sub-
Saharan Africa and has arisen independently in Papua New Guinea (16). However, it is likely 
there are other invasion pathways possible, in which the RBPs may be implicated, as P. vivax 
infections have been reported to occur in Duffy-negative individuals (183-187), although 
infections are still less likely than in Duffy-positive individuals (187). 
The induction of binding inhibitory antibodies against the receptor binding residues within 
PvDBP region II does not commonly occur following natural exposure (188, 189). However, 
these antibodies (when they occur) were associated with strain-transcending protection 
against P. vivax re-infection in a prospective cohort study in Papua New Guinea (31). 
Importantly, the presence of naturally-acquired high-titre binding inhibitory antibodies against 
PvDBP_RII were associated with reduced risk of P. vivax infection, as well as lower P. vivax 
parasite densities, following infection in the prospective study. This observation suggests that 
antibodies produced following vaccination with PvDBP_RII should be able to block diverse 
strains of P. vivax (16). Similar observations show that antibodies raised against recombinant 
SalI strain PvDBP_RII in rabbits can inhibit binding of heterologous polymorphic PvDBP_RII 
domains derived from diverse field isolates (105).  
Immunisation with recombinant PvDBP_RII can elicit high-titre antibodies in mice and monkeys 
that block binding of this antigen to recombinant DARC or Duffy-positive erythrocytes by in 
vitro assay (157, 190, 191). Following intravenous challenge of New World Aotus monkeys with 
blood-stage P. vivax, longer pre-patent periods and lower parasitaemias were observed in 
immunised animals in comparison to controls. Protection was conferred following 
immunisation with protein vaccine in Freund’s adjuvant but not Montanide ISA 720 (although 
antibody levels induced by ISA 720 were surprisingly low in this study) (107).  
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In this Chapter I will describe the first clinical trial to assess a vaccine against the blood stage of 
P. vivax, using the viral vectored vaccines previously developed in Oxford, ChAd63 PvDBP and 
MVA PvDBP. As this was a first-in-human trial it was primarily conducted to assess safety in 
healthy malaria-naïve adult volunteers, through collection and analysis of adverse event data. 
The immunogenicity of the vaccines was also assessed and the results of these assays are also 
discussed in this Chapter, along with the safety data. 
3.3 VAC051 Methods 
Detailed methods of the recruitment and enrolment of volunteers, as well as the assays used 
in this trial can be found in Chapter two: Materials and Methods.  
3.3.1 VAC051 Study Design 
This study was a Phase Ia open-label, dose escalation, first-in-human, non-randomised trial of 
the viral vectored vaccines ChAd63 PvDBP and MVA PvDBP given in a prime-boost regime with 
an eight week interval (Figure 3-1). The study was conducted at the Centre for Clinical 
Vaccinology and Tropical Medicine, University of Oxford, Oxford, UK. Healthy, malaria-naïve 
males and non-pregnant females aged 18-50 were invited to participate in the study. 
Allocation to study groups occurred at screening based on sequential recruitment of groups 
and volunteer preference.  
Groups 1 and 2A received ChAd63 PvDBP alone on Day 0. Groups 2B and 2C received the 
ChAd63 PvDBP vaccine at day 0 and the MVA PvDBP vaccine at day 56 (nominal study days are 
reported throughout; a window of 7 days either side of day 56 was permitted in the study 
protocol). The sample size for this study was chosen to allow determination of the magnitude 
of the outcome measures, especially of serious and severe adverse events, rather than aiming 
to obtain statistical significance. Four volunteers were enrolled into Groups 1 and 2A as initial 
safety cohorts. The decision to enrol eight volunteers into Groups 2B and 2C was based on a 
power calculation to have 76% power (1-β) to detect a mean two-fold improvement (two-
94 
 
tailed) at a significance level (α) of P = 0.05 in immunogenicity (IgG and T cell response) 
between Groups 2B and 2C following MVA PvDBP boost vaccination. 
Group 
Number 
Number 
of 
volunteers 
Dose ChAd63 PvDBP Dose MVA PvDBP 
1 4 5 x 109 vp IM -- 
2 
A 4 5 x 1010 vp IM -- 
B 8 5 x 1010 vp IM 1 x 108 pfu IM 
C 8 5 x 1010 vp IM 2 x 108 pfu IM 
Figure 3-1: VAC051 study groups 
3.3.2 VAC051 Ethics 
The study received ethical approval from the Oxfordshire Research Ethics Committee A in the 
UK (REC reference 13/SC/0001). The study was also reviewed and approved by the MHRA 
(reference 21584/0312/001-0001). Volunteers signed written consent forms and consent was 
verified before each vaccination. The trial was registered on Clinicaltrials.gov (NCT 01816113). 
3.3.3 VAC051 Study Objectives and Endpoints 
Primary Objective 
To assess the safety of ChAd63 PvDBP when administered alone, and in heterologous prime-
boost with MVA PvDBP in healthy volunteers. 
Primary Outcome Measures 
The specific endpoints for safety and reactogenicity were actively and passively collected data 
on adverse events. These data were collected using diary cards which were completed by 
volunteers for 14 days following ChAd63 PvDBP and 7 days following MVA PvDBP, as well as 
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recording any adverse event reported or detected (e.g. laboratory abnormalities) at clinic visits 
throughout the trial. 
Secondary Objectives 
To assess the cellular and humoral immunogenicity of ChAd63 PvDBP when administered 
alone, and in a heterologous prime-boost regime with MVA PvDBP in healthy volunteers.  
Secondary Outcome Measures 
Immunogenicity outcome measures following ChAd63/MVA PvDBP included: 
 Induction of antigen-specific T cells (assessed by ex-vivo IFN-γ ELISPOT) 
 Induction of antigen-specific IgG (assessed by anti-PvDBP ELISA) 
 Measurement of antigen-specific ASCs and mBCs following vaccination. 
 Functional activity of antigen-specific IgG (assessed using a PvDBP – DARC binding 
inhibition assay). 
T cell ELISPOT assays, PvDBP ELISA assays, ASC ELISPOT assays and mBC ELISPOT assays were 
carried out in the Jenner Institute laboratories in Oxford. Kathryn Milne and Sarah Silk carried 
out the T cell ELISPOT s, Sarah Silk and I carried out the ELISA assays and I carried out the ASC 
and mBC ELISPOT assays, with support from Sean Elias. The PvDBP – DARC binding inhibition 
assays were carried out both Oxford by Tom Rawlinson and in a collaborating laboratory 
outside of the UK by Rushdi Shakri- at the ICGEB. Volunteers were consented for samples to be 
shipped to collaborating laboratories. 
3.3.4 VAC051 Participants 
All volunteers were recruited and vaccinated at the Centre for Clinical Vaccinology and Tropical 
Medicine (CCVTM), part of the Oxford Vaccine Centre (OVC) at the University of Oxford. 
Twenty four volunteers were enrolled in total. All volunteers signed written consent forms, 
and consent was checked to ensure volunteers were willing to proceed before each 
vaccination. The inclusion and exclusion criteria for participation are described below. 
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3.3.4.1  VAC051 Inclusion Criteria 
The volunteer had to satisfy all the following criteria to be eligible for the study: 
 Healthy adult aged 18 to 50 years. 
 Able and willing (in the Investigator’s opinion) to comply with all study requirements. 
 Willing to allow discussion of their medical history with their GP. 
 For females only, willingness to practice continuous effective contraception during the 
study and a negative pregnancy test on the days of screening and vaccination. 
 Agreement to refrain from blood donation during the course of the study. 
 Provision of written informed consent. 
3.3.4.2  VAC051 Exclusion Criteria 
The volunteer could not enter the study if any of the following applied: 
 Participation in another research study involving receipt of an investigational product 
in the 30 days preceding enrolment or during the study period.  
 Prior receipt of an investigational malaria vaccine or any other investigational vaccine 
likely to impact on interpretation of the trial data. 
 Administration of immunoglobulins and/or any blood products within the three 
months preceding vaccination. 
 Any confirmed or suspected immunosuppressive or immunodeficient state, including 
HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) 
immunosuppressant medication within the past 6 months (inhaled and topical steroids 
were allowed). 
 History of allergic disease or reactions likely to be exacerbated by any component of 
the vaccine, e.g. egg products, Kathon. 
 History of clinically significant contact dermatitis. 
 Any history of anaphylaxis in reaction to vaccination. 
 Pregnancy, lactation or willingness/intention to become pregnant during the study. 
 History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in 
situ). 
 History of a serious psychiatric condition. 
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 Any other serious chronic illness requiring hospital specialist supervision. 
 Suspected or known alcohol abuse as defined by an alcohol intake of greater than 42 
units every week. 
 Suspected or known injecting drug abuse in the 5 years preceding enrolment. 
 Seropositive for hepatitis B surface antigen (HBsAg). 
 Seropositive for hepatitis C virus (antibodies to HCV) with positive PCR for hepatitis C 
at screening. 
 History of clinical malaria (any species). 
 Travel to a malaria endemic region during the study period or within the previous six 
months. 
 Any clinically significant abnormal finding on screening biochemistry or haematology 
blood tests or urinalysis. 
 Any other significant disease, disorder or finding which may significantly increase the 
risk to the volunteer because of participation in the study, affect the ability of the 
volunteer to participate in the study or impair interpretation of the study data. 
 Inability of the study team to contact the volunteer’s GP to confirm medical history 
and safety to participate. 
3.3.5 ChAd63 PvDBP and MVA PvDBP Vaccines 
The ChAd63 PvDBP and MVA PvDBP vaccines are described in Chapter two, Section 2.1.1. Final 
certification of these products and associated labelling took place at the CBF in Oxford by a 
qualified person (QP).  
An eight week interval between adenovirus prime and heterologous MVA boost has been 
shown to optimise IgG induction in animal models as well as previous clinical trials (192). This 
was therefore chosen as the regime for this study. 
3.3.6 VAC051 Interventions 
Vaccination of volunteers was carried out at the CCVTM in Oxford. Vaccines were stored at -
80°C in a locked freezer. Administration of vaccines was carried out by me and a research 
nurse after I had checked consent and ongoing eligibility (i.e. no change in medical status or 
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medications that would exclude the volunteer from the trial). One of us was required to give 
the vaccine and the other to check the volume drawn and countersign the procedure. Vaccines 
were all administered intramuscularly (IM) into the deltoid muscle. If more than one vaccine 
was given (i.e. volunteers in Groups 2B and 2C) these were given into opposite arms. The 
Investigator administering the vaccine wore an apron, gloves and eye protection. The vaccines 
are genetically modified organisms (GMOs) and therefore all waste from a vaccination 
procedure was autoclaved to minimise dissemination of the recombinant vectored vaccine 
virus into the environment. This is in accordance with UK Genetically Modified Organisms 
(Contained Use) Regulations (2000). 
Volunteers were required to remain at the CCVTM for an hour after vaccination (2 hours for 
the first recipient of a new vaccine dose). Their vital signs and the vaccination site were 
checked at 30 minutes (at which time the vaccination site dressing was removed and discarded 
as GMO waste) and 60 minutes to check for evidence of any immediate reactions to the 
vaccine.  
Four volunteers were vaccinated with 5 x 109 vp ChAd63 PvDBP (diluted in 0.9% NaCl and 
administered in 310 µL) in Group 1. Following a safety review, twelve volunteers (Groups 2A 
and 2B) were vaccinated with 5 x 1010 vp ChAd63 PvDBP. Volunteers in Group 2B were boosted 
with MVA PvDBP 1 x 108 pfu in the opposite arm 8 weeks later. A further safety review was 
carried out before the final eight volunteers received full dose (2 x 108 pfu) MVA PvDBP eight 
weeks after vaccination with ChAd63 PvDBP 5 x 1010 vp (Group 2C). Volunteers in Group 1 
were followed up for approximately 3 months, and volunteers in Group 2 were followed up for 
approximately 5 months. Volunteers attended follow-up visits on days 2, 14, 28, 56 and 84 in 
Group 1; days 0, 2 ,14, 28, 56, 63, 84 and 140 in Group 2A; and days 0, 2, 14, 28, 56, 58, 63, 84 
and 140 in Groups 2B and 2C. Safety data were collected throughout the study, as detailed in 
the next Section. Baseline antibody and T cell responses were checked on day 0. 
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3.3.7 Assessment of Safety of ChAd63/MVA PvDBP 
Safety data were assessed by actively and passively collected data on adverse events occurring 
throughout the VAC051 trial. Volunteers were asked to complete a paper diary card for 14 
days after vaccination with ChAd63 PvDBP and a second diary for7 days after vaccination with 
MVA PvDBP, with details of any adverse events experienced during these periods, and any 
medication taken. Severity grading of adverse events was as described in Chapter two. A 
longer diary card period was chosen following the initial vaccination because, at the time, 
there had been less experience of the ChAd63 viral vector compared with MVA. Adverse event 
data were also collected at all follow-up visits by study staff who asked the participant to recall 
any adverse events since the last visit, which were then recorded in the participant’s CRF. 
Blood tests for safety (full blood count [FBC], liver function tests [LFTs], urea and electrolytes 
[U&Es]) were carried out at all visits after vaccination except days 2 and 58.  
Prior to each dose escalation (i.e. between Groups 1 and 2 for ChAd63 PvDBP, and between 
Groups 2B and 2C for MVA PvDBP) safety of the vaccines was reviewed by the Local Safety 
Monitor (LSM), who chairs the Local Safety Committee (LSC). The LSC consists of at least two 
other appropriately qualified committee members. The LSM reviewed a report on the adverse 
event profiles of the vaccines (solicited and unsolicited adverse events) and advised on 
whether the study should proceed. The LSM for this study was Dr Brian Angus, a Clinical Tutor in 
Medicine, Honorary Consultant Physician and Director, Centre for Tropical Medicine at the 
University of Oxford. 
3.4 VAC051 Results  
3.4.1 VAC051 Participant Flow 
Thirty volunteers were screened in total, of which twenty four were enrolled. Recruitment 
took place between May 2013 and February 2014. Four volunteers were recruited to Groups 1 
and 2A, and eight volunteers to Groups 2B and 2C. In total, fifteen females and nine males 
were enrolled. The mean age of volunteers was 25 years 9 months (range 18 – 40 years). Four 
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volunteers were enrolled into Group 1 and received 5 x 109 vp of the ChAd63 PvDBP vaccine. 
There was a 3 week interval between vaccination of the final Group 1 volunteer and the first 
Group 2 volunteer to allow a safety review prior to dose escalation of ChAd63 PvDBP to 5 x1010 
vp. Four volunteers in Group 2A received ChAd63 PvDBP alone. Eight volunteers were enrolled 
into Groups 2B and 2C. These volunteers received ChAd63 PvDBP followed 8 weeks later with a 
‘boost’ vaccination of MVA PvDBP at a dose of 1 x 108 pfu (Group 2B) or 2 x 108 pfu (Group 2C). 
There was a 2 week interval between the final vaccination in Group 2B with MVA PvDBP at the 
lower dose of 1 x 108 pfu and the first vaccination with MVA PvDBP 2 x 108 pfu in Group 2C, 
with a safety review prior to dose escalation. One volunteer withdrew from Group 2B prior to 
the MVA PvDBP vaccination due to personal commitments. Following a discussion with the 
safety monitor, the decision was made not to replace her but continue the study with a total of 
7 volunteers in Group 2B. The trial flow diagram is shown in Figure 3-2. 
 
Figure 3-2: VAC051 flow chart of study design and volunteer recruitment. 
 
Excluded (n = 6) 
   Not meeting inclusion criteria (n = 2) 
   Declined to participate (n = 3) 
   Other reasons (n = 1) 
Group 1  (n = 4) 
 
ChAd63 PvDBP 
5 x 109 vp 
Group 2A  (n = 4) 
 
ChAd63 PvDBP 
5 x 1010 vp 
 
Group 2B  (n = 8) 
 
ChAd63 PvDBP 
5 x 1010 vp 
 
Group 2C  (n = 8) 
 
ChAd63 PvDBP 
5 x 1010 vp 
Enrollment 
MVA PvDBP 
1 x 108 pfu 
(n= 7) 
MVA PvDBP 
2 x 108 pfu 
(n= 8) 
 
Withdrew (n = 1) 
(personal reasons) 
Completed follow-up 
(n = 7) 
Completed follow-up 
(n = 8) 
Completed follow-up 
(n = 4) 
Completed follow-up 
(n = 4) 
Follow-Up 
Assessed for eligibility (n = 30) 
Day 0 
Day 56 
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3.4.2 VAC051 Vaccine safety and reactogenicity 
There were no SAEs or unexpected reactions during the course of the trial and no volunteers 
withdrew due to vaccine-related AEs. ChAd63 PvDBP and MVA PvDBP demonstrated 
favourable safety profiles, similar to those seen in previous clinical trials with the same viral 
vectors (with different malaria antigens) at similar doses in healthy adults (84, 155). 
The maximum severity of solicited AEs reported by volunteers following ChAd63 PvDBP is 
shown in Figure 3-3. All AEs following ChAd63 PvDBP 5 x 109 vp were mild, as were the vast 
majority following the higher dose in Group 2, although some volunteers did report moderate 
or severe adverse events following the higher dose. The majority of solicited adverse events 
following ChAd63 PvDBP occurred within 48 hours of vaccination (Figure 3-5A, B). 
Unsolicited adverse events occurring after ChAd63 PvDBP and deemed possibly, probably or 
definitely related to vaccination were all mild in nature. These are shown in Table 3.1. 
There was only one laboratory adverse event following ChAd63 PvDBP that was considered 
possibly, probably or definitely related to vaccination. This was mild lymphopenia in one 
volunteer vaccinated with ChAd63 PvDBP 5 x 1010 vp which resolved spontaneously. 
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Figure 3-3: Solicited local and systemic AEs following ChAd63 PvDBP.  
Only the highest intensity of each AE per subject is listed. Data are combined for all AEs for all volunteers 
receiving the same vaccine at the stated dose. (A) Local AEs post ChAd63 PvDBP at 5 x 10
9
 vp (G1; 4 
volunteers) and 5 x 10
10
 vp (G2; 20 volunteers). (B) Systemic AEs post ChAd63 PvDBP at 5 x 10
9
 vp (G1) 
and 5 x 10
10
 vp (G2). Data were exported from the OpenClinica database into Excel and the percentages 
of volunteers experiencing each AE following vaccinations at different doses were calculated.  
Unsolicited AEs post ChAd63 PvDBP 5 x 109 vp  AE start day Severity 
Bad dreams overnight 1 Mild 
General malaise following lack of sleep and drinking alcohol  2 Mild 
Unsolicited AEs post ChAd63 PvDBP 5 x 1010 vp  AE start day Severity 
Arthralgia in hip area  0 Mild 
Blocked nose 0 Mild 
Bruising at site of vaccination 1 Mild 
Coryzal symptoms 1 Mild 
Unsolicited AEs post MVA PvDBP 1 x 108 pfu  AE start day Severity 
Bruise at vaccine site 0 Mild 
Unsolicited AEs post MVA PvDBP 2 x 108 pfu AE start day Severity 
Sore throat  0 Mild 
Dry cough  1 Mild 
5mm diameter red mark 2 inches from vaccination site, felt warm  1 Mild 
Slight tightness of the chest 5 Mild 
Raised lymph nodes in neck 3 Mild 
Table 3.1: Unsolicited adverse events considered possibly, probably or definitely related to 
vaccination with ChAd63 PvDBP or MVA PvDBP. 
AE data were extracted from the Openclinica database and grouped by vaccination dose. 
Causality was assessed as per the criteria in Table 2.4 
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Solicited adverse events following MVA PvDBP at 1 – 2 x 108 pfu are shown in Figure 3-4A 
(local) and Figure 3-4B (systemic). The higher dose of MVA PvDBP was more reactogenic with 
half of the volunteers reporting at least 1 severe AE, although no systemic AE was reported as 
severe for more than 24 hours. Reactogenicity following MVA PvDBP peaked in the first two 
days after vaccination (Figure 3-5C, D). 
Unsolicited AEs following MVA PvDBP that were considered possibly, probably or definitely 
related to vaccination were mild in nature and are shown in Table 3.2.  
There was only one laboratory AE following MVA PvDBP that was considered possibly, 
probably or definitely related to vaccination. This was moderate eosinophilia in one volunteer 
vaccinated with MVA PvDBP 1 x 108 pfu which peaked more the 4 weeks after vaccination and 
resolved spontaneously. 
 
Figure 3-4: Solicited local and systemic AEs following MVA PvDBP.  
Only the highest intensity of each AE per subject is listed. Data are combined for all AEs for all volunteers 
receiving the same vaccine at the stated dose. There were no immunisation related serious AEs. (A) Local 
AEs post MVA PvDBP 1 x 10
8
 pfu (G2B; 7 volunteers) and MVA PvDBP 2 x 10
8
 pfu (G2C; 8 volunteers). (B) 
Systemic AEs post MVA PvDBP (G2B and G2C). Data were exported from the OpenClinica database into 
Excel and the  percentage of volunteers experiencing each AE following vaccinations at different doses 
were calculated. 
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Figure 3-5: VAC051 Percentage of volunteers reporting solicited adverse events by day. 
Data shown for all volunteers post ChAd63 PvDBP (A, B) and MVA PvDBP (C, D), regardless of dose 
received. Data were exported from the Openclinica database into Excel and the percentages of 
volunteers reporting each solicited AE by day post vaccination were calculated. 
 
3.4.3 ChAd63/MVA PvDBP T cell immunogenicity assessed by ex-vivo IFN-γ 
ELISPOT 
The kinetics and magnitude of the T cell response to PvDBP were assessed over time by ex-vivo 
IFN-γ ELISPOT following re-stimulation of PBMC with overlapping peptides spanning the entire 
PvDBP_RII insert present in the viral vectored vaccines.  
Vaccination with ChAd63 PvDBP and MVA PvDBP induced antigen-specific T cell responses in 
all volunteers as measured by ex-vivo IFN-γ ELISPOT, with median group responses shown in 
Figure 3-6A Following the ChAd63 PvDBP prime at doses of 5 x 109 vp (Group 1 [G1]) and 5 x 
1010 vp (Group 2 [G2]) there was no significant difference between the groups two weeks after 
vaccination, Figure 3-6B. However, one week after the MVA PvDBP boost (Figure 3-6C) there 
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were significantly stronger median responses in G2B and G2C compared to G2A who did not 
receive the boost (median of 368, 2061 and 2459 SFU/million PBMC in G2A, G2B and G2C 
respectively). There was a trend towards better maintained responses at day 140 in G2C 
compared with G2B (median 1871 vs 385.3 SFU/million PBMC). 
 
Figure 3-6: T cell responses following ChAd63/MVA PvDBP vaccination.  
T cell responses were measured by ex vivo IFNγ ELISPOT using fresh PBMC following ChAd63 PvDBP 
prime vaccination (d0) for G1 (5x10
9
 vp; n=4) and G2 (5x10
10
 vp; n=20) and heterologous boost with MVA 
PvDBP (d56) to G2B (1x10
8
 pfu; n=7) and G2C (2x10
8
 pfu; n=8). All vaccinations were given IM. (A) Group 
median responses. (B) Two weeks post ChAd63 PvDBP vaccination (d14) low dose G1 vs full dose G2. (C) 
One week post MVA PvDBP boost vaccination (d63) in G2B and G2C compared to G2A (ChAd63 PvDBP 
prime only). (D) 12 weeks post boost of G2B and G2C compared to G2A prime only. Spots were counted 
using an automated plate counter and exported into an Excel worksheet where results were obtained by 
subtracting any background response (from negative control wells) and then taking the average of 
triplicate wells. Data were then imported into GraphPad Prism for statistical analyses. *P<0.05, Kruskal-
Wallis test with Dunn’s correction for multiple comparisons. 
 
3.4.4 ChAd63/MVA PvDBP antibody response assessed by ELISA 
The kinetics and magnitude of the serum IgG antibody responses were assessed over time by 
an ELISA to recombinant PvDBP_RII protein (Figure 3-7). Vaccination with the full dose of 
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ChAd63 PvDBP (5x1010vp) induced antigen-specific antibody responses in all volunteers, with 
responses boosted following the MVA PvDBP vaccination in Groups 2B and 2C. Median 
responses are shown in Figure 3-7A. Following the ChAd63 PvDBP prime doses of 5 x 109 vp 
and 5 x 1010 vp there was no significant difference between the two groups four weeks post 
vaccination, but only volunteers in G2 seroconverted to above the threshold of 20 AU. 
However, four weeks post MVA DBP boost (Figure 3-7C), there were significantly stronger 
median responses in G2C compared with G2A who received ChAd63 PvDBP alone (median 
3899 vs 95.5 anti-PvDBP_RII IgG AU), and responses were still significantly higher at day 140 in 
G2C compared to G2A (median 1378 vs 71.70 anti-PvDBP_RII IgG AU). 
 
Figure 3-7: Serum IgG antibody responses following ChAd63/MVA PvDBP measured by ELISA. 
PvDBP_RII-specific IgG responses are shown following ChAd63 PvDBP (d0) in G1 (5x10
9
 vp; n=4) and G2 
(5x10
10
 vp; n=20) and MVA PvDBP boost (d56) in G2B (1x10
8
 pfu; n=7) and G2C (2x10
8
 pfu; n=8). (A) 
Group median responses. (B) Four weeks post ChAd63 PvDBP (d28) low dose G1 vs full dose G2. (C) Four 
weeks post MVA PvDBP boost (d84) in G2B and G2C compared G2A prime only. (D) 12 weeks post boost 
of G2B and G2C compared to G2A prime only. The absorbance at 405nm (OD405) was read using a Biotek 
ELx800 microplate reader with Gen5 software. Data were exported into an Excel worksheet and values of 
internal controls and samples in triplicate were assessed for any aberrant readings. The results were 
obtained by taking an average of triplicate wells, and using the standard curve to assign ELISA arbitrary 
units (AU). The limit of the assay is 20 AU (marked by a dotted line), below which is classed as negative. 
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Data were then imported into GraphPad Prism for statistical analyses. **P<0.01, Kruskal-Wallis test with 
Dunn’s correction for multiple comparisons.  
 
3.4.5 Anti-PvDBP IgG avidity and antibody isotype response profiles  
An avidity ELISA was carried out on Group 2 samples four weeks post MVA PvDBP boost (d84; 
the peak timepoint for IgG response). This assay used displacement of sodium thiocyanate at 
different concentrations to ascertain the avidity of the IgG antibodies for each volunteer. The 
avidity of the anti-PvDBP IgG was similar for all responders in G2 (Figure 3-8) with the IC50 
ranging from 2.5-3.3 M, similar to antibodies produced in boosted PfMSP1 vaccinees (193) and 
higher than PfAMA1 vaccine induced IgG (167).  
An isotype ELISA was also carried out in order to determine the antibody subclass response 
profile following ChAd63/MVA PvDBP vaccination. The response was predominantly composed 
of IgG1, and IgG3 (Figure 3-9), as has been seen previously with viral vectored vaccines (193). 
 
 
Figure 3-8: IgG Avidity assessment following ChAd63/MVA PvDBP vaccinations.  
Anti-PvDBP total IgG avidity was assessed by NaSCN-displacement ELISA against Sal1 PvDBP_RII protein 
and is reported as the molar concentration of NaSCN required to reduce the OD405 to 50% of that without 
NaSCN (IC50). Sera were diluted to give an OD405 = 1.0 and exposed to a dilution curve of NaSCN (0-7M). 
The IC50 is shown for individual responses in each group at the peak time-point (d84) (G2A n=1, G2B n=7, 
G2C n=8). Avidity for samples negative for Total IgG ELISA could not be measured. The absorbance at 
405nm (OD405) was read using a Biotek ELx800 microplate reader with Gen5 software. Data were 
exported into an Excel worksheet and the average value of duplicate readings calculated. Data were 
then imported into GraphPad Prism for statistical analyses. There were no significant differences 
between groups using the Kruskal-Wallis test with Dunn’s correction for multiple comparisons. 
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Figure 3-9: Antibody isotype profile following ChAd63/MVA PvDBP vaccination.  
Antibody isotype was assessed by ELISA. Baseline (d0) response for all Groups (n=20), 12 weeks post 
ChAd63-PvDBP prime for G1 (n=2) and G2A (n=4) and 4 weeks post MVA-PvDBP boost for G2B (n=7) and 
G2C (n=8) (d84) are shown. Individual and median responses are shown for every isotype. The 
absorbance at 405nm (OD405) was read using a Biotek ELx800 microplate reader with Gen5 software. 
Data were exported into an Excel worksheet and the average OD values of duplicate samples calculated. 
Data were then imported into GraphPad Prism for statistical analyses *P<0.05, ***P<0.001, Kruskal-
Wallis test with Dunn’s correction for multiple comparisons. 
 
3.4.6 Detection of anti-PvDBP ASCs following ChAd63/MVA PvDBP 
Previous studies have demonstrated that ASC responses are detectable in peripheral blood 
around 7 days after boost vaccination using a ChAd63/MVA viral vectored heterologous prime-
boost regime (194). Samples from boosted volunteers (G2B and G2C) were assessed by ex-vivo 
ASC ELISPOT at the d63 timepoint using frozen PBMC. There was no significant difference in 
the responses between the two groups (Figure 3-10). 
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Figure 3-10: ASC responses following ChAd63/MVA PvDBP vaccination.  
PvDBP-specific peripheral blood ASCs measured from frozen PBMC isolated 7 days following MVA PvDBP 
vaccination (d63) using ex-vivo ELISPOT from volunteers in G2B (n=7) and G2C (n=8). Spots were counted 
using an AID ELISPOT reader and automated counts were corrected by eye to ensure only spots 
consistent with IgG secreting ASCs were counted. Data were exported into an Excel worksheet and then 
imported into GraphPad Prism for statistical analyses. There was no significant difference between the 
two groups using a Mann Whitney t test. 
 
3.4.7 Anti-PvDBP peripheral mBC responses following ChAd63/MVA PvDBP 
Peripheral mBC responses were assessed by identifying PvDBP-specific mBC-derived plasma 
cells by ex-vivo ELISPOT following a 6-day polyclonal culture of PBMC (Figure 3-11). The 
responses were measured at the peak IgG response (d84) and demonstrated a significant 
difference between the median response in G2B and G2C, both as a measure of mBC-derived 
ASC per million PBMC (Figure 3-11A), and when comparing antigen-specific cells as a 
percentage of total IgG+ (Figure 3-11B). As has been seen previously (194), the mBC derived 
ASC response correlated with the peak (d84) antibody response measured by ELISA (Figure 3-
11C, D). 
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Figure 3-11: mBC responses following ChAd63/MVA PvDBP vaccination.  
mBC derived ASC measured at the peak of the response at d84 using ex-vivo ELISPOT. (A) Comparison 
between vaccine Groups 2B (n=7) and 2C (n=8) (mBC derived ASC per million cultured PBMC). (B) 
Comparison between vaccines Groups 2B and 2C (mBC derived ASC as a % of total IgG ASC). Individual 
and median responses are shown. (C-D) Correlations between mBC derived ASC and peak (d84) antibody 
response as measured by anti-DBP ELISA mBC ELISPOT spots were counted using an AID ELISPOT reader 
and automated counts were corrected by eye .Data were exported into an Excel worksheet and then 
imported into GraphPad Prism for statistical analyses. *P<0.05, Mann-Whitney test for comparing 
groups, Spearman rank for correlation analysis. 
 
3.4.8 PvDBP_RII – DARC Binding Inhibition Assay 
The functional activity of the antibodies induced by vaccination with ChAd63/MVA PvDBP was 
assessed in a binding inhibition assay using recombinant PvDBP_RII and its receptor, DARC 
(Figures 3-12 and 3-13). These assays were carried out both in Oxford and in a collaborating 
laboratory at ICGEB in India. Both assays demonstrated inhibition of binding in all volunteers 
who received the prime-boost regime and one volunteer who received full-dose ChAd63 
PvDBP alone. The assay carried out in Oxford demonstrated that as serum was diluted the 
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binding inhibition decreased (Figure 3-12). The assay carried out at ICGEB (Figure 13-3) 
demonstrated that the antibodies induced by vaccination were able to block the binding of not 
just the homologous PvDBP allele (Sal I) but three other variants as well. This is important as 
an effective P. vivax vaccine based on PvDBP would need to have strain-transcending activity, 
particularly given the concerns about polymorphism in this antigen. 
 
 
Figure 3-12: PvDBP_RII – DARC Binding Inhibition Assay (Oxford).  
Sera were tested for ability to block binding of PvDBP_RII protein to its receptor DARC in an ELISA-based 
assay carried out in Oxford for the Sal I allele using a serum dilution series. Percentage binding inhibition 
is shown for Groups 1 (n=4), 2A (n=4), 2B (n=7) and 2C (n=8). The OD of the ELISA plates was read at 405 
nm on Bio-tek ELx800 Microplate Reader with Gen5 software. Plates were developed to a point 
determined by the OD of the development controls wells (i.e. when the negative control wells reached an 
OD = 1.0). Data were exported into and Excel worksheet and then imported into GraphPad Prism for 
graphical presentation and analyses.  
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Figure 3-13: PvDBP_RII – DARC Binding Inhibition Assay (ICGEB).  
Sera from G2A (n=4), G2B (n=7) and G2C (n=8) were independently tested in an ELISA-based assay at 
ICGEB in India using four different alleles (Sal I, AH, O and P) and serum diluted in series (1:10, 1:50, 
1:100, 1:500 and 1:1,000). Each serum dilution was pre-incubated with the relevant test variant of 
PvDBP_RII (0.025 µg/mL) before being added to DARC-coated plates. A standard curve was generated 
from a series of concentrations (0 – 0.025 µg/mL) of the relevant test PvDBP_RII protein variant. The OD 
was measured at 492 nm using SoftMax Pro software, that interpreted the OD values as concentrations 
of bound PvDBP_RII based on the standard curve on each plate. Percent inhibition at each dilution was 
determined as (100 % – % binding). 
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3.5 Discussion  
There are an estimated 2.5 billion people living at risk of P. vivax malaria globally (195). The 
revised 2030 Malaria Vaccine Technology Roadmap now recognises the urgent need for a 
vaccine to tackle P. vivax if the goal of malaria eradication is to ever be achieved (7). This is 
particularly important given the development of resistance to standard P. vivax treatment, 
with associated mortality (43). In 2015, the World Health Assembly endorsed the target of 
eliminating malaria from 35 countries and reducing case incidence and mortality rates by 90% 
globally by 2030 (196). This is an ambitious goal, for which P. vivax presents particular 
challenges. In countries with few cases of malaria each year, where eradication would appear 
more feasible, P. vivax is the predominant form of malaria accounting for over 70% of cases 
(197). The difficulty of detecting asymptomatic infection, the ability of P. vivax to relapse, and 
the appearance of gametocytes prior to the onset of disease all contribute to difficulties in 
eradication of this infection. A blood-stage P. vivax vaccine, even if only partially effective, 
would allow natural immunity to develop with reduced disease severity (198). A blood-stage 
vaccine would also, importantly, protect against relapses due to the hypnozoite (as long as 
relapses occurred within the duration of protective blood-stage immunity provided by 
vaccination), which would not be the case for pre-erythrocytic or transmission-blocking 
vaccine candidates.  
There are many hurdles to be overcome in development of an effective vaccine against P. 
vivax. Polymorphism of the parasite has been well described, particularly in blood-stage 
antigens (199, 200) with limited polymorphism described in transmission-blocking candidates – 
presumably due to reduced human immune pressure as these antigen targets occur within the 
mosquito (201). This is likely to cause significant problems in vaccine development unless a 
conserved antigen can be found or multiple antigens are included in a vaccine. Cost-effective 
formulation and ease of delivery are also likely to be challenges, particularly if vaccines are 
used as a control method where vaccine coverage will have to be extremely high and migrant 
populations will pose some difficulty. A vaccine will have to be acceptable to the populations 
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targeted with the intervention, and a vaccine active against disease may be more readily 
accepted than a transmission-blocking vaccine. 
For many years the P. vivax Duffy binding protein has been considered a leading vaccine 
candidate but has never previously reached clinical trial. The VAC051 Phase Ia clinical trial was 
the first study to evaluate this antigen (and, in fact any blood-stage P. vivax antigen) as a 
vaccine candidate. Having long been considered an attractive antigen for vaccine 
development, production of the protein to GMP standards has proved difficult (202). The use 
of the viral vectors meant that a vaccine regime suitable for human use was successfully 
produced (157). This trial demonstrated that the vaccines were well tolerated, with no safety 
concerns, and an acceptable reactogenicity profile. As has been seen in previous vaccine trials 
with the same viral vectors (84, 155), the higher doses of both vaccines were associated with 
increased frequency and severity of AEs. 
The ChAd63/MVA PvDBP heterologous prime-boost regime was immunogenic, producing both 
antigen-specific T cells and B cells. There was no significant difference between either of the 
boosted groups (2B or 2C) in the levels of antigen-specific T cells or IgG at peak time-points, 
although there was a trend towards better maintenance of T cell levels at the final time-point 
following the higher MVA PvDBP dose.  
The T cell response seen in the VAC051 trial was similar in magnitude to other malaria vaccines 
using the same viral vectors (83, 84). The ChAd63/MVA heterologous prime-boost regimen has 
previously been shown to induce increases in both CD4+ and CD8+ T cells, with broader and 
more potent responses than those seen using prime-boost regimens of DNA and poxvirus 
vectors. (148). This broader response is anticipated to not only act by helping to facilitate an 
antibody response through CD4+ helper cells but also to contribute to direct clearance of 
pathogens through cell-mediated effector mechanisms. The role of cell-mediated immunity in 
a blood-stage malaria vaccine is not fully understood. However, both CD4+ and CD8+ T cells 
have been shown to be activated in acute blood-stage malaria infection, and probably 
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maintained after infection, in a mouse model (using the murine parasite P. yoelli), with cells 
phenotypically similar to those seen after other bacterial and viral infections (203). This 
supports the view that an optimised blood-stage malaria vaccine should be tailored to induce 
both an antibody and T-cell immune response. 
The ChAd63/MVA PvDBP vaccines were able to induce an antigen-specific IgG response, with a 
predominance of IgG1 and IgG3 isotypes, as has been seen previously with viral vectored 
vaccines (193). I also demonstrated induction of antigen-specific memory B cells in boosted 
volunteers, and the appearance of antigen-specific antibody-secreting cells in peripheral blood 
around 7 days post boost vaccination with MVA PvDBP. This has been described previously 
following ChAd63/MVA viral vectored vaccines and these cells are thought to arise from mBC 
re-stimulation in the lymphoid system (following the boost vaccination). They are seen 
transiently in the blood stream and this is likely to be as they travel to the bone marrow where 
they remain as plasma cells (194). The antibodies induced by vaccination were able to block 
the binding of the Duffy-binding protein to its receptor, DARC, in an in vitro assay carried out in 
Oxford, with similar results seen in both Groups 2B and 2C. This functional activity was also 
demonstrated in an independent experiment carried out in a collaborating laboratory in the 
ICGEB. Encouragingly, the antibodies were able to block not only the reference strain (Salvador 
I) but several other P. vivax strains as well. This is encouraging as one of the potential 
problems of using viral vectored vaccines is that they cause protein expression to occur in situ 
following vaccination, meaning that the immunogen produced cannot be fully characterised 
and may not have folded correctly or been transported through secretory pathways 
successfully (204). The ability of the antibodies produced by vaccination to bind to 
recombinant PvDBP and block binding of the protein to DARC implies that expression of a 
correctly folded protein occurred following ChAd63/MVA PvDBP vaccination.  
The functional activity seen in the VAC051 trial may, however, not translate into vaccine 
efficacy. Assays to determine invasion inhibition of antibodies against P. vivax blood-stage 
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antigens are more complicated to carry out than in P. falciparum studies due to the lack of 
ability for long term culture of vivax parasites in vitro. This generally limits these assays to 
being carried out in countries where P. vivax is endemic, and necessitates collection of blood 
from vivax-infected individuals for use in the assays (132). Translation of in vitro blocking 
activity to efficacy in an in vivo infection setting has not previously been assessed.  
The use of a standardised, reproducible CHMI model for early proof-of-concept efficacy testing 
has been a useful tool in the development of P. falciparum antimalarial drugs (205, 206) and 
vaccines (11). The ability to induce infection consistently and closely observe infected 
individuals means that much smaller numbers are needed for these Phase IIa clinical trials than 
would be needed to test efficacy in a Phase IIb field trial. This has substantial implications for 
cost and time, with only candidates that show efficacy being taken forward to larger, more 
expensive trials. CHMI for P. vivax has been far less utilised than for P. falciparum, with only a 
small handful of studies reported in the last few years, with only one published study assessing 
the efficacy of a vaccine against vivax malaria, the pre-erythrocytic vaccine candidate VMP001 
(77). Deliberate infection with P. vivax was practiced for the treatment of neurosyphilis 
patients almost a century ago by the Austrian psychiatrist Julius Wagner-Jauregg. This initially 
involved injecting neurosyphilis patients with blood taken from soldiers hospitalised with 
malaria, and later passaging malaria through patients (207). The practice was widely adopted 
as it was the only effective treatment for neurosyphilis available at the time, with up to 50% 
efficacy in curing or improving the disease, but was not without risk – mortality rates of 5-15% 
were reported in treated patients, although these patients had significant comorbidities (22). 
CHMI studies conducted in the USA in the 1940s to 1970s explored the biology of P. vivax and 
the potential for inducing immunity through exposure to irradiated sporozoites delivered by 
mosquito bite which conferred short term (3 – 5 months) protection from subsequent 
exposure to infection (61, 64). CHMI studies with P. vivax were discontinued, and only 
relatively recently have been reinstated as a potential method for assessing vaccine and drug 
efficacy.  
117 
 
Several CHMI trials by mosquito bite have been assessed by a group in Cali, Columbia using 
mosquitoes infected with P. vivax from patients presenting for treatment (136, 137, 208). 
Additionally, the VMP001 candidate vaccine was assessed at WRAIR in the USA using 
mosquitoes infected from a donor in Thailand and then transported to the USA (77). These 
studies have demonstrated that the mosquito-bite CHMI model is possible for vivax malaria, 
but there are several limitations with this method. Fresh gametocytes from an infected patient 
are required because long-term P. vivax culture is not currently possible. This poses significant 
logistical challenges as it requires at least part of the trial to be undertaken in an endemic 
setting with appropriate entomological facilities established to produce an infected mosquito 
lot after screening and enrolling a donor patient. Subsequently, the mosquito lot can be used 
in trials in the same location, or transported to non-endemic areas but the timing for this in 
the setting of vaccine efficacy testing will be crucial. Furthermore, a different isolate of P. vivax 
will inevitably be used for every trial, meaning CHMI assessment of vaccines is almost certainto 
be with a heterologous strain to that used in the vaccine; that the parasites may have different 
susceptibility to antimalarial treatment between strains; and these differences will be 
unknown at the time of CHMI. As seen in the trials carried out in Cali, different strains are 
likely to have different pre-patent periods which can limit comparability between trials (137). 
The use of sporozoites for CHMI also necessitates a liver-stage of infection, with a high risk of 
hypnozoite formation and potential relapse. This requires participants to be screened for G6PD 
deficiency in order to avoid haemolysis with primaquine, and now also requires assessment of 
the volunteers’ ability to metabolize primaquine (requiring analysis of cytochrome P450 2D6 
phenotype) to maximise safety. Volunteers with poor or intermediate metaboliser CYP2D6 
phenotypes should not be enrolled for such studies (51).  
An alternative approach to mosquito-bite CHMI is to use blood-stage CHMI, as has been 
developed for P. falciparum (Chapter four, (209)). There have been four P. vivax blood-stage 
CHMI studies to-date successfully carried out at QIMR Berghofer in Brisbane, Australia using 
two different inocula (James McCarthy, personal communication). The first pilot study, carried 
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out in two healthy volunteers, demonstrated that infection with P. vivax from a frozen 
inoculum was possible and there were no safety concerns (210). Blood-stage CHMI is obviously 
limited to studies of vaccines or drugs targeting the blood-stage of infection so cannot be used 
for pre-erythrocytic vaccine candidates. It does however have several advantages in situations 
where it can be used. Practical advantages include the ability to carry out CHMI studies more 
easily in a non-endemic setting; having access to the P. vivax strain genetic data before CHMI; 
being able to carry out multiple studies with the same strain (for which a safety database can 
be established); and being able to use the same inoculum size for each volunteer. There are 
also advantages for participants with this method – the use of blood-stage parasites means 
there is no liver-stage of infection, and therefore no risk of hypnozoite formation or relapse. 
This means participants do not require primaquine treatment, and therefore do not require 
G6PD deficiency or cytochrome P450 2D6 phenotype screening. The sensitivity of the parasite 
to antimalarial treatment can also be known in this scenario prior to CHMI, removing the risk 
of using a drug-resistant strain which is a potential possibility with the mosquito-bite CHMI 
model. 
In this Chapter I have described the results of the first Phase Ia clinical trial of a blood-stage P. 
vivax vaccine candidate, ChAd63/MVA PvDBP, demonstrating that in healthy malaria-naïve 
volunteers the vaccine was well tolerated and immunogenic, inducing functional antibodies 
against the PvDBP antigen. Future work will aim at developing the blood-stage CHMI model for 
P. vivax to assess the efficacy of this and other blood-stage P. vivax vaccines. This model has 
proved very useful for P. falciparum, as discussed in Chapter four, for the blood-stage P. 
falciparum vaccine candidate, FMP2.1/AS01B. I conducted a Phase I/IIa study to assess the 
safety, immunogenicity and efficacy of this vaccine using a homologous blood-stage CHMI 
model (209). 
The WHO Malaria Vaccine Technology Roadmap calls for a vaccine with an efficacy against 
clinical disease of 75% for both P. falciparum and P. vivax by 2030 (7). The focus on vaccine 
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development must therefore not be based solely on one parasite or the other but work to 
target both. This is unlikely to be achieved with a single antigen, and will probably require a 
multi-component malaria vaccine. Chapters four and five discuss the development and 
assessment of candidate vaccines against P. falciparum blood-stage antigens conducted 
alongside this P. vivax study with this eventual goal in mind.  
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Chapter Four:
 A Phase I/IIa clinical trial to 
assess the safety, immunogenicity 
and efficacy of FMP2.1/AS01B, an 
asexual blood-stage vaccine for 
Plasmodium falciparum Malaria 
(VAC054) 
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4.1 Authorship statement 
I set up the VAC054 clinical trial with the assistance of Alison Lawrie, Rachel Roberts, Ian 
Poulton, Adrian Hill (CI) and Simon Draper. This involved preparation of the study documents 
with submission for ethical, regulatory approval for all sites, and Research and Development 
(R&D) department approval for NHS sites (in Southampton and London).  
I screened and enrolled volunteers from Oxford and London (NIHR WTCRF, Imperial College 
Healthcare NHS Trust) for the trial. Study staff at the NIHR WTCRF in Southampton carried out 
screening and enrolment of volunteers at this site. Vaccinations and follow-up visits were 
conducted by local site study teams, including myself. The Principal Investigator (PI) in 
Southampton was Saul Faust and the PI in London was Graham Cooke. 
The blood-stage CHMI inoculum was prepared in the Jenner Institute laboratories by Rebecca 
Brown and Simon Draper. It was administered to volunteers at the CCVTM in Oxford by me, 
assisted by Morven Wilkie, Navin Venkatraman, Ian Poulton, Mary Smith, Paula Marriott and 
Raquel Lopez-Ramon. Thick blood films following CHMI were read by qualified microscopists 
Joseph Muita, Pauline Titus and Kebba Konteh from Kemri, Kenya. qPCR was carried out in 
Oxford by Nick Edwards and a team of laboratory staff. 
Laboratory assays assessing vaccine and CHMI immune responses were carried out in Oxford 
by Kathryn Milne, Sarah Silk, Sean Elias and me. The GIA assays were carried out at the NIH 
reference center laboratory in the USA by Kazutoyo Miura. 
The clinical trial described in this Chapter has been published in the Journal of Infectious 
Diseases (209). 
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4.2 Introduction 
4.2.1 Blood stage P. falciparum vaccines 
There has been considerably more research into P. falciparum vaccines than P. vivax vaccines 
in the past. The antigens that have been most widely investigated as blood-stage vaccine 
candidates are AMA1 and MSP1, both of which are proteins found on the merozoite surface. 
Field studies have shown that merozoite surface antigens including AMA1 and MSP1 are 
targets of naturally occurring protective blood-stage immunity (211, 212). Both of these 
antigens have been tested as protein-in-adjuvant formulations (95) and in viral vectored 
vaccines (83), with limited success.  
The ability of a blood-stage vaccine to significantly reduce parasite replication in the blood is 
deemed essential, in order for a blood-stage vaccine to effectively prevent illness when pre-
erythrocytic control measures have failed (25). Numerous factors have hindered development 
of vaccines against the merozoite including:  substantial levels of polymorphism in candidate 
antigens; redundant erythrocyte invasion pathways; and the apparent need for very high 
antibody concentrations to prevent rapid erythrocyte invasion (25, 213). Furthermore, the best 
approach to assessment of vaccine efficacy, including ‘proof of concept’ (POC) studies, against 
the blood-stage parasite in humans has been widely debated (214). 
This trial looked at the safety, immunogenicity and efficacy of a recombinant protein vaccine 
based on the 3D7 clone sequence of P. falciparum AMA1, known as FMP2.1 (93) and 
formulated in the Adjuvant System AS01 from GSK. The vaccine has previously been developed 
and tested in a series of Phase Ia/b safety and immunogenicity trials using the AS01 and AS02 
Adjuvant Systems (94-96, 215). A subsequent Phase IIb field trial in 400 Malian children using 
the FMP2.1/AS02 formulation reported strain-specific efficacy against parasites with 3D7 
AMA1-like sequence in a secondary efficacy endpoint analysis (97). The trial I led, as described 
in this Chapter, aimed to assess POC blood-stage efficacy by inoculating volunteers with blood-
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stage malaria parasites after vaccination and comparing the results in PMR between 
vaccinated volunteers and unvaccinated infectivity controls. 
4.2.2 AMA1 as an antigen 
As described in Chapter one, P. falciparum AMA1 is a precursor protein of 83 kDa (93) located 
in the apical end of the merozoite in the micronemes prior to schizont rupture. The N terminus 
is cleaved to give a 66 kDa form which is found on the merozoite surface following schizont 
rupture, whereas the 83 kDa form is localised apically (89, 90). AMA1 binds to another parasite 
protein, PfRON2, which is inserted by the parasite into the host red cell membrane, forming 
the tight / moving junction and allowing invasion to take place. Antibodies to AMA1 have been 
shown to prevent processing and circum-merozoite redistribution and shedding of the protein. 
Without AMA1 undergoing these processes red blood cell invasion is inhibited (92). 
FMP2.1 is a lyophilised preparation of the majority of the ectodomain of P. falciparum AMA1. 
The gene encoding the FMP2.1 protein was chemically synthesised to contain an E. coli-
optimised codon usage to encode 478 amino acids representative of amino acids 83 to 531 of 
the AMA1 protein with two attached His-tags. The amino acid sequence is: 
MAHHHHHHPGGSGSGTMH-[AMA1 amino acids 83 to 531]-AAALEHHHHHH. 449 of the amino 
acids are derived from the merozoite protein AMA1 of the 3D7 clone of P. falciparum. The 
protein was produced in and purified from E. coli bacteria at the WRAIR BioProduction Facility 
under GMP (93, 95, 97). 
4.2.3 The AS01 Adjuvant System 
Adjuvants have been known to increase the immune response against a given antigen for over 
80 years. GSK Biologicals have developed ‘Adjuvant Systems’ which are formulations of 
classical adjuvants (e.g. aluminium salts, liposomes) mixed with immunomodulatory molecules 
(e.g. Toll-like receptor [TLR] agonists), with an aim of impacting the innate and/or adaptive 
immune responses. AS01 is a liposome-based Adjuvant system with a specific aim to improve 
cell-mediated immunity (122). It is also one of the best adjuvants available for inducing 
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antibody production following vaccination (216). The Adjuvant System contains 3-0-desacyl-4’ 
monophosphoryl lipid A (MPL), a TLR4 ligand derived from the cell wall lipopolysaccharide 
(LPS) of the Gram negative Salmonella minnesota R595 strain. The LPS is detoxified by 
hydrolytic treatment and purification to provide a powerful adjuvant without the toxic effects 
of the parent molecule. The AS01 adjuvant system also contains QS21, a triterpene glycoside 
purified from the bark of the South American tree Quillaja saponaria. QS-21 has been shown 
to impact antigen presentation to antigen presenting cells (APCs) and favours the induction of 
cytotoxic T lymphocytes (122). AS01 is produced in an adult formulation, AS01B and a 
paediatric formulation, AS01E, which contains half the amount of MPL and QS21 as the adult 
version (217). The AS01B adjuvant system used in this trial contains 50 micrograms of MPL and 
50 micrograms of Stimulon QS21 in a liposome-based formulation in a 0.5 mL dose (95). 
AS01 is closely related to another Adjuvant System, AS02, which contains the same 
immunostimulants MPL and QS21. AS02 is an oil-in-water, rather than liposomal, formulation 
so has smaller particle size than AS01 (218). The adult formulation is termed AS02A whilst the 
paediatric formulation is termed AS02D. The clinical evaluation of GSK’s leading malaria 
vaccine candidate RTS,S started with AS02 but a Phase IIa sporozoite CHMI study 
demonstrated that the safety and reactogenicity of RTS,S/AS01 was comparable to that of 
RTS,S/AS02, with a trend towards improved vaccine efficacy (VE) against infection (50.5% [95% 
CI: 32.9, 67.1] vs 31.8% [95% CI: 17.6, 47.6]) (73). This was confirmed in a subsequent study in 
Ghent, Belgium (219). The RTS,S vaccine has been given to thousands of individuals, including 
children in phase I – III trials with no significant safety concerns and moderate efficacy (57). 
AS01 has been taken forward as the preferential Adjuvant System for malaria vaccines given 
the improvement in immunogenicity seen with compared with AS02. The VAC054 trial 
therefore used this rather than AS02. 
125 
 
4.2.4 Previous trials of FMP2.1 
4.2.4.1  FMP2.1 with AS02A 
Phase Ia 
FMP2.1 was evaluated with AS02A in a Phase Ia dose escalation study in 23 healthy, malaria-
naïve adult volunteers at WRAIR in 2007 by Polhemus et al. The final dose used was 43 μg of 
lyophilised protein which was mixed with AS02A just prior to immunisation, so that 
approximately 8, 20 or 40 μg of FMP2.1 was delivered in a final volume of 0.5mL of AS02A. 
There were 8 volunteers enrolled into each of the lower dose groups and 7 volunteers in the 
group receiving 40 μg. Three vaccinations were scheduled for each volunteer at 0, 1 and 2 
months. Nineteen volunteers completed the study, receiving all vaccines. There were no SAEs 
related to vaccination and the most common local AE was injection site pain. Swelling at the 
injection site was also noted, particularly in the high dose group, but this was generally mild. 
The most common systemic AEs noted were headache (18 incidents over 63 vaccinations) and 
myalgia (14 incidents over 63 vaccinations). The vast majority of AEs resolved within 72 hours 
of vaccination. The vaccine showed favourable safety data and was immunogenic, with the 
induction of humoral and Th1-biased cellular immune responses (94). 
Phase Ib (Adults) 
A Phase Ib study was carried out in Mali in 60 healthy adults exposed to seasonal malaria. The 
doses used were FMP2.1 25 µg/AS02A 0.25 mL (half dose) or FMP2.1 50 µg/AS02A 0.5 mL (full 
dose). 20 volunteers were recruited into each of the groups to receive FMP2.1/AS02A and the 
remaining 20 received rabies vaccine as controls. The dosing schedule was as for the Phase Ia 
study – 0, 1 and 2 months. Local solicited AEs were higher in the FMP2.1/AS02A vaccine groups 
compared with controls. The most common local AEs were pain and swelling at the injection 
site. Grade 3 swelling was much more common in the full dose FMP2.1/AS02A group. The 
swelling was generally not associated with significant functional impairment, and all local AEs 
resolved within the 8 day follow-up period following vaccination. Headache, myalgia and 
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malaise were the most common systemic AEs, and were more common in the groups receiving 
the full dose FMP2.1 vaccine. There were no severe systemic AEs, and all solicited systemic AEs 
resolved within the 8 day follow up period. There were no SAEs noted in this study. The 
vaccine showed favourable safety data and was immunogenic, with a trend towards higher 
antibody responses in the full dose FMP2.1/AS02A group compared to the half dose group. 
There was also significantly greater in vitro GIA in the post-vaccination sera from the full dose 
group than sera from the control group, but not in sera from the half dose group, against both 
homologous (3D7) and heterologous (FVO) parasites (96). 
Phase Ib (Children) 
A Phase Ib double-blind randomised controlled dose escalation trial was conducted in healthy 
Malian children exposed to seasonal P. falciparum malaria. 100 children aged 1-6 years were 
enrolled, and placed into 3 cohorts (1 group of 20 and 2 groups of 40). Within each cohort, 
participants were randomised in a 3:1 fashion to receive approximately 10, 25 or 50 μg of 
FMP2.1 with a proportionate volume of the AS02A adjuvant system, or rabies vaccine as a 
control. In the first cohort (n=20) 14 of the 15 children vaccinated with 10 μg FMP2.1 with 
0.1mL AS02A received all 3 vaccinations and all 5 controls received 3 vaccinations. The whole 
cohort completed 1 year of follow up. In the second cohort (n=40) 27 of the 30 children 
randomised to receive 25 μg FMP2.1 received all three vaccinations and 8 of the 10 controls in 
this arm received three doses of rabies vaccine. 27 of the 30 children in the vaccine arm and all 
10 controls completed 1 year of follow up. In the third cohort (n=40) 27 children received all 
three vaccinations of 50 μg FMP2.1 with 0.5 mL AS02A and all 10 controls received 3 doses of 
rabies vaccine. 29 children in the vaccine arm and all 10 controls completed 1 year of follow 
up. The most common local AEs were injection site swelling and pain, which tended to 
diminish with subsequent vaccinations (particularly in the lowest dose group). Grade 3 swelling 
was seen in all vaccine groups, but more so in the 50 μg malaria vaccine group. All local AEs 
resolved within the 7 day follow-up period after vaccination. The most common systemic AE 
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was fever and this was more frequent in malaria vaccine recipients than controls. There were 
no severe solicited systemic AEs and all resolved within the 7 day follow-up period. Four SAEs 
were reported in the study. One of these was a raised white blood cell count, which was 
thought to be secondary to malaria infection. The other three SAEs were related to raised liver 
transaminases, one of which was found to be due to acute hepatitis A infection and the other 
two related to hepatitis B, although an additional increase in ALT related to vaccination could 
not be ruled out. All four SAEs resolved within 3 to 4 weeks of follow up with no sequelae. 
FMP2.1/AS02A showed favourable safety data in children, with acceptable tolerability. All 
three dose levels of the FMP2.1/AS02A vaccine elicited high levels of antibodies recognising 
AMA1 after a single vaccination, peaking a month after the third vaccination. Based on this 
study the dose of 50 μg was selected to go forward for further evaluation, although there was 
no significant difference in anti-AMA1 antibody titres between the different dose groups (215). 
Phase IIb (Children) 
A Phase IIb double-blind, randomised efficacy study was carried out in which 400 healthy 
Malian children aged 1 to 6 years were vaccinated with either FMP2.1/AS02A or a control 
(rabies) vaccine and followed up for 6 months. The dose of FMP2.1 used was 50 μg suspended 
in 0.5 mL of AS02A. Children were randomised in a 1:1 ratio to either receive the malaria 
vaccine or control vaccine at 0, 1 and 2 months. The primary endpoint was a clinical episode of 
malaria (defined as fever with an asexual P. falciparum parasite density of >2500 
parasites/mm3). Secondary endpoints included one or more episodes of clinical malaria with 
AMA1 genotypes identical to the 3D7 vaccine strain with respect to eight designated 
immunologically important AMA1 polymorphisms in the cluster 1 loop of domain I and 
multiple episodes of clinical malaria. Children received the vaccines at 0, 1 and 2 months and 
were then followed up for 6 months with blood tests. Blood smears were only read at the time 
of collection if the child was symptomatic. DNA was extracted from dried-blood spots collected 
during clinical malaria episodes, and the gene encoding P. falciparum AMA1 was sequenced. 
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Clinical episodes were classified into those that matched the vaccine strain (in terms of AMA1 
genotype) and those that did not. The unadjusted efficacy of the vaccine was 17.4% (hazard 
ratio for the primary endpoint 0.83; 95% confidence interval [CI], 0.63 to 1.09; P=0.18), 
however, efficacy against clinical malaria with the vaccine strain AMA1 was 64.3% (hazard ratio 
of vaccine vs. control 0.36; CI, 0.08 to 0.86; P=0.03). There were no safety concerns relating to 
the vaccine and no vaccine-related SAEs reported. Swelling was the most common local AE, 
and was more common in the malaria vaccine group than controls. Fever was the most 
common systemic AE and was also significantly more common in the malaria vaccine group 
(97). The allele-specific efficacy against homologous parasites seen in the first malaria season 
did not extend into the second season of follow-up (99). 
4.2.4.2  FMP2.1 with AS01B and AS02A 
Phase I/IIa (Adults) 
AS01B has been used with FMP2.1 in 20 healthy volunteers in a trial by Spring et al. at WRAIR 
(95). This trial compared FMP2.1 given with the AS02A and AS01B adjuvant systems. Five 
volunteers received low dose FMP 2.1/AS01B with 3 doses of 10 μg FMP2.1 in 0.5 mL of 
AS01B. 14/15 volunteers received 3 doses of full dose FMP2.1/AS01B (50 μg FMP2.1 in 0.5 mL 
of AS01B). A further 14/15 volunteers received 3 doses of full dose FMP2.1/AS02A (50 μg 
FMP2.1 in 0.5 mL of AS02A). There was no significant difference in the antibody titres across 
the groups, except at day 42 (two weeks after the second vaccination) when full dose 
FMP2.1/AS01B induced higher concentrations than low dose FMP2.1/AS01B and full dose 
FMP2.1/AS02A. The geometric mean concentration (with 95% CI) for anti-AMA1 IgG measured 
by ELISA two weeks after the third vaccination were 196 µg/mL (103–371 µg/mL) in the low 
dose FMP2.1/AS01B group, 279 µg/mL (210–369 µg/mL) in the full dose FMP2.1/AS01B and 
216 µg/mL (169–276 µg/mL) in the full dose FMP2.1/AS02A group. Some boosting of IgG was 
seen after the third vaccination but the levels were not significantly higher than those reached 
after the second vaccination in any vaccine group. 
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There were no safety concerns with the FMP2.1/AS01B vaccine and no SAEs were noted. Local 
AEs following vaccination were common, and tended to increase with subsequent 
vaccinations. The most common local AEs were injection site pain, erythema and swelling. No 
severe pain was noted and the erythema and swelling were not associated with significant 
functional impairment. Headache, malaise and fatigue were the most common systemic 
effects noted. Systemic AEs also tended to increase with subsequent vaccinations, and were 
most severe in the full dose AS01B group, with 5 volunteers reporting a grade 3 systemic AE in 
this group. The majority of AEs occurred and resolved within 72 hours of vaccination. Vaccine 
efficacy of both vaccines was tested following CHMI via five infectious mosquito bites (3D7 
clone parasites). Six of the volunteers vaccinated with full dose FMP2.1/AS01B and ten of the 
volunteers vaccinated with full dose FMP2.1/AS02A underwent CHMI, along with six 
unvaccinated controls. All vaccinees became parasitaemic with no delay to parasitaemia as 
determined by thick blood film compared with controls. Level of parasitaemia was examined 
by qPCR post-CHMI from day 7 to day 12 (inclusive). There was a statistically significant 
difference among both vaccination groups and the infectivity control group in the longitudinal 
measurement of peripheral parasitaemia on days 7-9 when parasitaemia was detectable by 
qPCR but antimalarial treatment had not yet been initiated (P=0.0002). Post-test analysis using 
Tukey’s Test showed a significantly lower parasitaemia in the volunteers who received full 
dose FMP2.1/AS02A (P=<0.0001) and a trend towards lower parasite burden in the volunteers 
who received full dose FMP2.1/AS01B P=0.084). There was a trend towards a decreased 
hepatic parasite burden with both vaccines, but this was not statistically significant. 
4.2.5 Blood-stage controlled human malaria infection (CHMI) 
As discussed in Chapter one, an alternative to infecting volunteers with malaria via mosquito 
bite is the intravenous administration of infected erythrocytes. This enables the blood-stage of 
infection to be examined in isolation, unlike the more widely used sporozoite CHMI models 
which have historically been used to assess vaccine efficacy of pre-erythrocytic vaccine 
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candidates in small proof-of-concept Phase IIa clinical trials (11, 220), although a few 
mosquito-bite CHMI trials have also been carried out for blood-stage vaccine candidates (83, 
95). More typically, the efficacy testing of blood-stage vaccines has relied on larger-scale, 
expensive Phase IIb field trials in endemic populations. Reasons for this include the assumption 
that blood-stage vaccine efficacy could not be assessed in the short time interval between 
parasite emergence from the liver (around days 6 or 7 post-sporozoite CHMI) and diagnosis of 
blood-stage infection by thick-film microscopy (typically 4-6 days later). 
The work in this Chapter aimed to further develop the blood-stage P. falciparum CHMI model 
to enable more accurate and rapid efficacy assessment of blood-stage vaccine candidates prior 
to field trial assessment. The underlying hypothesis for this study was that an effective blood-
stage vaccine should demonstrate a measurable effect on the PMR in malaria-naïve 
individuals, most likely to be seen against homologous challenge. PMR can be modelled for 
each individual from quantitative real-time PCR (qPCR) data of blood-stage parasitaemia, prior 
to patency and diagnosis by thick-film microscopy (177). This CHMI model should allow for a 
longer period of qPCR monitoring, homologous challenge and, in comparison to the mosquito-
bite CHMI model, consistency in the initial number of blood-stage parasites in all volunteers. 
The uniformity of the known starting inoculum and more datapoints available for modelling 
should also lead to improved confidence of the calculated PMRs and thus greater power to 
observe partial vaccine efficacy (141, 175, 214). 
The infectious inocula used in this study were produced by Drs Gregor Lawrence, Allan Saul 
and colleagues at QIMR in Brisbane, Australia in 1994 (166). Procedures were designed to 
minimise the risk of other infectious agents in the cryopreserved samples. A volunteer with 
blood group O, Rhesus negative was deliberately infected with a chloroquine-sensitive strain of 
the P. falciparum clone 3D7 (homologous to the vaccine candidate antigen) via the bites of 
laboratory-reared Anopheles stephensi mosquitoes. Blood was taken from the volunteer after 
fever developed, when parasites were visible on thick blood film.  
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Initial development of the blood inoculum to be used in this study and its use in five volunteers 
is described by Cheng et al. 1997 (166). Blood was collected at the Australian Red Cross Blood 
Bank in an aseptic manner using standard blood bank equipment. The blood was leukocyte-
depleted prior to cryopreservation and the amount of serum potentially transferred is reduced 
by a factor of approximately 1000 by the thawing and washing process. The volume of 
inoculum to be given to each volunteer contains a very small volume of red blood cells, 
equivalent to only 1.5 to 4 microlitres of blood. The red cells were cryopreserved using a 
protocol from the American Association of Blood Banks Technical Manual that is normally 
employed for freezing blood from patients and donors with rare blood groups.  
Prior to this trial, over 100 volunteers had received the inoculum with a varied number of 
infected erythrocytes (from 30 to 6000). CHMI using this method has always resulted in 
parasitaemia as detected by PCR (140).  
4.2.6 VAC054 Hypothesis 
Vaccination with FMP2.1/AS01 will induce antibodies against AMA1 which will inhibit P. 
falciparum invasion of red blood cells, detectable as a reduced PMR in vaccinated volunteers 
compared with unvaccinated infectivity controls following a blood-stage CHMI with a 
homologous parasite. 
4.3 VAC054 Methods 
Detailed methods of the recruitment and enrolment of volunteers, as well as the assays used 
in this trial can be found in Chapter two: Materials and Methods. 
4.3.1 VAC054 Study Design 
This study was an open-label non-randomised phase I/IIa trial of the blood-stage malaria 
vaccine candidate FMP2.1/AS01, with efficacy assessed by blood-stage CHMI in vaccinated 
volunteers compared with infectivity controls (Figure 4-1). The study was conducted at the 
CCVTM, University of Oxford, Oxford, UK. Volunteers were also recruited and vaccinated at 
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two other trial sites (the NIHR WTCRF, University Hospital Southampton NHS Foundation Trust 
and the NIHR WTCRF, Imperial College Healthcare NHS Trust) but CHMI for all volunteers took 
place in Oxford. Allocation to study group was based on time of enrolment (vaccinees were 
enrolled before controls) and volunteer preference. 
The sample size for the study was determined from power calculations performed by the 
Centre for Statistics in Medicine at the University of Oxford. Data were available from small 
studies undertaken with the same inoculum in Oxford (174, 175), as well as at the Radboud 
University Nijmegen Medical Centre in the Netherlands (179). These historical data suggested 
the coefficient of variation in the controls may range from 22% (Nijmegen where mean PMR = 
10) to 33% (Oxford where mean PMR = 12). A study design (where the maximum number of 
volunteers = 30) with 15 controls versus 15 vaccinees consistently provided the best power 
(≥80% ) to observe a 33% reduction in mean PMR when allowing for the coefficients of 
variation.  
Group 1 
FMP2.1/AS01B  
Day 0: 50 µg/0.5 mL IM 
(n=15) 
 
Group 2 
Unvaccinated Infectivity 
Controls 
(n=15) 
  
 
  
FMP2.1/AS01B 
Day 28: 50 µg/0.5 mL IM 
  
FMP2.1/AS01B 
Day 56: 50 µg/0.5 mL IM 
  
Blood-Stage CHMI 
Day 70 
Blood-Stage CHMI 
Day 70 
Figure 4-1: VAC054 Overview of trial groups.  
IM = intramuscular; CHMI = controlled human malaria infection 
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4.3.2 VAC054 Ethics 
The study received ethical approval from the Oxfordshire Research Ethics Committee A in the 
UK (Ref 13/SC/0596), and the Western Institutional Review Board (WIRB) in the USA (Ref 
20131985). The study was approved by the UK MHRA (Ref 21584/0326/001-0001). The trial 
was registered with Clincaltrials.gov (NCT02044198) and was conducted according to the 
principles of the current revision of the Declaration of Helsinki 2008 and in full conformity with 
the ICH guidelines for Good Clinical Practice. 
4.3.3 VAC054 Objectives and Endpoints 
Primary objective 
To establish whether the FMP2.1/AS01B vaccine can demonstrate a reduced PMR in 
vaccinated subjects compared to infectivity controls against vaccine-homologous 3D7 clone 
parasites in a Phase I/IIa blood-stage CHMI model. 
Primary endpoint 
PCR-derived PMR was the primary study endpoint, and comparison of the endpoint between 
the two groups constituted the primary analysis for efficacy. The secondary analyses for 
efficacy were: 
 Time to microscopic patency compared between the two groups. 
 A test of the hypothesis that there is a relationship between in vitro GIA induced by 
the FMP2.1 vaccine and PMR. 
 A test of the hypothesis that there is a relationship between anti-AMA1 antibody 
responses induced by the FMP2.1 vaccine and PMR. 
 
Secondary objectives 
To assess the safety of FMP2.1/AS01B in healthy malaria-naïve adults in the UK. 
To assess immunological readouts for association with a reduced parasite multiplication rate. 
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Secondary endpoints 
The safety of the FMP2.1/AS01 vaccine was assessed according to the following endpoints: 
 Occurrence of each solicited AE within a 7-day follow-up period (day of vaccination 
and 6 subsequent days) after each vaccination. 
 Occurrence of unsolicited AEs within 30 days (day of vaccination and 29 subsequent 
days) after each vaccination*. 
 Occurrence of a serious adverse event from the first vaccination to the end of the 
study. 
Solicited and unsolicited AE data was collected at each clinic visit from diary cards, clinical 
review, clinical examination (including observations) and laboratory results. These AE data 
were tabulated and frequency, duration and severity of AEs were compared between groups. 
* The occurrence of unsolicited AEs was in fact monitored until the day 90 post-CHMI visit, but 
only those events occurring within 30 days of each vaccination were used for the analysis of 
this safety endpoint. 
4.3.4 VAC054 Participants 
Healthy, malaria-naïve males and non-pregnant females aged 18-45 were invited to participate 
in the study. All volunteers gave written informed consent prior to participation. Volunteers 
were recruited and vaccinated at three sites in the UK (Oxford, Southampton and London), 
with blood-stage CHMI and follow-up for all volunteers carried out at the CCVTM, University of 
Oxford. The inclusion and exclusion criteria for participation are described below. 
4.3.4.1  VAC054 Inclusion Criteria 
 Healthy, male or non-pregnant female adult aged 18 - 45 years. 
 Subject willing and able to give written informed consent for participation in the study. 
 Resident in or near Oxford for the duration of the CHMI part of the study. Or for 
volunteers not living in Oxford: agreement to stay in arranged accommodation close to 
the trial centre during a part of the study (from the day before CHMI until anti-malarial 
treatment is completed). 
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 Female subjects of child bearing potential willing to practice continuous effective 
contraception for the duration of the study. 
 Able (in the Investigator’s opinion) and willing to comply with all study requirements. 
 Willing to allow his or her GP and consultant, if appropriate, to be notified of 
participation in the study. 
 Agreement to permanently refrain from blood donation, as per current UK Blood 
Transfusion and Tissue Transplantation Services guidelines (221). 
 Reachable (24 hours a day) by mobile phone during the period between CHMI and 
completion of antimalarial treatment. 
 Willingness to take a curative anti-malaria regime following CHMI. 
 Answer all questions on the informed consent questionnaire correctly. 
4.3.4.2  VAC054 Exclusion Criteria 
 History of clinical malaria (any species). 
 Travel to a malaria endemic region during the study period or within the preceding six 
months with significant risk of malaria exposure. 
 Use of systemic antibiotics with known antimalarial activity within 30 days of CHMI 
(e.g. trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin, 
erythromycin, fluoroquinolones and azithromycin). 
 Prior receipt of an investigational malaria vaccine or any other investigational vaccine 
likely to impact on interpretation of the trial data.  
 Receipt of an investigational product in the 30 days preceding enrolment, or planned 
receipt during the study period. 
 History of sickle cell anaemia, sickle cell trait, thalassaemia or thalassaemia trait or any 
haematological condition that could affect susceptibility to malaria infection. 
 Any confirmed or suspected immunosuppressive or immunodeficient state, including 
HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) 
immunosuppressant medication within the past 6 months (inhaled and topical steroids 
are allowed). 
 Use of immunoglobulins or blood products within 3 months prior to enrolment or 
previous severe adverse reaction to a blood transfusion.  
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 History of allergic disease or reactions likely to be exacerbated by any component of 
the vaccine (or malaria infection). 
 Any history of anaphylaxis post vaccination. 
 Pregnancy, lactation or intention to become pregnant during the study. 
 Use of medications known to cause prolongation of the QT interval and existing 
contraindication to the use of Malarone. 
 Use of medications known to have a potentially clinically significant interaction with 
Riamet and Malarone. 
 Contraindications to the use of all three proposed anti-malarial medications; Riamet, 
Malarone and Chloroquine. 
 Any clinical condition known to prolong the QT interval. 
 Family history of congenital QT prolongation or sudden death. 
 Positive family history in 1st and 2nd degree relatives < 50 years old for cardiac 
disease. 
 History of cardiac arrhythmia, including clinically relevant bradycardia. 
 An estimated, ten year risk of fatal cardiovascular disease of ≥5%, as estimated by the 
Systematic Coronary Risk Evaluation (SCORE) system (222). 
 Any clinically significant abnormal finding on biochemistry or haematology blood tests, 
urinalysis or clinical examination. In the event of abnormal test results, confirmatory 
repeat tests may be requested at the discretion of the Investigator.  
 History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in 
situ). 
 History of serious psychiatric condition that may affect participation in the study. 
 Any other serious chronic illness requiring hospital specialist supervision. 
 Suspected or known current alcohol abuse as defined by an alcohol intake of greater 
than 42 standard UK units every week. 
 Suspected or known injecting drug abuse in the 5 years preceding enrolment. 
 Seropositive for hepatitis B surface antigen (HBsAg). 
 Seropositive for hepatitis C virus (antibodies to HCV) at screening. 
137 
 
 Any other significant disease, disorder, or finding which may significantly increase the 
risk to the volunteer because of participation in the study, affect the ability of the 
volunteer to participate in the study or impair interpretation of the study data. 
 Volunteers unable to be closely followed for social, geographic or psychological 
reasons. 
4.3.5 VAC054 Assessment of Safety 
Safety data were assessed by actively and passively collected data on adverse events (AEs) 
occurring throughout the VAC054 trial. Volunteers were asked to complete a paper diary card 
for seven days after each vaccination, recording both solicited and unsolicited AEs, as well as 
any medication taken. Solicited AEs included local AEs (injection site pain, redness, swelling, 
itch and warmth) and systemic AEs (fever, feverishness, myalgia, arthralgia, nausea, malaise, 
headache and fatigue). The information from the diary card was then entered into the 
OpenClinica eCRFs.  
Adverse event data for were also collected at follow-up visits throughout the trial, until the 
visit 90 days after CHMI. Following this, only data on serious adverse events and adverse 
events of special interest were collected. The adverse events of special interest in this trial 
were: 
 Severe hypersensitivity reactions (eg. Anaphylaxis). 
 Any new, suspected auto-immune disease. 
 Meningitis. 
Baseline safety blood tests (FBC, U&Es, LFTs) were carried out at a volunteer’s screening visit 
and at Days 0, 7, 14, 28, 35, 42, 56 and 63 for vaccinees, and days 69 (C-1), C+9, day of 
diagnosis, C+28 and at C+90 for both groups. Any laboratory AEs were graded as per site-
specific grading tables, using local laboratory reference ranges (see Appendix 6). Causality 
relating to vaccination was assigned by the lead investigator and peer-reviewed. 
Following CHMI volunteers were seen twice daily from C+2 (once on day C+1). At each visit 
they were asked a list of symptoms commonly associated with malaria infection (‘solicited’ 
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symptoms). These included pyrexia, low back pain, chills, rigors, feverishness, myalgia, 
arthralgia, headache, fatigue, nausea, sweats, vomiting and diarrhoea. In addition, following 
commencement of antimalarials, volunteers were also asked about the following symptoms, 
which may be associated with antimalarial treatment: dizziness, abdominal pain, palpitations, 
itchy skin, rashes, cough and insomnia. If any of these symptoms were present they were 
asked to grade the severity from 1 (mild) to 3 (severe), using the same severity grading criteria 
as used for AEs after vaccination. Any other symptoms reported by the volunteers were also 
recorded.   
4.3.5.1  Stopping and Holding Rules 
For this trial, safety stopping and holding rules were introduced to ensure participant safety 
during the trial. These applied to Group 1 volunteers only as Group 2 volunteers did not 
receive any vaccinations. The holding and stopping rules used in the VAC054 protocol are 
shown below. 
Holding rules (only applicable to Group 1) 
Solicited local adverse events: 
 A Grade 3 solicited local adverse event beginning within 2 days after vaccination (day 
of vaccination and one subsequent day) and persisting at Grade 3 for >48 hrs in more 
than 3/15 of Group 1 participants. 
Solicited systemic adverse events:  
 A Grade 3 solicited systemic adverse event beginning within 2 days after vaccination 
(day of vaccination and one subsequent day) and persisting at Grade 3 for >48hrs in 
more than 3/15 of Group 1 participants. 
Laboratory adverse events: 
 Immunisation of Group 1 could be put on hold if 3/15 participants developed a Grade 
2 laboratory AE which lasted for ≥ 48 hours or 2/15 participants developed any Grade 
3 laboratory AE considered to be associated with immunisation. 
A serious adverse event considered possibly or probably related to vaccination occurred 
139 
 
Individual stopping rules (for all vaccinated individuals) 
In addition to the above stated group holding rules, stopping rules for individual subjects 
applied (i.e. indications to withdraw individuals from further vaccinations): 
Local reactions:  
 Injection site ulceration, abscess or necrosis. 
Laboratory adverse events: 
 If a participant developed a Grade 3 laboratory AE considered possibly or probably 
related within 2 days after vaccination (day of vaccination and one subsequent day) 
which persisted continuously at Grade 3 for > 72hrs, they should not continue in the 
trial. 
Systemic solicited adverse events: 
 If a participant developed a Grade 3 systemic solicited adverse event considered 
possibly or probably related within 2 days after vaccination (day of vaccination and 
one subsequent day) which persisted continuously at Grade 3 for > 72hrs, they should 
not continue in the trial. 
Unsolicited adverse events: 
 If a participant had any Grade 3 adverse event considered possibly or probably related 
to vaccination, persisting continuously at Grade 3 for >72hrs, they should not continue 
in the trial. 
 If a participant had a serious adverse event considered probably related to vaccination 
they should not continue in the trial. 
 If a participant had an acute allergic reaction or anaphylactic shock following the 
administration of vaccine investigational product they should not continue in the trial. 
4.3.6 VAC054 Interventions 
4.3.6.1  FMP2.1/AS01 vaccine preparation 
The vaccine FMP2.1 was produced under GMP at the WRAIR BioProduction Facility and 
supplied as a lyophilised preparation. FMP2.1 was mixed with the AS01 adjuvant system from 
GSK immediately prior to vaccination. A 50 µg dose of FMP2.1 was administered in 0.5 mL of 
AS01 as an IM injection into the deltoid muscle of the non-dominant arm. The vaccine was 
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administered at days 0, 28 and 56 (nominal study days are used) with an allowed window 
between vaccinations of a minimum of 21 days and maximum of 35 days. Volunteers also 
attended follow-up visits on days 3, 7, 14, 31, 35, 42, 59, 63 and 69 before CHMI on day 70. 
4.3.6.2  Blood-Stage CHMI 
CHMI took place 2 weeks (range 14-16 days) after the final vaccination (day 70/ day of CHMI 
[dC]) at the CCVTM in Oxford, with the 15 infectivity controls (Group 2) inoculated at the same 
time as the vaccinees. Inoculation was carried out in three clinic rooms simultaneously 
alternating between Group 1 and Group 2 volunteers in each room. A single vial of blood-stage 
inoculum was thawed, washed & diluted under aseptic conditions (see Chapter two). 
Sequencing of the parasite’s AMA1 gene confirmed 100% identity with the FMP2.1 vaccine.  
The intended inoculum was 1000 parasitised erythrocytes per volunteer. A limiting dilution 
assay on the inoculum was set up at the time the last volunteer was infected which 
demonstrated 69% viability (i.e. an effective inoculum of 690 parasites per volunteer).  
Following CHMI, blood samples were taken once on the day after CHMI (dC+1) and twice daily 
from dC+2 for P. falciparum qPCR and thick blood film. Diagnosis of malaria was made 
according to Table 4.1. The PMR was calculated from qPCR data as per the methods described 
in Chapter two. 
 
 THICK FILM MICROSCOPY  
MALARIAL SYMPTOMS Positive Negative 
Symptomatic Positive diagnosis Positive diagnosis if any 
available PCR result is ≥ 500 
parasites/mL 
Asymptomatic Positive diagnosis if any 
available PCR result is ≥ 500 
parasites/mL 
(Otherwise delay 
treatment) 
 
Negative diagnosis 
Table 4.1: VAC054 Malarial Diagnosis Criteria. 
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4.4 Results  
4.4.1 VAC054 Participant Flow 
Forty-five volunteers were screened in total and fifteen were recruited to each group, with 
more males recruited than females in both (Group 1 = 66.7% male; Group 2 = 73.3% male). The 
age range of volunteers in Group 1 was 23 – 43 years (mean 33 years) and 19 – 34 years in 
Group 2 (mean 22 years). Three volunteers in Group 1 withdrew from the trial prior to 
completing the vaccination phase, and one volunteer in Group 1 also withdrew post-CHMI 
(time-point dC+8.5), all for personal reasons. The trial flow diagram is shown in Figure 4-2. 
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Figure 4-2: VAC054 trial flow diagram. 
Vaccinations began on 28
th
 April 2014, blood-stage CHMI occurred on 4
th
 July 2014 and all follow-up 
visits were completed by 23
rd
 December 2014. All vaccinees received their immunisations as scheduled, 
except for three volunteers in Group 1 who withdrew during the vaccination phase. 
 
4.4.2 VAC054 Vaccine Safety and Reactogenicity 
There were no SAEs or unexpected reactions during the course of the trial and no volunteers 
withdrew due to vaccine-related AEs. The safety profile of the FMP2.1/AS01 vaccine was 
 
 
CONSORT 2010 Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility (n= 45) 
Excluded (n= 15) 
Not meeting inclusion criteria (n= 7) 
Declined to participate (n= 8) 
 
Analysed (n= 12) 
Excluded from analysis (n= 3) 
- 3 volunteers withdrew prior to CHMI 
*One volunteer withdrew during CHMI follow-up 
(time-point dC+8.5) but was qPCR positive, 
therefore included in the primary endpoint 
analysis 
Allocated to Group 1 (n= 15) 
Received 3 doses FMP2.1/AS01B vaccine (n= 12) on 
days 0, 28 and 56 
Did not receive 3 doses FMP2.1/AS01B vaccine (n= 3) 
 2 volunteers withdrew due to personal reasons 
(no longer able to commit to trial dates) 
 1 volunteer withdrew due to an aversion to 
venipuncture 
Followed up to 90 days post-CHMI (n= 15) 
Lost to follow-up (n= 0) 
Allocated to Group 2 (n= 15) 
Infectivity control group; no intervention prior to 
CHMI 
 
Analysed (n= 15) 
Excluded from analysis (n= 0) 
 
Allocation 
Analysis 
Follow-Up 
Enrollment 
Day 70: Blood-stage CHMI with 690 parasites 
(n=12) 
Blood-stage CHMI with 690 parasites (n=15) 
Followed up to 170 days post-CHMI (n= 11) 
Withdrew from 
follow-up (n= 1*) 
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similar to that reported previously in healthy US adult volunteers (95), with the second and 
third vaccinations reported as more reactogenic than the first. 
Information on solicited (expected) AEs was collected for 7 days after each vaccination by 
means of a diary card completed daily by volunteers and at clinic visits during this time. The 
percentage of volunteers experiencing these AEs at the maximum severity they reported is 
shown in the graph in Figures 4-3 and 4-4, and in Table 4.2. The grading of AEs is described in 
Chapter two. 
 
Figure 4-3: Maximum severity of Local AEs following FMP2.1/AS01B. 
Only the highest intensity of each AE per subject is listed. Data were exported from the OpenClinica 
database into Excel and the percentages of volunteers experiencing each AE following each vaccination 
were calculated (Vacc 1: n= 15, Vacc 2: n=13, Vacc 3: n=12). 
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Figure 4-4: Maximum reported severity of systemic AEs following FMP2.1/AS01B. 
Only the highest intensity of each AE per subject is listed. Data were exported from the OpenClinica 
database into Excel and the percentages of volunteers experiencing each AE following vaccinations at 
each timepoint were calculated (Vacc 1: n= 15, Vacc 2: n=13, Vacc 3: n=12). 
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Table 4.2: Maximum Solicited Reactogenicity Summary Following FMP2.1/AS01B Vaccination. 
This Table shows the maximum severity of all solicited adverse events reported by volunteers (i.e. those for which a severity score was required in the diary card for 7 days 
following each vaccination). Frequency is calculated as the number of subjects counted once at worst severity.
 1
st
 Vaccination FMP2.1/AS01B (n= 15) 2
nd
 Vaccination FMP2.1/AS01B (n= 13) 3
rd
 Vaccination FMP2.1/AS01B (n= 12) 
Mild Moderate Severe Total Mild Moderate Severe Total Mild Moderate Severe Total 
Local 
Adverse 
Events 
Pain 53.3% 20.0% 6.7% 80.0% 46.2% 38.5% 0.0% 84.6% 66.7% 8.3% 0.0% 75.0% 
Redness 20.0% 13.3% 0.0% 33.3% 15.4% 30.8% 30.8% 76.9% 16.7% 16.7% 8.3% 41.7% 
Warmth 60.0% 0.0% 0.0% 60.0% 46.2% 15.4% 0.0% 61.5% 41.7% 16.7% 0.0% 58.3% 
Swelling 13.3% 6.7% 13.3% 33.3% 15.4% 0.0% 38.5% 53.8% 25.0% 0.0% 25.0% 50.0% 
Itch 0.0% 0.0% 0.0% 0.0% 30.8% 0.0% 0.0% 30.8% 16.7% 0.0% 0.0% 16.7% 
Systemic 
Adverse 
Events 
Fatigue 33.3% 13.3% 0.0% 46.7% 38.5% 23.1% 23.1% 84.6% 16.7% 25.0% 0.0% 41.7% 
Feverish 0.0% 6.7% 0.0% 6.7% 23.1% 15.4% 30.8% 69.2% 25.0% 33.3% 0.0% 58.3% 
Malaise 33.3% 6.7% 6.7% 46.7% 30.8% 23.1% 15.4% 69.2% 25.0% 0.0% 0.0% 25.0% 
Headache 6.7% 0.0% 13.3% 20.0% 23.1% 23.1% 15.4% 61.5% 25.0% 8.3% 0.0% 33.3% 
Arthralgia 26.7% 0.0% 0.0% 26.7% 30.8% 7.7% 15.4% 53.8% 25.0% 0.0% 0.0% 25.0% 
Myalgia 13.3% 13.3% 0.0% 26.7% 15.4% 15.4% 15.4% 46.2% 50.0% 0.0% 0.0% 50.0% 
Fever 0.0% 0.0% 0.0% 0.0% 15.4% 30.8% 0.0% 46.2% 25.0% 8.3% 8.3% 41.7% 
Nausea 6.7% 0.0% 0.0% 6.7% 23.1% 7.7% 0.0% 30.8% 16.7% 0.0% 0.0% 16.7% 
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Data on unsolicited AEs were also collected. These were AEs reported either outside of the 
diary card period or adverse events other than those listed above reported within 7 days of 
vaccination. These AEs were collected throughout the trial. Unsolicited AEs were assigned a 
causality score, relating to vaccination, as described in Chapter two. This was agreed between 
myself, as lead clinician of the trial, and an independent clinician who provided peer review. 
All unsolicited AEs were assigned a Medical Dictionary for Regulatory Activities (MedDRA) 
code. Unsolicited AEs following vaccination are shown in the tables below classed by MedDRA 
System Organ Class, Higher Level Term and Preferred Term. AEs occurring before CHMI and 
considered possibly, probably or definitely related to vaccination are shown in Table 4.3. AEs 
considered unlikely or unrelated to vaccination occurring before CHMI are shown in Table 4.4 
 
Vaccination  System Organ Class Higher Level Term Preferred Term 
No. of volunteers 
reporting AE (%) 
1 
Gastrointestinal (GI) 
disorders 
GI and abdo pains (excl 
oral and throat) Abdominal pain 
1   (6.7%) 
1 
Nervous system disorders 
Neurological signs and 
symptoms NEC  Dizziness 
1   (6.7%) 
2 
General disorders and 
administration site 
conditions Pain and discomfort NEC Chest pain 1   (7.7%) 
2 
Nervous system disorders 
Neurological signs and 
symptoms NEC  Dizziness 1   (7.7%) 
2 Psychiatric disorders  Parasomnias Nightmare 1   (7.7%) 
2 
Skin and subcutaneous 
tissue disorders  Erythemas  Erythema (arm) 1   (7.7%) 
3 
Skin and subcutaneous 
tissue disorders  Erythemas  Erythema (arm) 1   (8.3%) 
Table 4.3: Related unsolicited AEs reported following vaccination with FMP2.1/AS01B. 
AEs considered possibly, probably or definitely related to vaccination. The number of volunteers 
reporting each AE is shown; the percentage of volunteers is calculated based on the numbers 
vaccinated at each vaccination timepoint (i.e. 15 volunteers for the first vaccination, 13 for the 
second vaccination and 12 for the third vaccination). 
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Vaccination  System Organ Class Higher Level Term Preferred Term 
No. of volunteers 
reporting AE (%) 
1 Ear and labyrinth disorders Ear disorders NEC Ear pain 1   (6.7%) 
1 Endocrine disorders  Thyroid hypofunction disorders Hypothyroidism 1   (6.7%) 
1 Eye disorders 
Conjunctival infections, irritations 
and inflammations  
Seasonal allergy  1   (6.7%) 
1 
General disorders and 
administration site 
conditions 
Asthenic conditions 
Fatigue 1   (6.7%) 
Malaise 1   (6.7%) 
1 
Musculoskeletal and 
connective tissue disorders  
Musculoskeletal and connective 
tissue pain and discomfort 
Pain in extremity  1   (6.7%) 
Musculoskeletal 
pain 
1   (6.7%) 
1 Nervous system disorders Headaches NEC  Headache 3 (20.0%) 
1 
Reproductive system and 
breast disorders 
Menstruation with increased 
bleeding  
Menorrhagia  1   (6.7%) 
1 
Respiratory, thoracic and 
mediastinal disorders  
Upper respiratory tract infections 
NEC  
Nasopharyngitis 1   (6.7%) 
Sinus headache 1   (6.7%) 
Oropharyngeal 
pain  
1   (6.7%) 
Nasal congestion and 
inflammations  
Nasal congestion  1   (6.7%) 
Upper respiratory tract signs and 
symptoms  
Sinus headache 1   (6.7%) 
1 
Skin and subcutaneous 
tissue disorders  
Erythemas  Erythema (neck) 1   (6.7%) 
2 Ear and labyrinth disorders Ear disorders NEC Ear pain 1   (7.7%) 
2 Eye disorders 
Lid, lash and lacrimal infections, 
irritations and inflammations  
Erythema of 
eyelid  
1   (7.7%) 
2 Gastrointestinal disorders 
Gastrointestinal and abdominal 
pains (excl oral and throat) 
Abdominal pain 1   (7.7%) 
2 Immune system disorders  Atopic disorders Seasonal allergy  2 (15.4%) 
2 Infections and infestations 
Dental and oral soft tissue 
infections  
Gingivitis 1   (7.7%) 
Upper respiratory tract infections Nasopharyngitis 1   (7.7%) 
2 
Musculoskeletal and 
connective tissue disorders  
Joint related signs and symptoms Arthralgia 1   (7.7%) 
Musculoskeletal and connective 
tissue pain and discomfort  
Musculoskeletal 
pain 
1   (7.7%) 
2 Nervous system disorders Headaches NEC  Headache 1   (7.7%) 
2 Psychiatric disorders  Parasomnias Nightmare 1   (7.7%) 
2 
Respiratory, thoracic and 
mediastinal disorders  
Upper respiratory tract infections 
NEC  
Sinusitis 1   (7.7%) 
Coughing and associated symptoms  Cough 1   (7.7%) 
Bronchospasm and obstruction  Wheezing 1   (7.7%) 
Upper respiratory tract signs and 
symptoms  
Oropharyngeal 
pain  
1   (7.7%) 
Rhinorrhoea 1   (7.7%) 
Coughing and associated symptoms  Cough 1   (7.7%) 
2 
Skin and subcutaneous 
tissue disorders  
Photosensitivity and 
photodermatosis conditions  
Sunburn 1   (7.7%) 
3 Immune system disorders  Atopic disorders Seasonal allergy  2 (16.7%) 
3 
Injury, poisoning and 
procedural complications  
Muscle, tendon and ligament 
injuries 
Ligament sprain  1   (8.3%) 
3 Nervous system disorders Headaches NEC  Headache 1   (8.3%) 
3 
Skin and subcutaneous 
tissue disorders  
Apocrine and eccrine gland 
disorders  
Miliaria  1   (8.3%) 
3 
Surgical and medical 
procedures 
Contraceptive methods female 
Intra-uterine 
contraceptive 
device insertion 
1   (8.3%) 
Table 4.4: Unrelated unsolicited AEs reported following vaccination with FMP2.1/AS01B. 
AEs considered unlikely related or unrelated to vaccination. The number of volunteers reporting 
each AE is shown; the percentage of volunteers is calculated based on the numbers vaccinated 
at each vaccination timepoint (i.e. 15 volunteers for the first vaccination, 13 for the second 
vaccination and 12 for the third vaccination). 
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Laboratory adverse events were graded as per the site-specific grading tables, using local 
laboratory reference ranges (Appendix 6). Causality relating to vaccination was assigned by the 
lead investigator and peer-reviewed. The agreed causality score is shown in Table 4.5 below. 
Lab AE  Volunteer Timepoint(s) Max severity Resolved by C-1 Causality 
No. of 
volunteers with 
lab AE (%) 
(n=15) 
Anaemia 
1054005 Day 56 Mild Yes 1 
2 (13.3%) 
1054008 Days 0 to C-1 Moderate No 0 
Elevated leukocytes 
2054102 Day 14 Moderate NA- withdrew 
before C-1 visit 
2 
2 (13.3%) 
2054105 Day 7 Mild 2 
Hyperbilirubinaemia 1054002 D63 Mild Yes 1 
1   (6.7%) 
Elevated alanine 
transaminase (ALT) 
1054004 Day 35 Mild Yes 3 
2 (13.3%) 
2054101 Day 63 Mild Yes 3 
Elevated Alkaline 
phosphatase 1054010 
Day 14, Day 
28 Mild Yes 1 
1   (6.7%) 
Hypernatraemia 1054002 Day 42 Mild Yes 1 
1   (6.7%) 
Hypokalaemia* 
1054001 C-1 Mild NA 0 
4 (26.7%) 
1054010 Day 56 Mild Yes 0 
1054011 Day 56 Mild Yes 0 
2054101 C-1 Moderate NA 0 
Elevated creatinine 2054103 Days 7, 56 Mild Yes 1 
1   (6.7%) 
Table 4.5: Laboratory AEs following vaccination and prior to CHMI. 
*Hypokalaemia is considered likely to be pseudohypokalaemia due to storage of samples 
before processing without centrifugation at the point of care, as described in a previous study 
in Oxford (223). 
 
4.4.3 CHMI Safety 
There were no serious adverse events or withdrawals from the trial due to CHMI-related 
adverse events. Participants were reviewed twice daily from day 2 following CHMI. The AEs 
relating to CHMI are shown in Figure 4-5, with maximum severity reported at each time-point. 
Data on AEs relating to treatment (with Riamet in 26 volunteers and Malarone in 1 volunteer) 
were collected at the visits 24 and 48 hours after diagnosis. These AEs are shown in Figure 4-6. 
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Figure 4-5: VAC054 Maximum reported severity of CHMI-related AEs before, at and after 
diagnosis/ treatment. 
Only the highest intensity of each AE per subject is listed. Data were exported from the OpenClinica 
database into Excel and the percentages of volunteers experiencing each AE following CHMI were 
calculated (n=27). 
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Figure 4-6: VAC054 Maximum reported severity of AEs considered possibly related to anti-
malarial therapy after initiation of treatment. 
These adverse events were only specifically asked about after initiation of antimalarial therapy. If these 
symptoms occurred before treatment they were recorded as ‘unsolicited AEs’. Only the highest intensity 
of each AE per subject is listed (n=27). Data were exported from the OpenClinica database into Excel and 
the percentages of volunteers experiencing each AE following treatment for CHMI were calculated. 
As well as the list of solicited adverse events collected at each visit participants were also 
asked to report any other adverse events that occurred, and these were recorded and assigned 
a MedDRA code. Any unsolicited adverse events reported by vaccinated volunteers were also 
assigned a causality score, as described above (causality relating to vaccination rather than 
CHMI). AEs occurring after CHMI are shown in Tables 4.6 and 4.7 (≤30 days and >30 days post-
CHMI respectively), and include AEs occurring in both vaccinated and control volunteers. None 
of the AEs occurring after CHMI were considered possibly, probably or definitely related to 
vaccination. 
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Group System Organ Class Higher Level Term Preferred Term 
No. of volunteers 
reporting AE (%)  
Vaccinees 
(Group 1) 
Gastrointestinal disorders 
Gastrointestinal and abdominal pains 
(excl oral and throat)  Abdominal pain lower 1   (3.7%) 
Diarrhoea (excl infective) Diarrhoea  1   (3.7%) 
Gastrointestinal signs and symptoms 
NEC  Abdominal discomfort  1   (3.7%) 
General disorders and 
administration site 
conditions 
Feelings and sensations NEC Hangover 1   (3.7%) 
Infusion site reactions 
Infusion site paraesthesia  1   (3.7%) 
Infusion site bruising  1   (3.7%) 
Immune system disorders  Atopic disorders Seasonal allergy  1   (3.7%) 
Infections and infestations 
Urinary tract infections Urinary tract infection  1   (3.7%) 
Abdominal and gastrointestinal 
infections  Gastroenteritis 1   (3.7%) 
Upper respiratory tract infections  Pharyngitis 1   (3.7%) 
Musculoskeletal and 
connective tissue disorders  
Joint related signs and symptoms Arthralgia  1   (3.7%) 
Musculoskeletal and connective tissue 
pain and discomfort  Pain in extremity  1   (3.7%) 
Nervous system disorders 
Neurological signs and symptoms NEC  Dizziness  1   (3.7%) 
Paraesthesias and dysaesthesias  Paraesthesia  1   (3.7%) 
Psychiatric disorders  Parasomnias Nightmare 1   (3.7%) 
Respiratory, thoracic and 
mediastinal disorders  
Lower respiratory tract infections NEC  
Lower respiratory tract 
infection 1   (3.7%) 
Upper respiratory tract signs and 
symptoms  
Oropharyngeal pain  1   (3.7%) 
Rhinorrhoea 1   (3.7%) 
Skin and subcutaneous 
tissue disorders  
Dermatitis and eczema  Dermatitis  1   (3.7%) 
Skin injuries and mechanical 
dermatoses Skin abrasion  1   (3.7%) 
Photosensitivity and photodermatosis 
conditions  Sunburn 1   (3.7%) 
Controls 
(Group 2) 
Gastrointestinal disorders 
Gastrointestinal and abdominal pains 
(excl oral and throat)  Abdominal pain lower 
1   (3.7%) 
Stomatitis and ulceration  Mouth ulceration 1   (3.7%) 
General disorders and 
administration site 
conditions  
Infusion site reactions  Infusion site erythema  1   (3.7%) 
Administration site reactions NEC 
Vessel puncture site 
haematoma 2   (7.4%) 
Vessel puncture site pain  1   (3.7%) 
Immune system disorders  
Atopic disorders Seasonal allergy  7.4% 
Allergic conditions NEC Allergy to plants  1   (3.7%) 
Metabolism and nutrition 
disorders Appetite disorders Decreased appetite 1   (3.7%) 
Musculoskeletal and 
connective tissue disorders 
Musculoskeletal and connective tissue 
pain and discomfort 
Musculoskeletal chest 
pain 1   (3.7%) 
Pain in extremity  1   (3.7%) 
Nervous system disorders 
Neurological signs and symptoms NEC  Dizziness  2   (7.4%) 
Paraesthesias and dysaesthesias  Paraesthesia  1   (3.7%) 
Disturbances in initiating and 
maintaining sleep  Insomnia  1   (3.7%) 
Renal and urinary disorders  Urinary abnormalities  Chromaturia 1   (3.7%) 
Respiratory, thoracic and 
mediastinal disorders  Breathing abnormalities  Dyspnoea 1   (3.7%) 
 
Upper respiratory tract signs and 
symptoms  
Oropharyngeal pain  
3 (11.1%) 
Table 4.6: VAC054 Unsolicited AEs reported in the first 30 days following CHMI.  
(n=27) CHMI occurred 2 weeks after the final vaccination. All AEs were considered unlikely 
related or unrelated to vaccination.  
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Group System Organ Class Higher Level Term Preferred Term 
No. of volunteers 
reporting AE (%) 
Vaccinees 
(Group 1) Infections and 
infestations 
Neisseria infections Gonorrhoea 
1   (3.8%) 
Upper respiratory tract infections  Rhinitis  
1   (3.8%) 
Investigations 
Physical examination procedures 
and organ system status Weight decreased 
1   (3.8%) 
Nervous system disorders Headaches NEC  
Headache 
2   (7.7%) 
Psychiatric disorders  Increased physical activity levels  
Psychomotor 
hyperactivity 
1   (3.8%) 
Renal and urinary 
disorders  
Renal infections and 
inflammations (excl nephritis) Kidney infection  
1   (3.8%) 
Controls 
(Group 2) 
Injury, poisoning and 
procedural complications  Bone and joint injuries NEC  Joint injury 
1   (3.8%) 
Respiratory, thoracic and 
mediastinal disorders  
Upper respiratory tract signs and 
symptoms  
Sneezing 
1   (3.8%) 
Oropharyngeal pain  
2   (7.7%) 
Table 4.7: VAC054 Unsolicited AEs reported more than 30 days after CHMI. 
(n=26) All AEs were considered unlikely related or unrelated to vaccination. 
Volunteers had blood tests prior to CHMI (C-1) and then at C+6, diagnosis, C+28 and C+90. 
Blood tests were also carried out at other timepoints if clinically indicated. Causality relating to 
vaccination was not assigned after CHMI. AEs were as expected following malaria infection and 
there were none which caused clinical concern. The laboratory AEs following CHMI are shown 
in Table 4.8. 
The donor of the infected blood for the CHMI inoculum was seropositive for EBV and CMV, so 
it was previously required for volunteers taking part in blood-stage CHMI studies with this 
inoculum to be seropositive for both viruses (174). However, this is no longer deemed to be 
necessary as the blood was leukodepleted prior to inoculum preparation and has since tested 
negative by PCR for both viruses. Several volunteers who were seronegative for one or both 
viruses had previously received the inoculum at other challenge centres in Australia (140) and 
the Netherlands (179) and none had seroconverted. To add to the safety database regarding 
this I checked serostatus prior to CHMI (the day before CHMI; C-1) and at the visit 90 days after 
CHMI (C+90). 37% of the 27 volunteers who underwent CHMI were seropositive for CMV and 
89% were seropositive for EBV. None of the volunteers who were seronegative for either virus 
at C-1 seroconverted during the trial, as demonstrated in Table 4.9. 
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Laboratory AE  Volunteer Timepoint(s) Max severity 
Resolved 
by C+28 
Resolved 
by C+90 
No. of volunteers 
with lab AE  (%) 
Anaemia 
1054008 
C+2, C+6, Diagnosis 
(C+10), C+28 Moderate No Yes 
2   (7.4%) 1054026 
Diagnosis (C+9), C+28, 
C+90 Mild No No 
Neutropenia 1054022 C-1, C, C+6 Mild Yes Yes 1   (3.7%) 
Lymphopenia 
1054008 C+2 Severe Yes Yes 
6 (22.2%_ 
1054010 Diagnosis (C+10.5) moderate Yes Yes 
1054016 Diagnosis (C+10) Severe Yes Yes 
1054017 Diagnosis (C+10.5) Mild Yes Yes 
1054020 C+6, Diagnosis (C+8.5) Mild Yes Yes 
1054026 Diagnosis (C+9) Mild Yes Yes 
Eosinophilia 
1054012 C+90 Mild NA NA 
3 (11.1%) 
1054018 C-1, Diagnosis (C+8.5) Mild Yes Yes 
3054208 
C+6, Diagnosis (C+9), 
C+28, C+90 Mild No No 
Thrombocytopenia 
1054011 Diagnosis (C+10) Severe Yes Yes 
2   (7.4%) 1054016 Diagnosis (C+10) Severe Yes Yes 
Hyperbilirubinaemia 
1054017 C+28 Moderate NA Yes 
4 (14.8%) 
1054007 C+90 Mild NA NA 
2054106 
C-1, C+6, Diagnosis 
(C+8.5) Mild Yes No 
3054208 
C-1, C+6, Diagnosis 
(C+9), C+28 Mild No Yes 
Elevated alanine 
transaminase (ALT) 
1054017 C+28 Mild NA Yes 
2   (7.4%) 3054208 C+28 Mild NA Yes 
Hypernatraemia 
1054010 C+28 Mild NA Yes 
2   (7.4%) 
1054013 C+28 Moderate NA Yes 
1054018 C+28 Moderate NA Yes 
1054026 C+28 Mild NA Yes 
Hypokalaemia* 
1054001 Diagnosis (C+8.5) Mild Yes Yes 
9 (33.3%) 
1054008 C+2 Mild Yes Yes 
1054016 C+28 Mild NA Yes 
1054018 Diagnosis (C+8.5) Mild Yes Yes 
1054019 
C-1, Diagnosis (C+8.5), 
C+28 Severe No Yes 
2054101 Diagnosis (C+8.5) Moderate 
Withdrew 
before 
C+28 
Withdrew 
before 
C+90 
3054201 Diagnosis (C+8.5) Moderate Yes Yes 
3054202 Diagnosis (C+9) Mild Yes Yes 
3054208 C-1 Mild Yes Yes 
Elevated urea 
2054104 C+28 Mild NA Yes 
2   (7.4%) 2054103 Diagnosis Mild Yes Yes 
Table 4.8: VAC054 Laboratory AEs following CHMI in vaccinated and control volunteers. 
*Hypokalaemia is considered likely to be pseudohypokalaemia due to storage of samples 
before processing without centrifugation at the point of care, as described in a previous study 
in Oxford (223). 
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CMV EBV 
Volunteer Timepoint C-1 Timepoint C+90 Timepoint C-1 Timepoint C+90 
1054001 Detected 
 
Detected  
1054002 Not Detected Not Detected Detected  
1054004 Not Detected Not Detected Detected  
1054005 Detected  Detected  
1054007 Detected  Detected  
1054008 Not Detected Not Detected Not Detected Not Detected 
1054010 Not Detected Not Detected Detected  
1054011 Not Detected Not Detected Detected  
1054012 Not Detected Not Detected Not Detected Not Detected 
1054013 Detected 
 
Detected  
1054016 Not Detected Not Detected Detected  
1054017 Detected 
 
Detected  
1054018 Not Detected Not Detected Not Detected Not Detected 
1054019 Not Detected Not Detected Detected  
1054020 Not Detected Not Detected Detected  
1054022 Not Detected Not Detected Detected  
1054024 Detected 
 
Detected  
1054026 Not Detected Not Detected Detected  
1054027 Not Detected Not Detected Detected  
2054101 Not Detected * Detected  
2054103 Not Detected Not Detected Detected  
2054104 Detected 
 
Detected  
2054106 Not Detected Not Detected Detected  
3054201 Detected 
 
Detected  
3054202 Not Detected Not Detected Detected  
3054206 Detected  Detected  
3054208 Detected  Detected  
Table 4.9: VAC054 EBV IgG and CMV IgG serostatus in volunteers before and after blood-
stage CHMI. 
C+90 data is shown for seronegative volunteers. *The volunteer who withdrew during the CHMI 
phase (2054101) was CMV seronegative and EBV seropositive at C-1; his serostatus was not 
rechecked after CHMI as he withdrew from the trial and declined any further blood tests.  
 
4.4.4 Blood-Stage CHMI and Vaccine Efficacy 
All volunteers developed patent blood-stage parasitaemia following CHMI and were diagnosed 
by thick blood film microscopy by dC+10.5 (Table 4.10), except for the one volunteer who 
withdrew on dC+8.5. This volunteer was asymptomatic and thick blood film negative so had 
not reached the criteria for commencing treatment, but was qPCR positive at the time of 
withdrawal and was included in the primary analysis. There was neither a delay to diagnosis in 
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vaccinees compared to controls, nor any difference in parasitaemia between the groups during 
follow-up (Figure 4-7). 
ID Number 
Group 
Diagnosis 
timepoint 
Symptomatic/ 
asymptomatic 
No. of parasites 
on TBF 
PCR at diagnosis 
(p/mL) 
MVT-1054001 1 8.5 Asymptomatic 2 7397 
MVT-1054002 1 8.5 Asymptomatic 1 27518 
MVT-1054004 1 7.5 Symptomatic 1 2371 
MVT-1054005 1 9 Asymptomatic 2 16585 
MVT-1054007 1 9 Asymptomatic 3 3276 
MVT-1054008 1 10 Asymptomatic 2 11882 
MVT-1054010 1 10.5 Symptomatic 3 29937 
MVT-1054011 1 10 Asymptomatic 3 164509 
MVT-2054101* 1 8.5 Asymptomatic 0 1697 
MVT-2054103 1 10 Asymptomatic 2 73615 
MVT-3054201 1 8.5 Asymptomatic 2 10320 
MVT-3054202 1 9 Asymptomatic 2 41198 
MVT-1054012 2 7.5 Asymptomatic 1 1645 
MVT-1054013 2 10.5 Symptomatic 2 70367 
MVT-1054016 2 10 Symptomatic 2 273247 
MVT-1054017 2 10.5 Symptomatic 1 16911 
MVT-1054018 2 8.5 Symptomatic 1 19670 
MVT-1054019 2 8.5 Asymptomatic 1 6932 
MVT-1054020 2 8.5 Asymptomatic 1 15025 
MVT-1054022 2 10 Asymptomatic 1 8865 
MVT-1054024 2 10 Asymptomatic 2 43707 
MVT-1054026 2 9 Symptomatic 1 9132 
MVT-1054027 2 9 Symptomatic 1 13421 
MVT-2054104 2 9 Asymptomatic 2 54085 
MVT-2054106 2 9 Symptomatic 3 14395 
MVT-3054206 2 10 Symptomatic 3 185576 
MVT-3054208 2 9 Symptomatic 1 1439 
Table 4.10: VAC054 CHMI thick blood film and PCR results at diagnosis 
Data are shown for all volunteers at diagnosis. All volunteers had a positive thick blood film 
(TBF), except 2054101 (*) who withdrew before diagnostic criteria were reached. Fifteen 
volunteers were asymptomatic at diagnosis and diagnosed on TBF and PCR criteria.  
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Figure 4-7: VAC054 Blood-stage CHMI efficacy outcomes. 
Individual qPCR data are shown for the VAC054 Phase IIa study including (A) Group 1 AMA1 vaccinees 
(n=12), and (B) the Group 2 unvaccinated infectivity controls (n=15). (C) The mean ± SEM parasitaemia is 
shown over time for each group. The lower limit of quantification is indicated by the dotted line at 20 
parasites/mL. (D) Kaplan-Meier plot of time to patent parasitemia in days for the VAC054 study. Median 
time to patent parasitemia = 9.0 d for both groups. Secondary pre-specified analysis in the protocol 
compared time to microscopic patency between the groups; P=0.81, Mann-Witney test of time to 
diagnosis (excluding the volunteer in Group 1 who withdrew on dC+8.5). Time = days (d) post blood-
stage CHMI. The PCR standard curve was generated automatically by the QIASymphony SP instrument. 
Data were imported into GraphPad Prism for graphical presentations and statistical analyses. 
 
The protocol pre-specified primary analysis for efficacy was comparison of PMR between the 
two groups. There was no difference in the mean PMRs between the two groups (Figure 4-8). 
The mean PMR for Group 1 was 10.32 (95% confidence interval (CI) 8.97-11.67; standard 
deviation (SD) =2.13) and for Group 2 was 10.31 (95% CI 9.00-11.62; SD=2.36), P=0.99 using 
two-tailed unpaired t test. 
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Figure 4-8: VAC054 PMR analysis. 
Primary endpoint analysis of PMR, showing each individual in Group 1 (AMA1; n=12) and Group 2 
(Controls; n=15), and the mean ± SD.  
 
4.4.5 T cell Responses in Vaccinees and Controls 
The FMP2.1/AS01 vaccine elicited T cell responses as assessed by ex-vivo IFN-γ ELISPOT, with 
median responses of 577 and 396 SFU/million PBMC at d42 and d69/C-1 respectively (Figure 4-
9A, C). These responses did not boost post-CHMI with a median of 148 SFU/million PBMC seen 
at d98/C+28. Modest responses were induced in the controls (median 29 SFU/million PBMC at 
the same time-point), with only two volunteers showing responses > 150 SFU/million PBMC 
(Figure 4-9B, D-F). There was a significant increase in IFN- γ secreting T cells following the 
second vaccination with FMP2.1/AS01 (day 14 vs day 42) (P = 0.01, Friedman non-parametic 
test with Dunn’s correction for multiple comparisons), but not following the third vaccination 
or after CHMI. 
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Figure 4-9. VAC054 T cell responses in vaccinees and controls. 
(A,B) T cell responses were assessed in each group by ex-vivo IFN-γ ELISPOT using fresh PBMC. (C) 
Median and individual responses are shown for vaccinees (Group 1; n=12) at the d14, d42 and d69/C-1 
time-points. (D-F) Median and individual responses are shown for vaccinees (G1; n=12) and controls (G2; 
n=15) at the d69/C-1, d98/C+28 and d160/C+90 time-points. Spots were counted using an automated 
plate counter and exported into an Excel worksheet where results were obtained by subtracting any 
background response (from negative control wells) and then taking the average of triplicate wells. Data 
were then imported into GraphPad Prism for statistical analyses. 
 
4.4.6 Antibody Responses in Vaccinees and Controls 
AMA1-specific serum IgG responses were measured by ELISA at the Jenner Institute 
laboratories in Oxford with median responses of 85 and 97 µg/mL at d42 and d69/C-1 
respectively. These responses did not boost post-CHMI with a median of 56 µg/mL seen at 
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d98/C+28. Only 1 of the 15 controls showed a de novo anti- AMA1 IgG response at d98/C+28 
(59 µg/mL) (Figure 4-10). 
 
Figure 4-10: VAC054 Serum antibody responses in vaccinees and controls (Oxford). 
(A,B) Serum anti-AMA1 (3D7) IgG responses were assessed in Oxford for each group by ELISA. Mean and 
individual responses are shown over time. Blood-stage CHMI took place on D70. (C) Median and 
individual responses are shown for the vaccinees (Group 1; n=12) at the d14, d42 and d69/C-1 time-
points. (D-F) Median and individual responses are shown for the vaccinees (G1; n=12) and controls (G2; 
n=15) at the d69/C-1, d98/C+28 and d160/C+90 time-points. The absorbance at 405nm (OD405) was read 
using a Biotek ELx800 microplate reader with Gen5 software. Data were exported into an Excel 
worksheet and values of internal controls and samples in triplicate were assessed for any aberrant 
readings. The results were obtained by taking an average of triplicate wells, and using the standard 
curve to assign ELISA arbitrary units. These were converted to µg/mL using a conversion factor as 
detailed in Section 2.3.4.1. Converted data were imported into GraphPad Prism for graphical 
presentation and analyses. 
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As well as measuring the anti-AMA1 antibody response by ELISAs, the avidity of antibodies 
induced by vaccination and the different isotypes present were also determined by ELISA. The 
avidity of the anti-AMA1 IgG was similar at d42, d69/C-1 and post-CHMI in the vaccinees 
(Figure 4-11), and very similar to that observed with other AMA1 vaccines in humans (167, 
193). The response was composed of IgG1, IgG3, IgA and IgM, and this profile was not affected 
by CHMI (Figure 4-12). 
 
 
Figure 4-11.VAC054 AMA1 antibody avidity. 
Avidity of serum IgG responses was assessed by NaSCN-displacement 3D7 AMA1 ELISA and is reported as 
the molar (M) concentration of NaSCN required to reduce the starting OD in the ELISA by 50% (IC50). 
Individual and mean responses are shown for Group 1 volunteers (n=12). The absorbance at 405nm 
(OD405) was read using a Biotek ELx800 microplate reader with Gen5 software. Data were exported into 
an Excel worksheet and the average value of duplicate readings calculated. Data were then imported 
into GraphPad Prism for graphical presentation and analyses. 
 
 
Time-point (d)
IC
5
0
 N
a
S
C
N
 (
M
)
d42 d69/C-1 d98/C+28
0
1
2
3
4
5
6
161 
 
 
Figure 4-12 VAC054 AMA1 antibody isotype profile 
Isotype profiles of serum antibody responses were assessed by 3D7 AMA1 ELISA. Responses are shown at 
baseline (d0), d42, d69/C-1 and post-CHMI at d98/C+28 for vaccinated volunteers in Group 1 (n=12). In 
all panels, individual and median responses are shown. The absorbance at 405nm (OD405) was read using 
a Biotek ELx800 microplate reader with Gen5 software. Data were exported into an Excel worksheet and 
the average value of duplicate readings calculated. Data were then imported into GraphPad Prism for 
graphical presentation and analyses. 
 
4.4.7 Measurement of antibodies to MSP1 in vaccinees and controls 
MSP1 is one of the most abundant proteins on the surface of the merozoite and antibodies 
against MSP1 can often be detected in those exposed to malaria in endemic areas (81). In 
order to see whether blood-stage CHMI induced antibodies against MSP1, sera from the 
control volunteers (Group 2) was analysed by ELISA for anti-MSP1 antibodies before CHMI (dC-
1) and 4 weeks after CHMI (dC+28). Sera from controls from six previous CHMI studies were 
also analysed in the same experiment for comparison (74, 83, 138, 172, 173). These previous 
studies used mosquito-bite (sporozoite) CHMI so the comparative timepoint is C+35 (i.e. 4 
weeks after the parasites enter the blood stream following the liver-stage of infection). This 
experiment demonstrated that only 4 of the 15 Group 2 volunteers seroconverted and 
developed antibodies against MSP1 following CHMI, whereas 30 of the 37 control volunteers 
across the other studies had seroconverted after CHMI (Figure 4-13). 
IgG1
Time-point (d)
O
D
4
0
5
d0 d42 d69/C-1 d98/C+28
0.1
1
IgG2
Time-point (d)
O
D
4
0
5
d0 d42 d69/C-1 d98/C+28
0.1
1
IgG3
Time-point (d)
O
D
4
0
5
d0 d42 d69/C-1 d98/C+28
0.1
1
IgG4
Time-point (d)
O
D
4
0
5
d0 d42 d69/C-1 d98/C+28
0.1
1
IgA
Time-point (d)
O
D
4
0
5
d0 d42 d69/C-1 d98/C+28
0.1
1
IgM
Time-point (d)
O
D
4
0
5
d0 d42 d69/C-1 d98/C+28
0.1
1
162 
 
 
Figure 4-13 VAC054 Antibody response to MSP1 in Group 2 (control) volunteers after CHMI. 
Anti-MSP1 antibodies were measured by ELISA in Group 2 volunteers (n=15) and in control volunteers 
from six previous CHMI studies (n=37) with samples from before CHMI (dC-1) and 4 weeks after blood 
stream infection (dC+28 in blood-stage CHMI and C+35 in mosquito-bite CHMI) (74, 83, 138, 172, 173). 
The absorbance at 405nm (OD405) was read using a Biotek ELx800 microplate reader with Gen5 software. 
Data were exported into an Excel worksheet and values of internal controls and samples in triplicate 
were assessed for any aberrant readings. The results were obtained by taking an average of triplicate 
wells, and using the standard curve to assign ELISA arbitrary units (AU). Data were then imported into 
GraphPad Prism for graphical presentation. 
 
4.4.8 Anti-AMA1 peripheral mBC responses following FMP2.1/AS01 
Peripheral mBC responses were assessed in vaccinated volunteers (Group 1) by identifying 
AMA1-specific mBC-derived plasma cells by ex vivo ELISPOT following a 6-day polyclonal 
culture of PBMC (Figure 4-14). Responses were measured at d69/ dC-1 and 4 weeks after CHMI 
(dC+28). There was no significant difference in detectable AMA1-specific mBC-derived ASCs at 
the two timepoints, either as a proportion of the cultured PBMC or as a percentage of 
detected total IgG.  
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Figure 4-14: Anti-AMA1 mBC responses following FMP2.1/AS01 vaccination. 
mBC- derived ASC in Group 1 volunteers (n=12) measured two weeks after final vaccination (dC-1) and 
four weeks after CHMI (dC+28) using ex vivo ELISPOT. (A) Comparison between timepoints dC-1 and 
dC+28 (mBC derived ASC per million cultured PBMC). (B) Comparison between timepoints dC-1 and 
dC+28 (mBC derived ASC as a % of total IgG ASC). Individual and median responses are shown. mBC 
ELISPOT spots were counted using an AID ELISPOT reader and automated counts were corrected by eye 
.Data were exported into an Excel worksheet and then imported into GraphPad Prism for graphical 
presentation and analyses. 
 
4.4.9 Measurement of in vitro GIA 
Serum was analysed at the GIA Reference Center at NIH, USA and IgG was purified from each 
sample. Samples from Group 1 volunteers prior to vaccination (d0) and Group 2 volunteers 
prior to CHMI (d69/dC-1) did not demonstrate any GIA above baseline. At a concentration of 
10 mg/mL purified IgG dC-1 samples from Group 1 volunteers following three vaccinations 
demonstrated in vitro GIA of median 59.5 % (range 38.5-86.5 %) (Figure 4-15A). As the purified 
IgG was diluted, GIA decreased (Figure 4-15B) and was related to AMA1-specific IgG 
concentration (Figure 4-15C), in close agreement with other independent studies (130, 167). 
The EC50 was calculated for each purified IgG, with a median of 8.1 mg/mL. To relate these 
results (using a normalised concentration of purified IgG) back to the original sera, the 
concentration of IgG in each original serum sample was also measured. This enabled 
calculation of the GIA50 serum titre, defined previously as the dilution factor of each serum 
sample required to reach the concentration of purified IgG that gives 50% GIA (104). The 
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median GIA50 titre for Group 1 was 1.5, with the maximum observed being a dilution factor of 
3.0 (Figure 4-15D). 
 
Figure 4-15: Assessment of functional GIA induced by FMP2.1/AS01. 
(A) In vitro GIA of purified IgG was assessed at 10 mg/mL against 3D7 clone P. falciparum parasites at 
the NIH GIA Reference Center. Each test IgG was incubated with synchronised human erythrocytes which 
contained late trophozoite and schizont stages of P. falciparum parasites prepared by Percoll gradient 
and/or 5% sorbitol treatment. GIA was assessed over for a single growth cycle, measuring parasite LDH 
after 40 hours of culture and using this to calculate relative parasitaemia levels. Individual data and 
medians are shown for each group (Group 1 shown in blue; n=12, Group 2 shown in red; n=15) at dC-1 as 
well as d0 for Group 1. Responses >12% are typically regarded as positive for 3D7. (B) Dilution series of 
purified IgG from Group 1 dC-1 samples. (C) Relationship between GIA and anti-3D7 AMA1 serum IgG 
concentrations measured by ELISA at the NIH. Non-linear regression curve is also shown (n=60). The EC50 
(level of anti-3D7 AMA1 response in this ELISA assay that gives 50% GIA, indicated by the dotted line) 
was 75.5 µg/mL, (95% CI 68.3-84.2). (D) Individual EC50 of each purified IgG is shown as well as the GIA50 
titres. Individual data and medians are shown for Group 1 dC-1. 
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4.5 Discussion 
AMA1 has long been considered a leading candidate antigen for a blood-stage malaria vaccine 
(224), but despite evidence that antibodies to AMA1 inhibit red blood cell invasion (92), 
significant efficacy has not been demonstrated as a primary endpoint of any Phase IIa/b clinical 
trial (25). Previous CHMI trials initiated by mosquito-bite have suggested some pre-
erythrocytic immunity can be afforded by vaccines encoding AMA1 alone (83, 95), or in 
combination with the circumsporozoite protein (CSP) (225). The traditional method for 
assessing blood-stage vaccines has been through large field trials rather than CHMI trials. A 
Phase IIb field trial in Malian children with the FMP2.1/AS02 vaccine reported 64.3% efficacy 
(hazard ratio 0.36, 95% CI 0.08-0.86, P=0.03) in a pre-defined secondary analysis. This reported 
efficacy was against clinical malaria with 3D7-type parasites, but the number of cases meeting 
this definition was small (97, 98) and the reported efficacy did not extend into the second 
malaria season (99). The aim of this Chapter was to use the blood-stage CHMI model to assess 
the FMP2.1/AS01 vaccine against homologous 3D7 clone parasites, and therefore evaluate 
whether the vaccine is able to induce immunity active against the erythrocytic stage of the 
malaria parasite life cycle. 
There were no safety concerns relating to vaccination with FMP2.1/AS01, and the AE profile 
was similar to that reported previously in healthy US adult volunteers, with injection site pain, 
erythema, warmth and swelling reported as the most frequent local AEs and headache, 
malaise and fatigue reported frequently as systemic AEs in both studies (95). The vaccine was 
more reactogenic than the viral vectored vaccines used in the VAC051 trial (Chapter three), 
with higher frequencies of volunteers reporting severe AEs, particularly following the second 
vaccination. Vaccine-related AEs were of short duration and all resolved spontaneously. There 
were also no safety concerns relating to the CHMI inoculum, and the cessation of only 
enrolling EBV and CMV seropositive volunteers into studies using this inoculum was further 
supported by the data from this trial which demonstrated no seroconversion in volunteers 
who were EBV and/or CMV seronegative prior to blood-stage CHMI. 
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The FMP2.1/AS01 vaccine was immunogenic in this trial, eliciting AMA1-specific T cell and 
antibody responses. IFN-γ T cell responses, measured by ELISPOT, were higher than those seen 
with other AMA1 protein-in-adjuvant vaccines tested using the same assay (174). This is likely 
to be due to the use of the AS01B adjuvant system which was specifically designed to improve 
Th1 responses (122). The actions of the AS01 adjuvant system are though to involve both the 
innate and adaptive immune systems. The MPL in the adjuvant stimulates the innate immune 
system via TLR4 receptors, thereby directly activating APCs which express TRLR4 (123). The 
response to MPL promotes production of IFN- γ by antigen specific CD4+ T cells (123, 124) and 
the QS21 in the adjuvant has been shown to stimulate CD8+ T cells (121). As discussed in 
Chapter three, it is thought likely that an optimised blood-stage malaria vaccine will have both 
T cell and antibody-inducing properties.  
The avidity and isotype profiles of the anti-AMA1 IgG antibodies were very similar to those 
observed following vaccination with other AMA1 vaccines in humans (167, 193), although it 
has been suggested that the AS01 adjuvant can aid promotion of antibody isotype switching 
(121). The serum antibody and GIA responses were comparable to another AMA1 vaccine 
candidate that failed to impact on PMR in a much smaller, and under-powered, blood-stage 
CHMI trial in Oxford (174). However, the anti-AMA1 antibody levels reported in this trial were 
substantially lower than those reported by Spring et al using the same vaccine at WRAIR in a 
previous trial (95). The reduced immunogenicity in this trial may have related to the age of the 
FMP2.1 protein, although the vaccine lot had passed all required testing prior to use in the 
VAC054 study.  
In this trial, FMP2.1/AS01 vaccine did not demonstrate any efficacy, with no vaccinees 
protected from malaria infection and no reduction in PMR compared with the infectivity 
control group. The difference in efficacy between this study and the Phase IIb field study could 
be due to a number of possible reasons: reduced vaccine immunogenicity; the use of AS01 
instead of AS02; an impact of this vaccine only at high parasite densities; a pre-erythrocytic 
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effect of the vaccine; or the fact that the Malian children, unlike UK adults, would have 
possessed pre-existing anti-malarial immune responses, including anti-AMA1 IgG, which may 
have acted in conjunction with the vaccine-induced anti-AMA1 responses. 
Despite the lack of efficacy demonstrated in this trial, the antibodies induced by the 
FMP2.1/AS01 vaccine were able to inhibit parasite growth in vitro, as assessed by GIA. 
However, the level of inhibition with 10 mg/mL of purified IgG was only a median of 59.5 % 
(range 38.5-86.5 %). The lack of efficacy in the VAC054 trial is consistent with previously 
reported data in Aotus monkeys (104, 226), including a study showing that only vaccinated 
animals that achieved >60% GIA using a purified IgG concentration of 2.5 mg/mL were 
protected against blood-stage challenge (104). This implies that the levels of anti-AMA1 
antibody required to achieve efficacy are far higher than were induced by FMP2.1/AS01. Given 
that the vaccine was given with a very effective adjuvant, and that the peak antibody response 
was median 97 µg/mL, it may not be possible to achieve high enough antibody levels in 
humans against AMA1 for this to be a successful vaccine candidate. Even if substantially higher 
levels of antibody could be induced, the polymorphism of AMA1 also raises a challenge for an 
effective vaccine, with only homologous efficacy demonstrated in any trial to date (97). 
The VAC054 trial may not have demonstrated vaccine efficacy, but did successfully 
demonstrate the reproducibility of the blood-stage CHMI model, with the largest blood-stage 
CHMI ever trial carried out (174, 175, 227). This has important implications for assessing future 
blood-stage vaccine candidates as it allows modest reductions in PMR to be measured with 
greater power than with a sporozoite CHMI model (209). Being able to assess efficacy with 
smaller numbers of participants whilst retaining power to see modest effects has important 
implications for the ethical conduct of these studies (using the smaller numbers reduces risk) 
as well as financial and logistical implications. With the PMR data from this trial I was able to 
calculate that a similar trial design in the future (i.e. 15 vaccinees vs 15 controls with the same 
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inoculum) would have >80% power to see a 33% mean reduction in PMR even with a standard 
deviation of 4 in PMR data for vaccinated volunteers.  
Given the issues with polymorphism of AMA1 and the difficulty in inducing sufficiently high 
levels of effective antibody, even with a leading adjuvant, a different approach will be needed 
if an effective blood-stage vaccine is to be developed. A multi-allele AMA1 vaccine is one 
approach to tackling the issue of polymorphism, such as the Diversity-Covering (DiCo) P. 
falciparum AMA1 vaccine candidate, which has recently completed a Phase I trial 
(NCT02014727; results not yet published). This vaccine showed cross-strain inhibition activity 
against three laboratory-adapted P. falciparum strains (FCR3, HB3 and NF54) when purified IgG 
from vaccinated rhesus macaques was tested in a GIA assay. Mean GIA levels for the DiCo 
vaccine given with the CoVaccine HT™ adjuvant were 56.3%, 57.8% and 83.7% respectively 
with 10 mg/ mL purified IgG (228). Efficacy against falciparum malaria was not assessed in this 
trial as rhesus macaques cannot be infected with P. falciparum, but given the results of the 
VAC054 trial with similar GIA levels, the levels of functional anti-AMA1 antibodies induced by 
the DiCo/HT vaccine may not be sufficient. 
Another alternative approach is to combine the AMA1 vaccine with another antigen to try to 
improve efficacy. However, this approach is not necessarily an easy one as antigen 
combinations do not necessarily improve efficacy. The co-administration of AMA1 and MSP1, 
using the ChAd63 and MVA viral vectors, has previously been shown to diminish the immune 
response against AMA1, with a dominant response to MSP1, and corresponding decrease in 
GIA compared with IgG from volunteers vaccinated with AMA1 alone (83). The combination of 
AMA1 with the RON2 rhoptry neck protein (which AMA1 binds to during the red blood cell 
invasion process) is a more promising combination, with pre-clinical data demonstrating 
improved efficacy in mice against lethal P. yoelii infection, compared with vaccination with 
AMA1 alone (229). This approach has not yet been tested in humans against P. falciparum 
malaria, so whether this result is relevant with regards to human malaria remains to be seen, 
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but the potential to induce improved quality antibodies could go some way to addressing the 
issue of needing high antibody titres against AMA1. 
The need to induce very high antibody levels for blood-stage vaccines requires very effective 
adjuvants. Despite the use of a leading adjuvant in the VAC054 study, the levels induced by 
vaccination were still insufficient to inhibit parasite growth in vivo. A recently re-evaluated 
approach for improving the immune response following malaria vaccines has been to use a 
delayed fractional dose. This approach was first discovered by chance due to a delay in 
vaccination in one of the early RTS,S vaccine trials due to safety concerns, meaning a reduced 
third dose was given at 7 months (following initial vaccinations at 0 and 1 month) as opposed 
to the planned 0, 1 and 2 month schedule. The vaccine efficacy in this CHMI trial was 86% for 
the RTS,S vaccine given with immune stimulants monophosphoryl lipid A and QS21 (71). This 
was higher than the efficacy reported in subsequent CHMI studies of RTS,S with similar 
adjuvants when given in a 0, 1 and 2 month regime (typically ~50%) (73). A more recent study 
has supported the finding of improved efficacy with a delayed fractional dose with the 
RTS,S/AS01 vaccine, with 86.7% vaccine efficacy reported, compared with 62.5% in volunteers 
who received the standard regime (230). It will be important to evaluate this with other 
vaccines/ target antigens and see whether this effect improves the immune response and 
efficacy, especially for blood-stage candidates where high antibody levels appear to be crucial 
for efficacy. 
In this Chapter, I have demonstrated the safety, immunogenicity and efficacy results of a Phase 
I/IIa clinical trial of the AMA1 candidate vaccine FMP2.1/AS01 which had previously been 
reported to have demonstrated efficacy against homologous parasites in a Phase IIb trial in 
Malian children. Despite the induction of antigen-specific antibodies which demonstrated 
functional activity in vitro, the vaccine demonstrated no efficacy against a homologous blood-
stage infection. The possible reasons for this have been discussed. Although the vaccine did 
not demonstrate any efficacy, I was able to demonstrate the reliability and reproducibility of 
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the blood-stage CHMI model, and its potential for the assessment of future blood-stage 
vaccine candidates. Researchers at the Jenner Institute, University of Oxford have been 
working on alternative targets for a blood-stage P. falciparum vaccine. An improved candidate 
will need to have fewer issues with polymorphism and ideally require lower antigen-specific 
antibody levels to be effective than the leading candidates to date (i.e. AMA1 and MSP1). The 
P. falciparum reticulocyte binding homologue 5 (PfRH5) antigen has been evaluated pre-
clinically as part of this research, with very promising results (104). This has now been 
developed as a vaccine candidate and is discussed in Chapter five. 
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Chapter Five: 
 A Phase Ia clinical trial to assess 
the safety and immunogenicity of 
the Plasmodium falciparum antigen 
RH5 in viral vectors ChAd63 and 
MVA (VAC057)  
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5.1 Authorship statement 
I set up the VAC057 clinical trial with the assistance of Alison Lawrie, Rachel Roberts, Ian 
Poulton, Adrian Hill and Simon Draper. This involved preparation of the study documents with 
submission for ethical, regulatory approval for all sites, and R&D department approval for NHS 
sites (in Southampton). 
I screened and enrolled volunteers for the trial in Oxford. Vaccinations and follow-up visits 
were conducted by me and by the nursing team: Oliver Griffiths, Paula Marriott, Megan Baker, 
Ian Poulton, and Raquel Lopez-Ramon. 
Volunteers were also enrolled at the NIHR WTCRF in Southampton. Enrolment, vaccination and 
follow-up of volunteers there were carried out by local study staff including: Hans de Graaf, 
Nicky Pugh, Prudence Miyanza and Nathan Brendish. The local PI at the site was Saul Faust. 
Volunteer-reported AE data were collected on an electronic diary which was designed by me 
and other members of the clinical team, and developed by Sylwester Pawluk. 
Laboratory assays in Oxford were carried out by me and by Sarah Silk and Sean Elias. The GIA 
assays were carried out at the NIH reference center laboratory in the USA by Kazutoyo Miura. 
5.2 Introduction 
5.2.1 Development of a new candidate blood-stage P. falciparum vaccine 
A viral vectored Plasmodium falciparum vaccine has been developed at the University of 
Oxford using the same viral vectors as were used in the VAC051 study (Chapter three), ChAd63 
and MVA. The viral vectors encode a blood-stage antigen from the P. falciparum parasite, 
reticulocyte-binding protein homologue 5 (RH5) and are therefore referred to as ChAd63 RH5 
and MVA RH5. They are given in a heterologous prime-boost regime, with an eight week 
interval between vaccinations. The VAC057 trial was the first trial in which this vaccine and the 
RH5 antigen were administered to humans. 
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5.2.2 RH5 as an antigen 
P. falciparum reticulocyte-binding protein homologue 5 (PfRH5/ RH5) is one of the reticulocyte 
binding-like (RBL or P. falciparum RBP homologue (PfRH)) proteins which are involved in 
parasite invasion of erythrocytes. It is expressed in merozoites and localises to the apical 
complex. PfRH5 is expressed in all P. falciparum strains tested so far, and is essential for 
parasite survival given two reports that the gene cannot be knocked out (100, 101). PfRH5 
binds to its receptor basigin, the Ok blood group antigen, and this interaction mediates an 
essential interaction required for erythrocyte invasion by all tested strains of P. falciparum 
(103). Low-level antibodies to PfRH5 can be found in the pooled serum of humans from 
malaria-endemic countries, but not from pooled malaria-non-exposed immune sera (231, 232). 
These responses have also been associated with clinical protection in an endemic setting, 
supporting the theory that these antibodies may play a part in controlling malaria infection 
(233). Importantly, although antibodies have been found, it appears that PfRH5 does not come 
under significant immune pressure. This may account for the limited polymorphism in PfRH5 
which was reported from the malaria whole genome sequencing project (234) (using >220 field 
isolates from Africa, Asia and Oceania) where only 12 single nucleotide polymorphisms were 
identified in this 526 amino acid antigen, and of these only 7 showed a frequency of >5% (235). 
The basigin binding site on PfRH5 may also be functionally constrained, thus limiting 
polymorphism, given just a few amino acid substitutions have been reported to affect basigin 
recognition and thus host erythrocyte tropism (101, 236, 237). Blocking of the PfRH5-basigin 
interaction has also been shown to be an important contributor of anti-PfRH5 antibody action 
(238). 
Polyclonal antibodies induced by PfRH5 vaccination (or by natural infection) overcome two of 
the major difficulties for blood-stage vaccination: firstly, antibodies can block erythrocyte 
invasion to high efficiency (requiring lower antibody concentrations than previously studied 
targets, such as PfAMA1) (235), and secondly, and even more importantly, these antibodies 
cross-inhibit in vitro all P. falciparum lines and field isolates tested to date (158, 233, 235, 239, 
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240). Importantly, high-level efficacy induced by PfRH5 vaccination against heterologous strain 
challenge in an in vivo Aotus monkey P. falciparum challenge model has also been 
demonstrated (104). This means that the PfRH5 antigen is a substantial step forward in the 
blood-stage malaria vaccine field. 
5.3 VAC057 Methods 
Detailed methods of the recruitment and enrolment of volunteers, as well as the assays used 
in this trial can be found in Chapter two: Materials and Methods. 
5.3.1 VAC057 Study Design 
VAC057 was a first-in-human, open-label, non-randomised, dose escalation Phase Ia clinical 
trial evaluating the safety and immunogenicity of the viral vectored vaccines ChAd63 Rh5 and 
MVA RH5 in a heterologous prime-boost regime with an eight week interval (Figure 5-1). The 
study was conducted in the UK at the Centre for Clinical Vaccinology and Tropical Medicine, 
University of Oxford, Oxford, and the NIHR WTCRF in Southampton. Healthy, malaria-naïve 
males and non-pregnant females aged 18-50 were invited to participate in the study. 
Allocation to study groups occurred at screening based on sequential recruitment of groups 
and volunteer preference. The sample size for this study was chosen to allow determination of 
the magnitude of the outcome measures, especially of serious and severe adverse events, 
rather than aiming to obtain statistical significance. The decision to enrol eight volunteers into 
Groups 2B and 2C was based on a power calculation to have 76% power (1-β) to detect a mean 
two-fold improvement (two-tailed) at a significance level (α) of P = 0.05 in immunogenicity 
(IgG and T cell response) between Groups 2B and 2C following MVA RH5 boost vaccination.  
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Group 
Number 
Number 
of 
volunteers 
Dose ChAd63 RH5 Dose MVA RH5 
1 4 5 x 109 vp IM -- 
2 
A 4 5 x 1010 vp IM -- 
B 8 5 x 1010 vp IM 1 x 108 pfu IM 
C 8 5 x 1010 vp IM 2 x 108 pfu IM 
Figure 5-1: VAC057 study groups 
 
5.3.2 VAC057 Ethics 
The trial was registered with Clincaltrials.gov (NCT 02181088) and was conducted according to 
the principles of the current revision of the Declaration of Helsinki 2008 and in full conformity 
with the ICH guidelines for Good Clinical Practice. The study received approvals from the UK 
NHS Research Ethics Service (Oxfordshire Research Ethics Committee A, Ref 14/SC/0120) and 
the UK MHRA (Ref 21584/0331/001-0001). 
5.3.3 VAC057 Objectives and Endpoints 
Primary Objective 
To assess the safety of ChAd63 RH5 when administered alone and in a heterologous prime-
boost regime with MVA RH5. 
Primary Outcome Measures 
The specific endpoints for safety and reactogenicity were actively and passively collected data 
on AEs. These data were collected using electronic diary cards which were completed by 
volunteers for 28 days after each vaccination, as well as recording any AEs reported by 
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volunteers or detected by study staff (e.g. laboratory abnormalities) at each clinic visit during 
this period. After 28 days only SAEs were recorded. 
Secondary Objective 
To assess the cellular and humoral immunogenicity of ChAd63 RH5 when administered alone, 
and in a heterologous prime-boost regime with MVA RH5 in healthy volunteers. 
Secondary Outcome Measures 
Immunogenicity outcome measures following ChAd63/MVA RH5 included: 
 Induction of antigen-specific T cells (assessed by ex-vivo IFN-γ ELISPOT); 
 Induction of antigen-specific IgG (assessed by anti-RH5 ELISA); 
 Measurement of antigen-specific antibody secreting cells (ASCs) and memory B 
cells (mBCs) following vaccination; 
 Functional activity of antigen-specific IgG (assessed by GIA assay). 
T cell ELISPOT assays, RH5 ELISA assays, ASC ELISPOT assays and mBC ELISPOT assays were 
carried out in the Jenner Institute laboratories in Oxford using the methods described in 
Chapter two. Sarah Silk and Sean Elias carried out the T cell ELISPOT s and the ASC and mBC 
ELISPOT assays; Sarah Silk and I carried out the ELISA assays. Samples were sent to the NIH 
reference center in the USA for GIA assays conducted by Kazutoyo Miura. Volunteers were 
consented for this. 
5.3.4 ChAd63 RH5 and MVA RH5 Vaccines 
The ChAd63 and MVA viral vectors are the same as those described in the VAC051 trial 
(Chapter three). Both viral vectors express a synthetic gene insert encoding the Plasmodium 
falciparum antigen RH5. The RH5 insert is a codon-optimised transgene encoding the RH5 
sequence from the 3D7 clone of Plasmodium falciparum.  
ChAd63 RH5 was manufactured under GMP conditions by Okairos, Italy (this company is now 
ADVENT S.r.l. since being acquired by GSK). MVA RH5 was manufactured under GMP 
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conditions by IDT, Germany. Both vaccines were labelled and released to trial by a QP at the 
CBF, University of Oxford following regulatory approval. 
5.3.5 VAC057 Participants 
Participants for this clinical trial were enrolled at two sites in the UK, the CCVTM in Oxford and 
the NIHR WTCRF in Southampton. Twenty four volunteers were enrolled in total and all 
completed study follow-up. All volunteers gave written informed consent prior to 
participation, and ongoing consent was confirmed before each vaccination. The inclusion and 
exclusion criteria for participation are described below: 
5.3.5.1  VAC057 Inclusion Criteria 
The volunteer had to satisfy all of the following criteria to be eligible for the study: 
 Healthy adult aged 18 to 50 years.  
 Able and willing (in the Investigator’s opinion) to comply with all study requirements. 
 Willing to allow the discussion of their medical history with their GP. 
 For females only, willingness to practice continuous effective contraception during the 
study and a negative pregnancy test on the days of screening and vaccination. 
 Agreement to refrain from blood donation during the course of the study. 
 Provision of written informed consent. 
 
5.3.5.2  VAC057 Exclusion Criteria 
The volunteer could not enter the study if any of the following applied: 
 Participation in another research study involving receipt of an investigational product 
in the 30 days preceding enrolment or during the study period.  
 Prior receipt of an investigational malaria vaccine or any other investigational vaccine 
likely to impact on interpretation of the trial data. 
 Administration of immunoglobulins and/or any blood products within the three 
months preceding vaccination. 
 Any confirmed or suspected immunosuppressive or immunodeficient state, including 
HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) 
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immunosuppressant medication within 6 months preceding vaccination (inhaled and 
topical steroids were allowed). 
 History of allergic disease or reactions likely to be exacerbated by any component of 
the vaccine, e.g. egg products. 
 Any history of anaphylaxis in relation to vaccination. 
 Pregnancy, lactation or willingness/intention to become pregnant during the study. 
 History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in 
situ). 
 History of serious psychiatric condition likely to affect participation in the study. 
 Any other serious chronic illness requiring hospital specialist supervision. 
 Suspected or known current alcohol abuse as defined by an alcohol intake of greater 
than 42 units every week. 
 Suspected or known injecting drug abuse in the 5 years preceding enrolment. 
 Seropositive for hepatitis B surface antigen (HBsAg). 
 Seropositive for hepatitis C virus (antibodies to HCV).  
 History of clinical malaria (any species). 
 Travel to a malaria endemic region during the study period or within the previous six 
months. 
 Any clinically significant abnormal finding on screening biochemistry or haematology 
blood tests or urinalysis. 
 Any other significant disease, disorder or finding which may significantly increase the 
risk to the volunteer because of participation in the study, affect the ability of the 
volunteer to participate in the study or impair interpretation of the study data. 
 Inability of the study team to contact the volunteer’s GP to confirm medical history 
and safety to participate. 
 
5.3.6 VAC057 Assessment of safety 
Following each vaccination, volunteers completed an electronic diary card for 28 days with any 
adverse event data. Further details about the scoring systems for the diary card can be found 
in Chapter two. The electronic diary was developed by Sylwester Pawluk in consultation with 
me, to provide a system which enabled participants to log their AE data in real time. The diary 
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was accessed over the internet and was designed so that it could be used on computers, 
tablets or smart phones. Participants were given a one-time login link and then had to set a 
password to access their diary. They were shown how to use the diary on the day of 
vaccination, and entries were checked at all visits during the 28 day diary period. Study staff 
were able to see all AE data for participants as soon as each day had been completed, and 
were able to edit entries if required (e.g. if further detail was desired). All changes were 
recorded on an audit log so that if changes had been made by study staff this was evident. 
Observations (heart rate, temperature and blood measure) were measured at the clinic visits 
from the day of vaccination until the 28 day follow-up visit. These were recorded directly into 
the OpenClinica eCRFs. Blood samples for safety (full blood count, liver function, urea and 
electrolytes) were carried out at screening, day 0, day 7 and day 28 for all groups, as well as on 
days 56, 63 and 84 for Groups 2B and 2C. These were processed at the NHS laboratories in 
Oxford and Southampton. 
5.3.6.1  VAC057 Stopping and holding rules 
Safety stopping and holding rules were used in this study to ensure participant safety, 
particularly given that this was a first-in-human dose escalation study. For safety reasons the 
first volunteer who received a new vaccine dose was vaccinated alone and there was at least a 
48 hour gap before subsequent volunteers were vaccinated. A further two further volunteers 
could be vaccinated 48 hours after the first, and then at least another 48 hours gap had to 
elapse before the rest of the volunteers receiving that dose of vaccine could be vaccinated. 
Group holding rules 
The study would have been put on hold if any of the following criteria were reached: 
Solicited local adverse events: 
 If more than 25% of doses of a vaccine were followed by Grade 3 solicited local 
adverse event beginning within 2 days after vaccination (day of vaccination and one 
subsequent day) and persisting at Grade 3 for >48 hrs. 
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Solicited systemic adverse events:  
 If more than 25% of doses of a vaccine were followed by Grade 3 solicited systemic 
adverse event beginning within 2 days after vaccination (day of vaccination and one 
subsequent day) and persisting at Grade 3 for >48hrs.  
Unsolicited adverse events: 
 If more than 25% of volunteers developed a Grade 3 unsolicited adverse event 
(including the same laboratory adverse event) that was considered possibly, probably 
or definitely related to vaccination and persisted at Grade 3 for > 48hrs. For the 
ChAd63 RH5 vaccination Groups 2A and 2B were considered as one group as they 
were enrolled simultaneously and received the same vaccine dose.  
A serious adverse event considered possibly, probably or definitely related to vaccination, a 
death or a life-threatening reaction occurred. 
Individual stopping rules (applied to all vaccinated individuals) 
In addition to the above stated group holding rules, stopping rules for individual volunteers 
applied (i.e. indications to withdraw individuals from further vaccinations). Volunteers would 
have been withdrawn from further vaccinations if any of the events listed below occurred and 
were considered possibly, probably or definitely related to vaccination.  
Local reactions:  
 Injection site ulceration, abscess or necrosis. 
Laboratory AEs: 
 If the volunteer developed a Grade 3 laboratory adverse event considered possibly, 
probably or definitely related within 7 days after vaccination which persisted 
continuously at Grade 3 for > 72hrs. 
Systemic solicited adverse events:  
 If the volunteer developed a Grade 3 systemic solicited adverse event considered 
possibly, probably or definitely related within 2 days after vaccination (day of 
vaccination and one subsequent day) which persisted continuously at Grade 3 for > 
72hrs. 
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Unsolicited adverse events: 
 If the volunteer had a Grade 3 adverse event, which persisted continuously at Grade 
3 for >72hrs. 
 If the volunteer had a serious adverse event. 
 If the volunteer had an acute allergic reaction or anaphylactic shock following the 
administration of the vaccine investigational product. 
 
5.3.7 VAC057 Interventions 
Vaccination of volunteers was carried out at the CCVTM in Oxford and NIHR WTCRF in 
Southampton. Vaccines were stored at -80°C in a locked freezer. Administration of vaccines 
was carried out by two members of the local study team (clinician or nurse). One of the clinical 
study staff was required to give the vaccine and the other to check the volume drawn and 
countersign the procedure. In Oxford I checked eligibility and consent prior to vaccination; this 
was done by the trial clinician in Southampton. Vaccines were all administered IM into the 
deltoid muscle, preferentially into the non-dominant arm unless there was a contraindication 
(or the volunteer stated a preference for the other arm). The Investigator administering the 
vaccine wore an apron, gloves and eye protection. The vaccines are GMOs and therefore all 
waste from a vaccination procedure was autoclaved to minimise dissemination of the 
recombinant vectored vaccine virus into the environment, in accordance with UK Genetically 
Modified Organisms (Contained Use) Regulations (2000). 
Volunteers were required to remain at the CCVTM for an hour after vaccination. Their vital 
signs and the vaccination site were checked at 30 minutes (at which time the vaccination site 
dressing was removed and discarded as GMO waste) and 60 minutes to check for evidence of 
any immediate reactions to the vaccine. 
Blood tests for exploratory immunology were taken at all visits except those occurring 2 days 
after each vaccination (i.e. days 2 and 58). The methods used to assess vaccine 
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immunogenicity (T cell ELISPOT, ASC and mBC ELISPOT, IgG ELISA, avidity ELISA, isotype ELISA 
and GIA) are all described in Chapter 2: Materials and methods.  
The four volunteers in Group 1 were vaccinated with 5 x 109 vp of ChAd63 RH5. Following a 
safety review, twelve volunteers (Groups 2A and 2B) were vaccinated with the ‘full dose’ of 
ChAd63 RH5 (5 x 1010 vp), eight of whom (Group 2B) went on to receive MVA RH5 1 x 108 pfu 
eight weeks later. A further eight volunteers were enrolled into the final group (Group 2C), and 
a safety review was carried out prior to the full dose MVA RH5 vaccinations (2 x 108 pfu) given 
eight weeks after ChAd63 RH5 prime with 5 x 1010 vp.  
Vaccination visits occurred on days 0 (all groups) and 56 (Groups 2B and 2C) (nominal study 
days are used throughout). Volunteers also attended follow-up visits on days 2, 7, 14, 28, 56 
and 84 in Group 1, on days 2, 7, 10 14, 28, 56, 63, 84 and 140 in Group 2A and on days 2, 7, 10, 
14, 28, 58, 63, 84 and 140 in Groups 2B and 2C, with a final follow-up phone call for these 
groups on day 240. 
5.4 Results  
5.4.1 VAC057 Participant Flow 
Thirty two volunteers were screened, of whom 24 were enrolled and 8 were excluded (Figure 
5-2). Vaccinations began on 18th August 2014 and all follow-up visits were completed by 28th 
October 2015. All vaccinees received their immunisations as scheduled and there were no 
withdrawals from the study. Similar numbers of males and females were enrolled (13 females, 
11 males). The mean age of volunteers was 28 years (range 19 – 48 years). The four Group 1 
volunteers received 5 x 109 vp of the ChAd63 RH5 vaccine. Following a safety review, the dose 
of ChAd63 RH5 was increased for Group 2 and volunteers received 4.26 – 4.77 x 1010 vp (a 
nominal figure of 5 x 1010 vp will be used throughout the rest of this Chapter). Four volunteers 
in Group 2A received ChAd63 RH5 alone. Eight volunteers were enrolled into Group 2B and a 
further eight into Group 2C. These volunteers received ChAd63 RH5 followed 8 weeks later 
with a ‘boost’ vaccination of MVA RH5 at a dose of 1 x 108 pfu (Group 2B) or 2 x 108 pfu (Group 
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2C). There was a 2 week interval between the final vaccination in Group 2B with MVA RH5 at 
the lower dose of 1 x 108 pfu and the first vaccination with MVA RH5 at the full dose of 2 x 108 
pfu in Group 2C, with a safety review prior to dose escalation. 
 
Figure 5-2: VAC057 Study Flow  
 
5.4.2 VAC057 Vaccine Safety and Reactogenicity 
There were no SAEs or unexpected reactions and no safety concerns during the course of the 
trial. No volunteers withdrew from the study. The reactogenicity of the vaccines was similar to 
that seen in previous malaria vaccine trials using the same viral vectors at similar doses in 
healthy adults (84, 155), with the higher doses of both vaccines associated with an increased 
number and higher severity of reported adverse events. The reactogenicity was also similar to 
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that seen with the P. vivax viral vectored vaccines using the same vectors described in Chapter 
three. 
5.4.2.1  Solicited Adverse Events 
The maximum reported severity of solicited AEs following ChAd63 RH5 are shown in Figure 5-
3A (local AEs) and Figure 5-3B (systemic AEs). The majority of AEs were mild but moderate AEs 
were reported by some volunteers in both groups, and two volunteers who received the full 
dose of ChAd63 RH5 reported severe AEs on the day of vaccination which resolved within 24 
hours. Similarly, solicited AEs following MVA RH5 are shown in Figures 5-4A (local AEs) and 5-
4B (systemic AEs). All moderate or severe solicited systemic AEs following MVA RH5 occurred 
in volunteers who had received the higher dose of vaccine. The majority of solicited AEs 
occurred within the first 2 days after vaccination (Figure 5-5) and the median duration of each 
systemic AE was between 1 and 2 days following either vaccine. 
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Figure 5-3: Solicited local and systemic AEs following ChAd63 RH5.  
Only the highest intensity of each AE per subject is listed. Data are combined for all AEs for all volunteers 
receiving the same vaccine at the stated dose. (A) Local AEs post ChAd63 RH5 in Group 1 (G1) at the 5 x 
10
9
 vp dose (4 volunteers) and Group 2 (G2) at the 5 x 10
10
 vp dose (20 volunteers). (B) Systemic AEs post 
ChAd63 RH5 in G1 and G2 at doses of 5 x 10
9
 vp and 5 x 10
10
 vp respectively. Data were exported from 
the OpenClinica database and the eDiary into Excel worksheets, and data were combined to calculate the 
percentages of volunteers experiencing each AE following vaccinations at different doses. 
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Figure 5-4: Solicited local and systemic AEs following MVA RH5.  
Only the highest intensity of each AE per subject is listed. Data are combined for all AEs for all volunteers 
receiving the same vaccine at the stated dose. (A) Local AEs post MVA RH5 in Group 2B (G2B) at the 1 x 
10
8
 pfu dose (8 volunteers) and Group 2C (G2C) at the 2 x 10
8
 pfu dose (8 volunteers). (B) Systemic AEs 
post MVA RH5 in G2B and G2C at doses of 1 x 10
8
 pfu and 2 x 10
8
 pfu respectively. Data were exported 
from the OpenClinica database and the eDiary into Excel worksheets, and data were combined to 
calculate the percentages of volunteers experiencing each AE following vaccinations at different doses.  
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Figure 5-5: VAC057 Percentage of volunteers reporting solicited local and systemic AEs by 
day  
Data are shown for 7 days after ChAd63 RH5 vaccination (n=24) (A, B) and MVA RH5 (n=16) (C, D) for all 
volunteers receiving each vaccine, regardless of dose. Data were exported from the Openclinica 
database and eDiary into Excel and the percentages of volunteers reporting each solicited AE by day post 
vaccination were calculated. 
 
5.4.2.1  Unsolicited Adverse Events 
Unsolicited AE data were collected for 28 days after each vaccination (SAE data were collected 
until the end of follow-up). Causality was assigned by the lead clinician and peer-reviewed by 
an independent clinician with an agreed final causality score. Causality was assessed as 
described in ‘Materials and Methods’ (Chapter two). One volunteer reported a severe 
unsolicited adverse event which was considered probably related to vaccination as it occurred 
the day after ChAd63 RH5 5 x 109 vp. This was abdominal cramping lasting around 30 minutes 
which resolved spontaneously and did not recur. There were no severe unsolicited adverse 
events reported after MVA RH5 vaccination. Unsolicited adverse events considered possibly, 
probably or definitely related to vaccination are shown in Table 5.1. 
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As well as the unsolicited adverse events listed below, five volunteers had mild hypertension 
recorded during the trial. This was recorded as a single reading in two volunteers, recorded 
twice in one volunteer and recorded intermittently for a further two volunteers, both of whom 
were noted to have mild hypertension at screening. One volunteer had a mild tachycardia 
recorded at two clinic visits (days 2 and 28) but this was not sustained. 
 
Table 5.1: VAC057 Unsolicited adverse events considered possibly, probably or definitely 
related to vaccination.  
Maximum reported severity shown. Timepoint(s) = days post vaccination. 
 
5.4.2.3  Laboratory Adverse Events 
There were no severe laboratory AEs following ChAd63/MVA RH5 vaccination. One volunteer 
had a moderately raised ALT at day 7 following ChAd63 RH5 which had resolved fully by day 
Unsolicited AEs following ChAd63 RH5 
Group Subject ID Timepoint(s)  Symptom Severity 
1 MVT-0571005 1 Abdominal cramping  3 
2A MVT-0571003 0 Numbness around the lips 1 
2A MVT-0571003 9, 11 Headache 2 
2A MVT-0571003 9 Fatigue 1 
2A MVT-0571009 9 painful injection site 1 
2A MVT-0571010 1 to 2 sore throat 1 
2B MVT-0571015 10 fatigue 2 
2C MVT-0571014 7 to 8 Temp 37.2;  feeling unwell 2 
2C MVT-0571014 8 Weakness 2 
2C MVT-0571014 8 Fatigue 2 
2C MVT-0571014 11 Headache 1 
2C MVT-0572211 2 Felt light headed and dizzy after going for a run. 1 
2C MVT-0572205 1 Palpitations 2 
2C MVT-0572205 1 Insomnia 2 
2C MVT-0572210 7 to 8 Sore throat  1 
2C MVT-0572210 9 to 12 mild sinus/nasal congestion 1 
Unsolicited AEs following MVA RH5 
Group Subject ID Timepoint(s) Symptom Severity 
2B MVT-0571012 1 to 11 Coryzal symptoms, cough and congestion 1 
2B MVT-0571018 0 to 1 abdominal pain  1 
2B MVT-0571020 4 to 5 Coryzal symptoms 1 
2B MVT-0572204 10 Headache 1 
2C MVT-0571014 8 Vomited x 1 2 
2C MVT-0572211 0 to 3 Disturbed sleep  1 
2C MVT-0572205 1 Tinnitus 1 
2C MVT-0571017 0 to 1 Small swelling/haematoma at vaccination site  1 
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28. One volunteer had moderate thrombocytopenia and mild leukopenia at day 28 following 
ChAd63 RH5 but had commenced post-exposure prophylaxis for HIV exposure the day before 
these bloods were taken, so these findings may have been due to the antiretroviral medication 
rather than the vaccination. All other laboratory AEs were mild and had resolved fully by day 
84 except for one volunteer who had a persistent mild anaemia. This had been present at 
screening and had not worsened over the course of the study so was not considered 
significant. 
5.4.3 ChAd63/MVA RH5 T cell immunogenicity assessed by ex-vivo IFN-γ 
ELISPOT 
The ChAd63/MVA RH5 vaccines elicited T cell responses as assessed by ex-vivo IFN-γ ELISPOT, 
with peak responses after the MVA boost (Figure 5-6). The median peak responses (day 63) 
were 2092 SFU/million PBMC for Group 2B and 2281 SFU/million PBMC for Group 2C. This 
difference was not statistically significantly different (P = 0.32; analysed by Mann Whitney 
test). The response at day 140 (final immunology timepoint) was also similar in both groups 
with a median response of 458 and 663 SFU/million PBMC in Groups 2B and 2C respectively. 
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Figure 5-6: VAC057 T cell responses as assessed by ex vivo IFN- γ ELISPOT  
Individual and median group results are shown for volunteers vaccinated with ChAd63 RH5 (all groups) 
and boosted with MVA RH5 (Groups 2B and 2C). Arrows indicate vaccination timepoints. Spots were 
counted using an automated plate counter and exported into an Excel worksheet where results were 
obtained by subtracting any background response (from negative control wells) and then taking the 
average of triplicate wells. Data were then imported into GraphPad Prism for statistical analyses. 
 
5.4.4 ChAd63/MVA RH5 antibody response assessed by ELISA 
The kinetics and magnitude of the serum IgG antibody responses were assessed over time by 
an ELISA to recombinant PfRH5 protein (Figure 5-7). The IgG response was higher in the group 
vaccinated with full dose (5 x 1010 vp) ChAd63 RH5 and peaked after MVA boost with similar 
IgG responses in both boosted groups (Groups 2B and 2C). The median peak response, seen 
four weeks after MVA RH5 (i.e. day 84) was 720 AU in Group 2B and 1696 AU in Group 2C. 
Most volunteers who received the lead-in dose of ChAd63 RH5 alone did not seroconvert 
(Group 1; Figure 5-7B), whereas those who received full dose did. The difference in peak 
median responses between Groups 2B and 2C at day 84 was not calculated to be significant 
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but the response in Group 2C was significantly higher than that in the unboosted volunteers in 
Group 2A (P value = 0.01; analysed by Kruskal-Wallis test).  
 
Figure 5-7: VAC057 Anti-RH5 IgG responses measured by ELISA  
Median responses for all groups (A), and individual and median responses following ChAd63 RH5 (B) (G1, 
n=4; G2, n=20) and following MVA RH5 in G2B (n=8) and G2C (n=8) (C and D) are shown. The absorbance 
at 405nm (OD405) was read using a Biotek ELx800 microplate reader with Gen5 software. Data were 
exported into an Excel worksheet and values of internal controls and samples in triplicate were assessed 
for any aberrant readings. The results were obtained by taking an average of triplicate wells, and using 
the standard curve to assign ELISA arbitrary units (AU). The limit of the assay is 20 AU (marked by a 
dotted line), below which is classed as negative. Data were then imported into GraphPad Prism for 
statistical analyses. 
 
5.4.5 Anti-RH5 IgG avidity and antibody response profile  
A NaSCN-displacement ELISA was carried out to assess the avidity of the serum IgG responses 
following ChAd63/MVA RH5 vaccination (Figure 5-8) and is reported as the molar 
concentration of NaSCN required to reduce the OD 405 to 50% of that without NaSCN (IC50). 
Avidity for samples negative for Total IgG ELISA cannot be analysed. The avidity of the anti-RH5 
IgG was significantly but marginally higher at the peak of the IgG response after MVA boost 
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than following ChAd63 RH5 alone. Avidity was lower with ChAd63/MVA RH5 than seen 
following ChAd63/MVA PvDBP (Chapter three). 
 
Figure 5-8: IgG Avidity assessment following ChAd63/MVA RH5 vaccinations.  
Individual and median responses at four weeks (d28) post ChAd63 PfRH5, twelve weeks post ChAd63 
PfRH5 (G1 and G2A d84) and four weeks post MVA PfRH5 boost (d84 G2B and G2C) are shown. Avidity 
for samples negative for Total IgG ELISA could not be measured. The absorbance at 405nm (OD405) was 
read using a Biotek ELx800 microplate reader with Gen5 software. Data were exported into an Excel 
worksheet and the average value of duplicate readings calculated. Data were then imported into 
GraphPad Prism for statistical analyses.  ***P<0.001 Kruskal-Wallis test with Dunn’s correction for 
multiple comparison. 
 
An isotype ELISA (Figure 5-9) demonstrated a similar antibody profile following ChAd63/MVA 
RH5 as was seen following ChAd63/MVA PvDBP (Chapter three) with a predominant IgG1 and 
IgG3 response. There was also a significant increase in IgA seen following ChAd63/MVA RH5 
vaccination. Although there was a significant increase in IgM, many of the baseline results 
were positive, suggesting there was some interference or background reactivity in the assay 
for this isotype. 
 
Avidity
Time-point (d)
IC
5
0
 N
a
S
C
N
 (
M
)
d
2
8
G
1
 +
 G
2
A
 d
8
4
G
2
B
 +
 G
2
C
 d
8
4
0
1
2 ***
193 
 
 
Figure 5-9: Antibody isotype profile following ChAd63/MVA RH5 vaccination.  
Antibody isotypes were assessed by ELISA. Baseline (d0) response, and response twelve weeks post 
ChAd63 RH5 for G1 (n=4) and G2A (n=4) and four weeks post MVA RH5 boost for G2B (n=8) and G2C 
(n=8) (d84) are shown. Individual and median responses are shown for every isotype. Dotted line 
represents ELISA cut-off (OD of 0.15, below which samples were considered negative). The absorbance at 
405nm (OD405) was read using a Biotek ELx800 microplate reader with Gen5 software. Data were 
exported into an Excel worksheet and the average OD values of duplicate samples calculated. Data were 
then imported into GraphPad Prism for statistical analyses ***P<0.001, ****P<0.0001 Wilcoxon 
matched-pairs signed rank test. 
 
5.4.6 Detection of anti-RH5 ASCs and mBCs following ChAd63/MVA RH5 
Samples from boosted volunteers (G2B and G2C) were assessed by ex-vivo ASC ELISPOT at the 
d63 timepoint using fresh PBMC, and at a later timepoint using frozen PBMC for comparison. 
There was no significant difference between Groups 2B and 2C using either fresh PBMC (P = 
0.15; Mann Whitney test) (Figure 5-10A) or frozen PBMC (P = 0.27; Mann Whitney test) (Figure 
5-10B). There was a trend towards RH5-specific ASC making up a higher percentage of the total 
IgG-secreting ASC in Group 2C but this was not statistically significant (P = 0.80; Mann Whitney 
test) (Figure 5-10C). 
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Peripheral mBC responses were assessed by identifying RH5-specific mBC-derived plasma cells 
by ex-vivo ELISPOT following a 6-day polyclonal culture of PBMC (Figure 5-11). The responses 
were measured at the peak IgG response (d84) and at the final timepoint (d140). There was no 
significant difference between the median response in G2B and G2C, both as a measure of 
mBC-derived ASC. 
 
 
Figure 5-10: ASC responses following ChAd63/MVA RH5 vaccination.  
RH5-specific peripheral blood ASCs measured from fresh PBMC (A) and frozen PBMC (B) isolated 7 days 
following MVA RH5 vaccination (d63) using ex-vivo ELISPOT. (C) RH5-specific ASC as a percentage of 
total IgG detected from frozen PBMC at d63. Data are shown for G2B (n=8) and G2C (n=8). Spots were 
counted using an AID ELISPOT reader and automated counts were corrected by eye to ensure only spots 
consistent with IgG secreting ASCs were counted. Data were exported into an Excel worksheet and then 
imported into GraphPad Prism for graphical presentation and statistical analyses. There were no 
significant differences between Groups 2B and 2C using the Mann Whitney test. 
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Figure 5-11: mBC responses following ChAd63/MVA RH5 vaccination 
mBC derived ASC measured at the peak of the response at d84 and at the final timepoint (d140) using ex-
vivo ELISPOT for Groups 2B (n=8) and 2C (n=8). Individual and median results for both groups are shown 
as (A) mBC derived ASC per million cultured PBMC and (B) as a percentage of total IgG ASC. mBC ELISPOT 
spots were counted using an AID ELISPOT reader and automated counts were corrected by eye .Data 
were exported into an Excel worksheet and then imported into GraphPad Prism for statistical analyses. 
There was no significant difference between the median response in G2B and G2C (assessed by Mann 
Whitney test). 
 
5.4.7 VAC057 Measures of in vitro GIA 
Serum was sent to the GIA Reference Center at NIH, USA and IgG purified from each sample. 
GIA was assessed against the vaccine homologous clone (3D7) for all volunteers who received 
both vaccines (Groups 2B and 2C). IgG was initially assessed at 10 mg/mL (Figure 5-12A) and 
then using a serial dilution. As expected, GIA decreased as the IgG was diluted (Figure 5-13). As 
discussed in Chapter four, a GIA of >60% with 2.5 mg/mL purified IgG was required in the 
Aotus animal model to correlate with protection against P. falciparum malaria (104) and none 
of the volunteers in VAC054 achieved greater than 40% GIA at this concentration of IgG. 
Therefore we expect that GIA levels are required to be >40% (and possibly >60%) at 2.5 mg/mL 
purified IgG if protection against P. falciparum blood-stage CHMI is likely to be seen. Figure 5-
12B demonstrates that none of the volunteers in VAC057 achieved >40% GIA at 2.5 mg/mL 
purified IgG after ChAd63/MVA RH5 vaccination. Nonetheless, the result was encouraging as 
the level of GIA achieved with the ChAd63/MVA RH5 viral vectors in this trial was similar to 
that seen with the FMP2.1 protein vaccine given with the potent AS01 adjuvant (209).  
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GIA was also assessed against a range of other P. falciparum strains (Figure 5-14). These data 
show that the antibodies induced by vaccination were able to inhibit the growth of all strains 
of P. falciparum tested, although the levels of GIA were not equal for all strains. 
 
Figure 5-12: VAC057 GIA against reference clone P. falciparum 3D7 at 10 mg/mL and 2.5 
mg/mL purified IgG. 
GIA for each group with individual and median responses are shown at a purified IgG concentration of 10 
mg/mL (A) and 2.5 mg/mL (B). Results are compared with purified IgG from vaccinees at the same 
dilution from the VAC054 trial (Chapter four). A single-cycle assay was used, with the readout measured 
after 48 hours. Data were received from the NIH reference center in an Excel worksheet and were 
imported into GraphPad Prism for graphical presentation and analyses. 
 
 
 
Figure 5-13: VAC057 GIA against reference clone P. falciparum 3D7 at 10 mg/mL purified IgG 
and serial dilutions.  
A single-cycle assay was used, with the readout measured after 48 hours in samples from volunteers in 
Groups 2B (n=8) and 2C (n=8). Data were received from the NIH reference center in an Excel worksheet 
and were imported into GraphPad Prism for graphical presentation and analyses. 
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Figure 5-14: VAC057 Growth inhibition activity of purified IgG at 10mg/mL against a range of 
P. falciparum strains compared with GIA against the reference 3D7 clone. 
 
5.5 Discussion  
As discussed in Chapter four, the development of vaccines against P. falciparum, and especially 
against the blood-stage parasite has proved extremely challenging, with no blood-stage 
candidate vaccine to date demonstrating significant efficacy against infection. The reasons for 
the lack of efficacy include difficulty in achieving adequate antibody concentrations (given the 
very short time interval in which the merozoite is exposed before erythrocyte invasion) and 
antigen polymorphism. The antibody levels required to block invasion differ according to the 
antigen, for example, higher concentrations of anti-MSP1 antibody are required to block 
invasion in a GIA assay compared with anti-AMA1 antibodies (130). The polymorphisms 
described for both MSP1 (87) and AMA1 (241-243) also create issues for vaccine development. 
One approach is to develop a multi-allele vaccine (244, 245), but covering all antigen variations 
would be difficult and it is possible that parasites may find other mechanisms for invasion. 
The PfRH5 antigen has important advantages over blood-stage antigens such as AMA1 and 
MSP1. Firstly, there is only limited polymorphism (235), presumably because PfRH5 appears 
not to come under significant immune pressure. Secondly, anti-RH5 antibodies are able to 
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block erythrocyte invasion with lower antibody concentrations than anti-AMA1 and anti-MSP1 
antibodies (130, 235) which means that lower antibody levels are potentially needed for an 
effective vaccine than for these candidate antigens. As discussed at the start of this Chapter, 
anti-RH5 antibodies induced by vaccination have been shown to inhibit multiple strains of P. 
falciparum in vitro (158, 235, 239, 240) and vaccination with RH5 vaccines protected Aotus 
monkeys against a heterologous strain challenge in vivo (104).  
In this Chapter, I have decribed the safety and immunogenicity of the candidate vaccines 
ChAd63/MVA RH5 in a first-in-human Phase Ia clinical trial. The vaccines were well tolerated 
with an acceptable reactogenicity profile, no SAEs and all volunteers completed follow-up in 
the study. In this study, as opposed to VAC051 (Chapter three) and VAC054 (Chapter four), I 
implemented an electronic diary to collect volunteer-reported AEs. This enabled the safety 
data to be monitored remotely for all enrolled volunteers in real time, as well as reducing the 
risk of data errors in transcribing from paper diaries to a database. Furthermore, use of the 
electonic diaries meant I collected data daily for 28 days after each vaccination rather than 7 
or 14, improving the accuracy of the data as data collected after day 7 did not rely purely on 
recall at clinic visits. The change of duration for collecting all AEs in this study also meant that 
the most relevant information regarding AEs was collected, i.e. those occurring within the first 
four weeks after vaccination, and any serious AEs. Blood samples for haematological and 
biochemical analyses were taken only over the same period as it was felt that any 
abnormalities attributable to vaccination would be detectable within this timeframe. 
The ChAd63/MVA RH5 vaccines were immunogenic, eliciting RH5-specific T cell and IgG 
reponses in vaccinees who received the higher dose of ChAd63 RH5 and peaking after MVA 
RH5 boost. There was a trend towards higher anti-RH5 IgG responses in Group 2C, who 
received the full dose of both vaccines, but the difference was not statistically significant. 
However, the number of RH5-specific ASCs measured at 7 days post-MVA RH5 were 
significantly higher following full dose MVA RH5 than the 1 x 108 pfu dose. There was also a 
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significant increase in IgG avidity after MVA RH5 boost. The RH5-specific T cell response was 
similar in both boosted groups, with a peak response seen 1 week after the MVA RH5 
vaccinations. Although it is likely that protection against blood-stage malaria is mainly 
antibody-mediated, T cells are important in providing B cell help and also in activating Th1 
responses which help mediate effector mechanisms of both antibodies and cell-mediated 
immunity (246).  
Antibodies induced by vaccination demonstrated in vitro efficacy against P. falciparum in a GIA 
assay. As discussed in Chapter three, the induction of functional antigen-specific antibodies 
provides evidence that the RH5 protein was produced as a correctly folded protein and 
secreted successfully following ChAd63/MVA RH5 vaccination. Most importantly, the purified 
IgG from vaccinated volunteers was able to block not only the strain homologous with the 
PfRH5 in the ChAd63/MVA RH5 vaccines, but also every other strain tested in this assay. This is 
the first time antibodies against a blood-stage antigen have demonstrated cross-strain 
inhibition following vaccination of humans with a monovalent P. falciparum candidate vaccine. 
The level of GIA differed according to strain, with some demonstrating greater inhibition than 
against the 3D7 reference clone whilst others had lower levels. This may be due to several 
reasons including: polymorphisms within the RH5 protein leading to slight differences in the 
binding site with basigin and therefore differences in activity of anti-RH5 antibodies; 
differences in the amount of RH5 expressed by the various strains; or differences in the release 
kinetics of RH5 between strains.  
The level of GIA seen against the 3D7 reference clone was similar to that seen following the 
FMP2.1/AS01 vaccine discussed in Chapter four, with a median GIA at 10 mg/mL purified IgG 
of 40% in Group 2B and around 50% in Group 2C (compared with around 60% in the VAC054 
trial). At 2.5 mg/mL purified IgG the GIA levels fell to a median of 14% for Group 2B and 26% 
for Group 2C (compared with 20% in the VAC054 volunteers). It is therefore unlikely that this 
vaccine regime would be protective against P. falciparum infection in a blood-stage CHMI trial. 
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However, the result is still encouraging as the levels of antibody induced by viral vectored 
vaccines are typically lower than those after protein-in-adjuvant vaccine regimes. A previous 
Phase Ia trial in Oxford demonstrated that purified IgG at 10 mg/mL from volunteers 
vaccinated with AMA1 given in viral vectored vaccines using the same vectors as were used in 
this trial gave less than 20% GIA (167). In this same study, a protein-in-adjuvant AMA1 vaccine 
was given following a ChAd63 AMA1 priming vaccine and this gave similar levels of GIA at 10 
mg/mL purified IgG to those seen in the VAC054 study with the AMA1 vaccine FMP2.1/AS01B 
(167, 209). This implies that antibody levels could be improved upon with a vaccine which was 
tailored to induce a stronger B cell response as the T cell response against this antigen is likely 
to have less of a role. Having said that, the GIA assay only assesses the functional activity of IgG 
and the response against P. falciparum infection may be better than predicted if T cells do play 
a role.  
To conclude, this study marked a major milestone in P. falciparum blood-stage vaccine 
development, showing that induction of antibodies active against multiple parasite strains is 
possible in humans. Future work will aim to develop a vaccine which is better at inducing 
antibodies than viral vectored vaccines, and this will hopefully lead to demonstrable efficacy 
against the parasite. 
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Chapter six: 
Concluding Remarks and Future 
Directions 
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6.1 Summary 
Malaria remains a significant global health burden, affecting millions of individuals each year. 
Most cases of malaria are due to P. falciparum, but a significant proportion of those in Asia and 
South America are due to P. vivax. The development of effective malaria vaccines has proved 
extremely challenging, with only one vaccine candidate (GSK’s P. falciparum pre-erythrocytic 
vaccine, RTS,S) reaching Phase III trials, and demonstrating only moderate efficacy (57). The 
most recent update to the Malaria Vaccine Technology Roadmap calls for a vaccine effective 
against both falciparum and vivax malaria by 2030 (7). Blood-stage malaria vaccines for P. 
falciparum have faced particular difficulties with the need for very high antibody levels and 
issues with polymorphism of candidate antigens. No blood-stage vaccine has demonstrated 
significant efficacy against infection to date, but the concept of a blood-stage vaccine is 
supported by the development of natural immunity in endemic areas with a corresponding rise 
in serum titres of antibodies against blood-stage malaria proteins (247). However, in natural 
immunity responses to a broad range of antigens are required (248) and strain-specificity has 
been demonstrated (249). Even in those who acquire natural immunity, protection is far from 
complete with a reduction in disease severity but ongoing risk of infection (247, 250). There 
had not previously been any blood-stage P. vivax vaccine to reach clinical trial, and there are 
reasons to believe that a vaccine against this parasite may be easier to achieve as in almost all 
cases P. vivax invades erythrocytes via DARC, making this an essential interaction for the 
parasite. Furthermore, there is evidence that antibodies against PvDBP are able to block 
multiple strains of P. vivax, meaning heterologous as well as homologous protection may be 
possible with a PvDBP-based vaccine (251). 
This thesis has described three clinical early-phase vaccine trials carried out in healthy adult 
volunteers at the Jenner Institute in Oxford. Two of the trials investigated P. falciparum 
candidate blood-stage vaccines, and one trial examined a P. vivax vaccine. One of the P. 
falciparum blood-stage vaccine trials also led to the development of a human blood-stage 
CHMI model to assess vaccine efficacy. All vaccines tested were safe and immunogenic. 
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However, despite functional AMA1-specific antibodies being induced by the FMP2.1/AS01 
vaccine, efficacy against homologous blood-stage CHMI was not seen. Similarly, functional 
antibodies against RH5 were seen following the ChAd63/MVA RH5 heterologous prime-boost 
regimen, but the level of GIA seen was thought unlikely to lead to protection against P. 
falciparum infection, although this currently remains untested. Importantly though, the 
functional activity seen was strain-transcending, a novel finding following vaccination of 
humans with a blood-stage vaccine candidate. The ChAd63/MVA PvDBP vaccine regimen was 
the first blood-stage P. vivax vaccine candidate ever to be tested in a clinical trial. Again, anti-
PvDBP antibodies were induced which demonstrated blocking of the PvDBP-DARC interaction 
in an in vitro assay, but as blood-stage vaccine efficacy has never been tested for P. vivax it is 
unknown whether this would be likely to translate into protection against infection in vivo. 
These studies have therefore highlighted some of the difficulties in blood-stage malaria 
vaccine development but have also made important progress in this field.  
6.2 Development of the CHMI model for assessing blood-stage P. 
falciparum vaccines 
The best method for assessing vaccine efficacy for blood-stage P. falciparum vaccines has been 
widely debated (214). It may be that efficacy only occurs at high parasite densities, which do 
not occur in CHMI trials as participants are treated as soon as malaria is diagnosed on thick 
blood film, even if asymptomatic. However, an effective vaccine against malaria will need to be 
able to control parasitaemia before the onset of symptoms if it is to be useful and acceptable. 
In order to assess early effects on parasitaemia, the effect on PMR following vaccination can 
be analysed as an efficacy endpoint. This allows for even small changes in the growth rate of 
the parasite to be detected, demonstrating partial efficacy as well as the potential for 
demonstrating sterile efficacy if a volunteer is protected from developing malaria. 
Demonstration of partial efficacy would still be an important finding as it infers that protection 
is possible and allows further development to produce an improved vaccine going forwards. 
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The vaccine tested in the VAC054 trial (Chapter four) had previously been reported as 
demonstrating evidence of strain-specific efficacy in Malian children. The trial reported 64.3% 
efficacy (hazard ratio 0.36, 95% CI 0.08-0.86, P=0.03) in a pre-defined secondary analysis 
against clinical malaria with 3D7-type parasites (defined by eight immunologically important 
AMA1 polymorphisms in the cluster 1 loop of domain I), although the number of cases meeting 
this definition was small (97, 98) and protection did not extend into the second season of 
follow-up (99). This vaccine was therefore selected to be used in developing the CHMI model, 
as the AMA1 clone (3D7) used in the vaccine was the same as that in the CHMI inoculum. 
Although the trial did not demonstrate any vaccine efficacy, the reproducibility of the CHMI 
model was successfully demonstrated, and the potential improvement in measuring modest 
changes in PMR compared with sporozoite CHMI was also shown (209). The lack of 
FMP2.1/AS01 efficacy in this trial, in contrast to the study in Malian children, could be due to a 
number of possible reasons. Firstly, there may have been reduced immunogenicity of the 
vaccine in the VAC054 trial. ELISA and functional GIA analysis were performed at WRAIR 
(where the vaccine was developed) as well as in Oxford (209) and these showed the responses 
to be modestly, but significantly, lower than those reported in a trial of FMP2.1 administered 
with AS01 or AS02 in healthy US adults (95). Secondly, the use of AS01 instead of AS02 may 
have impacted the immunogenicity and efficacy. Thirdly, the vaccine may only have an impact 
at high parasite densities which would not be detected in a CHMI trial where participants are 
treated before high parasite densities are allowed to develop. Fourthly, the vaccine may have 
had a pre-erythrocytic effect which would not be detected with blood-stage CHMI. Finally, 
Malian children, unlike UK adults, would have possessed pre-existing anti-malarial immune 
responses, including anti-AMA1 IgG, which may have acted in conjunction with the vaccine-
induced anti-AMA1 responses. 
This was the largest blood-stage CHMI trial conducted to date and the model should accelerate 
proof-of-concept testing of new blood-stage malaria vaccines as the study can be powered to 
detect relatively low efficacy even with a small number of participants (fifteen vaccinees and 
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fifteen infectivity controls). This will enable much faster and more cost-effective testing of new 
candidate vaccines compared with the traditional field trial approach, and requires fewer 
participants than the sporozoite model in order to achieve the same power, which is an 
important ethical and logistical consideration.  
It will be very important to the field to correlate any vaccine efficacy seen with future blood-
stage candidate vaccines with levels of GIA. This has been shown to correlate in the Aotus 
monkey model (104, 226, 252) and the rhesus macaque monkey model using P. knowlesi 
parasites (253), but as no blood-stage P. falciparum vaccine has demonstrated efficacy with 
this model it is not definitively known whether the same can be said for a correlation in 
humans between GIA and vaccine efficacy.  
6.3 Development of safety data collection and analysis for early-
phase clinical trials 
Over the course of the clinical trials described in this thesis, which commenced in May 2013 
(VAC051) and were completed by December 2015 (VAC057) I made several changes to the way 
safety data were collected and analysed to improve accuracy and reduce bias. These changes 
included the use of an eCRF for live entry of data in clinic, which removed the risk of 
transcription errors and allowed data to be viewed in real time as there was no delay between 
a participant being seen and the data being available in the database. I also led the 
development of an eDiary system for volunteers to enter AE data into directly, rather than 
using paper diaries which then had to be transcribed into the OpenClinica database. This 
system was developed in conjunction with the other clinicians working across many different 
trials in the Jenner Institute by Sylwester Pawluk. This system enabled me to see when 
volunteers were completing the diary cards and meant I had access to AE data in real time, 
unlike with paper diary cards which were only reviewed when participants were seen in clinic. 
This meant that any severe AEs could be noted quickly and further review of volunteers could 
be planned if necessary, as well as ensuring that the safety stopping and holding rules were 
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adhered to. From anecdotal evidence, as a study team we were aware that volunteers 
sometimes completed paper diary cards on the day they were seen in clinic, which could be 
seven or fourteen days after vaccination. This meant the data were inaccurate as data was 
subject to substantial recall bias, as was the collection of AE data in clinic after the paper diary 
cards had been completed. By introducing a 28 day diary and only collecting SAE data after this 
(as was done in VAC057) I believe I have improved the quality and reliability of AE data 
collected. As safety of the vaccines is a primary endpoint for any Phase I trial, this is extremely 
important. As well as improving data accuracy, the eDiaries have substantially reduced the 
amount of time required for data entry and analysis as the data are already processed when 
the Excel spreadsheet extraction is done; unlike with OpenClinica data extracts which require 
further processing.  
The analysis of laboratory AE data is another area in which I sought to improve accuracy and 
comparability of data. Having recognised that the different study sites in which trials were 
being carried out all had some variability in normal reference ranges for several of the 
parameters we were measuring, I sought to develop site-specific laboratory AE grading tables 
which took these into account. This was done in collaboration with other Jenner and study site 
clinicians and these tables are now used across all Jenner Institute trials. This has improved the 
quality of these safety data as it ensures that laboratory results are correctly defined as an AE 
where necessary, and are graded at an appropriate severity. I believe that for early-phase 
vaccine trials this is extremely important as any haematological or biochemical abnormalities 
need to be assessed and the relationship to vaccination determined. I also introduced day 0 
safety bloods after the VAC051 trial as this is a more accurate baseline than using the bloods 
checked at screening, which could be up to 90 days before vaccination. This means the 
causality of any laboratory AEs noted after vaccination can be more accurately assigned. 
Finally, the other change made to safety data analysis since I started this work is the 
assignment of causality. This was originally done in real time for all AEs by the local site 
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clinician (me) for VAC051, but I was concerned that this meant there was potential for 
significant bias in these data and that rare events may be incorrectly assigned as ‘not related’ 
or ‘unlikely to be related’, especially in multi-site trials. I therefore suggested to the Sponsor 
(University of Oxford) that the process be changed so that causality was assigned at interim 
analyses and at the end of the study by the lead clinician (me). I also changed the causality 
assignment procedure to state that any solicited AEs occurring within the first seven days 
should be considered at least possibly related to vaccination. Furthermore, causality is now 
peer-reviewed by a clinician from another group within the Jenner Institute and any 
discrepancies discussed by the lead clinician for the trial and the clinician who performed the 
peer review. This enables rare events to be assessed more accurately, especially if they occur 
at different trial sites, and reduces bias in the causality assignment.  
There is a need for standardisation across early-phase vaccine trials, with consensus on 
severity grading so that accurate comparisons of vaccines in different populations and settings 
can be made. Some progress has been made in this area by the Brighton Collaboration 
Methods Working Group (254, 255) but there is no globally accepted standard for measuring 
vaccine reactions. The changes mentioned above have enabled standardisation across the 
trials conducted at the Jenner Institute, but global standards would be a further improvement. 
6.4 Future work 
6.4.1 Improving vaccine immunogenicity 
As highlighted in the trials described in this thesis, improvements in vaccine design are needed 
to improve the immunogenicity, specificity and efficacy of blood-stage vaccines. There are 
several methods being evaluated with this goal in mind. These either work to improve the 
immunogenicity of the vaccine itself by improving antigen presentation, for example through 
the use of virus-like particles (VLPs) or molecular adjuvants (e.g. IMX313), improve 
immunogenicity through use of a more potent adjuvant, or design vaccines with specific 
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epitopes known to be involved in antigen binding. This section will discuss the progress being 
made in these areas for blood-stage vaccines in particular. 
6.4.1.1  Viral vectored vaccines 
Two of the trials I conducted used heterologous prime-boost with the ChAd63 adenoviral 
vector followed eight weeks later with an MVA boost. The advantages of these types of 
vaccines are that they can be made to GMP relatively easily and quickly, are extremely good at 
inducing T cell responses and do not require an adjuvant to be co-administered. As access to 
adjuvants has historically been limited, requiring collaboration with pharmaceutical companies 
for access to the most effective, viral vectors were an attractive means of developing vaccines. 
The use of the ChAd63/MVA platform meant that the world’s first blood-stage P. vivax blood-
stage vaccine reached clinical trial. Although the PvDBP antigen had been of interest as a 
vaccine candidate for many years GMP production of the protein had proved difficult (202) but 
use of viral vectors meant a vaccine suitable for human use was successfully produced (157). 
Viral vectors induce moderate antibody responses, and this is a disadvantage for antigens that 
require high antibody levels in order to be effective. Antibody responses are generally lower 
than those seen following protein-in-adjuvant vaccine formulations (167) and there are 
logistical implications for the required storage conditions (stored at -80⁰C). Historically there 
have been concerns about difficulties in scaling up the production process to produce large 
amounts of vaccine but this has been addressed to some extent recently with the rapid 
manufacture of thousands of doses of the ChAd3 ZEBOV Ebola vaccine candidate in response 
to the 2014 – 2015 Ebola outbreak in West Africa (153). Recent work in Oxford has also looked 
at other ways of boosting the response to antigens encoded within viral vectors, including the 
use of a molecular adjuvant IMX313, which is currently being evaluated with the viral vectors 
in a Phase I trial (NCT02532049) of a novel transmission blocking vaccine (ChAd63/MVA Pfs25-
IMX313) after preclinical studies showed improved immunogenicity compared with viral 
vectors encoding the Pfs25 protein alone. The IMX313 causes the Pfs25 antigen to 
heptamerise so that a nanoparticle is expressed from the viral vectors rather than a Pfs25 
209 
 
monomer. In preclinical studies, the heptamer induced a significantly higher percentage of 
germinal centre B cells in the draining lymph nodes compared with monomeric Pfs25, which 
was thought to account for the difference in antibody responses (119).  
In 2013 GSK acquired Okairos, the company which owned the ChAd63 viral vector platform 
(256), so trials in Oxford since then have required collaboration with GSK to use this vector. 
This collaboration has led to the Jenner Institute having improved access to GSK adjuvants and 
vaccines (172, 209) for clinical trials, which has broadened the types of vaccines developed and 
tested here.  
6.4.1.2  Recombinant protein vaccines 
The VAC054 trial (Chapter four) used a recombinant protein vaccine given with the Adjuvant 
System AS01. This approach was chosen to try to achieve as high an anti-AMA1 antibody 
concentration as possible, as this is deemed necessary for protection. Recombinant protein 
vaccines are typically better at inducing an antibody response than a cell-mediated response, 
and are therefore an attractive option for blood-stage vaccine candidates. The main 
disadvantages of recombinant protein subunit vaccines are the difficulties in producing 
soluble, conformationally correct proteins in sufficient quantity to GMP standards (257) and 
access to effective adjuvants, which are essential for inducing a substantial immune response.  
Significant improvements have been made in recombinant protein vaccine production in the 
past few years (258). New expression systems have been developed, for example, the S2 
Drosophila insect-cell system (169, 259), which enables expression of proteins that have not 
been successfully expressed using bacterial or yeast systems. The use of fusion proteins, such 
as the IMX313 carrier protein, can improve immunogenicity of candidate vaccines when 
expressed as a protein nanoparticle (119). Long synthetic peptides enable multi-epitope 
vaccines which can include several B, CD4+ and CD8+ T lymphocyte epitopes capable of 
binding different MHC class I and II molecules in the same peptide(s), overcoming MHC 
restriction. They also allow rapid production of stable proteins (260). Protein complexes of two 
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antigens may also act synergistically to improve the immune response, for example, the 
AMA1-RON2 complex (229), compared with a single antigen. The vaccine candidate GMZ2 
consists of a fusion protein of the blood-stage antigens Glutamate Rich Protein (GLURP) and 
MSP3. This has been assessed in Phase Ia, Ib and IIb trials, in adults and children, and 
demonstrated low level efficacy against malaria in an endemic setting (261-264). The use of 
VLPs which express antigens on their surface are another successful method for improving 
vaccine production and immunogenicity; these will be discussed further in the next section. 
Although these techniques may improve the ease of production of recombinant proteins, it is 
also essential to focus on the quality of the antibody response to ensure that as high a 
percentage as possible of the antibodies induced are functional. Ways of improving antibody 
quality include structure-based immunogen design, where vaccines are designed based on 
how antibodies successfully inhibit the parasite. This potentially enables the identification of 
conserved epitopes which could be utilised in vaccine development (265). Other future 
prospects are the discovery of new antigens (ideally those which are not under significant 
immune pressure in endemic settings but required for invasion), the use of new antigen 
combinations, improved methods for vaccine production and delivery, and improvements in 
adjuvants which augment the immune response (258). 
6.4.1.3  Virus-like particles 
The only malaria vaccine to have reached Phase III trials, RTS,S, is based on a recombinant VLP 
of Hepatitis B surface antigen (HBsAg) displaying repeats from the P. falciparum CS protein 
(57). This enabled a significant improvement in vaccine efficacy compared with recombinant 
CS protein alone (266). VLPs have several advantages as vaccine platforms. Firstly, they are a 
similar size to pathogenic organisms, and are therefore more easily recognised and taken up 
by antigen-presenting cells at the vaccination site (267, 268). Secondly, they typically have a 
high density of repetitive epitopes on the particle surface, which are recognised by pattern 
recognition receptors, triggering the innate immune system, and subsequently the adaptive 
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immune system and leading to higher affinity antibodies. Thirdly, there may be a ‘depot’ effect 
with gradual release of the target antigen from the particle and, finally, the particle may allow 
immunostimulatory adjuvants (e.g. TLR agonists) to be delivered to the same APC as the 
antigen, ensuring a specific APC activation (268).  
Few blood-stage vaccine candidates have been developed using VLP platforms to date. There 
was a suggestion of a protective effect with a virosome-based VLP conjugated with PfAMA1 
and PfCS in children in a Phase Ib trial (269) although the AMA1-virosome and CS-virosome did 
not show any efficacy when assessed individually in a Phase IIa CHMI trial (268). The GLURP-
MSP3 fusion protein has been assessed pre-clinically in a virosome-based vaccine, and induced 
similar antibody levels to the recombinant fusion protein (GMZ2) administered with alum or 
Montanide ISA 20 adjuvants (270). There is therefore potential to further develop these 
platforms to improve blood-stage vaccine production, delivery and immunogenicity, and 
thereby, efficacy.  
6.4.1.4  Whole parasite blood-stage vaccines 
The most advanced whole parasite vaccine to date is the pre-erythrocytic vaccine developed 
by Sanaria, PfSPZ, which involves injection of radiation-attenuated sporozoites intravenously, 
and has demonstrated high-level efficacy, particularly in malaria-naïve individuals (68). A pre-
erythrocytic whole parasite vaccine needs to be 100% effective as even a single parasite 
transmitted by an infected mosquito after vaccination can cause malaria disease if it escapes 
through to the blood-stage. In contrast, a blood-stage whole parasite vaccine could potentially 
be beneficial even if only partially effective, mimicking natural infection and allowing 
asymptomatic infection with lower parasitaemias (271). A vaccine with these qualities would 
need to ensure that parasites were no able to grow above a disease ‘threshold’ 100% of the 
time in order to be safe for use. 
The whole-parasite blood-stage vaccine approach was thought to be supported by a study 
conducted at QIMR, Brisbane, Australia in which four volunteers were exposed to very low 
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doses of red blood cells infected with malaria parasites (using the same inoculum as was used 
for CHMI in VAC054) and treated when malaria DNA was detectable in blood by PCR but 
before they became symptomatic. They received a total of three rounds of submicroscopic 
malaria infections for which they were treated before CHMI, following which three of the four 
were sterilely protected and one had a delay in parasitaemia and asymptomatic infection 
(272). This study was flawed however, as participants were treated with atovaquone-proguanil 
after each malaria infection, and this has subsequently been shown to inhibit parasite 
development for up to six weeks after treatment. This implies that the suppression of malaria 
in these individuals was likely due to residual atovaqone rather than development of immunity 
(273).  
Techniques investigating this approach are ongoing, and involve assessment of regimes using 
killed blood-stage parasites, live radiation-attenuated parasites, chemically attenuated 
parasites or genetically attenuated parasites. There are various challenges to be overcome if 
this approach is to be used, however, including issues relating to the use of human blood 
products (e.g. transmission of other infections), possible underattenuation of parasites or 
reversion of parasites to wild-type,  the need for a potent adjuvant if killed parasites are used 
and the logisitical challenges of culturing large quantities of P. falciparum and producing a 
vaccine to GMP (271). 
6.4.1.5  P. vivax blood-stage vaccines 
The ChAd63/MVA PvDBP vaccines (157) in the Phase Ia clinical trial (VAC051) described in 
Chapter three were the first blood-stage P. vivax vaccines ever to reach clinical trial. The 
results from this trial were encouraging with inhibition of PvDBP-DARC binding in vitro. The 
efficacy of this regime remains to be seen, however, and the in vitro results will need to be 
correlated with efficacy results when data are available. It is likely that a recombinant protein 
platform will induce higher antibody levels than the viral vectors, as discussed previously. 
Other techniques to improve vaccine immunogenicity include using a TLR-agonist in the 
213 
 
vaccine formulation, which improved the range of response against polymorphic variants (111) 
and designing a vaccine with fewer of the polymorphic variant epitopes to focus the immune 
response towards more conserved epitopes (DBPII-DEKnull). It is hoped that this might improve 
the breadth of response against PvDBP variants and avoid the development of strain-specific 
immunity (274).  
Although the PvDBP antigen is considered the leading blood-stage vaccine candidate for P. 
vivax, it has now been established that the parasite is able to infect Duffy-negative individuals, 
albeit with a significantly reduced prevalence (187). A highly conserved duplication in the 
PvDBP gene has been identified in parasites in some of the Duffy-negative individuals infected 
with vivax malaria, implying a recent evolutionary change in the parasite (275). These findings 
suggest that other blood-stage antigens may also need to be targeted if a vaccine is going to be 
widely effective, and in order to reduce the risk of the parasite developing resistance to the 
vaccine through use of an alternative invasion pathway. 
P. vivax MSP1 has been evaluated pre-clinically alone and in combination with PvDBP, but has 
not entered clinical testing. Similarly, PvAMA1 has been studied in both a viral vectored 
vaccine and a recombinant protein pre-clinically. The anti-PvAMA1 antibodies were functional 
against diverse P. vivax strains (276). The use of these antigens as vaccine candidates may be 
more effective in combination with, for example, PvDBP, but that will require further clinical 
development and testing to ascertain.  
6.4.2 Assessing vaccine efficacy 
Malaria vaccine efficacy has traditionally been assessed either in large field trials in endemic 
countries or in small CHMI studies in healthy volunteers, the majority of which have been 
conducted in non-endemic settings. CHMI trials are used for proof-of-concept early-phase 
testing and aid decisions in vaccine development but ultimately a malaria vaccine will have to 
be effective in an endemic setting if it is to be useful. Many studies have demonstrated that 
there are significant differences in the efficacy seen in these different populations. RTS,S, for 
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example, had an efficacy of between 50-75% in CHMI trials (73, 172) but only 18-28% in young 
infants and children in Africa (57). The differences in immune response following repeated 
malaria exposure is an area that would benefit from further research, and potentially 
incorporated into vaccine design. Recently a few CHMI trials have taken place in endemic 
populations (139, 277), with the aim of developing a model for early assessment of candidate 
vaccines in endemic settings. These studies also allow a deeper understanding of the 
mechanisms of infection and the immune response in those with previous exposure and 
potentially a degree of natural immunity. 
Chapter four described the development of a CHMI model to assess blood-stage vaccine 
efficacy for P. falciparum with power to see a fairly small effect on parasite multiplication rate. 
The consistency of the model has provided further data for using this model with even greater 
confidence of being able to detect an effect in the future with other blood-stage vaccine 
candidates. Although the ChAd63/MVA RH5 vaccines discussed in Chapter five did not elicit an 
antibody response that was likely to lead to efficacy, a recombinant protein vaccine with this 
antigen has been developed in Oxford (169) and will shortly commence clinical testing. It is 
anticipated that the efficacy of this vaccine will be assessed with blood-stage CHMI. If this 
vaccine demonstrates a reduction in PMR compared with infectivity controls it will be the first 
blood-stage vaccine in humans to do so. The blood-stage CHMI model could also be used to 
further evaluate the response to malaria infection, especially if repeated infections were given, 
mimicking the repeated exposure that occurs naturally in endemic settings. 
As discussed in Chapter three, CHMI models for P. vivax are being developed, with one pre-
erythrocytic vaccine candidate having been assessed in a Phase IIa trial (77). The recently 
developed blood-stage inocula for vivax CHMI should allow for blood-stage vaccine candidates 
to be assessed relatively rapidly in proof-of-concept trials before larger, more expensive field 
trials. This should enable the development of vaccines to progress efficiently with only 
candidates which demonstrate efficacy being taken forward. Similarly, the use of in vitro 
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assays alongside efficacy data could help to inform decisions about vaccine development and 
the likelihood of a novel vaccine succeeding in preventing or reducing infection. It is planned to 
take forward the ChAd63/MVA PvDBP vaccines to a Phase IIa trial where efficacy can be 
assessed against heterologous blood-stage infection using an infected blood inoculum for 
CHMI. 
6.4.3 Closing remarks 
To conclude, this thesis has demonstrated the early-phase testing of three blood-stage malaria 
vaccine candidates, all of which were safe and immunogenic, but also highlighted some of the 
challenges in developing and assessing new vaccines. In recent years there have been 
substantial improvements in the development and production of candidate vaccines, and in 
the adjuvants available meaning that real progress has been made in this field. However, 
despite this, relatively few vaccines have reached efficacy testing, and none of the blood-stage 
vaccine candidates to date have demonstrated significant levels of efficacy. Nonetheless, new 
antigens are being discovered, and as described in this thesis, new vaccines have reached 
clinical trial. There is still much to be understood about the mechanisms used by Plasmodium 
parasites to invade cells and evade the immune system. Further research into these areas is 
likely to aid the design of improved vaccines. 
The clinical trials I led were important milestones in the blood-stage malaria vaccine field. 
VAC051 (Chapter 3) was the first, and only blood-stage P. vivax vaccine to reach clinical trial to 
date. This trial demonstrated that antibodies induced by a vaccine against PvDBP are able to 
block binding between the antigen and its receptor, DARC. This vaccine regime needs to be 
further assessed in an efficacy trial, and a Phase IIa CHMI trial is planned to assess this in the 
future. The VAC054 trial (Chapter 4) was the largest blood-stage CHMI trial ever conducted 
and enabled the development of a proof-of-concept efficacy model which can be used to 
assess other blood-stage vaccine candidates in the future. 
216 
 
An effective malaria vaccine, either for P. falciparum, P. vivax or both parasites, is likely to 
require a multi-component approach. This may involve targeting different stages of the life 
cycle or targeting multiple antigens in the same stage. Once a blood-stage vaccine has been 
developed which demonstrates efficacy, this can then be assessed in combination with other 
antigens to look for evidence of synergy as has been suggested pre-clinically for some antigen 
combinations. Early proof-of-concept efficacy testing of candidate vaccines using CHMI models 
should allow more rapid development, especially if these trials are also conducted in 
previously exposed individuals in endemic settings and information from these studies is used 
to inform vaccine design. 
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Appendix 1: Participant information sheets (PIS) 
VAC051 Participant information sheet v3.0 
 
Prof. Adrian Hill 
E-mail:vaccinetrials@well.ox.ac.uk 
Tel: 01865 857401 
 
 
NRES Committee South Central - 
Oxford A ref number: 13/SC/0001 
 
Centre for Clinical Vaccinology and 
Tropical Medicine, 
Churchill Hospital, Old Road, 
Headington 
Oxford, OX3 7LE 
Tel: 01865 857417  
 
PARTICIPANT INFORMATION SHEET: VAC051 
A study to assess new Plasmodium vivax malaria vaccines;  
ChAd63 PvDBP and MVA PvDBP 
A phase Ia clinical trial to assess the safety and immunogenicity of new Plasmodium 
vivax malaria vaccine candidates ChAd63 PvDBP alone and with MVA PvDBP 
We would like to invite you to take part in a research study.  Before you decide, it is 
important for you to understand why the research is being done and what it would 
involve.  Please take time to read the following information carefully and discuss it 
with friends, relatives and your General Practitioner (GP) if you wish.  
 Part 1 tells you the purpose of the study and what will happen to you if you 
take part. 
 Part 2 tells you more information about the conduct of the study. 
Ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part. 
Part 1 
What is the purpose of the study? 
Malaria is caused by 5 different types of malaria parasite. The most common 2 types 
are Plasmodium falciparum and Plasmodium vivax. Although Plasmodium 
falciparum causes the most severe disease and deaths, Plasmodium vivax is 
geographically the most widespread, and accounts for up to 50% of malaria cases in 
South and South East Asia, and up to 81% in South America. There are estimated to 
be between 106 and 313 million cases of vivax malaria per year. Although vivax 
malaria does not cause as many deaths as falciparum malaria it does still cause 
significant levels of illness, and can cause severe illness and death in some cases. It 
is therefore a major problem for those who live in affected areas and for travellers. 
There is a great need for a safe, effective malaria vaccine. Researchers around the 
world, including members of Professor Hill’s group at the University of Oxford, have 
been investigating malaria for over 15 years. Over the last 10 years, we have been 
conducting clinical studies of new malaria vaccines. So far these studies have been 
looking at vaccines for falciparum malaria, but if malaria infection is to be controlled 
worldwide, it is vital to develop a vaccine for vivax malaria as well. 
The purpose of this study is to examine the safety and immune response to two new 
vivax malaria vaccines; ChAd63 PvDBP and MVA PvDBP administered either as 
ChAd63 PvDBP alone or in combination with MVA PvDBP. These vaccines are 
made from viruses which are inactivated so that they are unable to multiply within 
the body. The viruses contain genetic information (DNA) from the vivax malaria 
parasite. This genetic material is a protein named PvDBP, and relates to a part of 
the parasite which it needs to infect human blood cells. PvDBP has not been used to 
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vaccinate humans before but it is believed to be a very important target for vivax 
malaria. This study is therefore the first time these vaccines have been used in 
humans. The aim is to use these vaccines to help the body make an immune 
response against this part of the vivax malaria parasite, and therefore prevent the 
parasite from being able to infect blood cells. 
The viruses used in these vaccines have been used before many times in clinical 
trials for malaria and other infections, and have been safe. We do not expect the 
side effect profiles of these vaccines to be significantly different from previous trials 
where these viruses have been used with different malaria proteins. 
The ChAd63 PvDBP vaccine is based on a weakened version of an adenovirus (a 
common cold virus). The strain of adenovirus we use for this vaccine usually affects 
chimpanzees. The MVA PvDBP vaccine is based on the modified vaccinia virus 
Ankara (MVA), which is a safer form of the vaccine virus previously widely used for 
smallpox vaccination. 
The purpose of this study is to assess the two vaccines at different doses and alone 
or in combination. This study will enable us to assess: 
1. The safety of the vaccine schedules in healthy volunteers. 
2. The response of the human immune system to different vaccine schedules.  
We will do this by giving volunteers one or two vaccinations and doing blood tests to 
assess the response of the immune system to the vaccines. We hope to recruit 24 
volunteers to be vaccinated.   
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do decide to take part 
you will be given this information sheet to keep and be asked to sign a consent form. 
You are free to withdraw at any time and without giving a reason but you may be 
asked to return to the clinic for follow up for safety reasons. 
What will happen if I decide to take part? 
This study involves having one or two vaccinations and then being followed up with 
blood tests. Volunteers are enrolled in groups depending on which vaccine schedule 
they will receive. You will be able to choose which group you are enrolled in, 
although as groups fill up there will be less choice. 
Length of research 
If you decide to take part in this study, you will be involved in the trial for 
approximately 3 to 5 months depending on what group you are in. 
Am I eligible to be involved in the trial? 
In order to be involved in the study you must: 
 Be a healthy adult aged between 18 and 50 years. 
 Be able and willing (in the investigators’ opinion) to comply with all study 
requirements. 
 Allow the investigators to discuss your medical history with your GP. 
 Practice continuous effective contraception for the duration of the study (women 
only). 
 Refrain from blood donation during the course of the study and for 6 months 
after the end of your involvement in the study.  
You cannot participate in this study if: 
 You have had malaria before. 
 You have travelled to a malaria endemic region in the six months preceding 
your involvement in the study or are intending to travel to a malaria endemic 
region during the study. 
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 You have participated in another research study in the 30 days preceding 
involvement in this study. 
 You are planning to participate in another study at the same time as 
participating in this study.  
 You have previously received an investigational malaria vaccine.  
 You have had immunoglobulins and/or any blood products in the three months 
preceding your involvement this trial. 
 You have problems with your immune system. 
 You are pregnant, breast feeding or intend to become pregnant during the 
study. 
 You have a history of a severe allergic reaction to a vaccination. 
 You have an allergy to eggs or Kathon (a biocide added to body washes, 
conditioners, liquid soaps, shampoos and wipes as a preservative) 
 You have a history of cancer. 
 You have a history of a serious psychiatric condition that may affect 
participation in the study. 
 You have any other serious chronic illnesses requiring hospital follow-up. 
 You drink on average more than 42 units of alcohol a week (a pint of beer is two 
units, a small glass of wine 1 unit and a shot of spirits one unit).  
 You have injected drugs at any time in the last 5 years. 
 You have hepatitis B, hepatitis C or HIV infection. 
 You have a history of autoimmune disease. 
Mild conditions, such as childhood asthma, which are well-controlled would not 
automatically exclude you from participating. If you are unclear whether you are eligible 
to be involved in the study you can contact the study team who will be able to advise 
you. 
CONSIDERATIONS BEFORE TAKING PART IN THIS STUDY 
Screening Visit: This takes place up to 3 months before the study starts at the 
Centre for Clinical Vaccinology and Tropical Medicine in Oxford and lasts up to one 
and a half hours. The purpose of the screening visit is for you to discuss the trial with 
us and decide if you still wish to enter the study. If you decide to participate, you will 
be asked to sign a consent form. We then need to check that you are eligible to 
participate. You will be asked some medical questions and a doctor will examine 
you. Some blood tests will be taken to check your red and white cells, your liver and 
your kidney function. These tests need to be normal for you to be enrolled in the 
study. Your blood will also be tested for infection with hepatitis B, hepatitis C or HIV. 
These viruses are transmitted by infected blood or sexually and can affect the 
immune response to infection. If you test positive to any of these infections, we will 
inform you of the result and offer referral for medical review and treatment (with your 
permission). 
All participants are asked for urine samples at screening to check for glucose (to 
exclude diabetes), protein and blood (which can indicate kidney disease). For women, 
a urine pregnancy test will also be performed. Pregnancy tests will also be repeated 
prior to each vaccination if you go on to take part in the study. To avoid repeated 
testing, if you are not enrolled into this study and apply to enter another study 
conducted by the Jenner Clinical Trials Group based at the Centre for Clinical 
Vaccinology & Tropical Medicine (CCVTM) the screening blood results may be used in 
that study, where appropriate. 
Blood Donation: Under current UK regulations, volunteers will not be able to donate 
blood during the study or for 6 months after the end of the trial. 
Private Medical Insurance: If you have private medical insurance you are advised to 
contact your insurance company before participating in this trial as involvement in the 
trial may affect the cover provided by private insurance. 
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Malaria Prophylaxis: You should note that the vaccines being tested in this trial are 
experimental. If you travel to a malaria endemic region in the future you should not 
assume that the vaccines you received in this study have given you any protection 
against malaria. Make sure you visit your GP or a travel clinic before travelling to a 
malaria endemic region and use prophylactic anti-malarial medications, bed nets and 
insect repellent during your trip as directed by your GP or the clinic. 
Contraception: The vaccines being tested in this study are at an early stage of 
development and it is currently unknown as to whether they are safe in pregnancy. For 
this reason, it is important that all women use adequate contraception for the duration 
of the trial. 
VACCINATIONS 
What are the vaccines that are being tested? 
We are testing two vaccines; ChAd63 PvDBP and MVA PvDBP These vaccines will 
be given into the muscle of your upper arm(s). Once these vaccinations have been 
given they cannot be undone, so it is important you are clear of the potential risks of 
the vaccines before you agree to be involved in the study. 
1. ChAd63 PvDBP 
ChAd63 PvDBP is based on a virus that infects chimpanzees called chimpanzee 
adenovirus 63 (ChAd63). We have genetically disabled the virus so that it is impossible 
for it to grow in humans, and added a gene encoding a protein from the vivax malaria 
parasite (the “PvDBP” part of the vaccine). We want to try and make the body develop 
an immune response to this malaria protein. This protein has not been given to humans 
before, but side effects from these types of vaccines are usually due to the viruses 
used rather than the proteins. We have given ChAd63 encoding other malaria proteins 
to over 250 volunteers, and it has been safe and well-tolerated. It can however, cause 
some short-lived side effects. 
Expected Side Effects:  
Volunteers receiving ChAd63 PvDBP in this trial may experience injection site pain. 
This is most likely to be mild, however there is a chance this could be moderate or 
severe in intensity. Volunteers may also experience redness, swelling, itching and 
warmth at the vaccine site, although these symptoms are likely to be mild if present. 
Generally volunteers report a transient ‘flu-like illness within 24 hours of vaccination 
which resolves within 48 hours. This can include headache, muscle aches, joint aches, 
feverishness, tiredness and feeling generally unwell. The majority of general symptoms 
are likely to be mild but there is a possibility of moderate or severe headache or feeling 
unwell. 
2. MVA PvDBP 
MVA PvDBP is based on a virus called modified vaccinia virus Ankara (MVA) and 
contains the gene encoding the same malaria protein as ChAd63 PvDBP (PvDBP). 
We have found that giving the MVA vaccine after a ChAd63 vaccine produces the 
best immune response. This regimen is termed a ‘prime-boost’ regimen. MVA 
encoding malaria antigens has been given to over 950 individuals, including 
children, in sub-Saharan Africa with no serious side effects. An MVA ‘boost’ vaccine 
has been given to over 160 healthy UK adults following a ‘prime’ vaccination with 
ChAd63 encoding the same malaria protein. It appears safe and well tolerated but 
can cause short-lived side-effects.  
Expected Side Effects:  
Volunteers receiving MVA PvDBP in this trial may experience injection site pain. This is 
most likely to be mild, but there is a chance this could be moderate in intensity. 
Volunteers may also experience redness, swelling, itching and warmth at the vaccine 
site, although these symptoms are likely to be mild if present.  Generally volunteers 
report a transient ‘flu like’ illness within 24 hours of vaccination which resolves within 48 
hours. This can include headache, muscle ache, joint ache, feverishness, tiredness 
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and feeling generally unwell. The majority of general symptoms are likely to be mild but 
there is a possibility of moderate headache, tiredness, muscle aches or feeling unwell.  
MVA tends to cause more reaction than ChAd63 vaccines so we have used a lower 
dose in this trial compared with previous studies. Part of this study will involve 
comparing a lose dose of MVA with a slightly higher dose to look at the effects on the 
immune response generated, and also compare the reaction to the vaccine. 
It is important to remember these are vaccines in the early stage of development; 
therefore the amount of safety data available is limited. The malaria protein (PvDBP) 
has not previously been used in this type of vaccine in humans before. For this 
reason there is a chance you could experience a side effect that is more severe than 
that described above, or that has not been seen before with these vaccines. You are 
encouraged to consider taking over the counter medications such as paracetamol or 
ibuprofen if you experience symptoms post vaccination as this is likely to reduce the 
intensity of any symptoms you have. 
All volunteers will be given one or two vaccinations. The number and doses of the 
vaccinations will vary between groups. The ChAd63 vaccine dose is measured in 
‘viral particles’ (vp) and the MVA vaccine dose is measured in ‘plaque forming units’ 
(pfu). All of the virus doses to be used in this study have been used safely in 
previous trials with the same viruses encoding different malaria proteins. 
The vaccination groups are summarised in the following table: 
 
Group Number Number of 
volunteers 
Dose ChAd63 PvDBP 
Day 0 
Dose MVA PvDBP 
Day 56 
1 4 5 x 10
9
 vp IM --  
2 A 4 5 x 10
10
 vp IM -- 
B 8 5 x 10
10
 vp IM 1 x 10
8
 pfu IM 
C 8 5 x 10
10
 vp IM 2 x 10
8
 pfu IM 
 
Severe Reactions 
With any vaccination there is a risk of rare serious adverse events, such as an 
allergic reaction, which may be related to the nervous system or the immune system. 
Severe allergic reactions to vaccines (anaphylaxis) are also rare but can be fatal. 
Doctors qualified in the management of anaphylaxis will be present at each 
vaccination. Reactions in the nervous system are also extremely rare following 
vaccination and can cause an illness called Guillain-Barré syndrome. Guillain-Barré 
syndrome is an illness in which people can develop severe weakness and can also 
be fatal. These adverse events have not previously been seen with the types of 
vaccines used in this study. If you experience unexpected events, or become in any 
way concerned you should contact one of the Investigators (who are available 24 
hours a day) using the contact details at the end of Part 2.   
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Vaccination Days 
If you are the first volunteer to receive a new dose of either vaccine we will ask you 
to wait for 2 hours after the vaccination with that new dose of vaccine, to make sure 
there are no immediate problems. For all other volunteers in the groups, we will ask 
you to wait for 1 hour after each vaccination. You will be assessed again before 
leaving and given a diary card, thermometer and tape measure to take away. We will 
ask you to record your symptoms and the size of any redness or swelling every day 
for 7-14 days after each vaccination. Your diary card will be collected from you at 
your next visit. 
We may ask to photograph your vaccination site and you can choose whether or not 
to agree to this when you sign the consent form. You will not be identifiable in these 
photographs, as only the vaccination site and your unique trial number will be visible. 
These photographs may be shown to other professional staff, used for educational 
purposes or included in a scientific publication. 
Number, timing and purpose of visits  
You will receive either 1 or 2 vaccinations and attend between 7 and 10 visits in 
total. Visits may include a medical assessment, temperature, pulse and blood 
pressure readings, examination by a doctor if needed and blood tests. All visits will 
take place at the Centre for Clinical Vaccinology & Tropical Medicine (CCVTM), on 
the Churchill Hospital site in Oxford (OX3 7LE). 
 
Timeline for vaccinations 
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OTHER INFORMATION 
Blood Tests 
We take blood tests as part of the screening visit to help us to assess your general 
health. Blood tests are also taken at the study visits in order for us to assess your 
immune response to the vaccine and for safety reasons. If you would like them, we 
will give you the results of the blood tests. We only send the results to your GP if you 
wish us to and will not report them to anyone without your permission. The total 
volume of blood taken during the study varies according to which group you are 
enrolled in but will not exceed 500 mL over five months. 
The following blood tests will be performed; 
 Tests for Hepatitis B, Hepatitis C and HIV are done at the screening visit. 
 HLA typing, a test of a component of the body’s immune system may be 
done at the first vaccination visit. 
 Tests of red and white blood cells and tests of liver and kidney function are 
done at the screening visit and most of the other visits when you come for 
vaccination or follow up after vaccination in order to check the vaccines are 
safe. 
 Tests of the immune responses to vaccines are done at most of the visits. 
 The volume of blood taken at each visit ranges from 5 to 75 mL. 
The blood samples we collect will be stored after testing, and may be used in future 
malaria research. Samples will be anonymised. You can request that your samples 
are destroyed at any time. As part of our study we may send samples to 
collaborators in other countries, including countries outside Europe. Again, these 
samples would be anonymised. You will be asked to consent specifically for blood to 
be stored, and for samples and anonymised data to be shared with research 
collaborators. 
Discomfort related to blood tests 
Drawing blood may cause slight pain and occasionally bruising at the site where 
blood tests are taken. Sometimes, people feel light-headed or even faint. The total 
volume of blood taken during the study (334-474mL) should not cause any problems 
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for healthy people, and is about the same amount that may be given during one 
donation to the National Blood Transfusion Service (typically 470mL). 
Urine Tests 
 A urine sample will be tested at screening in order to check for glucose (to 
exclude diabetes), protein and blood (which can indicate kidney disease). 
 All women will have urinary pregnancy testing at screening and before each 
vaccination.  
Abnormal Results 
If abnormal results or undiagnosed conditions are found in the course of the study 
these will be discussed with you and, if you agree, your GP will be informed. For 
example, a new diagnosis of high blood pressure might be made. Any newly diagnosed 
conditions will be looked after by your GP within the NHS.  
Expenses and Payments 
You will be compensated for: 
 
o Travel expenses:   £10 per visit 
o Time required for visit:  £20 per hour  
o Inconvenience of blood tests:  £10 per blood donation 
 
Group No Time in Trial 
(approx.) 
No. of 
Visits 
No. of Blood 
Tests 
Maximum Volume 
of Blood Taken 
1 3 months 7 6 334mls 
2A 5 months 9 8 464mls 
2B 5 months 10 8 474mls 
2C 5 months 10 8 474mls 
 
The total compensation for taking part in the study, if all follow-up is completed, will 
be between £330- £520. If you choose to leave the study early or are withdrawn from 
the study, you will be compensated according to the length of your participation 
based on the figures above. You should note that compensation payments received 
in this trial may have an impact on your entitlement to benefits. 
What do I have to do? 
 You must provide a name and 24 hour phone number for someone who lives 
near to you and who will know where you are for the duration of the study.  
 You must attend all the visits that are outlined above  
 You should record in the study diary all the things you notice about injection 
sites, any other  change in your health or the way you feel after each injection. 
 Women must use effective contraception for the duration of the study. 
 Women will be asked to provide urine for pregnancy testing when required. If you 
become pregnant during the study, you must inform us immediately. 
 You must not donate blood during the study or for 6 months after the end of the 
trial (current National Blood Service guidelines). 
 You must not enrol in another clinical trial for the duration of this study. 
What alternatives are present? 
At present, there is no malaria vaccine licensed anywhere in the world. There are 
other malaria vaccines in various stages of development, but very few targeting 
vivax malaria. This study may help develop an effective vivax malaria vaccine. 
What are the possible benefits of taking part? 
This study will not benefit you, but the information gained from the study might help 
to prevent vivax malaria infection and disease in those who live in areas where 
malaria is common and in travellers. 
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What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. The detailed information on this is 
given in Part 2. 
What happens when the research study stops? 
If you have any queries or concerns once the study is over please do not hesitate to 
get in touch with us. 
Will my taking part in the study be kept confidential?  
Yes. All the information about your participation in this study will be kept confidential. 
The details are included in Part 2. 
 
This completes Part 1 of the Information Sheet. If the information in Part 1 has 
interested you and you are considering participation, please continue to read 
the additional information in Part 2 before making any decision. 
 
Part 2 
What if relevant new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about the vaccine that is being studied, for example if unexpected side 
effects occur. If this happens, we will tell you about it and discuss whether you want 
to or should continue in the study. If you decide to continue in the study you will be 
asked to sign an updated consent form. On receiving new information, we may 
consider it to be in your best interests to withdraw you from the study. 
 
What will happen if I don’t want to carry on with the study? 
If, at any time after agreeing to participate you change your mind about being 
involved with this study, you are free to withdraw without giving a reason. Your 
compensation would be paid as a proportion of the total compensation according to 
the length of your participation. Unless you state otherwise any blood taken whilst 
you have been in the study will continue to be stored and used for research as 
detailed above. You are free to request that your blood samples are destroyed at 
any time during or after the study. 
 
What if there is a problem? 
 
Complaints:  
If you have a concern about any aspect of this study, you should ask to speak with 
the researchers who will do their best to answer your questions. If you wish to 
complain formally about any aspect of the way you have been approached or treated 
during the course of this study you should approach the University’s Clinical Trials 
and Research Governance office (Clinical Trials and Research Governance, Joint 
Research Office, University of Oxford, Block 60, Churchill Hospital, Old road, Oxford, 
OX3 7LE. Telephone: 01865 572224, or the head of CTRG- email: 
ctrg@admin.ox.ac.uk). 
 
Harm:  
The investigators recognise the important contribution that volunteers make to medical 
research, and will make every effort to ensure your safety and well-being. In the 
unlikely event of harm during the research, the University has arrangements in place to 
provide for harm arising from participation in the study for which the University is the 
Research Sponsor. In the unlikely event of harm being suffered, while the University 
will cooperate with any claim, you may wish to seek independent legal advice to ensure 
that you are properly represented in pursuing any complaint. At any time during the 
study you will be entirely free to change your mind about taking part, and to withdraw 
from the study. This will not affect your subsequent medical care in any way. 
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Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the research will be 
coded with a study number and kept strictly confidential. The information is available 
to the study team, the safety monitors, the ethical review committee, the sponsors, 
government regulatory agencies and external monitors who can ask to audit or 
monitor the study. Any information about you that leaves the hospital or clinic will 
have your name and address removed so that you cannot be identified from it. Your 
information is stored on a secure server and any paper notes will be kept in a locked 
filing cabinet. 
 
Involvement of the General Practitioner/Family doctor (GP) 
In order to enrol into this study, you will be required to sign a form, documenting that 
you consent for us to contact your GP. This is to inform them that you are interested in 
being involved in the study and to ensure there are no medical reasons that they are 
aware of why this would not be safe. The researchers will not enrol you in the trial if 
they have any concerns about your eligibility or safety; therefore we need to have 
communication from the GP confirming this before you can be enrolled. We will write to 
your GP to let them know whether or not you are finally enrolled in the study so they 
can update your medical records accordingly. 
 
Prevention of ‘Over Volunteering’ 
Volunteers participating in this study must not be concurrently involved in another 
study. In order to check this, you will be asked to provide your National Insurance or 
Passport number (if you are not entitled to a NI number). This will be entered on to a 
national database which helps prevent volunteers from taking part in too many clinical 
trials. More information can be found at www.tops.org.uk. Your national insurance or 
passport number is also required to allow processing of compensation payments. 
 
What will happen to any samples I give? 
If you consent, some of your leftover blood samples will be stored and may be used 
for further studies of the human body’s immune response to malaria and vaccination. 
Any such tests will have an appropriate ethical review. Tests that may be performed 
include measurements of antibody levels, white blood cell activity and the ability of 
blood to inhibit the growth of malaria parasites in the laboratory. Samples may also 
be used to assess what genes are expressed by cells following vaccination. Upon 
your request at any time, your remaining blood samples will be destroyed. Your 
participation in this study will not be affected by your decision to allow or not allow 
storage and future use of your leftover blood samples.  The blood tests mentioned in 
part 1 will be analysed in the hospital laboratory, and Oxford University research 
laboratories. Other blood tests to look at the response of your body to the vaccine 
may be done with collaborating laboratories in other countries. Any samples or data 
sent to them would be anonymous.  
 
Will any genetic tests be done?   
Yes. Some blood may be used to look at the pattern of your genes that can affect 
the immune system (including the Human Leukocyte Antigen or HLA genes). The 
immune response to vaccines is in part genetically controlled, so knowing your 
pattern of genes that regulate immune responses (such as HLA type) may help us to 
understand the responses to vaccination. We will also look at the expression of 
certain genes which relate specifically to the immune response to the vaccines and 
may also perform DNA sequencing on your blood, so we can understand how 
people respond to the vaccines – you can opt out of DNA testing if you wish, without 
any effect on your participation in the trial.  
 
What will happen to the results of the research study? 
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The results of this research study may be published in a scientific medical journal. 
This may not happen until 1 or 2 years after the study is completed. If you contact 
the researchers in the future you can obtain a copy of the results. You will not be 
identified in any report or publication. 
Data from this study may be used as part of a student post-graduate degree, for 
example a MD. 
Who is organising and funding the research?   
The study is funded by Okairòs Srl (a clinical-stage biopharmaceutical company), the 
Wellcome Trust, the National Institute of Health Research Biomedical Research Centre 
and the Medical Research Council. 
 
Neither your GP, nor the researchers are paid for recruiting you into this study. 
 
The study is organised by a research team at The Jenner Institute at the University of 
Oxford, headed by Dr Simon Draper. 
 
Who has reviewed the study?  
This study has been reviewed by Oxford Research Ethics Committee and has been 
given a favourable ethical opinion. The Medicines and Healthcare products Regulatory 
Agency (MHRA) which regulates the use of all medicines in the UK has reviewed the 
study design and has granted permission to use these unlicensed vaccines in this 
clinical study. 
 
Thank you for reading this information sheet. If you are interested in being 
involved in the study please contact the study team at the Centre of Clinical 
Vaccinology and Tropical Medicine (details below) to arrange a screening 
appointment.  
 
Contact details for further information: 
E-mail:vaccinetrials@well.ox.ac.uk 
Telephone: 01865 857401 
Centre of Clinical Vaccinology and Tropical Medicine, 
Churchill Hospital, Old Road, Headington, Oxford, OX3 7LE 
 
Out of hours mobile number for emergencies: 07917882967 
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PARTICIPANT INFORMATION SHEET: VAC054 
A study to assess the safety and effectiveness of an experimental malaria vaccine by 
infecting vaccinated volunteers with malaria parasites using malaria-infected red blood cells 
 
A Phase I/IIa Study of the Safety, Immunogenicity and Efficacy of FMP2.1/AS01B, an Asexual 
Blood-Stage Vaccine for Plasmodium falciparum Malaria 
 
We would like to invite you to take part in a research study. Before you decide, it is important 
for you to understand why the research is being done and what it would involve. Please take 
time to read the following information carefully and discuss it with friends, relatives and your 
General Practitioner (GP) if you wish. 
 Part 1 tells you the purpose of the study and what will happen to you if you take part. 
 Part 2 tells you more information about the conduct of the study. 
 
Ask us if there is anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. 
 
Part 1 
What is the purpose of the study? 
Malaria remains a major public health problem accounting for an estimated 219 million cases 
of malaria and 660,000 deaths worldwide in 2010. It is a major problem for those who live in 
affected areas and for travellers. There is a great need for a safe, effective malaria vaccine as 
the range of effective medicines for treating malaria is limited and resistance to commonly 
used medicines is increasing. Researchers around the world, including the University of Oxford, 
have been investigating malaria vaccines for many years. Unfortunately there is currently no 
licensed malaria vaccine available. 
 
The purpose of this study is to evaluate an experimental malaria vaccine for its ability to 
prevent malaria infection or disease in a blood-stage challenge model (when volunteers are 
infected with malaria parasites using malaria-infected red blood cells). The vaccine we are 
testing is a protein called FMP2.1, which is given with an adjuvant (a substance to improve the 
body’s response to a vaccination) called AS01B. The protein has been given to over 340 people, 
including over 200 children with no vaccine-related serious adverse events. The AS01B 
adjuvant has been given to several hundred adults, in combination with other proteins, with 
no major concerns, such as illness. The FMP2.1/AS01B combination has been given to 20 
adults without any serious adverse events. 
 
The aim is to use this protein and adjuvant to help the body make an immune response against 
parts of the malaria parasite. This study will enable us to assess: 
 
1. The ability of the vaccine to prevent malaria infection. 
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2. The safety of the vaccine in healthy participants. 
3. The response of the human immune system to the vaccine. 
 
We will do this by giving participants three vaccinations and then exposing them to malaria 
infection by transfusing a small number of red blood cells infected with malaria under carefully 
regulated conditions. We will follow participants closely to observe if and when they develop 
malaria. If the vaccine provides some protection against malaria, participants will take longer 
to develop malaria than usual or will not develop malaria at all. We hope to recruit 15 
participants to be vaccinated and then challenged with malaria. 
 
We will also recruit 15 individuals to be control subjects – these participants won’t receive any 
vaccinations but will be challenged with malaria in the same way. It is extremely important to 
have control participants, as by developing malaria infection, they help us prove our method 
of giving participants malaria is effective. Otherwise we may think our vaccines have worked 
when actually the malaria parasites in the red blood cells weren’t infective. 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. Your decision will not result in any 
penalty, or loss of benefits to which you are otherwise entitled. If you do decide to take part, 
you will be asked to complete a questionnaire assessing your understanding of the study in 
order for us to be confident that you fully understand what taking part will involve. You need 
to answer all questions correctly in order to take part in the study. If you don’t answer all the 
questions correctly the first time, you will be able to complete the questionnaire again after 
discussion with the Investigator. You will then be asked to sign a consent form. You are free to 
withdraw at any time without giving a reason, but you may be asked to return to the clinic for 
follow up for safety reasons. 
 
The University of Oxford does not urge, influence, or encourage any employees/students of 
the institution to take part in this research study.  Your decision to not participate in the study, 
or a decision on your part to withdraw from the study, will have no effect whatsoever on your 
employment/student status at the University. 
 
What will happen if I decide to take part? 
You will either; 
 Receive three vaccinations according to the schedule below and then undergo 
challenge infection with malaria (Group 1) 
or  
 Receive no vaccines and undergo challenge with malaria (Group 2) 
 
Group 1 
FMP2.1/AS01B  
 (n=15) 
Vaccine on Day 0 
 
Group 2 
Unvaccinated 
Infectivity Controls 
(n=15) 
  
 
  
FMP2.1/AS01B 
Vaccine on Day 28 
  
FMP2.1/AS01B 
Vaccine on Day 56 
  
Malaria Infection on 
Day 70 
Malaria Infection only 
on Day 70 
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You can choose whether you would like to receive the malaria vaccines or not, providing there 
is space available in the group. 
 
Length of research 
Group 1 participants will participate in the study for approximately 8 months from the time 
they have the first vaccination. Group 2 participants will take part in the study for 
approximately 3 months from the time they are enrolled (1 day before challenge). 
Am I eligible to be involved in the trial? 
In order to be involved in the study you must be: 
 A healthy adult aged between 18 and 45 years. 
 Able and willing (in the Investigators’ opinion) to comply with all study requirements. 
 Willing to allow the Investigators to discuss your medical history with your GP 
(General Practitioner). 
 Willing to refrain from future blood donation in the UK. 
You cannot participate in this study if: 
 You have had malaria before. 
 You have travelled to a malaria endemic region in the last 6 months or are intending 
to travel to a malaria endemic region during the study period. 
 You have used antibiotics which could treat malaria (e.g. doxycycline) in the 30 days 
prior to malaria challenge. 
 You have previously received an investigational malaria vaccine. 
 You have sickle cell anaemia, sickle cell trait, thalassameia trait or thalassemia or any 
other haematological condition that might affect susceptibility to malaria infection. 
 You have had immunoglobulins and/or any blood products in the three months 
preceding your involvement in this trial. 
 You have problems with your immune system. 
 You have an abnormal heart rhythm. 
 You have a family history of congential QT prolongation or sudden death. 
 Close family members have developed heart disease when aged less than 50 years. 
 You are pregnant, breast feeding or intend to become pregnant during the study. 
 You have a history of allergic disease or reactions likely to be exacerbated by any 
component of the vaccine, by malaria infection or by the medications used to treat 
malaria infection. 
 You have had an anaphylaxis after vaccination. 
 You have a history of cancer. 
 You have a history of a serious psychiatric condition that may affect participation in 
the study. 
 You have any other serious long-term illnesses requiring hospital follow-up. 
 You drink on average more than 42 units of alcohol a week (a pint of beer is two units, 
a small glass of wine 1 unit and a shot of spirits one unit). 
 You have injected drugs at any time in the last 5 years. 
 You have hepatitis B, hepatitis C or HIV infection. 
 You are unable to stay in Oxford from the day before challenge to up to 3 weeks 
following the malaria challenge. 
 
Mild conditions, such as childhood asthma which is well controlled would not automatically 
exclude you from participating. If you are unclear whether you are eligible to be involved in 
the study you can contact the study team (details at the end of this information sheet) who 
will be able to advise you. 
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CONSIDERATIONS BEFORE TAKING PART IN THIS STUDY 
Screening Visit: This takes place up to 3 months before the study starts and lasts up to two 
and a half hours. This visit will take place in your local trial site (in Oxford, London or 
Southampton). The purpose of the screening visit is for you to discuss the trial with us and 
decide if you still wish to enter the study. If you decide to participate, you will be asked to 
complete a questionnaire to assess your understanding of the study and to sign a consent 
form. 
 
We then need to check that you are eligible to participate. You will be asked some medical 
questions and a doctor will examine you. Some blood tests will be taken to check your red and 
white cells, your liver and your kidney function. These tests need to be normal for you to be 
enrolled in the study. Your blood will also be tested for infection with hepatitis B, hepatitis C 
or HIV. These viruses are transmitted by infected blood or sexually and can affect the immune 
response to infection and vaccines. If you test positive to any of these infections, we will 
inform you of the result and offer referral for medical review and treatment with your 
permission. Positive results may be reported to the appropriate health authority. Your blood 
will also be tested for cholesterol to calculate your cardiovascular risk over the next 10 years. 
If your cardiovascular risk is > 5% you cannot participate in the trial. An electrocardiogram 
(ECG; to check the rhythm of the heart) will be done at your screening visit, to ensure that 
there are no rhythm problems with the heart. 
 
All participants are asked for urine samples at screening to check for glucose (to exclude 
diabetes), protein and blood (which can indicate kidney disease). For women, a urine 
pregnancy test will also be performed. To avoid repeated testing, if you are not enrolled into 
this study and apply to enter another study conducted by the Jenner Clinical Trials Group 
based at the Centre for Clinical Vaccinology & Tropical Medicine (CCVTM) the screening blood 
results may be used in that study, where appropriate. 
 
Blood Donation: Under current UK regulations, you would not be permitted to donate blood 
after taking part in this trial. This is because the malaria challenge involves the injection of red 
blood cells from another person, which is classified as a small blood transfusion. 
 
Medications: You should not take any drugs other than vitamin pills, contraceptive pills or 
those medications assessed as appropriately safe during a malaria challenge by the doctor at 
screening. This also applies for drugs bought over the counter. Of course, your health and 
well-being is much more important than the conduct of this study and if at any time you need 
any medication then you should take it. However, it is very important that you let us know 
before you start on any treatment. For example, any antibiotics that you take within 4 weeks 
of the planned challenge day may affect the malaria parasite. If you ask the prescribing doctor 
to discuss with a study doctor (contact details at the end of this information sheet) before you 
start treatment then he or she may be able to advise on an appropriate antibiotic that will 
treat you but won’t interfere with the study. If during the study any other treatment, 
especially with antifungal, antidepressant, antipsychotic or anti-arrhythmic drugs becomes 
necessary, it is important that you inform us immediately, since many of these drugs might 
interfere with the treatment against malaria you would receive. 
 
Pregnancy and Contraception: The potential effect of the vaccine used in this study on a 
foetus is unknown. Also, malaria infection can be particularly dangerous during pregnancy to 
both the mother and the foetus. Women are therefore asked to use an effective method of 
contraception for the whole study period to avoid pregnancy during the study. Volunteers will 
take the antimalarial medication, Riamet, for three days, to treat malaria infection. As Riamet 
may temporarily reduce the effectiveness of hormonal contraceptives, women taking 
hormonal contraceptives will need to use an additional form of contraception while taking 
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Riamet and until the start of the next menstruation after Riamet treatment. A urinary 
pregnancy test will be carried out at screening, just prior to each study vaccination (as 
applicable), before malaria challenge and again before anti-malarial treatment is started. 
 
If you are a woman using a hormonal contraceptive, you will need to use an alternative 
method of contraception while you are taking the medication for malaria, and until the start of 
the next menstrual period. 
 
Private Insurance: If you have private medical or travel insurance you are advised to contact 
your insurance company before participating in this trial, because involvement in this study 
may affect the cover provided by private insurance. 
 
VACCINATIONS 
 
What is the vaccine being tested? 
FMP2.1/AS01B is a ‘protein in adjuvant’ vaccination, using the protein FMP2.1 and the 
adjuvant AS01B. FMP2.1 is a part of a malaria protein known as AMA1 which is expressed by 
the malaria parasite during infection. AS01B is an adjuvant – a substance that helps improve 
the body’s immune response to a vaccine. 
 
FMP2.1 has been given to over 340 people, including over 200 children, with no serious safety 
concerns. It has been given with a different adjuvant (AS02A) in the majority of cases, but has 
been given with AS01B in a previous trial to 20 healthy adults with no serious safety concerns. 
AS01B used with other antigens has been used in hundreds of adults with no emerging specific 
safety concerns. The same adjuvant at a paediatric dose, AS01E, has been used in thousands 
of children in the only malaria vaccine to reach Phase III clinical trials, RTS,S. 
 
Vaccinations will be given into the muscle of the upper arm. Control volunteers (Group 2) will 
receive no vaccinations. 
 
Vaccination Visits: Group 1 
Vaccination visits will take place at your local trial site (in Oxford at the CCVTM, Churchill 
Hospital; in Southampton at the NIHR WTCRF; or in London at the Hammersmith Hospital). We 
will ask you to wait for 60 minutes after each vaccination to check there are no immediate 
problems. You will be given a diary card, thermometer and tape measure to take away. We 
will ask you to record your symptoms and the size of any redness or swelling at the injection 
site, every day for 7 days after each vaccination on the diary card. 
 
We may ask to photograph your vaccination site(s) and you can choose whether or not to 
agree to this when you sign the consent form. You will not be identifiable in these 
photographs, as only the vaccination site and your unique trial number will be visible. These 
photographs may be shown to other professional staff, used for educational purposes or 
included in a scientific publication. 
 
Number, timing and purpose of follow-up visits post vaccination: 
The diagram below shows the timing of post vaccination follow-up visits. Visits include a 
medical assessment, temperature, pulse and blood pressure readings, examination by a 
doctor if needed and blood tests. Vaccinations and visits after vaccination will take place at 
your local clinic site (i.e. Southampton, London or Oxford). 
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Group 1 visits up to malaria challenge. Screening visits (S), vaccination visits and pre-
challenge follow-up visits, will take place at your local trial site; whereas the C-1 (the day 
before challenge) and challenge (Day 70) visits will take place at the CCVTM in Oxford. 
 
 
Group 2 visits up to malaria challenge. Screening visits (S) will take place at your local trial 
site; whereas the C-1 (the day before challenge) and challenge (day 0) visits will take place at 
the CCVTM in Oxford. 
 
THE MALARIA CHALLENGE 
 
What happens during the challenge? 
The best way of assessing how well new malaria vaccines work is to test whether they protect 
against malaria – as we plan to do in this trial. The malaria challenge is 70 days after the 
vaccination group (Group 1) receive their first vaccination, and the day after the C-1 visit for 
control volunteers (Group 2), and will take place at the CCVTM in Oxford for all trial 
participants (i.e. including those recruited in Southampton and London). All volunteers will 
need to attend the CCVTM the day before challenge (C-1) where blood tests will be taken and 
female volunteers will have a urinary pregnancy test. On the day of challenge an intravenous 
cannula (‘drip’) will be inserted into a vein in your arm. After this, a small amount (5 ml or 1 
teaspoonful) of a solution containing red blood cells which are infected with malaria parasites 
will be injected into the vein. You will need to stay in CCVTM for 1 hour after being given the 
injection, in case you have an immediate reaction. 
 
What happens at follow up after the Malaria Challenge? 
The malaria challenge follow up visits are very important for your safety. We need to assess 
you once the day after the malaria challenge, (C+1, or day 71) then twice daily until C+12 
(inclusive) and once daily until C+23 or until you have completed antimalarial treatment if you 
develop malaria (see diagram below). All these clinic visits will take place at the Centre for 
Clinical Vaccinology & Tropical Medicine (CCVTM) at the Churchill Hospital in Oxford. It is 
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essential that you reside in Oxford during this time for careful monitoring and regular review 
by the study team. If you do not normally live in or close to Oxford and if you joined the study 
at the Southampton or London sites, accommodation will be provided for this time as well as 
transportation to and from Oxford. You will be required to stay in Oxford until you have had 
two negative malaria films after starting antimalarial treatment, or completing 2 days of 
antimalarial treatment at day 21 if you do not develop malaria. We will give you a medication 
diary card on which you will be asked to record all medications that you take. 
 
Each time we see you, we will assess your symptoms and a doctor will examine you, if 
necessary. A small amount of blood will be taken and examined under the microscope for 
malaria parasites. This is called a thick film and it is the standard test for diagnosing malaria 
infection. Your blood will also be tested for malaria parasite genetic material (DNA) using a 
technique called polymerase chain reaction (PCR). These visits will last approximately 10 
minutes, although you may have to wait to be seen. The total number of visits post challenge 
will vary depending on when and if you get malaria. It is important you are able to attend all 
the visits. If you plan to travel outside of Oxford at any time from the day before challenge 
to 21 days following the challenge, then you should discuss your plans with one of the study 
physicians before participating in this study. 
 
 
 
If you are diagnosed with malaria you will be immediately started on a course of anti-malarial 
tablets. Usually the blood test result is available after you have already left clinic, although if 
you wish to wait for the result after each test you are welcome to do so. If you have left and 
your blood test is positive for malaria we will contact you by telephone and ask you to return 
to the CCVTM as soon as possible to start treatment. It is therefore essential that we are able 
to contact you at all times on your telephone and that you are available to return to the 
CCVTM to start treatment at short notice any time between day 2 – 21 post challenge. The 
drug you will be treated with is called Riamet®. It is a licensed drug in the UK for the treatment 
of malaria caused by Plasmodium falciparum, the type of malaria you will be infected with. 
Each Riamet® tablet is a combination of 20mg artemether and 120mg lumefantrin. Each dose 
is 4 tablets and you will need 2 doses each day for 3 days. We will give you the first dose and 
ask you to take the second dose 8 hours later. The next day and the day after that, you will 
need to take 2 doses, 12 hours apart. We will watch you take one dose each day. Tablets 
should be taken with a meal. 
 
When you start treatment, you may not feel better straight away, but most people start to 
feel better after about 24 hours. After starting treatment, you will need a blood test once 
every day until two blood tests in a row have been negative for malaria parasites. 
 
If you are feeling unwell and your symptoms are like malaria, but no malaria parasites are seen 
in your blood, we may not treat you straight away. If you are feeling ill for one or two days, we 
may decide to start treatment even if no parasites are seen. If you have still not developed 
 
C 
C+2 to C+12 
twice daily visits 
= Blood test 
C+1 C+90 C+28 
Start antimalarial 
treatment (Riamet
®
) 
C+21 or upon diagnosis 
 
Malaria challenge schedule 
 
C = Malaria challenge 
C+13 to C+23 
Once daily visits 
261 
 
malaria after 21 days, you will be given the malaria treatment regardless of whether or not we 
have seen malaria parasites in your blood. 
 
If there any problems with Riamet® for any reason, we have different anti-malarial treatments 
available which are called Malarone or chloroquine. 
 
Our experience tells us that the malaria parasites should disappear from your blood within 2 
or 3 days of starting the treatment. If you do develop malaria then you will be seen each day 
during the treatment until there are no malaria parasites in your blood on two consecutive 
days. We will give you a diary card when you finish treatment on which to note when any on-
going symptoms of malaria stop. 
 
If you become unwell with malaria then you may be admitted to the John Warin ward (the 
Infectious Diseases and Tropical Medicine Unit at the Churchill Hospital in Oxford) as a 
precaution until you have recovered, but it is very unlikely that this will be necessary. 
If the vaccines do not work or you are in the control group (group 2) you are most likely to 
develop malaria between day 7 and 9 following challenge. If the vaccines protect you against 
malaria you may develop malaria later than day 9 or not at all. If we do not find malaria 
parasites in your blood by day 21 post challenge then we will presume the vaccines have 
protected you against malaria and give you a course of antimalarial treatment anyway so that 
any parasites that we have not detected are killed. 
 
Days 28 and 90 after malaria challenge 
You will be seen in clinic on day 28 and day 90 post challenge. At these visits a blood sample 
will be taken. The appointments will last about 10 minutes and will take place at your local 
clinic site (i.e. London, Southampton or Oxford). 
 
WHAT ARE THE RISKS OF TAKING PART IN THE STUDY? 
 
The potential risks in the study can be divided into seven categories; 
 
1. Blood Tests 
 
The total volume of blood taken during the study depends on the group. The amount taken at 
each visit will vary between around 3mL (less than a teaspoon) to around 92 mL (about 6 
tablespoons). The volume of blood being taken over the course of the trial should not cause 
any problems in healthy people. There may be some temporary mild discomfort, such as 
bruising and tenderness at the site where the blood tests are taken from. You may experience 
faintness as a result of collecting blood. We will give you a copy of your blood tests if you 
request them, will only send the results to your GP if you wish us to and will not report them 
to anyone without your permission. 
 
If abnormal results or undiagnosed conditions are found in the course of the study these will 
be discussed with you and, if you agree, your GP will be informed. For example, a new 
diagnosis of anaemia might be made. Any newly diagnosed conditions will be looked after by 
your GP within the NHS. 
 
Once malaria has been diagnosed and treated, with 2 consecutive negative thick blood films 
confirmed after treatment, the twice daily / daily blood tests after challenge will no longer be 
required. 
 
Blood tests that will be taken during visits for Participants in GROUP 1:  
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Screenin
g 
Vaccinatio
n Visits 
Vaccinatio
n follow 
ups 
Days Post - Challenge follow up Visits 
Tests of Red and 
White Blood 
Cells* 
X X X 
Within 24 hrs of diagnosis & at Days 6, 28 & 90 
post challenge 
Test of Liver and 
Kidney Function* 
X X X 
Within 24 hrs of diagnosis & at Days 6, 28 & 90 
post challenge 
Hepatitis B, 
Hepatitis C & HIV 
infection  
X    
EBV and CMV
$
   X Day 90 post challenge 
Cholesterol X    
HLA typing  X
£
   
Tests of Immune 
Response to 
Vaccines 
 X X Day of diagnosis and days 28 & 90 post-challenge  
Tests for malaria 
# 
   Days 1-23 post challenge 
 
*We will test your red and white blood cells and liver and kidney function at various points throughout the study to 
check you remain well and whether the vaccines are safe. 
 
$
 EBV and CMV are viruses that cause glandular fever. We will check to see whether you have been exposed to these 
before. Whether you have or not will not affect your ability to take part in the trial.This will be checked once prior to 
malaria challenge (at C-1 visit) and once later in the trial. 
 
# Tests for malaria use only small volumes of blood (3mL). We perform one prior to challenge to ensure we get 
accurate readings during the follow-up post challenge. These tests will be performed until you have had 2 negative 
blood films following starting antimalarial treatment or until day 23 post-challenge if you do not develop malaria. 
 
£
 This will only be performed once 
 
Blood tests that will be taken during visits for Participants in GROUP 2:  
 
 
Screening 
Visit 
Day before 
Malaria 
Challenge 
Follow ups Post Challenge 
Tests of Red & White Blood 
Cells* 
X X 
Within 24 hrs of diagnosis & at Days 6, 
28 & 90 post Challenge 
Tests of Liver & Kidney 
Function* 
X X 
Within 24 hrs of diagnosis & at Days 6, 
28 & 90 post Challenge 
Hepatitis B, Hepatitis C & HIV 
infection  
X   
EBV and CMV
$
  X Day 90 post challenge 
Cholesterol X   
HLA Typing  X  
Tests of Immune Response to 
Malaria 
 X 
Alternate days from day 2 post-
challenge until Day of diagnosis 
(inclusive) and days 28 & 90 post-
challenge 
Tests for malaria 
#
  X Days 1 – 23 post Challenge 
 
* We will test your red and white cells and your liver and kidney function at various points throughout the study in 
order to check you remain well. 
 
$
 EBV and CMV are viruses that cause glandular fever. We will check to see whether you have been exposed to these 
before. Whether you have or not will not affect your ability to take part in the trial.This will be checked once at the 
beginning of the study and once at the end. 
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#
Tests for malaria use only small volumes of blood (3mL). We perform one prior to challenge to ensure we get 
accurate readings during the follow-up post challenge.If you are in the control group you are likely to get malaria 
within 7-9 days after challenge, therefore it is very unlikely that you would continue to have blood tests to day 23. 
These tests will be performed until you have had 2 negative blood films following starting antimalarial treatment or 
until day 23 post-challenge if you do not develop malaria. 
 
2. Vaccination Side Effects (Group 1 only) 
 
Side effects of Vaccination 
It is likely that you will experience some symptoms at the vaccination site as well as general 
symptoms due to vaccination. It is important to remember these are vaccines in the early 
stage of development therefore the amount of safety data available is limited.  
For this reason there is a chance you could experience a side effect that is more severe than 
that described below, or that has not been seen before with these vaccines. 
 
The vaccine being tested in this trial has been used before, in small numbers of healthy 
volunteers, so we can predict from past experience what the symptoms should be like. We 
don’t expect any new symptoms and we expect that symptoms will be mild in strength most 
of the time, but symptoms may also be moderate or severe in how strong they are. All 
symptoms should resolve completely within a few days. 
 
Local Reactions 
You may experience some discomfort at the site as the injection is given. This usually gets 
better in 5 minutes. Later, you might experience pain resulting in some difficulty moving your 
arm but should resolve within a few days. In addition to pain, you may experience redness, 
swelling, or warmth at the injection site. 
 
General reactions 
You may experience flu-like symptoms such as muscle aches, joint aches, feverishness, chills, 
headache, nausea, tiredness and/or feeling generally unwell in the first 24 - 48 hours after the 
injection, which should generally resolve within a few days. 
 
You are encouraged to take over the counter medications such as paracetamol or ibuprofen as 
soon as you experience these symptoms as this is likely to reduce the intensity of any 
symptoms you have. 
 
Serious Reactions 
With any vaccination there is a risk of rare serious adverse events, such as an allergic reaction, 
which may be related to the nervous system or the immune system. Severe allergic reactions 
to vaccines (anaphylaxis) are also rare, but can be fatal. Reactions in the nervous system are 
also extremely rare following vaccination and can cause an illness called Guillain-Barré 
syndrome. Guillain-Barré syndrome is an illness in which people can develop severe weakness 
and can also be fatal. These adverse events have not previously been seen following 
administration of this vaccine. 
 
Autoimmune diseases are a class of diseases resulting from a disordered attack of the immune 
system on the body's own organs and tissues. Such diseases have been reported in individuals 
having received components similar to components present in FMP2.1/AS01B. The 
relationship of the product or any of its components to these events has not been established 
but cannot be excluded. Evaluation of these and similar events continues. 
 
The Investigators are contactable any time if you are concerned about any possible vaccine 
side effects. 
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3. Blood Transfusion Reaction 
 
The malaria challenge in this trial involves receiving a very small number of malaria-infected 
red blood cells. If blood is given from one person to another there is a risk of an allergic 
reaction. Normally, the blood groups of the blood donor and the individual receiving the blood 
must be the same to avoid allergic reactions. The donor of the blood we will be using was 
blood group O, rhesus negative. This means the donor’s blood can be given to people of the 
same or any other blood group, without causing an allergic reaction. 
 
4. Transmission of Blood-borne Infection  
 
The blood transfused in this study has a smaller risk of infection than normal blood 
transfusions. Firstly, the volunteer who donated the malaria-infected blood was screened for a 
wide range of blood borne diseases both before and after the blood was collected. The blood 
was then kept frozen for over 1 year while the donor was observed and retested for any 
evidence of infection. During this time the donor remained healthy and repeat screenings did 
not reveal any infections that may have not been detected by initial tests. This procedure took 
place over 15 years ago and the donor has remained healthy since. Secondly, the volume of 
blood injected for this study (0.1mL) is thousands of times smaller than the volume in a 
transfused unit of blood (400mL). Thirdly, the blood cells have been washed and the white 
blood cells removed, both of which lower the risk of infection due to transfusion. 
 
The donor was known to have had viral infections with Epstein-Barr virus and Cytomegalovirus 
in the past. These are viruses which, over a person’s lifetime, they are very likely to be 
exposed to, and are the most common causes of ‘glandular fever’. They remain within white 
blood cells after the initial infection so there is a theoretical risk of transmitting these 
infections from the donor to someone receiving the transfused blood. This risk is extremely 
small however, given that the white blood cells have been removed from the blood. The blood 
has also been tested since to look for the virus and these tests were negative. Furthermore, 
over 30 volunters who had not had these viruses before have received the inoculum and none 
of them have acquired the infection. 
 
5. Malaria Infection 
 
If untreated, the malaria infection that we propose to give you could result in death. 
Worldwide over 1300 people have been deliberately infected with malaria and all have made 
a complete recovery. In Oxford more than 400 people have been infected with malaria.  The 
risks of taking part in this study are low provided that you return for follow-up as outlined 
above. 
 
The early symptoms of malaria include a flu-like illness, fever, chills, headache, muscle aches, 
diarrhoea and vomiting. If you develop any of these then you must let one of the study 
physicians know immediately. Study doctors can be contacted 24 hours a day. We hope to 
diagnose and treat your infection before the onset of symptoms but in previous studies most 
participants did experience some of the above symptoms. About one-fifth of participants 
temporarily develop symptoms graded as severe (i.e. symptoms that prevent daily activities). 
It is possible that you might need to take one or two days off work due to symptoms of 
malaria. We will prescribe pain-killers such as paracetamol and anti-sickness tablets which you 
can take as required. Symptoms can start or persist after treatment has started but usually last 
no more than 1 to 3 days. If malaria is not treated appropriately, possible complications 
include jaundice, kidney failure, fluid on the lung, low blood sugar and collapse. Seizures, 
altered consciousness, coma and even death may occur. It is for this reason it is crucial that 
you attend all the scheduled follow-up visits and contact us immediately if you have any 
265 
 
symptoms at all. 
 
In the unlikely event that it is necessary, you may be admitted to the Infectious Diseases ward 
(the John Warin ward) at the Churchill Hospital, Oxford for observation and treatment. In the 
last 10 years, only 4 participants out of more than 400 challenged with malaria in Oxford have 
required hospital admission. There have been no long term problems in participants 
challenged with malaria. 
 
There have been two unexpected serious adverse events in persons infected in malaria 
challenge studies in The Netherlands. The first individual experienced an episode of chest pain 
diagnosed as acute coronary syndrome that occurred two days after completion of malaria 
treatment with a full recovery. It is uncertain whether this was a form of coronary artery 
spasm or blockage or cardiac inflammation. More recently, a second individual was found to 
have an abnormal blood test suggesting cardiac inflammation. This second individual 
subsequently suffered a very short episode of chest pain. They were also found to be suffering 
with a viral upper respiratory tract infection (common cold virus) at the time. Again, this 
individual made a full recovery. It is unclear at this stage whether these findings were related 
to the malaria vaccine the participants received, the malaria infection, malaria treatment or 
some other cause. As a result of these events we will exclude people at high risk of heart 
disease from involvement in this study. These individuals will be identified by medical history, 
family history, appropriate blood tests, and performing an ECG. 
 
In 2010 in a malaria challenge study in Oxford, a participant failed to attend for a scheduled 
study visit after being infected with malaria. The police were immediately informed and began 
a nationwide search for the individual that involved the national media. The participant was 
found 17 days following challenge when he had mild malaria symptoms. He was admitted to a 
local hospital where he received treatment for malaria and made a full recovery. The reason 
for the participant’s disappearance was unrelated to the malaria vaccine he received or the 
malaria challenge. 
 
It is important that you understand that if you fail to attend a clinic appointment after 
challenge but before you have completed a full course of anti-malarial therapy, the police 
may be notified and your name may be released to the national media in order to find you. 
 
For 6 months after the challenge if you develop any of the symptoms of malaria as detailed 
above please contact one of the study doctors or your General Practitioner and remind them 
that you have been involved in this study. 
 
6. Treatment of Malaria 
 
The drug you will be treated with is called Riamet. It is a licensed drug in the UK for treatment 
of acute uncomplicated malaria caused by Plasmodium falciparum (the type of malaria you 
will be infected with). Riamet is a combination drug consisting of 20mg artemether and 120mg 
lumefantrine per tablet. 
 
A treatment course of Riamet consists of 6 doses of 4 tablets. The first 4 tablets will be given 
when diagnosis is made, followed by additional doses after 8, 24, 36, 48 and 60 hours. We will 
need to watch you take at least three of these doses. We will continue taking blood to look for 
parasites until 2 consecutive blood tests are negative for malaria parasites. Blood tests usually 
become negative for malaria parasites after 24 hours of treatment. Tablets should be taken 
with a meal or snack.  We will provide a light snack with your doses of Riamet which we 
observe at the CCVTM. You should avoid taking grapefruit juice while taking Riamet. 
 
Riamet is generally well tolerated, but may cause some side effects. Side effects can include 
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headache, dizziness, abdominal pain and loss of appetite, sleeping problems, palpitations, 
nausea, vomiting, diarrhoea, skin rash, cough, muscle or joint pain and fatigue. Side effects 
such as dizziness may impact on the performance of skilled tasks such as driving. Riamet can 
have an effect on the electrical conduction in the heart (increase in the QT interval) which 
could potentially increase the risk for a cardiac arrhythmia as an extremely rare side effect; as 
a precaution we will use a different malaria treatment if we find any reason that you would be 
at increased risk. Severe allergic reactions could potentially occur, but the exact frequency is 
unknown. 
  
Signs of severe allergic reactions include rash and itching, sudden wheezing, tightness of the 
chest or throat, or difficulty breathing, swollen eyelids, face, lips, tongue or other part of the 
body. If you experience any of these symptoms you should contact the trial doctor 
immediately on the emergency contact number you will be provided with, or telephone 999 
and ask for an ambulance if you are having difficulty breathing. 
 
Taking some other medicines is not compatible with taking Riamet at the same time. If you 
cannot take Riamet or need to stop taking Riamet during the study, then there are other anti-
malarial drugs that can be used effectively instead. If at screening the doctor thinks you may 
not be able to take Riamet they will discuss with you an alternative medication (Malarone or 
Chloroquine) and give you an information sheet from the manufacturer for this drug to take 
away. 
 
7. Treatment of Symptoms Associated with Challenge 
 
Provided there are no contraindications, all participants will be given some medications to 
help with symptoms associated with malaria challenge. These are licensed, commonly used, 
medications. If you wish you can see the sheets from the manufacturers, provided inside the 
packets of these medications, prior to taking part in the study. As with all medications, these 
drugs can cause a severe allergic reaction in a small number of people. If you develop any 
concerning symptoms you should contact the trial doctor on the emergency contact number 
you will be provided with immediately. 
 
Cyclizine: This is a tablet that can be taken as and when needed to help reduce nausea and 
vomiting. Cyclizine is generally well tolerated however side effects include skin rashes or 
itching, drowsiness, headache, dry mouth, nose or throat, blurred vision, palpitations, 
difficulty passing water, constipation, anxiety, or difficulty sleeping. It should be noted that 
drowsiness may affect your performance of skilled tasks such as driving. 
 
Paracetamol: Is a tablet that can be taken as and when needed to reduce feverishness, muscle 
and joint pain, back ache and headache. Paracetamol is generally well tolerated. 
 
There may be risks, or side effects which are unknown at this time. 
 
OTHER INFORMATION 
Expenses and Payments 
You will be compensated for: 
o Travel expenses: £10 per visit to local clinic  
o Time required for visit: £20 per hour 
o Inconvenience of blood tests: £10 per blood donation  
o Compensation for illness  £480 
 
If you choose to leave the study early or are withdrawn from the study you will be 
compensated according to the length of your participation based on these figures. You should 
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note that compensation payments received in this trial may have an impact on your 
entitlement to benefits. 
 
GroupNo. Time in Trial 
(approx.) 
Maximum No. of 
Clinic Visits* 
Maximum Volume 
of Blood Taken (ml) 
Compensation 
Amount  
1 
 
8 months 51 787-823** £2285 
2 
 
3 months 39 627-639** £1540 
*The exact number of visits depends on when/if you are diagnosed with malaria following challenge. 
 
**The exact amount of blood taken will depend on when/if you are diagnosed with malaria and also where you are 
recruited- blood volumes for volunteers outside of Oxford may be slightly higher than those for Oxford volunteers. 
 
In addition to the 15 participants to be included in group 2, we will also recruit a number of 
‘back-up participants’ for this group. These participants will be asked to be available to take 
part in the study in group 2 at short notice if another participant is unavailable to take part at 
the last minute. ‘Back-up participants’ who are not enrolled in the study will be compensated 
£200 in addition to compensation for visits they may have attended. 
 
What do I have to do? 
 You must provide a name and 24 hour phone number for someone who lives near to you 
and who will know where you are for the duration of the study. If you fail to attend for 
review during the 21 days after challenge and are un-contactable we will contact this 
person. If you cannot be located we will take additional steps to locate you which may 
involve contacting the police and national media. 
 You must attend all the visits that are outlined above. 
 Women must use an effective method of contraception for the duration of the study. If 
you are using a hormonal contraceptive, you will need to use an alternative method of 
contraception while you are taking the medication for malaria, and until the start of the 
next menstrual period. 
 You must not donate blood in the UK following participation in the study. 
 
What alternatives are present? 
Your alternative is not to participate in this study. 
 
What are the possible benefits of taking part? 
This study will not benefit you, but the information gained from the trial might help to prevent 
malaria infection and disease in those who live in areas where malaria is common and in 
travellers. At present, there is no malaria vaccine licensed anywhere in the world. There are 
other malaria vaccines in various stages of development. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible harm 
you might suffer will be addressed. The detailed information on this is given in Part 2. 
 
What happens when the research study stops? 
If you have any queries or concerns once the study is over, please do not hesitate to get in 
touch with us. 
 
Will my taking part in the study be kept confidential? 
Yes. All the information about your participation in this study will be kept confidential. The 
details are included in Part 2. 
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This completes Part 1 of the Information Sheet.  If the information in Part 1 has interested 
you and you are considering participation, please continue to read the additional 
information in Part 2 before making any decision. 
 
Part 2 
 
What if relevant new information becomes available? 
Sometimes during the course of a research project, new information becomes available.  If this 
happens, we will tell you about it and discuss whether you want to or should continue in the 
study. If you decide to continue in the study you will be asked to sign an updated consent 
form. On receiving new information, we might consider it to be in your best interests to 
withdraw you from the study. Your participation in this study may also be stopped at any time by 
the study doctor or the Sponsor without your consent for other reasons. 
 
What will happen if I don’t want to carry on with the study? 
If at any time after agreeing to participate you change your mind about being involved with 
this study, you are free to withdraw without giving a reason. Your decision will not result in 
any penalty, or loss of benefits to which you are otherwise entitled. However, if you wish to 
leave after malaria challenge then you must take the treatment course of Riamet (or an 
agreed alternative) because of the potentially very serious consequences of untreated 
malaria infection. Your compensation would be paid as a proportion of the total 
compensation according to the length of your participation. 
 
What if there is a problem? 
 
Complaints: 
If you wish to complain about any aspect of the way in which you have been approached or 
treated during the course of this study, you should ask to speak with the researchers who will 
do their best to answer your concerns. You can contact the researchers via the contact details 
provided at the bottom of this information sheet. Alternatively, you may contact the 
University of Oxford Clinical Trials and Research Governance (CTRG) office on 01865 572224 or 
the head of CTRG, email ctrg@admin.ox.ac.uk. 
 
Harm: 
The Investigators recognise the important contribution that participants make to medical 
research, and will make every effort to ensure your safety and well-being.  If you are harmed 
as a result of taking part in this study, the study doctor can advise you of further action and 
refer you to a doctor within the NHS for treatment, if necessary.  The University has a 
specialist insurance policy in place which would operate in the event of any participant 
suffering harm as a result of their involvement in the research (Newline Underwriting 
Management Ltd, at Lloyd’s of London) as you may be entiltled to compensation. NHS 
indemnity operates in respect of the clinical treatment which may be provided if you needed 
to be admitted to hospital. In the event of harm being suffered, while the University will 
cooperate with any claim, you may wish to seek independent legal advice to ensure that you 
are properly represented in pursuing any complaint. At any time during the study you will be 
entirely free to change your mind about taking part, and to withdraw from the study. This will 
not affect your subsequent medical care in any way. 
Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the research will be coded with 
a study number and kept confidential. The information is available to the study team, the 
safety monitors, the ethical review committee(s), the Western Institutional Review Board 
(WIRB), the Sponsor (University of Oxford), government regulatory agencies, authorised 
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collaborators and external monitors who can ask to audit or monitor the study. Subject’s 
research records may be independently reviewed by United States Agency for International 
Development (USAID) staff and consultants to ensure compliance with USAID regulations for 
protection of human research subjects. Any information about you that leaves the clinic will 
have your name and address removed so that you cannot be identified from it. Your 
information is stored on a secure server and on paper in a locked filing cabinet. Records are 
stored for at least 5 years, and in accordance with the applicable regulations. 
 
Information generated from this study will be shared with GlaxoSmithKline (GSK), who are 
providing the AS01B adjuvant for this trial. GSK is a company that studies and makes vaccines, 
medicines and other health products. GSK will have access to the study data collected, 
however, the link between your name and the code number will not be shared. Only the code 
number and coded information will be sent to GSK. 
 
Involvement of the General Practitioner (GP)/Family doctor 
In order to enrol into this study you will be required to sign a form documenting that you 
consent for us to contact your GP. This is to inform him / her that you are interested in being 
involved in the study and to check there are no medical reasons that they are aware of why 
that would make your participation inappropriate. Your GP may be asked to share information 
about your medical history and give access to any other medical records as required. The final 
decision about your eligibility will be the responsibility of the study Investigators. 
 
Prevention of ‘Over Participating’ 
Subjects participating in this study must not be concurrently receiving medications or vaccines 
in another study. In order to check this, you will be asked to provide your National Insurance 
(NI) or Passport number (if you do not have a NI number). This will be entered on to a national 
database which helps prevent participants from taking part in too many clinical trials. More 
information can be found at www.tops.org.uk. Your national insurance or passport number is 
also required to allow processing of compensation payments. 
 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required 
by U.S. law. This Web site will not include information that can identify you. At most, the Web 
site will include a summary of the results. You can search this Web site at any time. 
 
What will happen to any samples I give? 
All samples will be stored in an anonymised form. The blood tests mentioned in part 1 will be 
analysed in your local hospital laboratory, Oxford University research laboratories, and our 
collaborating research laboratories. If you consent, some of your leftover blood samples will 
be stored and may be used for further studies of the human body’s immune response to 
malaria and/or the vaccines used in this study, and/or your safety. Any such tests will have an 
appropriate ethical review. Upon your request at any time, your remaining blood samples will 
be destroyed. Your participation in this study will not be affected by your decision to allow or 
not allow storage and future use of your leftover blood samples. 
 
Will any genetic tests be done? 
Yes. Some blood will be used to look at the pattern of your genes that can affect the immune 
system (including the Human Leukocyte Antigen or HLA genes). The immune response to 
vaccines is in part genetically controlled, so knowing your pattern of genes that regulate 
immune responses (such as the HLA type) may help us to understand the responses to 
vaccination. 
 
What will happen to the results of the research study? 
The results of this research study may be published in a scientific medical journal or presented 
270 
 
at scientific conferences and meetings. Publication may not happen until 1 or 2 years after the 
study is completed. If you contact the researchers in the future you can obtain a copy of the 
results. You will not be identified in any report or publication. 
 
The anonymised data from this study will be shared with the collaborating partners who are 
organising and funding this research work, including GSK. 
 
Data from this study may be used to file patents, licence vaccines in the future or make profits 
in other ways. You will not be paid for any part of this. 
 
Data from this study may be used as part of a student post-graduate degree, for example an 
MD. 
 
Who is organising and funding the research? 
The study is organised by the University of Oxford. The major collaborators are the PATH 
Malaria Vaccine Initiative, Walter Reed Army Institute of Research (WRAIR), US Agency for 
International Development (USAID) and a division of the pharmaceutical company 
GlaxoSmithKline (GSK Vaccines). The study is funded through financial support to Oxford 
University from several funders, primarily PATH (an international public health organisation) 
with support provided by the Infectious Disease Division, Bureau for Global Health, US Agency 
for International Development (USAID); the UK Medical Research Council (MRC); and the 
National Institutes of Health Research through the Oxford Biomedical Research Centre. 
Neither your GP nor the researchers are paid for recruiting you into this study. 
 
Who has reviewed the study? 
This study has been reviewed by NRES Committee South Central - Oxford A (Reference 
number: 13/SC/0596). Review is also provided by the Western Institutional Review Board, 
USA. The Medicines and Healthcare products Regulatory Agency (MHRA) which regulates the 
use of all medicines in the UK has reviewed the study design and has granted permission to 
use these unlicensed vaccines in this clinical study. 
 
Thank you for reading this information sheet.  If you are interested in being involved in the 
study please contact the study team at your local trial site below to arrange a screening 
appointment. 
 
E-mail:vaccinetrials@ndm.ox.ac.uk 
Telephone: 01865 857406 
Centre of Clinical Vaccinology and Tropical Medicine, 
Churchill Hospital, Old Road, Headington, Oxford, OX3 7LE 
 
Contact Professor Adrian Hill, DM, FRCP, at +44 1865 857401 if you have questions, concerns 
or complaints about the research or if you feel you have been injured due to your 
participation in the study. 
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Professor Adrian Hill 
E-mail: vaccinetrials@ndm.ox.ac.uk 
Tel: 01865 857401 
 
NRES Committee South Central - 
Oxford A ref number: 14/SC/0120 
 
Centre for Clinical Vaccinology and 
Tropical Medicine (CCVTM) 
Churchill Hospital,  
Oxford,      
OX3 7LE 
 
Recruitment Co-ordinator   01865 857406 
 
PARTICIPANT INFORMATION SHEET: VAC057 
 
A study to assess new malaria vaccines ChAd63 RH5 and MVA RH5 
A Phase Ia clinical trial to assess the safety and immunogenicity of new Plasmodium 
falciparum malaria vaccine candidates ChAd63 RH5 alone and with MVA RH5 
 
We would like to invite you to take part in a research study. Before you make a 
decision, it is important you take the time to understand why the research is being done 
and what it would involve. Please read the following information carefully and discuss it 
with friends, relatives and your General Practitioner (GP) if you wish. Please ask us if 
there is anything that is not clear or if you would like more information. 
 Part 1 tells you the purpose of the study and what will happen to you if you 
take part. 
 Part 2 tells you more information about the conduct of the study. 
Part 1 
What is the purpose of the study? 
Malaria is a major global problem, affecting around 216 million people each year and 
causing around 655,000 deaths. There is a great need for a safe, effective malaria 
vaccine as the range of effective medicines for treating malaria is limited and 
resistance to commonly used medicines is increasing. Currently there is no approved 
vaccine available for malaria. 
The purpose of this study is to assess two new malaria vaccines, ChAd63 RH5 and 
MVA RH5, at different doses and alone or in combination. The study will enable us to 
assess the safety of the vaccines and the extent of the immune response in healthy 
volunteers. We will do this by giving volunteers one or two vaccinations, doing blood 
tests and collecting information about any symptoms that occur after vaccination. This 
is the first trial to use these vaccines in humans. We plan to recruit a total of 24 
volunteers to be vaccinated. 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do decide to take part 
you will be given this information sheet to keep (or sent it electronically) and be asked 
to sign a consent form. You are free to withdraw at any time and without giving a 
reason, but you may be asked to return to the clinic for follow up for safety reasons. 
What will happen if I decide to take part? 
This study involves having one or two vaccinations and then being followed up with 
blood tests. You will be asked to complete a diary, recording any symptoms you 
experience after the vaccination. You will be able to choose which group you are 
enrolled in, although as groups fill up there will be less choice. 
Length of research 
272 
 
If you decide to take part in this study, you will be involved in the trial for approximately 
6 to 8 months, depending on what group you are in. 
Am I eligible to be involved in the trial? 
In order to be involved in the study you must: 
 Be a healthy adult aged between 18 and 50 years. 
 Be able and willing (in the Investigator’s opinion) to comply with all study 
requirements. 
 Allow the Investigators to discuss your medical history with your GP. 
 Practice continuous effective contraception for the duration of the study 
(women only). 
 Refrain from blood donation during the course of the study.  
You cannot participate in this study if: 
 You have had malaria before. 
 You have travelled to a malaria endemic region in the last 6 months or are 
intending to travel to a malaria endemic region during the time you would be 
involved in the study. 
 You have participated in another research study in the last 30 days. 
 You are planning to participate in another study at the same time as this study.  
 You have previously received an investigational malaria vaccine.  
 You have had immunoglobulins and/or any blood products (such as a blood 
transfusion) in the 3 months preceding your involvement this trial. 
 You have problems with your immune system. 
 You are pregnant, breast feeding or intend to become pregnant during the 
study. 
 You have a history of a severe allergic reaction to a vaccination. 
 You have a history of cancer. 
 You have a history of a serious psychiatric condition that may affect 
participation in the study. 
 You have any other serious long-term illnesses requiring hospital follow-up. 
 You drink on average more than 42 units of alcohol a week (a pint of beer is 2 - 
3 units, a small glass of wine (125mL) 1 unit and a shot of spirits (25mL) one 
unit).  
 You have injected drugs at any time in the last 5 years. 
 You have hepatitis B, hepatitis C or HIV infection. 
Mild conditions, such as childhood asthma, which are well-controlled, would not 
automatically exclude you from participating. If you are unclear whether you are eligible 
to be involved in the study you can contact the study team who will be able to advise 
you. 
CONSIDERATIONS BEFORE TAKING PART IN THIS STUDY 
Screening Visit: This takes place at your local study site and will last approximately 
one and a half hours. The purpose of the screening visit is for you to discuss the trial 
with us and decide if you wish to enter the study. If you decide to participate, you will 
be asked to sign a consent form and we will check that you are eligible to participate. 
During the screening visit: 
 You will be asked some medical questions 
 A doctor will examine you 
 Blood samples and a urine sample will be taken. These tests will need to be 
normal for you to be enrolled in the study 
 All women will have a urinary pregnancy test  
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Please note – The screening blood tests will look at your blood counts (e.g. to check if 
you are anaemic), your liver function and your kidney function. We will also test your 
blood to see if you are infected with hepatitis B, hepatitis C or HIV, as these conditions 
can affect your body’s response to the vaccines we are assessing. If you test positive 
to any of these, we will let you know and offer to refer you for treatment. We may also 
report positive results to the appropriate health authority. 
Blood Donation: Under current UK regulations, volunteers will not be able to donate 
blood during the course of the study. 
Private Medical Insurance: If you have private medical insurance you are advised to 
contact your insurance company before participating in this trial, as involvement may 
affect the cover provided. 
Malaria Prophylaxis: If in future you travel to an area where malaria is common, you 
should not assume that the experimental vaccines you received in this study will give 
you any protection against malaria. Make sure you visit your GP or a travel clinic before 
travelling to a malaria endemic region and follow their advice on prevention measures. 
Contraception: It is currently unknown whether the vaccines being tested are safe 
during pregnancy. For this reason, it is important that all women use adequate 
contraception throughout the trial. If you were to become pregnant during the trial you 
must tell us immediately and you will be withdrawn from the study, although we will ask 
to follow you up for safety reasons. 
VACCINATIONS 
What are the vaccines that are being tested? 
We are testing two vaccines; ChAd63 RH5 and MVA RH5. These vaccines will be 
injected into the muscle of your upper arm(s). 
ChAd63 RH5 
ChAd63 RH5 is based on a virus (ChAd63) that has been genetically altered so that it 
is impossible for it to grow in humans. To this virus we have added a gene containing a 
protein from the malaria parasite called RH5. The malaria parasite needs this protein in 
order to get into red blood cells, which is when malaria makes people sick. We are 
hoping to make the body develop an immune response to this protein, in order to stop 
the malaria parasite from getting into blood cells. RH5 has not been given to humans 
before, but side effects from these types of vaccines are usually due to the viruses 
used rather than the proteins. We have given the virus with other genes for malaria 
proteins to over 1000 volunteers and it has been safe and well-tolerated. It can, 
however, cause some short-lived side effects as described below. 
MVA RH5  
MVA RH5 is based on a different virus (MVA) but contains the same malaria gene as 
the ChAd63 RH5 vaccine. We have given MVA carrying genes for other malaria 
proteins to over 1000 people with no serious side effects. It appears safe and well 
tolerated but can cause short-lived side-effects. 
What are the expected side effects from these vaccines? 
Once the vaccinations have been given they cannot be undone, so it is important 
you are clear of the potential risks of the vaccines before you agree to be involved in 
the study. 
These particular vaccines have not been used in humans before but we do not expect 
the side effects of these vaccines to be significantly different from previous trials where 
these viruses have been used with different malaria proteins. 
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 Injection site pain (most likely mild; however there is a chance this could be 
moderate or severe in intensity). MVA vaccines have tended to cause more 
reaction than ChAd63 vaccines in previous studies. 
 Redness, swelling, itching and warmth at the vaccine site (symptoms are likely 
to be mild if present). 
 A ‘flu-like illness within 24 hours of vaccination which usually resolves within 48 
hours. (This can include headache, muscle aches, joint aches, feverishness, 
tiredness and feeling generally unwell). The majority of general symptoms are 
likely to be mild but there is a possibility of moderate or severe symptoms 
occurring. 
 
It is important to remember these are vaccines in the early stage of development; 
therefore the amount of safety data available is limited. The malaria protein (RH5) has 
not previously been given to humans before, so there is a chance you could experience 
a side effect more severe than or different to those described. 
Severe Reactions 
With any vaccination there is a rare risk of serious reactions, which may be related to 
the nervous system or the immune system. Severe allergic reactions to vaccines 
(anaphylaxis) are very rare but can be fatal. Doctors qualified in the management of 
anaphylaxis will be present at each vaccination. Reactions in the nervous system are 
also extremely rare following vaccination, but can cause an illness called Guillain-Barré 
syndrome. Guillain-Barré syndrome is an illness in which people can develop severe 
weakness and may be fatal. However, these reactions have not previously been seen 
with the types of vaccines used in this study. If you experience unexpected symptoms, 
or become in any way concerned you should contact one of the Investigators (who are 
available 24 hours a day) using the emergency contact details that you will be given 
once you have been vaccinated. 
Vaccination days 
All women will have a urinary pregnancy test before each vaccination. We will ask you 
to wait for 1 hour after each vaccination to check there are no immediate problems. 
You will be assessed again before leaving and we will ask you to record your 
symptoms and measure any redness or swelling every day for 7 days after each 
vaccination. After these 7 days we will ask you to record if you feel unwell or take any 
medications over the next 3 weeks. 
We may ask to photograph your vaccination site. You will not be identifiable in these 
photographs and you can choose whether or not to agree to this when you sign the 
consent form. Photographs may be shown to other professional staff, used for 
educational purposes or included in a scientific or academic publication. 
Number, timing and purpose of visits 
You will receive either 1 or 2 vaccinations and attend between 8 and 12 visits in total, 
plus a final telephone call. Visits may include a medical assessment, temperature, 
pulse and blood pressure readings, examination by a doctor if needed and blood tests. 
All visits will take place at your local trial site – either the CCVTM in Oxford on the 
NIHR WTCRF in Southampton. During the course of the trial you may be asked to 
attend for an extra visit, for example, if a blood test needs to be repeated. You will be 
compensated for the time and inconvenience of any extra visits. 
You will be able to choose which group you are enrolled in, although as groups fill up 
there will be less choice. 
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The vaccination groups are summarised in the following table: 
Timeline for vaccinations 
 
 
 
Group 1 
 
Day 0 Day 
2 
Day 
14 
 
S 
            KEY 
 
    = Blood test 
 
S = Screening visit 
 
   = Telephone review 
Day 
28 
Day 
56 
Day 
84 
Vaccination: 
ChAd63 RH5 low dose 
Day 
7 
 
Day 
180  
Group 2A 
 
Day 0 Day 
2 
Day 
14 
Day 
 84 
 
Day 
140 
S 
Day 
28 
Day 
56 
Day 
63 
Vaccination:  
ChAd63 RH5 full dose 
Day 
7 
 
Day 
180 
Day 
10 
 
Group 2B 
 
Day 0 Day 
14 
Day 
 84 
Day 
140  
S 
Day 
28 
Day 
56 
Day 
58 
Day 
63 
First Vaccination: 
ChAd63 RH5 full dose 
Second Vaccination:  
MVA RH5 low dose 
Day 
2 
Day 
7 
 
Day 
240 
Day 
10 
 
Group Number Number 
of 
volunteers 
Dose ChAd63 RH5 
Day 0 
Dose MVA RH5 
Day 56 
1 4 Low dose --  
2 A 4 Full dose -- 
B 8 Full dose Low dose 
C 8 Full dose Full dose 
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OTHER INFORMATION 
Blood Tests 
We take blood tests as part of the screening visit and at the study visits in order for us 
to assess your general health, immune response to the vaccine and for safety reasons. 
The volume of blood taken at each visit ranges from 10 to 75 mL. If you would like 
them, we can give you the results of your blood tests. Anonymised blood samples will 
be stored after testing, and may be used in future malaria research. You will be asked 
to consent specifically for blood to be stored and shared with other researchers. 
Group 2 will have an additional blood test at day 10. Some cells from this blood may be 
used to produce specific antibodies with activity against malaria (known as ‘monoclonal 
antibodies’) in the laboratory. We will also use blood from other time-points for this 
work (e.g. 7 days after the boost vaccination). These antibodies will help us investigate 
the response to vaccination in greater detail and could be useful commercially in 
providing antibodies or products for preventing or treating malaria in the future. If this 
occurs there will be no financial or other benefit to participants who have provided the 
blood samples from which products are developed. 
To avoid repeated testing, if you are not enrolled into this study and apply to enter 
another study conducted by the Jenner Clinical Trials Group based at the CCVTM in 
Oxford, the screening blood results may be used in that study, where appropriate. 
Abnormal Results 
If abnormal results or undiagnosed conditions are found in the course of the study 
these will be discussed with you and, if you agree, your GP (or a hospital specialist, if 
more appropriate) will be informed. Any newly diagnosed conditions will be looked after 
within the NHS.  
Expenses and Payments 
You will be compensated for: 
o Travel expenses:   £10 per visit 
o Time required for visit:  £20 per hour  
o Inconvenience of blood tests:  £10 per blood donation 
 
Group 
No. 
Time in 
Trial 
(approx.) 
Number of Visits 
Number
. of 
Blood 
Tests 
Approximate 
Volume of Blood 
Taken 
1 6 months 
8 
(+ telephone review) 
7 400mL 
2A 6 months 
10 
(+ telephone review) 
10 530mL 
2B and 2C 8 months 
11 
(+ telephone review) 
10 570mL 
Group 2C 
 
Day 0 Day 
14 
Day 
 84 
Day 
140  
S 
Day 
28 
Day 
56 
Day 
58 
Day 
63 
First Vaccination: 
ChAd63 RH5 full dose 
Second Vaccination:  
MVA RH5 full dose 
Day 
2 
Day 
7 
 
Day 
240 
Day 
10 
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The total compensation for taking part in this study is between £360 and £540, 
depending on which group you are in. If you choose to leave the study early or are 
withdrawn from the study, you will be compensated according to the length of your 
participation based on these figures. Please note that if you do leave the study early it 
can take several weeks for your final payment to be made. You should note that 
compensation payments received in this trial may have an impact on your entitlement 
to benefits. 
What alternatives are present? 
At present, there is no malaria vaccine approved anywhere in the world. There are 
other malaria vaccines in various stages of development. This study may help develop 
an effective malaria vaccine. 
What are the possible benefits of taking part? 
This study will not benefit you, but the information gained from the study might help to 
prevent malaria infection and disease in those living in areas where malaria is common 
and in travellers to those areas. 
 
Will my taking part in the study be kept confidential?  
Yes. All the information about your participation in this study will be kept confidential. 
The details are included in Part 2. 
 
This completes Part 1 of the Information Sheet. If the information in Part 1 has 
interested you and you are considering participation, please continue to read 
the additional information in Part 2 before making any decision. 
Part 2 
What if relevant new information becomes available? 
Sometimes during the course of a trial, new information becomes available about the 
vaccine being studied. If this happens, we will tell you about it and discuss whether you 
want to or should continue in the study. If you decide to continue to take part you will 
be asked to sign an updated consent form. On receiving new information, we may 
consider it to be in your best interests to withdraw you from the study. 
What will happen if I don’t want to carry on with the study? 
If, at any time after agreeing to participate you change your mind about being involved 
with this study, you are free to withdraw without giving a reason. Unless you state 
otherwise, any blood taken whilst you have been in the study will continue to be stored 
and used for research as detailed above. You are free to request that your blood 
samples are destroyed at any time during or after the study. 
What if there is a problem? 
The University of Oxford, as Sponsor, has appropriate insurance in place in the 
unlikely event that you suffer any harm as a direct consequence of your participation 
in this trial. 
The investigators recognise the important contribution that volunteers make to 
medical research, and make every effort to ensure your safety and well-being. In the 
unlikely event of harm being suffered, while the University will cooperate with any 
claim, you may wish to seek independent legal advice to ensure that you are 
properly represented in pursuing any complaint. At any time during the study you will 
be entirely free to change your mind and withdraw from the study. This will not affect 
your subsequent medical care in any way. 
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Complaints statement 
If you wish to complain about any aspect of the way in which you have been 
approached or treated during the course of this study, you should contact your local 
trial team (contact details at the end of this document) or you may contact the 
University of Oxford Clinical Trials and Research Governance (CTRG) office on 
01865 572224 or the head of CTRG, email ctrg@admin.ox.ac.uk. 
Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the research will be 
coded with a study number and kept confidential. The information is available to the 
study team, safety monitors, ethical review committee, Sponsors, government 
regulatory agencies and external monitors who can ask to audit or monitor the study. 
Any information about you that leaves the hospital or clinic will have your name and 
address removed so that you cannot be identified from it. Your information is stored 
electronically on a secure server and any paper notes are kept in a locked filing 
cabinet. 
Involvement of the General Practitioner/Family doctor (GP) 
In order to enrol into this study, you will be required to sign a form, documenting that 
you consent for us to contact your GP. This is to inform them that you are interested in 
being involved in the study and to check there are no medical reasons that they are 
aware of why your participation would be unadvisable. The researchers will not enrol 
you in the trial if they have any concerns about your eligibility or safety. We will write to 
your GP to let them know whether or not you are finally enrolled in the study, and 
whether or not you completed the study, so they can update your medical records 
accordingly. 
Prevention of ‘Over Volunteering’ 
Volunteers participating in this study must not be involved in another study at the same 
time. In order to check this, you will be asked to provide your National Insurance or 
Passport number. This will be entered on to a national database which helps prevent 
volunteers from taking part in too many clinical trials. More information can be found at 
www.tops.org.uk. Your national insurance or passport number is also required to allow 
processing of compensation payments. 
What will happen to any samples I give? 
If you consent, some of your leftover blood samples will be stored and may be used for 
further studies of the human body’s immune response. Any such tests will have an 
appropriate ethical review. Upon your request at any time, your remaining blood 
samples will be destroyed. Your participation in this study will not be affected by your 
decision whether to allow storage and future use of your leftover samples.   
Your study visit blood tests will be analysed in the hospital laboratories and Oxford 
University research laboratories. Other blood tests to look at the response of your body 
to the vaccine may be done with collaborating laboratories in other countries. Any 
samples or data sent to them would be anonymous.  
Will any genetic tests be done?   
Yes. Some blood may be used to look at the pattern of your genes that can affect the 
immune system (for example ‘human leukocyte antigen [HLA] type). The immune 
response to vaccines is in part genetically controlled, so knowing your pattern of genes 
that regulate immune responses may help us to understand the responses to 
vaccination. You can opt out of ‘genetic tests’ if you wish, without any effect on your 
participation in the trial.  
What will happen to the results of the research study? 
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The results of this research study may be presented at scientific meetings or 
conferences and published in a scientific medical journal. This may not happen until 1 
or 2 years after the study is completed. If you contact the researchers in the future you 
can obtain a copy of the results. You will not be identified in any report or publication.  
The anonymised data from this study will be shared with the collaborating partners 
who are organising and funding this research work, including the pharmaceutical 
company GlaxoSmithKline (GSK). Data from this study may be used to file patents, 
licence vaccines in the future or make profits in other ways. You will not be paid for 
any part of this. Data from this study may be used as part of a student post-graduate 
degree, for example a MD or PhD.  
Who is sponsoring, organising and funding the research? 
The study is sponsored by the University of Oxford and funded by European 
Commission funding. 
The study is organised by a research team at The Jenner Institute at the University of 
Oxford, headed by Dr Simon Draper. Neither your GP, nor the researchers are paid for 
recruiting you into this study. 
Who has reviewed the study?  
This study has been reviewed by Oxford Research Ethics Committee A and has been 
given a favourable ethical opinion. The Medicines and Healthcare products Regulatory 
Agency (MHRA) which regulates the use of all medicines in the UK has reviewed the 
study design and has granted permission to use these unlicensed vaccines in this 
clinical study. 
 
Thank you for reading this information sheet. If you are interested in taking 
part in the study please contact the study team at your local study site to 
arrange a screening appointment.  
Contact details for further information: 
 
Recruitment Co-ordinator 
Tel: 01865 857406 
Email: vaccinetrials@ndm.ox.ac.uk  
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Appendix 2: Participant consent forms 
VAC051 Consent form v2.0 
 
A phase Ia study to assess the safety and immunogenicity of new 
Plasmodium vivax malaria vaccine candidate ChAd63 PvDBP alone and 
with MVA PvDBP 
 
Chief Investigator: Prof AVS Hill Study Code: VAC051 
NRES Committee South Central - Oxford A ref number: 13/SC/0001 
 
  Please initial 
1 I confirm that I have read and understand the Volunteer Information Sheet, Version_____, 
dated __________________ for the above study. I have I have spoken 
to__________________________________ and had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
1…………… 
2 I agree to have blood tests for this study, including testing for HIV and Hepatitis B and C. 2………….. 
3 I agree that my blood samples are a gift to the University of Oxford and I understand I will 
not gain any direct personal benefit from these. 
3………….. 
4 I agree that blood tests looking at the immune response to vaccination, including some 
genetic tests, can be carried out. 
(Participation in this study will not be affected by your decision to allow or not allow genetic tests to 
be carried out) 
4………….. 
5 I agree that some of my leftover blood samples will be stored indefinitely and 
that my stored blood may be used for further ethically approved studies of the 
body’s immune response to malaria vaccination and malaria. I understand 
that I can ask for these to be destroyed at any time. 
(Participation in this study will not be affected by your decision to allow or not allow storage and 
future of blood samples) 
5………….. 
6 I agree that samples may be passed in an anonymised form to research collaborators, 
including collaborators in other countries. 
6………….. 
7 I agree to abstain from donating blood for the duration of the study 7………….. 
8 I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
8………….. 
9 I give permission for relevant sections of any of my medical notes and data collected 
during the study to be looked at by responsible individuals from regulatory authorities and 
the University of Oxford, and Clinical Trials Research Governance (CTRG) for the 
purposes of audit. 
9………….. 
10 I understand that I will be given live (attenuated) viral vector vaccine(s) during the course 
of this study. 
10………… 
11 I agree to my GP being contacted and being asked to share information about my medical 
history and give access to any other medical records as required. 
11………… 
Malaria Vaccine Trials 
Centre for Clinical Vaccinology and Tropical Medicine 
University of Oxford  
Churchill Hospital 
Old Road, Headington 
Oxford OX3 7LE 
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12 I agree to my details being registered with and checked against a confidential national 
database (TOPS) to prevent me taking part in more than one trial at a time. 
12………… 
13 I have received enough information about the vaccine and follow up schedule. 13………… 
14 Women only: I agree to use effective contraception for the whole study and understand 
that I will be required to have pregnancy tests at regular intervals during the trial. 
14………… 
15 I agree to allow photographs of the injection site(s) to be taken for clinical comparison. I 
understand I will not be identifiable in these photographs other than by my unique study 
number. 
15………… 
16 I agree to take part in this study. 16………… 
 
 
 
Signature of Volunteer:      Date:    
 
 
Name of Volunteer:     
(in block letters) 
 
 
Signature of Investigator:      Date:    
 
 
Name of Investigator:    
 
(in block letters)                                                            When completed 1 for volunteer, 1 for research file, (both 
original signatures) 
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VAC054 Consent form v2.0 (Oxford) 
 
A Phase I/IIa Study of the Safety, Immunogenicity and 
Efficacy of FMP2.1/AS01B, an Asexual Blood-Stage 
Vaccine for Plasmodium falciparum Malaria  
APPROVED 
Jan 30, 2014 
WIRB

 
 
Chief Investigator: Prof AVS Hill 
E-mail: vaccinetrials@ndm.ox.ac.uk 
Tel: 01865 857401 
Study Code: VAC054 
REC REF : 13/SC/0596 
 
Subject ID:__________  
 
Study Procedures Please initial  
1. I confirm that I have read and understand the Information Sheet pertaining to 
VAC054 Version_____, Dated______________ and have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily. 
 
 
1.............. 
 
2. I have spoken to (name of investigator): 
_____________________________________.  2.............. 
 
3. I agree to have blood tests as part of this trial including testing for HIV, 
Hepatitis B & C,  cytomegalovirus (CMV) and Epstein-Barr Virus (EBV). 
 
3.............. 
 
4. Group 1 only: I understand that I will be given three injections of an 
investigational protein-in-adjuvant malaria vaccine.  
 
4.............. 
N/A 
□ 
5.  I understand that I may develop local and/or general 
13
symptoms after 
vaccination. 5.............. 
 
6.  I understand I will be given blood containing malaria parasites during this trial 
with the intention of giving me malaria. 
 
6.............. 
 
7. I understand that there is potentially a very small risk of acquiring a blood-
borne infection, including EBV or CMV (the viruses that most commonly cause 
glandular fever).  7.............. 
 
8. I understand that I may develop symptoms of malaria which may be severe. 8..............  
9. I understand that I will not be able to donate blood in the UK again. 9..............  
10. I have received enough information about the challenge procedure, the 
follow-up schedule and the proposed anti malarial therapies. 
 
10.............. 
 
Personal Information   
11. I agree to my GP being contacted and being asked to share information 
about my medical history and give access to any other medical records as 
required. 
 
11............. 
 
12. I agree to my details being registered with and checked against a confidential 
national database (TOPS) to prevent me taking part in more than one trial at a 
time.  
 
12............. 
 
13. I give permission for relevant sections of any of my medical notes and data 
collected during the study to be looked at by responsible individuals from the 
study group, regulatory authorities, collaborators, the University of Oxford and 
the external monitor for the purposes of audit. 
 
 
 
13.............. 
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14. I agree that investigators may speak to my nominated contact, next of kin, 
the police and national media if I fail to attend for follow up after being infected 
with malaria. 
 
14............. 
 
Withdrawing from the study   
15. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or 
legal rights being affected.  
 
15............. 
 
16. If I should wish to withdraw from the trial after I have been infected with 
malaria, I understand that I must take a course of anti-malarial medication, and 
that I will be asked to attend for review on at least 2 further days for safety 
reasons.  
 
 
16............. 
 
17. I understand that should I fail to return for review as outlined in the 
volunteer Information sheet that I may become seriously ill and die.  17............. 
 
18. I understand that if I withdraw my consent, the blood samples collected 
before my withdrawal will be used unless I specifically request otherwise. 18............. 
 
Contraception   
19. Women: I understand the crucial need to use an effective method of birth 
control for the whole study and that I will be required to have pregnancy tests at 
regular intervals during this trial.  I understand that Riamet may temporarily 
reduce the effectiveness of hormonal contraceptives, and the need to use an 
additional form of contraception while taking Riamet and until the start of the 
next menstruation after Riamet treatment. 
 
 
19............. 
N/A 
□ 
Consent   
20. I agree to take part in this study.  20.............  
The following are optional, answering "No" to any or all will not affect your 
ability to participate in the study.  
 
21. To avoid repeated testing, I agree that if I am not enrolled into this study and 
apply to enter another study conducted by the Jenner Clinical Vaccine Trials 
Group based at the CCVTM, my screening blood results may be used in that 
study, where appropriate. 
 
 
21............. 
No 
□ 
22. I agree that my leftover blood samples will be a gift to the University of 
Oxford, where they may be stored in accordance with the Human Tissue Act 
2004 indefinitely.  
 
22............. 
□ 
23. I understand that my samples will be identifiable only by a unique ID number 
and I will not be identifiable to researchers. 
 
23............. 
□ 
24. I agree that my stored blood samples may be used for further studies of the 
body’s immune response to malaria in future ethically approved research. 
 
24............. 
□ 
25. I agree that my leftover blood samples may also be shared with other 
collaborating study teams based within the United Kingdom. 
 
25…………… 
□ 
26. I agree that my leftover blood samples may also be shared with other 
collaborating study teams based in the European Union, United States of 
America and with responsible institutions around the world. 26............. 
□ 
27. I understand I am able to withdraw consent for the storage and use of 
samples at any time. 
 
27............. 
□ 
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Signature of 
Volunteer:............................................................Name:.................................................Date:
............................  
 
Signature of 
Investigator:.........................................................Name:.................................................Date:
............................  
 
When completed 1 for volunteer, 1 for research file, (both original signatures) 
28. I agree to allow photographs to be taken for clinical comparison, and I 
understand I will not be identifiable in these photographs other than by the 
unique study number.  
 
28............. 
□ 
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VAC057 Consent form v3.0 (Oxford) 
 
A Phase Ia clinical trial to assess the safety and immunogenicity of new 
Plasmodium falciparum malaria vaccine candidates ChAd63 RH5 alone and with 
MVA RH5 
Chief Investigator: Prof AVS Hill Study Code: VAC057 
NRES Committee South Central - Oxford A ref number: 14/SC/0120 
 
 
 
 
Please 
initial/tick 
1 I confirm that I have read and understand the Participant Information Sheet, Version_____, dated 
__________________ for the above study. I have spoken 
to__________________________________ and had the opportunity to consider the information, 
ask questions and have had these answered satisfactorily. 1…………… 
2 I agree to have blood tests for this study, including testing for HIV and Hepatitis B and C. 2………….. 
3 I agree that my blood samples are a gift to the University of Oxford, to be used for looking at the 
immune response to vaccination, and I understand I will not gain any direct personal benefit from 
these. 3………….. 
4 I agree that blood tests looking at the immune response can include some genetic tests. 
(Participation in this study will not be affected by your decision to allow or not allow genetic tests to be carried 
out) 
4 Yes □ 
   No  □ 
5 I agree that some of my leftover blood samples will be stored indefinitely and that my 
stored blood may be used for further ethically approved studies of the body’s immune 
response to malaria vaccination and malaria. I understand that I can ask for these to be 
destroyed at any time. 
(Participation in this study will not be affected by your decision to allow or not allow storage and future of blood 
samples.) 5………….. 
6 I agree that cells from my blood may be used to produce specific antibodies (‘monoclonal 
antibodies’) which could be used in commercial activity in the future. I understand that I will not gain 
any direct personal benefit from this. 6………….. 
7 I agree that samples may be passed in a coded form to research collaborators, including 
collaborators in other countries. 7………….. 
8 I agree that coded data may be passed on to other organisations, which may include commercial 
organisations. 8………….. 
9 I agree to abstain from donating blood for the duration of the study. 9………….. 
10 I understand that my participation is voluntary and that I am free to withdraw at any time, without 
giving any reason, without my medical care or legal rights being affected. 10………… 
11 I give permission for relevant sections of any of my medical notes and research data collected during 
the study to be looked at by responsible individuals from regulatory authorities, the University of 
Oxford, and University Hospital Southampton NHS Foundation Trust for the purposes of audit and 
monitoring. 11………… 
12 I understand that I will be given live (attenuated) viral vector vaccine(s) during the course of this 
study. 12………… 
13 I agree to my GP being contacted and being asked to share information about my medical history 
and give access to any other medical records as required. 13………… 
14 I agree to my details being registered with and checked against a confidential national database 
(TOPS) to prevent me taking part in more than one trial at a time. 14………… 
 
E-mail: vaccinetrials@ndm.ox.ac.uk 
Tel: 01865 857401 
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15 Women only: I agree to use effective contraception for the whole study and understand that I will be 
required to have pregnancy tests at regular intervals during the trial. 15………… 
16 I agree to allow photographs of the injection site(s) to be taken for clinical comparison. I understand 
I will not be identifiable in these photographs other than by my unique study number. 16 Yes □ 
     No  □ 
17 I agree to take part in this study. 17………… 
 
Signature of Volunteer:     Date:    
 
Name of Volunteer:     
(in block letters) 
 
Signature of Investigator:     Date:    
 
Name of Investigator:    
(in block letters)                                                             
When completed 1 for volunteer, 1 for research file, (both original signatures) 
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Appendix 3: VAC054 Informed Consent Questionnaire v1.0 
Professor Adrian V.S. Hill (DM 
FRCP) 
 
E-mail: vaccinetrials@ndm.ox.ac.uk 
 
Tel: 01865 857401 
 
  
 
 
REC REF : 13/SC/0596 
 
 
A study to assess the safety and effectiveness of an experimental 
malaria vaccine by infecting vaccinated volunteers with malaria 
parasites using malaria-infected red blood cells 
 
A Phase I/IIa Study of the Safety, Immunogenicity and Efficacy of FMP2.1/AS01B, an 
Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria (VAC054)    
INFORMED CONSENT QUESTIONNAIRE 
This questionnaire is designed to test your understanding of the study in order for us to be 
confident that you fully understand what taking part will involve. Please make sure you 
have read the information sheet in full and asked the Investigator any questions you have. 
You need to answer all questions correctly in order to take part in the study. If you don’t 
answer all the questions correctly the first time, you will be able to complete the 
questionnaire again after discussion with the Investigator. 
 
Volunteer Name:.…………………………………… 
Volunteer Trial Number:…..…………..…..……. 
Date……………..……Time.…………. 
Attempt Number………. of ………… 
 
Please clearly circle one answer for each question; 
 
1. By participating in this study you may develop which of the following:  
A. Tuberculosis 
B. Malaria 
C. Typhoid 
 
2. The study involves volunteers being given malaria by: 
A. Intramuscular injection 
B. Mosquito bite 
C. Transfusion of infected red blood cells 
 
3. Is it likely that a single treatment course will be effective to treat malaria in this study? 
A. Yes 
B. No 
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4. Medical screening for this study will include which of the following? 
A. Laboratory tests (including an HIV test) 
B. Physical examination 
C. Review of medical history 
D. All of the above 
E. None of the above 
 
5. If you wish to withdraw from the study you may: 
A. Withdraw voluntarily at any time provided you complete a course of anti-malarial 
therapy (if needed) 
B. Withdraw from the study only if the investigators say it is ok 
C. Never withdraw from the study 
 
6. Which of the following are true regarding pregnancy and participation in this study? 
A. Pregnant women may participate in this study 
B. Women should not get pregnant for 12 months after getting malaria 
C. An effective method of birth control is required for women while participating in this 
study 
 
7. What are common symptoms associated with malaria infection? 
A. Fever 
B. Chills 
C. Headache 
D. All of the above 
E. None of the above 
 
8. If you develop any concerning symptoms in between clinic visits after being given 
malaria, what should you do? 
A. Wait until your next clinic appointment 
B. Call the 24hr emergency phone number and talk to the trial doctor 
C. Ask a friend for advice 
 
9. What will happen if you fail to attend a follow-up visit after being given malaria?  
A. The police may be informed 
B. Your next of kin may be contacted 
C. Your identity may be given to the press 
D. All of the above 
 
10. How is malaria diagnosed in the study? 
A. Looking at a sample of blood under a microscope 
B. Chest X-ray 
C. Having you walk on a treadmill 
 
11. If you develop malaria, we will: 
A. Treat you immediately with effective medications 
B. See how sick you can get without treating you 
 
12. If you take part in this study, for how long will you be unable to donate blood? 
A. 1 year 
B. 2 years 
C. Never able to donate blood again 
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13. In the follow-up period when you may be diagnosed with malaria, which of the 
following is true? 
A. You must remain in Oxford and the surrounding area 
B. You must be contactable by the study team at all times 
C. You must be able to attend clinic at short notice 
D. All of the above 
 
 
_____________________________________________________________ 
Volunteer signature / date 
 
 
Score: ___/13  Reviewer signature / 
date_________________________________________ 
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Appendix 4: Schedules of attendance 
VAC051 Schedules of attendance 
VAC051: Schedule of attendances for Group 1 
(Windows refer to time since last visit rather than time since scheduled attendance). S = 
screening visit; (x) = If considered necessary; * Biochemistry will include Sodium, Potassium, 
Urea, Creatinine, Albumin, Liver Function Tests; & ^ Physical observations includes blood 
pressure, pulse and temperature. 
$
Exploratory immunology will include PvDBP IFN-γ T cell 
ELISPOT, B cell ELISPOT, and PvDBP antibody ELISA; anti-adenovirus antibodies may be 
measured from serum at a later date.           
 
 
 
S 
ChAd63 
PvDBP 
   
 
 
Attendance number 1 2 3 4 5 6 7 
Timeline (days)  0 2 14 28 56 84 
Window (days)   ±1 ±2 ±7 ±7 ±7 
Inclusion / Exclusion criteria X       
Informed consent X       
Medical History X (x) (x) (x) (x) (x) (x) 
Physical Examination^ X (x) (x) (x) (x) (x) (x) 
Urinalysis  X       
B-HCG urine test (♀) X X      
Review contraindications X X      
Vaccination  X      
Physical observations X X X X X (x) (x) 
AEs reviewed  X X X X X X 
Diary cards provided  X      
Diary cards collected    X    
HLA typing (mL)  4      
HBV,HCV,HIV (mL) 5       
Haematology (mL) 2   2 2 2 2 
Biochemistry (mL)* 3   3 3 3 3 
Exploratory immunology(/ 
serology)
$
 
 60  60 60 60 60 
Blood volume per visit (mL) 10 64  65 65 65 65 
Cumulative blood volume 
(mL) 
10  74 74 139 204 269 334 
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VAC051 Schedule of attendances for Group 2A 
(Windows refer to time since last visit rather than time since scheduled attendance). S = 
screening visit; (x) = If considered necessary; * Biochemistry will include Sodium, Potassium, 
Urea, Creatinine, Albumin, Liver Function Tests; & ^ Physical observations includes blood 
pressure, pulse and temperature. 
$
Exploratory immunology will include PvDBP IFN-γ T cell 
ELISPOT, B cell ELISPOT, and PvDBP antibody ELISA; anti-adenovirus antibodies may be 
measured from serum at a later date. 
 
 
S 
ChAd63 
PvDBP 
    
   
Attendance number 1 2 3 4 5 6 7 8 9 
Timeline (days) ≥-90 0 2 14 28 56 63 84 140 
Window (days)  0 ±1 ±2 ±7 ±7 ±7 ±7 ±14 
Inclusion / Exclusion 
criteria 
X X        
Informed consent X (X)        
Medical History X (X) (X) (X) (X) (X) (X) (X) (X) 
Physical Examination X (X) (X) (X) (X) (X) (X) (X) (X) 
Urinalysis X         
Β-HCG urine test (♀) X X        
Review 
contraindications 
X X        
Vaccination  X        
Physical observations X X X X X (X) (X) (X) (X) 
AEs reviewed  X X X X X X X X 
Diary cards provided  X        
Diary cards collected    X      
HLA typing (mL)  4        
HBV,HCV,HIV (mL) 5         
Haematology (mL) 2   2 2 2 2 2 2 
Biochemistry (mL) 3   3 3 3 3 3 3 
Exploratory 
immunology(/serology)
$
 
 60  60 60 60 60 60 60 
Blood volume per visit 
(mL) 
10 64  65 65 65 65 65 65 
Cumulative blood 
volume (mL) 
10 74  139 204 269 334 399 464 
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VAC051 Schedule of attendances for Groups 2B and 2C 
(Windows refer to time since last visit rather than time since scheduled attendance). S = 
screening visit; (x) = If considered necessary; * Biochemistry will include Sodium, Potassium, 
Urea, Creatinine, Albumin, Liver Function Tests; & ^ Physical observations includes blood 
pressure, pulse and temperature. 
$
Exploratory immunology will include PvDBP IFN-γ T cell 
ELISPOT, B cell ELISPOT, and PvDBP antibody ELISA; anti-adenovirus antibodies may be 
measured from serum at a later date. 
 
S 
ChAd63 
PvDBP 
   
MVA 
PvDBP 
 
   
Attendance number 1 2 3 4 5 6 7 8 9 10 
Timeline  
(days) 
 0 2 14 28 56 58 63 84 140 
Window (days)   ±1 ±2 ±7 ±7 ±1 ±2 ±7 ±14 
Inclusion / Exclusion 
criteria 
X X    X     
Informed consent X (X)    (X)     
Medical History X (X) (X) (X) (X) (X) (X) (X) (X) (X) 
Physical Examination X (X) (X) (X) (X) (X) (X) (X) (X) (X) 
Urinalysis  X          
Β-HCG urine test (♀) X X    X     
Review 
contraindications 
X X    X     
Vaccination  X    X     
Physical observations X X X X X X X X X (X) 
AEs reviewed  X X X X X X X X X 
Diary cards provided  X    X     
Diary cards collected    X    X   
HLA typing (mL)  4         
HBV,HCV,HIV (mL) 5          
Haematology (mL) 2   2 2 2  2 2 2 
Biochemistry (mL) 3   3 3 3  3 3 3 
Exploratory 
immunology(/serology)
$
 
 60  60 60 60  70 60 60 
Blood volume per visit 
(mL) 
10 64  65 65 65  75 65 65 
Cumulative blood 
volume (mL) 
10 74  139 204 269  344 409 474 
293 
 
VAC054 Schedules of attendance 
 S 
FMP2.1/
AS01B (1) 
   
FMP2.1/
AS01B (2)  
  
FMP2.1/
AS01B (3)  
 C-1 C C+1 C+2-12 
(Day of 
diagnosis) C+13-23 C+28 C+90 C+170 
Attendance number  1 2 3 4
 
5 6 7 8 9
 
10 11 12 13 14 15 16-37  38-48 49 50 51 
Timeline (days)  0 3 7 14 28 31 35 42 56 59 63 69 70 71 
72-82 
(AM+PM) 
 83-93 98 160 240 
Window (days) (-90)  ±1 ±2 ±2 
 
±1 ±2 ±2  ±1 ±2   0 0  0 ±3 ±7 ±14 
Inclusion / Exclusion 
criteria 
X X    X 
 
  X 
 
  X        
Informed Consent 
Questionnaire 
X                     
Informed consent X                     
Medical History X (x) (x) (x) (x) (x) (x) (x) (x) (x) (x) (x) (x) (x)        
Physical Examination X (x) (x) (x) (x) (x) (x) (x) (x) (x) (x) (x) (x) (x)        
Urinalysis X                     
Electrocardiogram X (X)                    
β-HCG urine (♀) X X    X 
 
  X 
 
 X    X     
Review 
contraindications 
X X    X    X 
 
 X X        
Vaccination  X    X    X            
Physical Observations^ X X X X X X X X X X X X X X X X X X X X  
AEs reviewed  X X X X X X X X X X X X X X X X X X X (x)
$
 
Diary card provided  X    X 
 
  X    X        
Diary card collected    X    X 
 
  X       X   
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 S 
FMP2.1/
AS01B (1) 
   
FMP2.1/
AS01B (2)  
  
FMP2.1/
AS01B (3)  
 C-1 C C+1 C+2-12 
(Day of 
diagnosis) C+13-23 C+28 C+90 C+170 
Medic Alert Card Given 
to Volunteers 
             X        
Treatment for Malaria                 X (X)    
HLA typing (mL)  4                    
HBV,HCV,HIV (mL) 5                     
EBV,CMV (mL)             5       5  
Serum for storage             5       5  
Haematology (mL) 2 2  2 2 2  2 2 2  2 2   2
£
 2  2 2  
Biochemistry (mL)** 3 3  3 3 3  3 3 3  3 3   3
£
 3  3 3  
Immunology  60   60 60  10 60 60  10 70    70  60 60  
Blood Film / PCR           
 
 3  3 3 x 22 3 3 x 11    
Blood volume per visit 
(mL) 
10 69 0 5 65 65 0 15 65 65 0 15 88 0 3 71 78 33 65 75 0 
Cumulative blood 
volume (mL) 
10 79 79 84 149 214 214 229 294 359 359 374 462 462 465 536 614 647 712 787 787* 
S = screening visit, (x) = If considered necessary, emphasising any acute complaints. 
^ Physical observations includes blood pressure, pulse and temperature, height and weight, however height and weight will only be measured at screening and dC-1.  
$ 
The visit on day 240 may be conducted by telephone and will involve collection of information about any SAEs that have occurred since the C+90 visit. 
** Biochemistry will include Sodium, Potassium, Urea, Creatinine, Albumin, Liver Function Tests, Magnesium & Cholesterol, however Magnesium and cholesterol will only be 
measured at screening. 
£ 
Biochemistry and haematology bloods will be checked on day 6 post malaria challenge 
*Cumulative blood volume for Oxford volunteers if blood taken as per schedule, and excluding any repeat safety blood test that may be necessary. Southampton and Hammersmith 
volunteers may have a slightly higher cumulative volume due to use of higher volume vacutainers for biochemistry, haematology and serology samples as per local Trust standard 
procedures. The maximum cumulative volume for these volunteers would be up to 823mL. 
VAC054 Schedule of attendances for Group 1 (Windows refer to time since last visit, but windows between vaccinations must be a minimum of 21 days and a 
maximum of 35 days. The window between final vaccination and challenge must be a minimum of 14 days and maximum of 16 days). 
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 S C-1 C C+1 C+2-12 
(Day of 
diagnosis) 
C+13-23 C+28 C+90 
Attendance number  1 2 3 4 5-26  27-37 38 39 
Timeline (days)  -1 0 1 
2-12 
(AM+PM) 
 13-23 28 90 
Window (days) (-90) -2 0 0 0  0 ±3 ±7 
Inclusion / Exclusion criteria X X X       
Informed Consent Questionnaire X         
Informed consent X         
Medical History X (x) (x)       
Physical Examination X (x) (x)       
Urinalysis X         
Electrocardiogram X (X)        
β-HCG urine (♀) X X    X    
Review contraindications X X X       
Vaccination          
Physical Observations^ X X X X X X X X X 
AEs reviewed  X X X X X X X X 
Diary card provided   X       
Diary card collected        X  
Medic Alert Card Given to Volunteers   X       
Treatment for Malaria      X (X)   
HLA typing (mL)  4        
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 S C-1 C C+1 C+2-12 
(Day of 
diagnosis) 
C+13-23 C+28 C+90 
HBV,HCV,HIV (mL) 5         
EBV,CMV (mL)  5       5 
Serum for storage  5       5 
Haematology (mL) 2 2   2
£
 2  2 2 
Biochemistry** (mL) 3 3   3
£
 3  3 3 
Immunology  70   20 x 6
#
 70 20 x 4
#
 60 60 
Blood Film / PCR  3  3 3 x 22 3 3 x 11   
Blood volume per visit(s) (mL) 10 92 0 3 191 78 113 65 75 
Cumulative blood volume (mL) 10 102 102 105 296 374 487 552 627* 
S = screening visit, (x) = If considered necessary, emphasising any acute complaints. 
^ Physical observations includes blood pressure, pulse and temperature, height and weight, however height and weight will only be measured at screening and C-1.     
** Biochemistry will include Sodium, Potassium, Urea, Creatinine, Albumin, Liver Function Tests, Magnesium & Cholesterol, however Magnesium and cholesterol will only be 
measured at screening. 
£ 
Biochemistry and haematology bloods will be checked on day 6 post malaria challenge 
#
 Immunology blood to be taken at AM visits on days 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20 (but only until day of diagnosis) 
* Cumulative blood volume for Oxford volunteers if blood taken as per schedule, and excluding any repeat safety blood test that may be necessary. Southampton and Hammersmith 
volunteers may have a slightly higher cumulative volume due to use of higher volume vacutainers for biochemistry, haematology and serology samples as per local Trust standard 
procedures. The maximum cumulative volume for these volunteers would be up to 639mL 
 
VAC054 Schedule of attendances for Group 2 (Windows refer to time since last visit). 
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VAC057 Schedules of attendance 
VAC057 Schedule of attendances for Group 1. 
S = screening visit; (x) = If considered necessary;  
*Biochemistry will include Sodium, Potassium, Urea, Creatinine, Albumin, and Liver Function Tests. 
^ Physical observations include blood pressure, pulse and temperature. 
$
Exploratory immunology will include PfRH5 IFN-γ T cell ELISPOT, B cell assays, PfRH5 antibody ELISA, 
and functional antibody assays; anti-adenovirus antibodies may be measured from serum at a later date. 
**Cumulative blood volume for Oxford volunteers if blood taken as per schedule, and excluding any 
repeat safety blood test that may be necessary. Southampton volunteers may have a slightly higher 
cumulative volume due to use of higher volume vacutainers for biochemistry, haematology and serology 
samples as per local Trust standard procedures. 
 
 
S 
ChAd63 
RH5 
      
Telephone 
review 
Attendance number 1 2 3 4 5 6 7 8 9 
Timeline (days) ≤90 0 2 7 14 28 56 84 180 
Window (days; since 
last visit rather than 
since scheduled 
attendance) 
  ±1 ±1 ±2 ±7 ±7 ±7 ±14 
Inclusion / Exclusion 
criteria 
X        
 
Informed consent X         
Medical History X (x) (x) (x) (x) (x) (x) (x)  
Physical Examination^ X (x) (x) (x) (x) (x) (x) (x)  
Urinalysis  X         
B-HCG urine test (♀) X X        
Review 
contraindications 
X X       
 
Vaccination  X        
Physical observations X X X X X X (x) (x)  
AEs reviewed  X X X X X (x) (x)  
SAEs reviewed  X X X X X X X X 
Diary cards provided  X  (x)      
Diary cards collected    (x)  X    
HLA typing (mL)  4        
HBV,HCV,HIV (mL) 5         
Haematology (mL) 2 2  2  2    
Biochemistry (mL)* 3 3  3  3    
Exploratory 
immunology
$
 
 60 0 60 60 60 60 60  
Blood volume per visit 
(mL) 
10 69 0 65 60 65 60 60  
Cumulative blood 
volume (mL) 
10 79 79 144 204 269 329 389**  
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VAC057 Schedule of attendances for Group 2A 
S = screening visit; (x) = If considered necessary;  
*Biochemistry will include Sodium, Potassium, Urea, Creatinine, Albumin, and Liver Function Tests. 
^ Physical observations include blood pressure, pulse and temperature. 
$
 Exploratory immunology will include PfRH5 IFN-γ T cell ELISPOT, B cell assays, PfRH5 antibody ELISA, 
and functional antibody assays; anti-adenovirus antibodies may be measured from serum at a later date. 
**Cumulative blood volume for Oxford volunteers if blood taken as per schedule, and excluding any 
repeat safety blood test that may be necessary. Southampton volunteers may have a slightly higher 
cumulative volume due to use of higher volume vacutainers for biochemistry, haematology and serology 
samples as per local Trust standard procedures. 
 
 
S 
ChAd
63 
RH5 
         
Telephone 
review 
Attendance 
number 
1 2 3 4 5 6 7 8 9 10 11 12 
Timeline (days)  0 2 7 10 14 28 56 63 84 140 180 
Window (days; 
since last visit 
rather than since 
scheduled 
attendance) 
  ±1 ±1 ±1 ±2 ±7 ±7 ±2 ±7 ±14 ±14 
Inclusion / 
Exclusion criteria 
X            
Informed consent X (x)           
Medical History X (x) (x) (x) (x) (x) (x) (x) (x) (x) (x)  
Physical 
Examination^ 
X (x) (x) (x) (x) (x) (x) (x) (x) (x) (x)  
Urinalysis  X            
B-HCG urine test 
(♀) 
X X           
Review 
contraindications 
X X           
Vaccination  X           
Physical 
observations 
X X X X X X X (x) (x) (x) (x)  
AEs reviewed  X X X X X X (x) (x) (x) (x)  
SAEs reviewed  X X X X X X X X X X X 
Diary cards 
provided 
 X  (x)         
Diary cards 
collected 
   (x)   X      
HLA typing (mL)  4           
HBV,HCV,HIV 
(mL) 
5            
Haematology 
(mL) 
2 2  2   2      
Biochemistry 
(mL)* 
3 3  3   3      
Exploratory 
immunology
$
 
 60  60 20 60 60 60 60 60 60  
Blood volume per 
visit (mL) 
10 69 0 65 20 60 65 60 60 60 60  
Cumulative blood 
volume (mL) 
10 79 79 144 164 224 289 349 409 469 
529*
* 
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VAC057 Schedule of attendances for Groups 2B and 2C 
S = screening visit; (x) = If considered necessary;  
*Biochemistry will include Sodium, Potassium, Urea, Creatinine, Albumin, and Liver Function Tests. 
^ Physical observations include blood pressure, pulse and temperature. 
$
 Exploratory immunology will include PfRH5 IFN-γ T cell ELISPOT, B cell assays, PfRH5 antibody ELISA, 
and functional antibody assays; anti-adenovirus antibodies may be measured from serum at a later date. 
**Cumulative blood volume for Oxford volunteers if blood taken as per schedule, and excluding any 
repeat safety blood test that may be necessary. Southampton volunteers may have a slightly higher 
cumulative volume due to use of higher volume vacutainers for biochemistry, haematology and serology 
samples as per local Trust standard procedures. 
 
S 
ChAd63 
RH5 
     
MVA 
RH5 
    
Telephone 
review 
Attendance 
number 
1 2 3 4 5 6 7 8 9 10 11 12 13 
Timeline  
(days) 
 0 2 7 10 14 28 56 58 63 84 140 240 
Window (days; 
since last visit 
rather than since 
scheduled 
attendance) 
  ±1 ±1 ±1 ±2 ±7 ±7  ±1 ±7 ±14 ±14 
Inclusion / 
Exclusion criteria 
X X      X      
Informed consent X (X)      (X)      
Medical History X (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X)  
Physical 
Examination 
X (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) (X)  
Urinalysis  X             
Β-HCG urine test 
(♀) 
X X      X      
Review 
contraindications 
X X      X      
Vaccination  X      X      
Physical 
observations 
X X X X X X X X X X X (X)  
AEs reviewed  X X X X X X (x) X X X (x)  
SAEs reviewed  X X X X X X X X X X X X 
Diary cards 
provided 
 X  (X)    X  (X)    
Diary cards 
collected 
   (X)   X   (X) X   
HLA typing (mL)  4            
HBV,HCV,HIV 
(mL) 
5             
Haematology (mL) 2 2  2   2 2  2 2   
Biochemistry (mL) 3 3  3   3 3  3 3   
Exploratory 
immunology
$
 
 60  60 20 60 60 60  70 70 60  
Blood volume per 
visit (mL) 
10 69 0 65 20 60 65 65 0 75 75 60  
Cumulative blood 
volume (mL) 
10 79 79 144 164 224 289 354 354 429 504 
564*
* 
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Appendix 5: Participant diary cards 
Generic paper diary card (example page) 
 
301 
 
Generic eDiary screenshots 
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Appendix 6: Site-specific severity grading tables for laboratory 
adverse events 
GRADING OF LABORATORY ADVERSE EVENTS- OXFORD v1.0 
Severity grading criteria for clinically significant laboratory abnormalities; adapted from FDA 
guidelines (1) using Oxford University Hospitals NHS Trust laboratory reference ranges. 
Laboratory Test Grade 1 Grade 2 Grade 3 
Hgb (female) – gm/dL 
Ref range 12.0 – 15.0 
10.5 – 11.5 9.0 – 10.4 <9.0 
Hgb (male) – gm/dL  
Ref range 13.0 – 17.0 
11.5 – 12.5  10.0 – 11.4 <10.0 
WBC- elevated (x10*9/L) 
Ref range 4.0-11.0 
11.50 – 15.00  15.01 – 20.00 >20.0 
WBC- low (x10*9/L) 
Ref range 4.0-11.0 
2.50 – 3.50 1.50 – 2.49 <1.50 
Neutrophils decrease (x10*9/L) 
Ref range 2.0-7.0 
1.00 – 1.49 0.50 – 0.99 <0.50 
Lymphocytes decrease (x10*9/L) 
Ref range 1.0-4.0 
0.75 – 1.00 0.50 – 0.74 <0.50 
Eosinophils (x10*9/L) 
Ref range 0.0-0.5 
0.65 – 1.50 1.51 – 5.00 >5.00 
Platelets (x10*9/L) 
Ref range 150-400 
125 – 135 100 – 124 <100 
Bilirubin – when accompanied by any increase in 
Liver Function Test increase by factor  
Ref range 3-17 (umol/L) 
1.1 – 1.25 x ULN  >1.25 – 1.5 x 
ULN  
>1.5 – 1.75 x 
ULN  
Bilirubin- when LFTs normal; increase by factor 
Ref range 3-17 (umol/L) 
1.3 – 1.5 x ULN 1.6 – 2.0 x ULN >2.0 x ULN 
ALT, AST; increase by factor 
Ref range 10-45 (IU/L) 
1.25 – 2.5 x ULN >2.5 – 5.0 x 
ULN 
>5.0 x ULN 
Alkaline phosphate- increase by factor 
Ref range 95-280 (IU/L) 
1.1 – 2.0 x ULN 2.1 – 3.0 x ULN >3.0 x ULN 
Albumin- low (g/L) 
Ref range 35-50 
28 – 31 25 – 27 <25 
Creatinine  
Ref range 54-145 (umol/L) 
1.1–1.5  x ULN >1.6–3.0 x ULN >3.0 x ULN 
Urea (mmol/L) 
Ref range 2.5-6.7 
8.2 – 8.9 9.0 – 11.0 >11.0 
Sodium- elevated (mmol/L) 
Ref range 135-145 
146 – 147 148 – 149 ≥150 
Sodium- low (mmol/L) 
Ref range 135-145 
132 – 134 130 – 131 ≤129 
Potassium- elevated (mmol/L) 
Ref range 3.5-5.0 
5.1 – 5.2 5.3 – 5.4 ≥5.5 
Potassium- low (mmol/L) 
Ref range 3.5-5.0 
3.2 –3.3 3.0 – 3.1 ≤2.9 
1. FDA. Toxicity Grading Scale for Healthy Adult & Adolescent Volunteers Enrolled in 
Preventative Vaccine Clinical Trials
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GRADING OF LABORATORY ADVERSE EVENTS- SOUTHAMPTON v1.0 
Severity grading criteria for clinically significant laboratory abnormalities; adapted from FDA 
guidelines (1) using University Hospital Southampton NHS Foundation Trust laboratory 
reference ranges. 
Laboratory Test Grade 1 Grade 2 Grade 3 
Hgb (female) – gm/L 
Ref range 120 – 150 
105 – 115 90 – 104 <90 
Hgb (male) – gm/L  
Ref range 130 – 170 
115 – 125  100 – 114 <100 
WBC- elevated (x10*9/L) 
Ref range 4.0-11.0 
11.50 – 15.00  15.01 – 20.00 >20.0 
WBC- low (x10*9/L) 
Ref range 4.0-11.0 
2.50 – 3.50 1.50 – 2.49 <1.50 
Neutrophils decrease (x10*9/L) 
Ref range 2.0-7.5 
1.00 – 1.49 0.50 – 0.99 <0.50 
Lymphocytes decrease (x10*9/L) 
Ref range 1.5-4.0 
0.75 – 1.00 0.50 – 0.74 <0.50 
Eosinophils (x10*9/L) 
Ref range 0.0-0.5 
0.65 – 1.50 1.51 – 5.00 >5.00 
Platelets (x10*9/L) 
Ref range 150-400 
125 – 135 100 – 124 <100 
Bilirubin – when accompanied by any increase 
in Liver Function Test increase by factor  
Ref range 0-20 (umol/L) 
1.1 – 1.25 x ULN  >1.25 – 1.5 x ULN  >1.5 – 1.75 x 
ULN  
Bilirubin- when LFTs normal; increase by factor 
Ref range 0-20 (umol/L) 
1.2 – 1.5 x ULN 1.6 – 2.0 x ULN >2.0 x ULN 
ALT, AST; increase by factor 
Ref range 7-40 (IU/L) 
1.25 – 2.5 x ULN >2.5 – 5.0 x ULN >5.0 x ULN 
Alkaline phosphate- increase by factor 
Ref range 30-130 (IU/L) 
1.1 – 2.0 x ULN 2.1 – 3.0 x ULN >3.0 x ULN 
Albumin- low (g/L) 
Ref range 35-50 
28 – 31 25 – 27 <25 
Creatinine  
Ref range 53-97 (umol/L) 
1.1–1.5  x ULN >1.6–3.0 x ULN >3.0 x ULN 
Urea (mmol/L) 
Ref range 2.5-7.8 
8.2 – 8.9 9.0 – 11.0 >11.0 
Sodium- elevated (mmol/L) 
Ref range 133-146 
147 – 148 149 – 150 >150 
Sodium- low (mmol/L) 
Ref range 133-146 
131 – 132 129 – 130 <129 
Potassium- elevated (mmol/L) 
Ref range 3.5-5.3 
5.4 – 5.5 5.6 – 5.7 >5.7 
Potassium- low (mmol/L) 
Ref range 3.5-5.3 
3.2 –3.3 3.0 – 3.1 ≤2.9 
1. FDA. Toxicity Grading Scale for Healthy Adult & Adolescent Volunteers Enrolled in 
Preventative Vaccine Clinical Trials
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GRADING OF LABORATORY ADVERSE EVENTS FOR HAMMERSMITH 
HOSPITALS v1.1 
Severity grading criteria for clinically significant laboratory abnormalities; adapted from FDA 
guidelines (1) using Hammersmith Hospitals NHS Trust laboratory reference ranges. 
Laboratory Test Grade 1 Grade 2 Grade 3 
Hgb (female) – gm/L 
Ref range 130 – 168 
105 – 115 90 – 104 <90 
Hgb (male) – gm/L  
Ref range 130 – 168 
115 – 125  100 – 114 <100 
WBC- elevated (x10*9/L) 
Ref range 4.2-10.6 
11.50 – 15.00  15.01 – 20.00 >20.0 
WBC- low (x10*9/L) 
Ref range 4.2-10.6 
2.50 – 3.50 1.50 – 2.49 <1.50 
Neutrophils (x10*9/L) 
Ref range 2.0-7.1 
1.00 – 1.49 0.50 – 0.99 <0.50 
Lymphocytes Decrease (x10*9/L) 
Ref range 1.1-3.6 
0.75 – 1.00 0.50 – 0.74 <0.50 
Eosinophils (x10*9/L) 
Ref range 0.0-0.5 
0.65 – 1.50 1.51 – 5.00 >5.00 
Platelets (x10*9/L) 
Ref range 130-370 
110 – 120 95 – 109 <95 
Bilirubin – when accompanied by any increase 
in Liver Function Test increase by factor  
Ref range 0-21 (umol/L) 
1.1 – 1.25 x ULN  >1.25 – 1.5 x ULN  >1.5 – 1.75 x ULN  
Bilirubin- when LFTs normal; increase by 
factor 
Ref range 0-21 (umol/L) 
1.2 – 1.5 x ULN 1.6 – 2.0 x ULN >2.0 x ULN 
ALT, AST; increase by factor 
Ref range 0-40 (IU/L) 
1.25 – 2.5 x ULN >2.5 – 5.0 x ULN >5.0 x ULN 
Alkaline phosphate- increase by factor 
Ref range 30-130 (IU/L) 
1.1 – 2.0 x ULN 2.1 – 3.0 x ULN >3.0 x ULN 
Albumin- low (g/L) 
Ref range 35-50 
28 – 31 25 – 27 <25 
Creatinine  
Ref range 60-125 (umol/L) 
1.1–1.5  x ULN >1.6–3.0 x ULN >3.0 x ULN 
Urea (mmol/L) 
Ref range 2.5-7.8 
8.2 – 8.9 9.0 – 11.0 >11.0 
Sodium- elevated (mmol/L) 
Ref range 133-146 
146 – 147 148 – 149 ≥150 
Sodium- low (mmol/L) 
Ref range 133-146 
132 – 134 130 – 131 ≤129 
Potassium- elevated (mmol/L) 
Ref range 3.5-5.3 
5.4 – 5.5 5.6 – 5.7 ≥5.8 
Potassium- low (mmol/L) 
Ref range 3.5-5.3 
3.2 –3.3 3.0 – 3.1 ≤2.9 
1. FDA. Toxicity Grading Scale for Healthy Adult & Adolescent Volunteers Enrolled in 
Preventative Vaccine Clinical Trials
308 
 
Appendix 7: Standard Operating Procedures 
ML002: Malaria PBMC Separation and Freezing 
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ML006: Ex Vivo ELISPOT 
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ML026: DBP ELISA 
 
1 Purpose 
During malaria vaccine trials, the Enzyme-Linked ImmunoSorbent Assay (ELISA) is the 
primary assay for monitoring the antibody responses induced by vaccination in the 
serum of human volunteers. This SOP contains the detailed experimental protocol for 
performing this assay for the antigen Plasmodium vivax Duffy-Binding Protein 
(PvDBP). There are multiple alleles of the PvDBP antigen, but only one is tested in this 
ELISA assay: PvDBP_RII (Salvador I allele). This SOP details the experimental 
protocol for performing this assay for this allele of PvDBP. 
2 Introduction 
The aim of our clinical vaccine trials is to induce protection against malaria in human 
volunteers and characterize the cells and/or antibodies involved in inducing protective 
immune responses. One of the primary endpoints in Phase I and Phase II trials of 
blood-stage malaria vaccines is immunogenicity as measured by ELISA, which 
quantifies the level of antigen-specific antibodies in the serum of immunized volunteers. 
In this case, the PvDBP antigen was provided by Jing Jin. The ELISA protocol has 
been standardised according to published methods (see reference in section 8). This 
protocol uses a reference serum on each ELISA plate to detect antibodies induced by 
experimental malaria vaccines. 
 
Different types of controls are included; reference serum from a high responding 
volunteer is included on each ELISA plate to produce a standard curve which is used to 
quantify and assign ELISA units to each unknown sample on the plate; also an internal 
positive control sample and negative control / no serum (“blank wells”) are used to 
perform QC analysis on each ELISA plate.  
 
ELISA plates are coated over-night with PvDBP_RII. The assay is performed by 
preparing a standard curve and internal controls from the reference serum and adding 
these samples to the plate. Unknown test serum samples from immunized volunteers 
are diluted and added in triplicate to the ELISA plate. After a two hour incubation 
period, the diluted sera are discarded, the plate is washed and a secondary polyclonal 
antibody against the γ–chain of human IgG is added. This secondary antibody is 
conjugated to the enzyme alkaline phosphatase. After another hour of incubation, 
followed by a wash step, the alkaline phosphatase substrate is added. The substrate is 
left to develop for 15-20 min and the absorbance at 405nm is read using a plate reader. 
The result is obtained by taking an average of the triplicate wells for each test sample, 
and using the standard curve to assign DBP_RII ELISA arbitrary units (AU). 
 
3 Scope 
This SOP covers all serum samples taken from volunteers in PvDBP_RII blood-stage 
malaria vaccine trials in Oxford for which ELISA is one of the primary readouts. It does 
not cover booking in of samples to the laboratory, which is described in ML001 Malaria 
lab sample handling. 
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4 Definitions 
ELISA = Enzyme-Linked ImmunoSorbent Assay. 
5 Responsibilities 
All staff employed by the University of Oxford who work on the blood-stage malaria 
vaccine trials, including clinicians or visiting scientists working in the lab, must follow 
these protocols. 
 
The Senior Immunologist ensures that staff are competent to perform these 
procedures. 
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6 Procedure 
6.1 Equipment & Reagents 
Where appropriate, equipment and reagents used in the processing of samples from 
clinical trials is dedicated to study work. Equipment used forms part of the laboratory 
maintenance and monitoring plan. 
  
Equipment: 
Fridge at +4oC 
Freezer at -20oC and -80oC 
Vortex 
Eppendorf Racks 
Pipettes including 8- or 12-well multi-channel and automatic multi-channel 
Pipetteboy 
Bio-tek ELx800 Microplate Reader with Gen5 ELISA software v1.10 
Timer 
Sufficient tips for pipettes. 0.1-10μl, 2-20μl, 20-200μl, 100-1000μl 
Safety Glasses 
PBS-Tween Hand Washer 
Timer 
 
Consumables & Reagents: 
 
Reagent Company Cat # 
NUNC Immuno Plates (442404) Fisher DIS-971-030J 
Blocker Starting Block T20 in PBS Fisher 10270404 
Goat anti-human IgG (γ-chain)-alk phos Sigma A3187 
Dulbecco’s PBS (DPBS) Sigma D8537 
5x Diethanolamine Buffer Fisher 34064 
4-Nitrophenyl Phosphate Tablets (20mg) Sigma N2765 
Tween-20 Sigma P7949 
Aluminium Foil Fisher AKL-300-040J 
1.5mL Eppendorf tubes Fisher FB74031 
Reagent Reservoirs (Costar 4870) Fisher PMP-331-010C 
10L PBS powder Invitrogen 21600-069 
 
Recombinant Protein Antigen:   
The recombinant protein antigen required for this SOP is: PvDBP (Salvador I allele) 
The PvDBP protein is provided by Jing Jin. It is stored in small aliquots (typically 
enough to coat two ELISA plates) at -20ºC in the human immunology freezer until 
needed. Coating antigen concentration is standard at 2µg/ml. 
Reference Serum: 
VAC051 Volunteer 028 day 84 serum is stored in the Equipment Bay MVT -80oC 
freezer. 
 
Buffers and Solutions:   
Make up buffer and solutions as follows: 
PBS/T (PBS with 0.05% Tween) for washing plates. Dissolve 10L PBS tub in 
10L deionised water (15.0 MΩ setting). Add 5mL Tween-20. Shake and return 
to the ELISA plate wash station. 
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6.2 Day 1: Coating ELISA plates on the bench.  
1. Print off a new MVT ELISA record sheet for each experiment. Number the 
experiment with the next experiment number and fill this in with the required 
information throughout the experiment. The next available experiment number can 
be found in the Excel spreadsheet contained in the same folder. Sign off the 
experiment number in the spreadsheet and re-save the file. Sheets can be found at: 
 
V:\1.Malaria\1. Master Files\5. Lab general trial info\Blood-Stage MVT\ Templates & 
Record Sheets 
 
2. Calculate the number of Nunc Immuno ELISA plates required (max number of 22 
test samples per plate). Thaw an aliquot of the recombinant antigen required. Make 
the coating solution by adding recombinant antigen to DPBS at a final concentration 
of 2µg/mL. Working on the bench, add 50 µl per well of the coating solution to the 
ELISA plate using a multi-channel pipette. Store the plates at 4°C (≥16 h), wrapped 
in cling film. Note time of coating and record on the experiment layout sheet.  
6.3 Day 2: Blocking plates.  
 
1. Bring Starting Block T20 to RT for >30mins and flick off the coating solution into 
the sink (wear eye protection). 
 
2. Wash the plates 6x in PBS/T using the handheld washer. 
 
3. Block the wells with 200 µL per well of Starting block T20 blocking buffer.  
 
4. Stack the plates (with an empty blank plate on top) and cover in foil. Leave for 1h 
(max 1h 30min) at RT. Note time of blocking and record on the experiment sheet. 
 
5. During blocking prepare test samples and reference standard dilutions as below.  
 
6.4 Sample Preparation 
 
i) Standard Curve 
 
1. Prepare dilutions of Volunteer 028 day 84 reference serum in Starting block T20 
Block buffer: 
 
Take the serum and prepare one 1:100 dilution in an eppendorf tube: add 9µL to 
891µL of blocking buffer. Label 1. Vortex to mix. 
 
Prepare a dilution curve in eppendorf tubes. To make a 1:3 dilution set (enough for 4 
ELISA plates): 
  
1. Add 600µL of Starting block T20 block to nine eppendorfs labelled 2-10.  
2. Add 300µL of the first dilution 1 to tube 2. Vortex to mix. 
3. Add 300µL of 2 to tube 3. Vortex to mix. And so on, repeat this through to tube 
10. 
4. Each tube should now contain 600µL of liquid (except 10 which contains 900µL), 
with a 3-fold dilution series running from tube 1 to 10. 
 
ii) Positive Control Sample 
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Prepare the positive control serum sample in Starting block T20 Block buffer and vortex 
to mix: 
 
For DBP, make a 1:81 dilution of the reference serum by adding 3µL to 240µL of 
blocking buffer. Then make a 1:8100 dilution by adding 3µl of the 1:81 stock to 297µl 
blocking buffer. 
 
Repeat this 2 more times to make 3 independent 1:8100 dilutions.  
 
iii) Test Serum Samples 
 
Prepare the test serum sample in Starting block T20 Block buffer. A dilution is required 
that will give an OD 405nm reading that is in the linear part of the standard curve (0.26 
≤ OD 405nm ≤ 2.1). Test samples can be tested at a single or multiple dilutions. The 
dilutions must be recorded on the ELISA record sheet. 
 
Typical dilutions for serum from the vaccine trials include 1:300 for samples taken from 
Adenovirus only immunised volunteers, or for most samples from volunteers receiving 
Adeno-MVA regimes taken between d0 – d56. Do not test samples at a dilution lower 
than 1:300. Serum samples taken on or after d63 should be typically tested at higher 
dilutions in the range e.g. 1:1000-1:5000 – the necessary dilution will depend on the 
strength of the response and may range from 1:600-1:40,000. 
 
 To prepare 1:300 dilutions: dilute 3µl serum in 897µl of Starting block T20 block. 
 
 To prepare higher dilutions: dilute the 1:300 dilution appropriately in Starting 
block T20 block.  
 
 Record all dilutions for each sample on the experimental record sheet. 
 
 Vortex all samples to mix. 
6.5 Plating Serum  
1. After blocking is complete, wash the plates 6x in PBS/T. Tap them dry on blue 
roll. 
 
2. Plate serum out using plate layout below. Each well should contain 50μl of 
sample. 
 
 
S1 to S22 (blue) = test sera (added in triplicate). 
Standard Curve (pink) = dilution 1 (column 1) to dilution 10 (column 10). Transfer 50μl 
from tubes 1-10 (see step 6.4.2) to the appropriate wells of rows G and H of the ELISA 
plate. Repeat for subsequent ELISA plates, etc. 
Blank = 50μl of Starting block T20 block solution. 
 
Internal control = 1:8100 V028 day 84 reference serum (see step 6.4.3).  
 1 2 3 4 5 6 7 8 9 10 11 12 
A S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 
B S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 
C S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 
D S13 S14 S15 S16 S17 S18 S19 S20 S21 S22 Internal 
Control 
 
E S13 S14 S15 S16 S17 S18 S19 S20 S21 S22 
F S13 S14 S15 S16 S17 S18 S19 S20 S21 S22 
G 1 2 3 4 5 6 7 8 9 10 
Blank 
H 1 2 3 4 5 6 7 8 9 10 
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3. Stack the plates (with an empty blank plate on top) and cover in foil. Leave for 2h 
(max 2h 30min) at RT. Note time of plating and record on the experiment sheet. 
 
6.6 Secondary Antibody  
 
1. After this time, wash the plates 6x in PBS/T. Tap them dry on blue roll. 
 
2. Dilute the secondary antibody 1:1000 in Starting block T20 block solution. 6mL is 
required per plate, i.e. 6μl secondary antibody in 6mL Starting block T20 block. 
Secondary antibody is goat anti-human IgG (γ-chain) Sigma A3187 (stored at 
+4˚C). Vortex to mix. 
 
3. Add 50μl secondary antibody per well. 
 
4. Stack the plates (with an empty blank plate on top) and cover in foil. Leave for 1h 
(max 1h 30min) at RT. Note time and record on the experiment sheet. 
 
5. Prepare development buffer – for each plate 10ml is required. Buffer must be 
made up in units of 20ml. Dilute 5x diethanolamine buffer (stored at +4˚C) in 
deionised water (18.2 MΩ setting). For each unit of 20ml, add one 20mg 4-
nitrophenylphosphate tablet (stored at -20˚C) to give a final concentration of 
1mg/ml. Prepare the buffer in a suitable tube wrapped in foil, to prevent exposure 
to light. Leave to stand at RT until required, and shake to mix before use. 
6.7 Development  
 
1. Wash the plates 6x in PBS/T. Tap them dry on blue roll. 
 
2. Make sure the computer and plate reader are available and turned on, 
before developing. 
 
3. Using a multi-channel automatic pipette, add 100µl development buffer to each 
well of plate one. Using the timer, wait 60-90s and then add development buffer 
to plate 2. Continue adding development buffer to each plate in turn at the same 
60-90s interval. Cover the plates in foil and leave on the bench. Make sure there 
are no bubbles in any of the wells, as this can aberrantly increase the 
absorbance readings. If bubbles are present, pop these with a clean yellow 
pipette tip (use a separate tip for each bubble to avoid cross-contamination of 
development buffer between wells). 
6.8 Reading Plates and Analysis  
1. During the development period, log on to ELISA station computer. 
2. Load Gen5 ELISA software. 
3. Create a new experiment using an existing protocol. 
4. Select DBP ELISA protocol stored in X:\S Draper\Clinical Trials\ELISA 
Protocols\150622 MVT PvDBP_RII SS and click OK. 
5. Click file menu and save as. 
6. Save experiment files as “MVT E xx followed by initials and date (yymmdd) in 
V:\1.Malaria\1.Master files\2.VAC Studies\VAC051\11.Immunology\ELISA 
data\Experiments. 
7. If you have more than one ELISA plate, right click on Plate 1 and select add 
plates. Add the number of extra plates required. 
8. Click on the + icon next to plate 1 to expand the menu, and select Sample IDs. 
9. Enter IDs for samples 1-22 (typically numbered 1-22) and then click OK. 
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10. Right click on Plate 1 and choose custom plate layout and select Yes. 
11. Double click on custom layout in the menu for plate 1. 
12. For Sample 1, select 3 vertical replicates and enter the dilution used. Click on 
Square A1. 
13. Enter the dilution used for sample 2 and then click on square A2. Repeat for 
Sample 3 and click on A3 and so on, until all 22 samples have been accounted 
for. For Samples 13-22 click on squares D1-D10. Click OK at the end. 
14. Repeat these steps for any extra plates in the experiment. 
15. After approximately 15 min, read the Abs at 405nm of Plate 1 using the Bio-tek 
ELx800 microplate reader. Right click on Plate 1 and then “read plate 1” or click 
green play button in toolbar, click READ and then OK. 
16. The Abs 405nm of the six wells of the internal control serum should have an 
average OD = 1.0 The typical total development time for DBP_II is ~ 20 min 
hence initial plate reading (in step 6.8.15) begins ~5min prior to this. 
17. Repeat step 6.8.15 until the mean OD of the internal controls wells on plate 1 = 
~ 1.0. 
18. Wait for the plate to read and then select Plate 2. Click read plate after the 60-
90s interval has expired.. 
19. Repeat for subsequent plates, reading each in order with the appropriate 60-
90s time interval between reading each plate. 
20. When you have read all the plates, save the experiment again (File menu, then 
save). 
21. Now right click on Plate 1 and select Export. 
22. Now right click on Plate 2 and select Export. Repeat this process for all plates in 
turn. 
23. Once finished, exit Gen5 software. 
24. Save the Excel worksheet on the V;\ drive in the correct experiment folder with 
the same name as the Gen5 Experiment. 
25. Each plate is displayed on a separate worksheet. For each plate: 
26. Check the R2 value for the standard curve is >0.994. 
27. Carefully review the Abs405 data for each well. Check for no aberrant readings 
in the triplicate values for each sample CV should be <20%. Check the Abs405 of 
the blank wells is <0.15. 
28. Check the reference value is within 20% of 8100. 
29. The worksheet will analyse the data and provide a readout in the bottom table 
for the antibody units of each sample (AU).  
30. Any readings that are below the Abs405 threshold of 0.26 should be regarded 
as negative. 
31. Any readings that are above the Abs405 threshold of 2.1 should be repeated in 
another ELISA assay at higher dilution. 
32. Fill in the volunteer number and timepoint for each sample. 
33. Copy the final data set to the DBP MVT ELISA database found at: 
V:\1.Malaria\1. Master Files\VAC Studies\ VAC051\ Immunology\ ELISA data. 
ELISA plates can be discarded once read.  
34. MVT ELISA record sheets should be stored in the relevant trial ring-binder 
folder. 
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7 Associated documents 
ELISA Experiment Record Sheets and Spreadsheet of MVT Exx numbers. Found at: 
 
V:\1.Malaria\1. Master Files\Lab general trial info\Blood-stage MVT\ Templates & 
Record Sheets 
 
MVT ELISA database stored at: 
 
V:\1.Malaria\1. Master Files\VAC Studies\ VAC051\ Immunology \ ELISA data  
 
8 References 
 
Miura, K., A. C. Orcutt, O. V. Muratova, L. H. Miller, A. Saul, and C. A. Long. 2008. 
Development and characterization of a standardized ELISA including a reference 
serum on each plate to detect antibodies induced by experimental malaria vaccines. 
Vaccine 26:193-200. 
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ML023 P. falciparum MSP1 and AMA1 ELISA 
 
1 Purpose 
During malaria vaccine trials, the Enzyme-Linked ImmunoSorbent Assay 
(ELISA) is the primary assay for monitoring the antibody responses induced by 
vaccination in the serum of human volunteers. This SOP contains the detailed 
experimental protocol for performing this assay for the antigens Plasmodium 
falciparum Merozoite Surface Protein 1 19kDa fragment (PfMSP119) and Apical 
Membrane Antigen 1 (PfAMA1). There are two alleles of the PfMSP119 antigen: 
i) 3D7/Mad20/ETSR – referred to here as ETSR, and ii) 
Wellcome/K1/FVO/QKNG – referred to here as QKNG. There are multiple 
alleles of the PfAMA1 antigen, but only two are tested in this ELISA assay: i) 
3D7 AMA1, and ii) FVO AMA1. This SOP details the experimental protocol for 
performing this assay for both these alleles of PfMSP119 and PfAMA1.  
2 Introduction 
The aim of our clinical vaccine trials is to induce protection against malaria in 
human volunteers and characterise the cells and/or antibodies involved in 
inducing protective immune responses. One of the primary endpoints in Phase I 
and Phase II trials of blood-stage malaria vaccines is immunogenicity as 
measured by ELISA, which quantifies the level of antigen-specific antibodies in 
the serum of immunized volunteers. In this case, the PfMSP119 antigens are 
recombinant GST-PfMSP119 fusion proteins produced in E. coli (Jenner 
Protocol J136) and the PfAMA1 antigens are provided by external collaborators 
(3D7 AMA1 (1) was provided by Dr Chetan Chitnis (ICGEB, New Delhi, India) 
and FVO AMA1 (2) was provided by Dr Mike Blackman (NIMR, London, UK)). 
The ELISA protocol has been standardized according to published methods (3). 
This protocol uses a reference serum on each ELISA plate to detect antibodies 
induced by experimental malaria vaccines. 
 
Different types of controls are included; a high-titre reference serum from 
naturally-immune African adults is included on each ELISA plate to produce a 
standard curve which is used to quantify and assign ELISA units to each 
unknown sample on the plate; also an internal positive control sample and 
negative control / no serum (“blank wells”) are used to perform QC analysis on 
each ELISA plate. A separate ELISA against GST only is also included for 
selected samples as a negative control for the PfMSP119 antigens.  
 
ELISA plates are coated over-night with the relevant recombinant GST or GST-
PfMSP119 fusion proteins or PfAMA1. The assay is performed by preparing a 
standard curve and internal controls from the reference serum and adding these 
samples to the plate. Unknown test serum samples from immunized volunteers 
are diluted and added in triplicate to the ELISA plate. After a two hour 
incubation period, the diluted sera are discarded, the plate is washed and a 
secondary polyclonal antibody against the γ–chain of human IgG is added. This 
secondary antibody is conjugated to the enzyme alkaline phosphatase. After 
330 
 
another one hour incubation, followed by a wash step, the alkaline phosphatase 
substrate is added. The substrate is left to develop for 10-25 mins (antigen 
dependent) and the absorbance at 405nm is read using a plate reader. The 
result is obtained by taking an average of the triplicate wells for each test 
sample, and using the standard curve to assign MSP1 or AMA1 ELISA arbitrary 
units (AU). 
 
3 Scope 
This SOP covers all serum samples taken from volunteers in MSP1 or AMA1 
malaria vaccine trials in Oxford for which ELISA is one of the primary readouts. 
It does not cover booking in of samples to the laboratory, which is described in 
ML001 Malaria lab sample handling. 
 
4 Definitions 
ELISA = Enzyme-Linked ImmunoSorbent Assay. 
5 Responsibilities 
All staff employed by the University of Oxford who work on the malaria vaccine 
trials, including clinicians or visiting scientists working in the lab, must follow 
these protocols. 
 
The Senior Immunologist ensures that staff are competent to perform these 
procedures. 
 
6 Procedure 
6.1 Equipment & Reagents 
Where appropriate, equipment and reagents used in the processing of samples 
from clinical trials is dedicated to study work. Equipment used forms part of the 
laboratory maintenance and monitoring plan. 
  
Equipment: 
Fridge at +4oC 
Freezer at -20oC and -80oC 
Vortex 
Eppendorf Racks 
Pipettes including 8- or 12-well multi-channel and automatic multi-channel 
Pipetteboy 
Bio-tek ELx800 Microplate Reader with Gen5 ELISA software 
Timer 
Sufficient tips for pipettes. 0.1-10μl, 2-20μl, 20-200μl, 100-1000μl 
Safety Glasses 
PBS-Tween Hand Washer 
Timer 
 
 
 Consumables & Reagents: 
 
Reagent Company Cat # 
NUNC Immuno Plates (442404) Fisher DIS-971-030J 
Blocker Casein in PBS Pierce 37528 
Goat anti-human IgG (γ-chain)-alk phos Sigma A3187 
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Dulbecco’s PBS (DPBS) Sigma D8537 
5x Diethanolamine Buffer Fisher 34064 
4-Nitrophenyl Phosphate Tablets (20mg) Sigma N2765 
Tween-20 Sigma P7949 
Aluminium Foil Fisher AKL-300-040J 
1.5mL Eppendorf tubes Fisher FB74031 
Reagent Reservoirs (Costar 4870) Fisher PMP-331-010C 
10L PBS powder Invitrogen 21600-069 
 
Recombinant Protein Antigens:   
Recombinant protein antigens required for this SOP include: 
i) GST-PfMSP119 ETSR [“ETSR”] 
ii) GST-PfMSP119 QKNG [“QKNG”] 
iii) GST control [“GST”] 
iv) PfAMA1 (3D7) 
v) PfAMA1 (FVO) 
These GST (fusion) proteins are produced in E. coli and purified by affinity 
chromatography according to Jenner Protocol J136. The PfAMA1 proteins are 
provided by collaborators. These are stored in small aliquots (typically enough 
to coat five ELISA plates) at -20ºC in the human immunology freezer until 
needed. Coating antigen concentration is standard at 2µg/ml. 
 
Reference Serum: 
Human hyperimmune serum (sample 5H) from Kilifi Kenya. Diluted 1:100 and 
stored in aliquots in the MVT -20°C freezer. 
 
Buffers and Solutions:   
Make up buffer and solutions as follows: 
i) PBS/T (PBS with 0.05% Tween) for washing plates. Dissolve 10L PBS 
tub in 10L deionised water (15.0 MΩ setting). Add 5mL Tween-20. 
Shake and return to the ELISA plate wash station. 
 
Day 1. 
6.2 Coating ELISA plates on the bench.  
 
1 Print off a new MVT ELISA record sheet for each experiment. Number the 
experiment with the next experiment number and fill this in with the required 
information throughout the experiment. The next available experiment number 
can be found in the Excel spreadsheet contained in the same folder. Sign off 
the experiment number in the spreadsheet and re-save the file. Sheets can be 
found at: 
 
V:\1.Malaria\1. Master Files\VAC Studies\VAC037\12. Immunology\ELISAs\ 
Templates & Record Sheets 
 
2 Calculate the number of Nunc Immuno ELISA plates required (max number of 
22 test samples per plate). Thaw an aliquot of the recombinant antigen 
required. Make the coating solution by adding recombinant antigen to DPBS at 
a final concentration of 2µg/mL. Working on the bench, add 50 µl per well of the 
coating solution to the ELISA plate using a multi-channel pipette. Store the 
plates at RT over-night (≥16 h), covered in foil (do not stack the plates, but 
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leave flat on the bench). Note time of coating and record on the experiment 
layout sheet. 
 
3 Store any spare recombinant protein antigen at 4°C for maximum 1 week. 
 
 
Day 2. 
6.3 Blocking plates.  
 
1  Flick off the coating solution into the sink (wear eye protection). 
 
2 Wash the plates 6x in PBS/T using the handheld washer. 
 
3 Block the wells with 200 µL per well of Casein blocking buffer.  
 
4 Stack the plates (with an empty blank plate on top) and cover in foil. Leave for 
1h (max 1h 30min) at RT. Note time of blocking and record on the experiment 
sheet. 
 
5 During blocking prepare test samples and reference standard dilutions as 
below.  
 
6.4 Sample Preparation 
 
iv) Standard Curve 
 
1 Standard curve dilution: Thaw an aliquot of the 1:100 reference serum (stored 
at -20°C in the human immunology freezer). 
 
2 Prepare dilutions of this reference serum in duplicate in Casein Block buffer: 
 
 For MSP1: Take the aliquot and prepare one 1:900 dilution in an eppendorf 
tube: add 100µL 1:100 to 800µL of blocking buffer. Label 1. Vortex to mix. 
 For AMA1: Take the aliquot and prepare one 1:1000 dilution in an eppendorf 
tube: add 100µL 1:100 to 900µL of blocking buffer. Label 1. Vortex to mix. 
 
Prepare a dilution curve in eppendorf tubes. To make a 1:2 dilution set (enough 
for 4 ELISA plates): 
  
 Add 450µL of Casein block to nine eppendorfs labelled 2-10.  
 Add 450µL of the first dilution 1 to tube 2. Vortex to mix. 
 Add 450µL of 2 to tube 3. Vortex to mix. And so on - repeat this through to 
tube 10. 
 Each tube should now contain 450µL of liquid (except 10 which contains 
900µL), with a 2-fold dilution series running from tube 1 to 10. 
 
 
v) Positive Control Sample 
 
3 Prepare the positive control serum sample in Casein Block buffer and vortex to 
mix: 
 
For MSP1, make a 1:3600 dilution of the reference serum by adding 50µL 1:100 
to 1750µL of blocking buffer.  
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For AMA1, make a 1:8000 dilution of the reference serum by adding 25µL 1:100 
to 1975µL of blocking buffer.  
 
 
vi) Test Serum Samples 
 
4 Prepare the test serum sample in Casein Block buffer. A dilution is required that 
will give an OD 405nm reading that is in the linear part of the standard curve 
(0.15 ≤ OD 405nm ≤ 1.6). Test samples can be tested at a single or multiple 
dilutions. The dilutions must be recorded on the ELISA record sheet. 
 
Typical dilutions for serum from the vaccine trials include 1:300 for samples 
taken from Adenovirus only immunised volunteers, or for most samples from 
volunteers receiving Adeno-MVA regimes taken between d0 – d56. Do not test 
samples at a dilution lower than 1:300. Serum samples taken on or after d63 
should be typically tested at higher dilutions in the range e.g. 1:3000-1:6000 – 
the necessary dilution will depend on the strength of the response and can 
range from 1:600-1:40,000. 
 
To prepare 1:300 dilutions: dilute 3µl serum in 897µl of casein block. 
 
To prepare higher dilutions: dilute the 1:300 dilution appropriately in casein 
block.  
 
Record all dilutions for each sample on the experimental record sheet. 
 
Vortex all samples to mix. 
 
6.5 Plating Serum  
 
1 After blocking is complete, wash the plates 6x in PBS/T. Tap them dry on blue 
roll. 
 
2 Plate serum out using plate layout below. Each well should contain 50μl of 
sample. 
 
 S1 to S22 (blue) = test sera (added in triplicate). 
  
Standard Curve (pink) = dilution 1 (column 1) to dilution 10 (column 10). 
Transfer 50μl from tubes 1-10 (see step 6.4.2) to the appropriate wells of rows 
G and H of the ELISA plate. Repeat for subsequent ELISA plates, etc. 
Blank = 50μl of casein block solution. 
Internal control = 1:3600 MSP1 or 1:8000 AMA1 reference serum (see step 
6.4.3).  
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 
B S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 
C S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 
D S13 S14 S15 S16 S17 S18 S19 S20 S21 S22 Internal 
Control 
 
E S13 S14 S15 S16 S17 S18 S19 S20 S21 S22 
F S13 S14 S15 S16 S17 S18 S19 S20 S21 S22 
G 1 2 3 4 5 6 7 8 9 10 
Blank 
H 1 2 3 4 5 6 7 8 9 10 
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3 Stack the plates (with an empty blank plate on top) and cover in foil. Leave for 
2h (max 2h 30min) at RT. Note time of plating and record on the experiment 
sheet. 
 
6.6 Secondary Antibody  
 
1 After this time, wash the plates 6x in PBS/T. Tap them dry on blue roll. 
 
2 Dilute the secondary antibody 1:1000 in casein block solution. 5mL is required 
per plate, i.e. 5μl secondary antibody in 5mL casein block. Secondary antibody 
is goat anti-human IgG (γ-chain) Sigma A3187 (stored at +4˚C). Vortex to mix. 
 
3 Add 50μl secondary antibody per well. 
 
4 Stack the plates (with an empty blank plate on top) and cover in foil. Leave for 
1h (max 1h 30min) at RT. Note time and record on the experiment sheet. 
 
5 Prepare development buffer – for each plate 10ml is required. Buffer must be 
made up in units of 20ml. Dilute 5x diethanolamine buffer (stored at +4˚C) in 
deionised water (18.2 MΩ setting). For each unit of 20ml, add one 20mg 4-
nitrophenylphosphate tablet (stored at -20˚C) to give a final concentration of 
1mg/ml. Prepare the buffer in a suitable tube wrapped in foil, to prevent 
exposure to light. Leave to stand at RT until required, and shake to mix before 
use. 
 
6.7 Development  
1 Wash the plates 6x in PBS/T. Tap them dry on blue roll. 
 
2 Make sure the computer and plate reader are available and turned on, before 
developing. 
 
3 Using a multi-channel automatic pipette, add 100µl development buffer to each 
well of plate one. Using the timer, wait 60-90s and then add development buffer 
to plate 2. Continue adding development buffer to each plate in turn at the same 
60-90s interval. Cover the plates in foil and leave on the bench. Make sure 
there are no bubbles in any of the wells, as this can aberrantly increase the 
absorbance readings. If bubbles are present, pop these with a clean yellow 
pipette tip (use a separate tip for each bubble to avoid cross-contamination of 
development buffer between wells). 
 
6.8 Reading Plates and Analysis  
1. During the development period, log on to ELISA station computer. 
2. Load Gen5 ELISA software. 
3. Create a new experiment. 
4. Select either the MSP1 or AMA1 MVT Clinical Trail ELISA Protocol v1 (links 
below if required) and click OK. 
V:\1.Malaria\1. Master Files\VAC Studies\VAC037\12. Immunology\ELISAs\ 
MSP1 Protocol 
V:\1.Malaria\1. Master Files\VAC Studies\VAC036\13. Immunology\ELISAs\ 
AMA1 Protocol 
5. Click file menu and save as. 
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6. Save experiment files as “MVT E xx followed by the date (yymmdd). It should 
save automatically to C:\Program Files\BioTek\Gen5 1.10\Experiments. 
7. If you have more than one ELISA plate, right click on Plate 1 and select add 
plates. Add the number of extra plates required. 
8. Click on the + icon next to plate 1 to expand the menu, and select Sample IDs. 
9. Enter IDs for samples 1-22 (typically numbered 1-22) and then click OK. 
10. Right click on Plate 1 and choose custom plate layout and select Yes. 
11. Double click on custom layout in the menu for plate 1. 
12. For Sample 1, select 3 vertical replicates and enter the dilution used. Click on 
Square A1. 
13. Enter the dilution used for sample 2 and then click on square A2. Repeat for 
Sample 3 and click on A3 and so on, until all 22 samples have been accounted 
for. For Samples 13-22 click on squares D1-D10. Click OK at the end. 
14. Repeat these steps for any extra plates in the experiment. 
15. After approximately 20mins (for MSP1) and 10mins (for AMA1), read the Abs at 
405nm of Plate 1 using the Bio-tek ELx800 microplate reader. Select Plate 1 
and then “read plate” in the toolbar menu (grey box with green arrow pointing 
left) and then click READ and then OK. 
16. The Abs 405nm of the six wells of the internal control serum should have an 
average OD = 1.0 (approx range 0.8 – 1.2). This value does not need to be 
exact, as the analysis takes this into account and antibody units are calculated 
in relation to the standard curve on each plate. The typical total development 
time for MSP1 is ~25mins and for AMA1 ~15mins, hence initial plate reading (in 
step 6.8.15) begins ~5mins prior to this. 
17. Repeat step 6.8.15 until the mean OD of the internal controls wells on plate 1 = 
~1.0. 
18. Wait for the plate to read and then select Plate 2. Click read plate after the 60-
90s interval has expired (from step 6.7.2). 
19. Repeat for subsequent plates, reading each in order with the appropriate 60-
90s time interval between reading each plate. 
20. When you have read all the plates, save the experiment again (File menu, then 
save). 
21. Now right click on Plate 1 and select power export. 
22. If the Excel format box appears on the screen, click Continue. Excel will remain 
open after power export, but no worksheet will be visible. 
23. Now right click on Plate 2 and select power export. Repeat this process for all 
plates in turn. 
24. Once finished, exit Gen5 software. 
25. An Excel worksheet should be saved in C:\Program Files\BioTek\Gen5 
1.10\Experiments with the same name as the Gen5 Experiment. 
26. Open the worksheet. 
27. Each plate is displayed on a separate worksheet. For each plate: 
 
28. Check the R2 value for the standard curve is >0.994. 
29. Carefully review the Abs405 data for each well. Check for no aberrant readings 
in the triplicate values for each sample. Check the Abs405 of the blank wells is 
<0.15. 
30. The worksheet will analyse the data and provide a readout in the bottom table 
for the antibody units of each sample (AU). These are multipled by a conversion 
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factor if the internal reference (highlighted in green) is > ±10% of the expected 
value. 
31. Any readings that are below the Abs405 threshold of 0.15 will be highlighted in 
bright blue. These should be regarded as negative. 
32. Any readings that are above the Abs405 threshold of 1.6 will be highlighted in 
bright yellow. These should be repeated in another ELISA assay at higher 
dilution. 
33. If you have tested two dilutions (e.g. sample positions 1&13, 2&14 etc), these 
are averaged in the final table and % difference calculated. This table can be 
ignored if only one dilution was tested for each sample. 
34. Fill in the volunteer number and timepoint for each sample. 
35. Copy the final data set to the MSP1 or AMA1 MVT ELISA database found at: 
V:\1.Malaria\1. Master Files\VAC Studies\VAC037\12. Immunology\ELISAs\ 
MSP1 ELISA Data. Note the data for each antigen are stored on separate 
worksheets (see tabs at the bottom). 
36. Copy the Gen5 Experiment and Excel sheet into a folder labelled with the MVT 
Exx number in the appropriate Immunology / ELISA data folder for the Vac 
study on the V:// drive. 
37. ELISA plates can be discarded once read.  
38. MVT ELISA record sheets should be stored in the ring-binder folder in the MVT 
office. 
 
7 Associated documents 
ELISA Experiment Record Sheets and Spreadsheet of MVT Exx numbers. 
Found at: 
 
V:\1.Malaria\1. Master Files\VAC Studies\VAC037\12. Immunology\ELISAs\ 
Templates & Record Sheets 
 
 
MVT ELISA database stored at: 
 
V:\1.Malaria\1. Master Files\VAC Studies\VAC037\12. Immunology\ELISAs\ 
MSP1 ELISA Data 
8 References 
1. Quelhas, D., L. Puyol, L. Quinto, E. Serra-Casas, T. Nhampossa, E. Macete, 
P. Aide, A. Mayor, I. Mandomando, S. Sanz, J. J. Aponte, V. S. Chauhan, C. 
E. Chitnis, P. L. Alonso, C. Menendez, and C. Dobano. 2008. Impact of 
intermittent preventive treatment with sulfadoxine-pyrimethamine on antibody 
responses to erythrocytic-stage Plasmodium falciparum antigens in infants in 
Mozambique. Clin Vaccine Immunol 15:1282-1291. 
 
2. Pizarro, J. C., B. Vulliez-Le Normand, M. L. Chesne-Seck, C. R. Collins, C. 
Withers-Martinez, F. Hackett, M. J. Blackman, B. W. Faber, E. J. Remarque, 
C. H. Kocken, A. W. Thomas, and G. A. Bentley. 2005. Crystal structure of 
the malaria vaccine candidate apical membrane antigen 1. Science 308:408-
411. 
 
3. Miura, K., A. C. Orcutt, O. V. Muratova, L. H. Miller, A. Saul, and C. A. Long. 
2008. Development and characterization of a standardized ELISA including a 
337 
 
reference serum on each plate to detect antibodies induced by experimental 
malaria vaccines. Vaccine 26:193-200. 
 
9 Review History 
The review history allows a record to be kept of when and who reviews the 
document to ensure it remains fit for purpose. Significant changes should be 
recorded in the ‘Detail’ section. 
 
 
Date Reviewed By 
(Print name) 
Version Detail (significant changes from 
previous version) 
Previous 
Version  
26/Jul/10 Simon Draper 
& Sumi Biswas 
1.0 
New document 
N/A 
   
 
 
   
 
 
338 
 
ML011: RH5 ELISA 
 
1 Purpose 
During malaria vaccine trials, the Enzyme-Linked ImmunoSorbent Assay 
(ELISA) is the primary assay for monitoring the antibody responses induced by 
vaccination in the serum of human volunteers. This SOP contains the detailed 
experimental protocol for performing this assay for the antigen Plasmodium 
falciparum reticulocyte-binding protein homologue 5 (PfRH5).  
2 Introduction 
The aim of our clinical vaccine trials is to induce protection against malaria in 
human volunteers and characterize the cells and/or antibodies involved in 
inducing protective immune responses. One of the primary endpoints in Phase I 
and Phase II trials of blood-stage malaria vaccines is immunogenicity as 
measured by ELISA, which quantifies the level of antigen-specific antibodies in 
the serum of immunized volunteers. In this case, the PfRH5 protein is cultured 
in S2 cells by Jing Jin. This assay will use RH5 v2 CTAG (batch: P0184). 
 
The ELISA protocol has been standardized according to published methods (1). 
This protocol uses a reference serum on each ELISA plate to detect antibodies 
induced by experimental malaria vaccines. 
 
Different types of controls are included; a reference serum from a high 
responding volunteer is included on each ELISA plate to produce a standard 
curve which is used to quantify and assign ELISA units to each unknown 
sample on the plate; also an internal positive control sample and negative 
control / no serum (“blank wells”) are used to perform QC analysis on each 
ELISA plate.  
 
ELISA plates are coated over-night with the RH5 protein. The assay is 
performed by preparing a standard curve and internal controls from the 
reference serum and adding these samples to the plate. Unknown test serum 
samples from immunized volunteers are diluted and added in triplicate to the 
ELISA plate. After a two hour incubation period, the diluted sera are discarded, 
the plate is washed and a secondary polyclonal antibody against the γ–chain of 
human IgG is added. This secondary antibody is conjugated to the enzyme 
alkaline phosphatase. After another one hour incubation, followed by a wash 
step, the alkaline phosphatase substrate is added. The substrate is left to 
develop for 25 minutes and the absorbance at 405nm is read using a plate 
reader. The result is obtained by taking an average of the triplicate wells for 
each test sample, and using the standard curve to assign RH5 ELISA arbitrary 
units (AU). 
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3 Scope  
This SOP covers all serum samples taken from volunteers in RH5 malaria 
vaccine trials in Oxford for which ELISA is one of the primary readouts. It does 
not cover booking in of samples to the laboratory, which is described in ML001 
Malaria lab sample handling. 
 
4 Definitions 
ELISA = Enzyme-Linked ImmunoSorbent Assay. 
5 Responsibilities 
All staff employed by the University of Oxford who work on the malaria vaccine 
trials, including clinicians or visiting scientists working in the lab, must follow 
these protocols. 
 
The Senior Immunologist ensures that staff are competent to perform these 
procedures. 
 
6 Procedure 
6.1 Equipment & Reagents 
Where appropriate, equipment and reagents used in the processing of samples 
from clinical trials is dedicated to study work. Equipment used forms part of the 
laboratory maintenance and monitoring plan. 
  
Equipment: 
Fridge at +4oC 
Freezer at -20oC and -80oC 
Vortex 
Eppendorf Racks 
Pipettes including 8- or 12-well multi-channel and automatic multi-channel 
Pipetteboy 
Bio-tek ELx800 Microplate Reader with Gen5 ELISA software 
Timer 
Sufficient tips for pipettes. 0.1-10μl, 2-20μl, 20-200μl, 100-1000μl 
Safety Glasses 
PBS-Tween Hand Washer 
Timer 
 
 Consumables & Reagents: 
 
Reagent Company Cat # 
NUNC Immuno Plates (442404) Fisher DIS-971-030J 
Blocker Casein in PBS Pierce 37528 
Goat anti-human IgG (γ-chain)-alk phos Sigma A3187 
Dulbecco’s PBS (DPBS) Sigma D8537 
5x Diethanolamine Buffer Fisher 34064 
4-Nitrophenyl Phosphate Tablets (20mg) Sigma N2765 
Tween-20 Sigma P7949 
Aluminium Foil Fisher AKL-300-040J 
1.5mL Eppendorf tubes Fisher FB74031 
Reagent Reservoirs (Costar 4870) Fisher PMP-331-010C 
10L PBS powder Invitrogen 21600-069 
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Recombinant Protein Antigens:   
Recombinant protein antigens required for this SOP include: 
i) RH5 v2 Ctag  
RH5 protein is cultured in S2 cells and purified by affinity chromatography by 
Jing Jin. The protein is stored in 28µl aliquots (enough to coat 2 ELISA plates) 
at          -80ºC in the blood stage trial freezer until needed. Coating antigen 
concentration is standard at 2µg/ml. 
 
Reference Serum: 
VAC057 Volunteer 1020 G2B d84 serum is stored in the blood stage trial -80°C 
freezer. 
 
Buffers and Solutions:   
Make up buffer and solutions as follows: 
ii) PBS/T (PBS with 0.05% Tween) for washing plates. Dissolve 10L PBS 
tub in 10L deionised water (15.0 MΩ setting). Add 5mL Tween-20. 
Shake and return to the ELISA plate wash station. 
 
Day 1. 
6.2 Coating ELISA plates on the bench.  
6.2.1 Print off a new MVT ELISA record sheet for each experiment. Number the 
experiment with the next experiment number and fill this in with the required 
information throughout the experiment. The next available experiment number 
can be found in the Excel spreadsheet contained in the same folder. Sign off 
the experiment number in the spreadsheet and re-save the file. Sheets can be 
found at: 
 
V:\1.Malaria\1. Master Files\5. Lab general info/blood stage mvt \Templates & 
Record sheets \ MVT ELISA record sheet 
 
6.2.2 Calculate the number of Nunc Immuno ELISA plates required (max number of 
22 test samples per plate). Thaw an aliquot of RH5 for >15minutes. Make the 
coating solution by adding RH5 to DPBS at a final concentration of 2µg/mL (DO 
NOT VORTEX). Working on the bench, add 50 µl per well of the coating 
solution to the ELISA plate using a multi-channel pipette. Store the plates at 4°C 
over-night (≥16 h), wrapped in cling film. Note time of coating and record on the 
experiment layout sheet. 
 
Day 2. 
6.3 Blocking plates.  
 
6.3.1 Bring casein to RT for >30mins and flick off the coating solution into the sink 
(wear eye protection). 
 
6.3.2 Wash the plates 6x in PBS/T using the handheld washer. 
 
6.3.3 Block the wells with 200 µL per well of Casein blocking buffer.  
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6.3.4 Stack the plates (with an empty blank plate on top) and cover in foil. Leave for 
1h (max 1h 30min) at RT. Note time of blocking and record on the experiment 
sheet. 
 
6.3.5 During blocking prepare test samples and reference standard dilutions as 
below.  
 
 
6.4 Sample Preparation 
 
vii) Standard Curve 
 
 
6.4.1 Prepare dilutions of VAC057 Volunteer 1020 day 84 reference serum in 
duplicate in Casein Block buffer: 
 
 For RH5: Take the serum and prepare one 1:100 dilution in an eppendorf 
tube: add 6µL to 594µL of blocking buffer. Label 1. Vortex to mix. 
 
Prepare a dilution curve in eppendorf tubes. To make a 1:2 dilution set (enough 
for 2 ELISA plates): 
  
 Add 300µL of Casein block to nine eppendorfs labelled 2-10.  
 Add 300µL of the first dilution 1 to tube 2. Vortex to mix. 
 Add 300µL of 2 to tube 3. Vortex to mix. And so on - repeat this through to 
tube 10. 
 Each tube should now contain 300µL of liquid (except 10 which contains 
600µL), with a 2-fold dilution series running from tube 1 to 10. 
 
 
viii) Positive Control Sample 
 
6.4.3 Prepare the positive control serum sample in Casein Block buffer and 
vortex to mix: 
 
For RH5, make a 1:100 dilution of the reference serum by adding 3µL to 297µL 
of blocking buffer. Then make a 1:3200 dilution by adding 28µL of the 1:100 
stock to 868µL blocking buffer. 
 
Repeat this 2 more times to make 3 independent 1:3200 dilutions. 
 
 
ix) Test Serum Samples 
 
6.4.4 Prepare the test serum sample in Casein Block buffer. A dilution is required that 
will give an OD 405nm reading that is in the linear part of the standard curve 
(0.15 ≤ OD 405nm ≤ 2.5). Test samples can be tested at a single or multiple 
dilutions. The dilutions must be recorded on the ELISA record sheet. 
 
Typical dilutions for serum from the vaccine trials include 1:100 for samples 
taken from Adenovirus only immunised volunteers, or for most samples from 
volunteers receiving Adeno-MVA regimes taken between d0 – d56. Do not test 
samples at a dilution lower than 1:100. Serum samples taken on or after d63 
should be typically tested at higher dilutions in the range e.g. 1:100-1:3000 – 
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the necessary dilution will depend on the strength of the response and can 
range from 1:100-1:40,000. 
 
To prepare 1:100 dilutions: dilute 3µl serum in 297µl of casein block. 
 
To prepare higher dilutions: dilute the 1:00 dilution appropriately in casein block.  
 
Record all dilutions for each sample on the experimental record sheet. 
 
Vortex all samples to mix. 
 
6.5 Plating Serum  
 
6.5.1 After blocking is complete, wash the plates 6x in PBS/T. Tap them dry on blue 
roll. 
 
6.5.2 Plate serum out using plate layout below. Each well should contain 50μl of 
sample. 
 
 S1 to S22 (blue) = test sera (added in triplicate). 
  
Standard Curve (pink) = dilution 1 (column 1) to dilution 10 (column 10). 
Transfer 50μl from tubes 1-10 (see step 6.4.2) to the appropriate wells of rows 
G and H of the ELISA plate. Repeat for subsequent ELISA plates, etc. 
 
Blank = 50μl of casein block solution. 
 
Internal control = 1:3200 RH5 reference serum (see step 6.4.3).  
 
 
6.5.3 Stack the plates (with an empty blank plate on top) and cover in foil. Leave for 
2h (max 2h 30min) at RT. Note time of plating and record on the experiment 
sheet. 
 
6.6 Secondary Antibody  
 
6.6.1 After this time, wash the plates 6x in PBS/T. Tap them dry on blue roll. 
 
6.6.2 Dilute the secondary antibody 1:1000 in casein block solution. 6mL is required 
per plate, i.e. 6μl secondary antibody in 6mL casein block. Secondary antibody 
is goat anti-human IgG (γ-chain) Sigma A3187 (stored at +4˚C). Vortex to mix. 
 
6.6.3 Add 50μl secondary antibody per well. 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 
B S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 
C S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 
D S13 S14 S15 S16 S17 S18 S19 S20 S21 S22 Internal 
Control 
 
E S13 S14 S15 S16 S17 S18 S19 S20 S21 S22 
F S13 S14 S15 S16 S17 S18 S19 S20 S21 S22 
G 1 2 3 4 5 6 7 8 9 10 
Blank 
H 1 2 3 4 5 6 7 8 9 10 
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6.6.4 Stack the plates (with an empty blank plate on top) and cover in foil. Leave for 
1h (max 1h 30min) at RT. Note time and record on the experiment sheet. 
 
6.6.5 Prepare development buffer – for each plate 10ml is required. Buffer must be 
made up in units of 20ml. Dilute 5x diethanolamine buffer (stored at +4˚C) in 
deionised water (18.2 MΩ setting). For each unit of 20ml, add one 20mg 4-
nitrophenylphosphate tablet (stored at -20˚C) to give a final concentration of 
1mg/ml. Prepare the buffer in a suitable tube wrapped in foil, to prevent 
exposure to light. Leave to stand at RT until required, and shake to mix before 
use. 
 
6.7 Development  
 
6.7.1 Wash the plates 6x in PBS/T. Tap them dry on blue roll. 
 
6.7.2 Make sure the computer and plate reader are available and turned on, 
before developing. 
 
6.7.2 Using a multi-channel automatic pipette, add 100µl development buffer to each 
well of plate one. Using the timer, wait 60-90s and then add development buffer 
to plate 2. Continue adding development buffer to each plate in turn at the same 
60-90s interval. Cover the plates in foil and leave on the bench. Make sure 
there are no bubbles in any of the wells, as this can aberrantly increase the 
absorbance readings. If bubbles are present, pop these with a clean yellow 
pipette tip (use a separate tip for each bubble to avoid cross-contamination of 
development buffer between wells). 
 
6.8 Reading Plates and Analysis  
1. During the development period, log on to ELISA station computer. 
2. Load Gen5 ELISA software. 
3. Create a new experiment using an existing protocol. 
4. Select the MVT PfRH5 ELISA Protocol (link below if required) and click OK. 
a. X:\S Draper\Clinical Trials\ELISA Protocols\150820 MVT PfRH5 ELISA 
protocol  
5. Click file menu and save as. 
6. Save experiment files as “MVT E xx followed by initials and the date (yymmdd) 
in  
a. V:\1.Malaria\1.Master files\2.VAC 
Studies\VAC057\12.Immunology\ELISA data\Standardised 
ELISAs\Experiments 
7. If you have more than one ELISA plate, right click on Plate 1 and select add 
plates. Add the number of extra plates required. 
8. Click on the + icon next to plate 1 to expand the menu, and select Sample IDs. 
9. Enter IDs for samples 1-22 (typically numbered 1-22) and then click OK. 
10. Right click on Plate 1 and choose custom plate layout and select Yes. 
11. Double click on custom layout in the menu for plate 1. 
12. For Sample 1, select 3 vertical replicates and enter the dilution used. Click on 
Square A1. 
13. Enter the dilution used for sample 2 and then click on square A2. Repeat for 
Sample 3 and click on A3 and so on, until all 22 samples have been accounted 
for. For Samples 13-22 click on squares D1-D10. Click OK at the end. 
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14. Repeat these steps for any extra plates in the experiment. 
15. After approximately 20minutes (for RH5), read the Abs at 405nm of Plate 1 
using the Bio-tek ELx800 microplate reader. Right click on Plate 1 and then 
“read plate 1” or click green play button in the toolbar menu, click READ and 
then OK. 
16. The Abs 405nm of the six wells of the internal control serum should have an 
average OD = 1.0. The typical total development time for RH5 ~25minutes, 
hence initial plate reading (in step 6.8.15) begins ~5mins prior to this. 
17. Repeat step 6.8.15 until the mean OD of the internal controls wells on plate 1 = 
~1.0. 
18. Wait for the plate to read and then select Plate 2. Click read plate after the 60-
90s interval has expired (from step 6.7.2). 
19. Repeat for subsequent plates, reading each in order with the appropriate 60-
90s time interval between reading each plate. 
20. When you have read all the plates, save the experiment again (File menu, then 
save). 
21. Now right click on Plate 1 and select export. 
22. Now right click on Plate 2 and select export. Repeat this process for all plates in 
turn. 
23. Once finished, exit Gen5 software. 
24. Save the Excel worksheet on the V:\ drive in the correct experiment folder with 
the same name as the Gen5 experiment. 
25. Each plate is displayed on a separate worksheet. For each plate: 
26. Check the R2 value for the standard curve is >0.994. 
27. Carefully review the Abs405 data for each well. Check for no aberrant readings 
in the triplicate values for each sample CV should be <20%. Check the Abs405 
of the blank wells is <0.15. 
28. The worksheet will analyse the data and provide a readout in the bottom table 
for the antibody units of each sample (AU). 
29. Any readings that are below the Abs405 threshold of 0.3 should be regarded as 
negative. 
30. Any readings that are above the Abs405 threshold of 2.5 should be repeated in 
another ELISA assay at higher dilution. 
31. Fill in the volunteer number and timepoint for each sample. 
32. Copy the final data set to the RH5 MVT ELISA database found at: 
V:\1.Malaria\1. Master Files\VAC Studies\VAC057\12. Immunology\ELISAs\ 
VAC057 ELISA Database. 
33. ELISA plates can be discarded once read.  
34. MVT ELISA record sheets should be stored in the relevant trial ring-binder 
folder. 
 
7 Associated documents 
ELISA Experiment Record Sheets and Spreadsheet of MVT Exx numbers. 
Found at: 
 
V:\1.Malaria\1. Master Files\5. Lab general info \ blood stage mvt \ Templates & 
Record sheets \ MVT ELISA record sheet 
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MVT ELISA database stored at: 
 
V:\1.Malaria\1. Master Files\VAC Studies\VAC057\12. Immunology\ELISA data 
\ VAC057 ELISA database 
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